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The important thing is not to stop questioning. 
Curiosity has its own reason for existing. 
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SUMMARY 
 
  Recent evidence on Histone deacetyase 6 (HDAC6) function underlines its role as a key protein in the 
innate immune response to viral infection. However, whether HDAC6 regulates innate immunity 
during bacterial infection remains unexplored. To assess the role of HDAC6 in the regulation of defence 
mechanisms against intracellular bacteria, we used the Listeria monocytogenes (Lm) infection model. 
Here we describe that in the absence of HDAC6 Granulocyte/Macrophage colony stimulating factor-
derived dendritic cells (GM-CSF DCs) display higher intracellular bacterial titres than their wild type 
(wt) counterparts. The impaired bacterial clearance appears to be caused by a defect in autophagy. 
This correlates with an increase in the accumulation of the autophagy marker p62 in Hdac6-/- DCs, due 
to a defective phagosome-lysosome fusion. We also identify higher levels of acetylated cortactin co-
localizing with intracellular bacteria in Hdac6-/- DCs compared to wt, suggesting that this Post-
translational modification (PTM) in cortactin could delay the phagosome-lysosome fusion.  
  Additionally, a lower expression of interferon-related genes and pro-inflammatory cytokines is 
detected in Hdac6-/- DCs after Lm infection. This observation is in accordance with lower nitrite 
production and inducible nitric oxide synthase (iNOS) induction during bacterial infection in Hdac6-/- 
DCs. Likewise, phosphorylation of Mitogen-activated protein kinase (MAPK) and mammalian target of 
rapamycin (mTOR) signalling pathways is reduced in Hdac6-/- DCs in response to Lm, suggesting an 
altered Toll-like receptor (TLR) signalling. A defective pro-inflammatory cytokine production in 
response to Lm and various TLR agonists is detected in both Hdac6-/- GM-CSF-derived and FMS-like 
tyrosine kinase 3 (FLT3L)-derived dendritic cells.  
  Interestingly, our data reveal the molecular association of HDAC6 with the TLR-adaptor protein 
Myeloid differentiation primary response gene 88 (MyD88), and how the absence of HDAC6 seems to 
diminish Nuclear factor κB (NF-κB) induction after TLR stimuli. Moreover, Hdac6-/- mice display low 
serum levels of the inflammatory cytokine IL-6 and correspondingly an increased survival to a systemic 
infection with a lethal dose of Lm. These data underline the important function of HDAC6 in DCs, not 
only in the control of bacterial burden through degradation by autophagy, but also in the proper 
activation of TLR signalling. These results thus underscore an important regulatory role for HDAC6 in 
almost every step of DC functions against intracellular bacterial infection, highlithing HDAC6 as a new 
player of innate immune responses. 
 
                                                                                                                Summary 
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RESUMEN 
 
  Las evidencias recientes sobre la función de la Histona desacetyase 6 (HDAC6) ponen de manifiesto 
su implicación como proteína esencial en la respuesta inmune innata durante la infección viral. Sin 
embargo, la función de HDAC6 en la inmunidad innata durante la infección bacteriana es desconocida. 
Para estudiar el papel de HDAC6 en la regulación de los mecanismos de defensa contra bacteria 
intracelulares, se usó el modelo de infección de Listeria monocytogenes (Lm). Aquí se describe como 
la ausencia de HDAC6 en las células dendríticas diferenciadas con el factor estimulador colonias de 
granulocito/macrófago (GM-CSG DCs) causa un incremento en la carga de la bacteria intracelular 
comparado con la silvestre (wt). La deficiente eliminación bacteriana parece estar causada por un 
defecto en la autofagia. Este dato concuerda con un incremento en la acumulación del marcador de 
autofagia p62 en las Hdac6-/- DCs, que es debido a un defecto en la fusión del fagosoma con el lisosoma.  
También se han identificado niveles más altos de cortactina acetilada co-localizando con bacterias 
intracelulares en Hdac6-/- DCs, lo que sugiere que esta modificación post-traduccional (PTM) en la 
cortactina podría estar retrasando la fusión fago-lisosomal.  
  Además, se han identificado menores niveles de expresión de genes relacionados con interferón y 
citoquinas pro-inflammatorias en las Hdac6-/- DCs después de la infección con Lm. Esta observación 
concuerda con una menor producción de nitrito e inducción de la sintetasa de óxido nítrico inducible 
(iNOS) durante la infección en las Hdac6-/- DCs. Así mismo, las Hdac6-/- BMDCs muestran una menor 
fosforilación de las rutas de señalización de proteínas quinasas activadas por mitógenos (MAPK) y de 
la diana de mamíferos de rapamicina (mTOR) en respuesta a la infección por Lm, sugiriendo una 
alteración en la señalización de la ruta de receptores tipo Toll (TLR). Tanto las DCs derivadas de GM-
CSF como las de la tirosina quinasa 3 de tipo FSM (FLT3L) tienen un defecto en la producción de 
citoquinas pro-inflamatorias en respuesta a Lm y a varios agonistas de TLR.  
  Se ha demostrado la asociación molecular de HDAC6 con la molécula adaptadora de TLR, el gen 88 
de respuesta primaria a diferenciación mieloide (MyD88), y como la ausencia de HDAC6 disminuye la 
inducción del factor nuclear κB (NF-κB) despúes del estímulo de los TLRs. Adicionalmente, los ratones 
Hdac6-/- muestran menores niveles séricos de la citoquina pro-inflamatoria IL-6, relacionado con una 
mayor supervivencia a la infección sistémica por la dosis letal de Lm. Estos datos remarcan la 
importante función de HDAC6 en las DCs, no solo por el control de la carga bacteriana por la 
degradación autofágica, sino también por la adecuada activación de la señalización de los TLRs.  
                                                                                                                   Resumen 
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1. INTRODUCTION  
  The immune response is carried out by a higly specialized system and is constituted by cells and 
molecules that work in a coordinated and cooperative manner to react against pathogens and 
external threats to protect the body. The “innate immunity”, constitutes the first line of defence 
against pathogens, acting very fast to counteract pathogens during the earliest phase of 
infection. Mechanisms involved in the recognition of microbes or damaged tissues and the 
subsequent reaction are repeated patterns common to groups of related pathogens. On the other 
hand, the “adaptive immune response” is highly effective and specific to fight against particular 
microbes.  The most important hallmark of adaptive immunity is “immunological memory”, 
essential to respond in a faster way and to generate a pool of memory cells that protect the body 
against reinfections. Innate and adaptive immune responses constitute a very precise integrated 
system of defence. In this regard, soluble factors delivered by innate immune responses to 
pathogens influence in the function of adaptive immune responses. Conversely, adaptive immune 
responses can focus the activity of innate immunity to be more effective to combat microbe insults. 
  The interest of this work is focused in the understanding of immunological mechanisms involved in 
the role played by HDAC6 in host cell defence against infection by the intracellular bacterium Listeria 
monocytogenes. 
1. Histone deacetylase 6 (HDAC6) 
1.1. Histone Deacetylase family (HDACs) 
  Histone deacetylases (HDACs) belong to a protein family with a mainly nuclear localization, which play 
an important role in the regulation of genetic expression together with other histone modifier proteins 
such as acetyltransferases (HATs), methylases or methyltransferases [118,51]. Histone acetylation 
(mediated by HDACs) is a versatile process that relax the chromatin structure, increasing gene 
transcription, whereas histone deacetylation, (carried out by HATs), compacts the chromatin structure, 
inducing genetic silencing. HDAC family is composed by proteins that at least contain one deacetylase 
catalytic domain responsible for the removal of acetyl groups from target proteins [51]. There are 18 
mammalian HDACs that are classified into four main groups according to their homology to yeast 
HDACs (Figure 1.1). Class I HDACs are orthologues of yeast reduced potassium dependency-3 (Rpd3) 
and comprise HDAC1, HDAC2, HDAC3 and HDAC8, which remain mainly localized in the nucleus. Class 
II HDACs are related to yeast Hda1 and according to their sequence homogy and domain structure, are 
subdivided into class IIa (HDAC4, HDAC5, HDAC7 and HDAC9) and class IIb (HDAC6 and HDAC10) [264]. 
Class III HDACs belong to the family of deacetylases called silent information regulator 2-like (Sir2) and 
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include seven sirtuins (Sirt-1 to 7). The class IV HDAC group is formed by HDAC11, which shares 
conserved catalytic core domains with Classes I and II HDACs, but shows a different structure [21]. 
HDAC3, Class IIa and IIb HDACs are able to interchange their cellular localization between nucleus and 
cytoplasm depending on several cellular signals. However, Sirt-1, 6 and 7 are mainly found in the 
nucleus, while Sirt-3, 4 and 5 are localized at mitochondria. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  The common characteristic of HDACs is that they use zinc (Zn2+) like enzymatic co-factors, belonging 
to the zinc-depending deacetylases groups [21]. This feature distinguishes them from sirtuins or NADH-
depending deacetylases [213,246].  HDACs are ubiquitous and pleiotropic proteins that can be found 
in all cell types, although Class II HDACs are enriched in specific tissues. All of them are expressed in all 
mammalian cells and are distributed in different compartments such as nucleus, cytosol and 
mitochondria [51]. HDACs controls gene expression and are involved in many biological processes such 
as cell growth, proliferation and differentiation, cytotoxicity and apoptosis [51]. 
1.2. HDAC6 Structure 
HDAC6 was the first characterized HDAC to be in the cytoplasm in an active form [91]. HDAC6 has a 
molecular weight of 130 KDa. This protein has two functional deacetylase domains (DD1 and DD2), 
Figure 1.1. HDACs family. Classification of the 18 mammalian HDACs which are classified into four groups based 
on sequence similarity to the catalytic domain of yeast prototypes. Class I HDACs include the yeast Rpd3 
homologs, HDAC 1, 2, 3 and 8. Class II HDACs encompass the yeast HDAC1/2 homologs, HDAC 4, 5, 6, 7, 9 and 10. 
They are further subclassified as IIa (HDAC 4, 5, 7 and 9) and IIb (HDAC 6 and 10). Class III HDACs (namely sirtuins) 
are composed by the yeast Sir2 orthologs SIRT 1, 2, 3, 4, 5, 6 and 7. HDAC11 belongs to the Class V HDACs, which 
has sequence similarity to both Rpd3 and Hda1. The subcellular localization is indicated as N: nuclear, M: 
mitochondrial and C: cytosolic. Sizes correspond to protein molecular weight and are expressed in kDa. From 
Shirakawa et al 2013 [223]. 
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which are involved in the removal of acetyl groups from target proteins such as tubulin, cortactin and 
Heat Shock Protein 90 (HSP90) [91,268,269,273] (Figure 1.2). Although both domains are functional, 
DD1 has a weak enzymatic activity and shows substrate specificity for C-terminal acetyl lysine residues, 
whereas DD2 displays broad substrate spectrum [78,156]. It also possesses the SE14 domain, built with 
8 consecutive repeats of a tetradecapeptide, essential for its cytosolic retention and for interaction 
with Tau [20]. Moreover, its N terminal nuclear export signal (NES) is stronger than its nuclear 
localization signal (NLS), leading to a predominant presence of HDAC6 in the cytosol. Both signals 
control the cytoplasmic-nuclear shuttling process of HDAC6. 
 
  To carry out its nuclear function, HDACs deacetylate histones modifying the packaging of the genetic 
material, however, HDAC6 also has a C-terminal zinc-finger ubiquitin-binding protein domain (ZnF-
UBP) namely BUZ domain, that mediates the direct binding to DNA, regulating gene transcription. 
Besides, the ZnF-UBP domain is composed by a conserved cysteines and histidines repeat, also present 
in a group of proteins called ubiquitin-specific proteases, which allows HDAC6 to interact with mono- 
and poly-ubiquitinated chains, present in ubiquitinated proteins and in ubiquitin-interacting proteins 
[183,179,180]. This feature highlights the wide magnitude of the HDAC6 interactome, where a large 
variety of molecules can bind to HDAC6 dependently or independently of its catalytic function [244].  
For this reason, HDAC6 is considered a crucial protein to link two cell signalling systems, mediated by 
acetylation and ubiquitination [244,31,216].   
1.3. General functions of HDAC6 
  Due to the predominantly cytosolic localization of HDAC6, this enzyme is able to regulate several 
important biological processes such as immune response, lymphocyte activation, immune synapse 
organization, cell adhesion, migration, proliferation, survival, and differentiation through both 
deacetylase- and ubiquitin-dependent mechanisms [244,134,31,216]. HDAC6 is also involved in 
various pathological disorders, including autoimmunity and inflammation (autoimmune and Dextran 
Figure 1.2. HDAC6 structure. HDAC6 protein is composed by the following domains. NLS: Nuclear localization 
signal, NES 1 and 2: Nuclear export signals 1 and 2, DD1 and DD2: functional deacetylase domains 1 and 2, DMB: 
dynein motor binding domain, SE14: cytoplasmic anchoring motifs, BUZ: Binder of Ubiquitin Zing finger domain. 
The corresponding amino acid (aa) sequence is showed below each domain by a range of numbers. Adapted from 
Li et al 2013 and Ageta-Ishihara et al 2013 [134,2].  
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sodium sulphate (DSS)-induced colitis, autoimmune arthritis, and encephalomyelitis) viral infections 
(Human Immunodeficiency Virus (HIV), influenza A virus (IAV), Sendai virus (SeV)), neurodegenerative 
diseases (Parkinson and Alzheimer) and tumour progression and metastasis (solid and haematological 
tumours) [75].  The role of HDAC6 in relevant physiological processes is summarized in the following 
chart (Figure 1.3). 
 
 
 
 
 
 
 
 
 
 
1.3.1. Deacetylase-dependent functions  
  The first characterized HDAC6 substrate was tubulin, which is acetylated at lysine 40 (Lys40) [91,184] 
[151]. HDAC6 enzymatic inhibition or downregulation results in tubulin acetylation, which enhances 
the stability of microtubule (MT) network and the binding of the two principal molecular motors of the 
cell, kinesin-1 and dynein, responsible for the anterograde and retrograde transport, respectively 
[7,115,272]. HDAC6 also binds to the dynein-activator complex, called dynactin. HDAC6 function is 
necessary to transport of misfolded protein aggregates (aggresomes) to proteasomes or lysosomes for 
degradation, avoiding cell toxicity [115,272,107,98,32].     
  One of the best characterized HDAC6 substrates is cortactin, a filamentous (F)-actin binding protein, 
which promotes actin polymerization and microfilament branching. Acetylated cortactin has 
diminished F-actin binding, influencing actin-mediated cellular processes such as endocytosis, 
migration, chemotaxis, adhesion or intracellular transport [268,140]. Besides, HDAC6 is able to 
regulate in a coordinate manner the intersection between microtubule cytoskeleton and actin 
filaments by the interaction with mediator proteins called formin homology proteins, mDia1 and 
mDia2 [56,19]. Other mediator proteins are septins, which are cytoskeletal guanosine triphosphatase 
proteins involved in providing a physical scaffold for HDAC6 to achieve MT deacetylation [2]. For these 
reasons, HDAC6 is considered as a crucial regulator of cell motility, able to connect both actin and 
Figure 1.3. Functions of HDAC6 in physiological processes. Cellular functions are indicated in boxes, where 
HDAC6-interacting proteins implicated in particular cellular functions are listed.  
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tubulin cytoskeletons. In fact, HDAC6 deregulation has been described in many tumours due to its 
implication in cytoskeleton, not only in cell progression, but also in angiogenesis and metastasis 
[91,184,3,76,103,136]. 
  HDAC6 deacetylates HSP90 changing its activity, which is implicated in the regulation of many 
fundamental cell processes. HSP90 acetylation at Lys294 favours its dissociation from its co-chaperone 
p23, promoting the instability of many HSP90-interacting proteins involved in cell growth and survival 
[202,110,13,116]. New HDAC6 substrates have been characterized in last years and are summarized in 
Table 1.1. 
Table 1.1. List of HDAC6 substrates. The table shows new non-histone HDAC6 client proteins, lysine residue 
susceptible of acetylation, related function and references.  
 
 
1.3.2. Ubiquitin-dependent functions  
  Through its BUZ domain, HDAC6 interacts with mono- and poly-ubiquitin chains, with a preferential 
binding for K63-linked ubiquitin chains [179,180]. For this reason, this protein participates in the 
formation of aggresomes, which transiently store toxic misfolded proteins (ubiquitinated protein 
aggregates). Besides, HDAC6 participates in the retrograde transport of aggregates along MT to be 
degraded by the primary quality control mechanism of the cell, the Ubiquitin-Proteasome System 
(UPS) [98,256,30,32]. HDAC6 also mediates the stability of ubiquitinated aggregates through its 
molecular association with the USP chaperone p97/valosin-containing protein (p97/VCP) and HSP90 
[32,58]. Ubiquitinated protein aggregates are subsequently disrupted by p97/VCP machinery from 
Substrates Deacetylated 
residues 
Related function References 
α-tubulin K40 IS formation, virus infection, cell migration 
and chemotaxis 
[91,151,220,243,36] 
Cortactin K87/124/161/189/198/ 
235/272/309/319 
Regulation of actin filaments, cell motility, 
fusion of vesicles 
[268,127] 
HSP-90 K294 kinase activation and macropinocytosis [116,110] 
Tat K48 Suppression of HIV transactivation [92] 
RIG-I K858 and K909 Viral RNA recognition [49,137] 
Ku70 K539/542 Suppression of apoptosis [232] 
β-catenin K49 Gene transcription activation [271,135,145] 
Peroxiredoxin-1 and 2 PrxI (K197) 
PrxII (K196) 
Redox regulation [187] 
Survivin K129 Anti-apoptotic function [207] 
MYH9 - Actin-binding regulation [267] 
HSC70 - Protein folding [267] 
DNAJA1 - Protein folding [267] 
HSPA5 K447 Suppression of breast cancer metastasis [45] 
HMGN2 K2 Gene transcription and breast cancer growth [153] 
Sam68 - Alternative splicing [167] 
14-3-3ζ K49/120 Suppression of growth and survival signalling [159] 
Tau - Neurodegeneration [39,155,133] 
Microtubule-associated 
protein 1 light-chain 3 
(LC3b) 
- Autophagy 
[138] 
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HDAC6 to deliver them to the proteasome for degradation, which promotes HDAC6 recycling [29]. In 
some situations, proteasomes are disrupted or overloaded, and aggresomes can be cleared by 
autophagy in a specific process called aggrephagy [98,58,186]. In this regard, HDAC6 is responsible for 
the dynein-mediated centripetal transport through MT of altered organelles and protein aggregates, 
concentrating them in perinuclear regions near the Microtubule Organizing Center (MTOC), where 
lysosomes are usually located [259,112,99]. Tubulin acetylation at Lys40 increases the recruitment and 
mobility of dynein through MT, enhancing the transport [59,203]. Therefore, HDAC6 has an important 
role in ubiquitin-selective quality-control autophagy, controlling the actin and tubulin networks [127]. 
Selective autophagy exclusively eliminates specific cellular components, as organelles like 
mitochondria (mitophagy) or unfolded protein aggregates (aggrephagy) [127,268,129,74,231]. 
Although HDAC6 is not required for autophagy induction, its deacetylase activity over cortactin is 
involved in autophagosome maturation. Deacetylation of cortactin induces the local assembly of actin 
microfilaments necessary for autophagosome fusion with the lysosome [127]. However, this is not 
dispensable for starvation-induced autophagy. SQSTM1/p62 interacts with HDAC6 and recruits F-actin 
filaments near HDAC6, promoting their deacetylation and the subsequent autophagosome-lysosome 
fusion [262]. Interestingly, the ubiquitin-like interferon (IFN)-stimulated gene 15 (ISG15) is able to 
interact with the BUZ domain of HDAC6 due to the structural similarity between K63-polyUb and ISG15 
post-translational modifications (PTMs), labelling proteins for autophagic degradation [166].  
  HDAC6 forms a complex with HSP90, p97/VCP and heat shock transcription factor 1 (HSF1), which is 
disrupted in the presence of misfolded proteins due to the binding of HDAC6 to ubiquitinated 
aggregates. Available HSF1 activates the heat shock response and aggregates are degraded in the 
proteasome, highligthting the HDAC6 ability to sense cellular stress [32,107]. The roles of HDAC6 in 
aggresome formation, aggrephagy, autophagy, mitophagy and Heat Shock response are 
schemmaticaly illustrated in Figure 1.4. 
  On the other hand, the lack of HDAC6 impairs mitofusin 1 deacetylation, which blocks the 
mitochondrial fusion induced by glucose deprivation, causing an excess of reactive oxygen species 
(ROS) responsible of cellular oxidative damage [126,11]. It has been reported other role of HDAC6 in 
the mitochondria by its interaction with parkin and HSP70, regulating the homeostasis of this organelle 
through the control of mitophagy [128,104]. Hence, HDAC6 is an essential player of cell homeostasis 
because of its regulation not only of the cross-talk between the two main cellular degradation systems, 
the autophagy and the proteasome, but also of mitochondrial metabolic balance [98,57,186,72,104]. 
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1.4. Regulation of HDAC6 
  There is growing evidence regarding the regulation of the HDAC6 activity that encompasses post-
translational modifications (PTMs), such as phosphorylation and acetylation, and RNA silencing by 
microRNAs. These mechanisms are able to control the levels of both cytoplasmic and nuclear HDAC6.  
1.4.1. Phosphorylation 
  Phosphorylation has been broadly observed to improve the deacetylase activity of HDAC6. For 
instance, phosphorylation at serine 22 (Ser22) of HDAC6 by the glycogen synthase kinase 3 (GSK3β) 
Figure 1.4. HDAC6 controls the principal clearance mechanisms of the cell. HDAC6 is involved in the regulation 
of aggresomes, proteasomes, Heat Shock response (HSR), and selective autophagy through the control of actin 
and tubulin networks and HSP90. (1) HDAC6 BUZ domain binds ubiquitinated protein aggregates and promotes 
aggresome formation to avoid cell toxicity. (2) HDAC6 is able to transport aggresomes through the MT due to its 
binding to the molecular motor dynein. Aggresomes are concentrated near the MTOC, where proteasomes are 
located. (3) HDAC6 binds to autophagosome-contained ubiquitinated substrates (protein aggregates and 
damaged mitochondria) and is implicated in their dynein-mediated transport to MTOC areas, where lysosomes 
are accumulated. Autophagy receptors p62 and NBR1 recognize protein aggregates and BNIP3L/NIX receptors 
detect damaged mitochondria by theirs UBA domains, whereas their LIR domains bind to the membrane 
autophagosome marker LC3. Acetylation of MT enhances dynein transport. (4) HDAC6 transfers aggresomes to 
the proteasome to be degraded and deacetylates HSP90 to start an HSR. Phosphorylation of HSF1 leads its 
nuclear import to initiate the transcription of HSP genes (HSP70, 40 and 27) (5) HDAC6 recruits cortactin to 
ubiquitinated substrates, whereas p62 asembles F-actin. HDAC6 deacetylates cortactin, promoting actin filament 
polymerization and branching and the subsequent autophagosome-lysosome fusion. Cortactin acetylation 
impairs this fusion. Adapted from Banreti et al 2013 and Richter-Landsberg et al 2013 [16,206]. 
38 
 
enhances its enzymatic activity, regulating mitochondrial transport in hippocampal neurons [47]. 
Similar results have been detected at Ser1035 of HDAC6 by the activation of epidermal growth factor 
receptor (EGFR)-RAS-RAF-MEK-ERK signalling axis in vivo, whereas ERK-1 is able to phosphorylate 
HDAC6 at threonine 1031 (Thr1031) and Ser1035 for the regulation of cell motility in vitro [254]. Casein 
kinase II (CK2) phosphorylates HDAC6 at Ser458, enhancing its activity during the formation and the 
clearance of aggresomes [251]. HDAC6 is also phosphorylated at unknown residues by G protein-
coupled receptor kinase 2 (GRK2) [119], Aurora A kinase [196], and protein kinase C isoform ζ (PKCζ) 
[61]. Moreover, SeV entry activates PKCα activity, which phosphorylates HDAC6, promoting the 
deacetylation and nuclear translocation of β-catenin to induce antiviral response [271].  
1.4.2. Acetylation 
  HDAC6 can be modified by acetylation, affecting its deacetylase activity. Currently, it remains 
unknown whether HDAC6 is able to acetylate itself. Acetyltransferase p300 is responsible for HDAC6 
acetylation at Lys16, imparing its tubulin deacetylation and Sp1 transcriptional activities [84]. 
Acetylation of HDAC6 changes its subcellular localization because this PTM breaks the interaction 
between HDAC6 and importin-α, promoting the cytosolic retention of HDAC6 and the subsequent 
inability to deacetylate histones [141].  
1.4.3. Regulators 
  It has been reported that several regulators interact with HDAC6 to directly inhibit its deacetylase 
activity. For example, tubulin polymerization-promoting protein-1 (TPPP/p25) binds to HDAC6, 
inhibiting its deacetylase activity on tubulin and β-catenin [238,215]. Paxillin also inhibits HDAC6 
tubulin deacetylation, regulating Golgi structure and polarized migration [54]. The deubiquitinating 
enzyme CYLD negatively regulates HDAC6 activity on tubulin, which affects cell-cycle progression [253]. 
However, inactivation of HDAC6 by CYLD promotes ciliogenesis [265]. Mdp3 blocks HDAC6 function, 
promoting the acetylation of tubulin and the subsequent stabilization of microtubules [235]. The 
microtubule-associated protein tau inhibits HDAC6 deacetylase function [190]. Ran-binding protein M 
(RanBPM) interacts with HDAC6, imparing its deacetylase function, which favours aggresome 
formation [212]. On the contrary, absence of p62 causes an enhanced deacetylase activity of HDAC6 
on tubulin and cortactin, necessary for the engulfment of aggresomes into autophagosomes [262].  
1.4.4. microRNA 
  Numerous microRNAs regulate HDAC6 expresion and function, such as miRNA-22 [90,147], miRNA-
26a [130], miRNA-221 [9], miRNA-433 [224,250,147] and miRNA-548m [143]. 
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1.5. HDAC6 functions in the immune system 
1.5.1. Role of HDAC6 in adaptive immunity 
  The regulation of tubulin cytoskeleton by HDAC6 is important in the cognate immune synapse (IS) 
between a T helper cell and an antigen presenting cell (APC) [220]. Acetylated microtubules are 
concentrated at the T cell contact area with APCs, surrounding CD3 and lymphocyte function-
associated antigen 1 (LFA-1) clusters. After antigen-specific engagement of T cell receptor (TCR), a 
transient deacetylation of microtubules is induced at early times, followed by their subsequent 
acetylation at late times. Early deacetylation is carried out by HDAC6, which specifically translocates 
and concentrates to APC-T cell contact sites. Moreover, overexpression of HDAC6 disorganizes CD3 
and LFA-1 clusters, translocation of microtubule organizing centre (MTOC), and IL-2 secretion, all 
necessary for a proper IS. However, overexpression of HDAC6-DD mutant does not exert the same 
effect and Trichostatin A (TSA) treatment reverts the effect, indicating the enzymatic contribution of 
HDAC6 during IS formation. 
  HDAC6 is also important for the chemotactic migration of the lymphocyte [36].  There is dynamic 
subcellular location of HDAC6 in the leading edge of lamellipodium and in the rear edge of uropod on 
migrating T cells. HDAC6 overexpression increases chemokine-mediated T cell migration and 
transendotelial migration under shear flow, whereas HDAC6 silencing diminishes T cell chemotactic 
capacity. The use of specific chemical inhibitors of HDAC6 and enzymatic activity mutants reveals that 
HDAC6 regulation of lymphocyte chemotactic migration is not mediated by its catalytic activity, but by 
an scaffold role.  
  HDAC6 plays a role in cytotoxic CD8+ T lymphocytes during DNA virus infection [176]. In vivo 
immunization studies reveal a defective cytotoxic response in HDAC6 knockout mice. CD8+ T 
lymphocyte adoptive transfer into Recombination-activating gene 1 (Rag1-/-) recipient mice 
demonstrates the specific impairment of cytotoxic response against vaccinia virus infection. The 
altered dynamics of lytic granules of HDAC6 deficient CD8+ T lymphocytes is due to the lack of binding 
of HDAC6 to kinesin-1-dynactin, involved not only in the altered terminal transport of these granules 
to the synapse but also in their defective exocytosis [176].  
  HDAC6 exerts a role in the adaptive response of CD4+ T cells in different autoimmune and 
inflammatory disorders such as colitis and cardiac-allograft rejection by the enhanced transcription of 
Foxp3 [52]. HDAC6 deficient CD4+ T cells express higher levels of the transcription factor Foxp3, 
deregulating the balance between pro- and anti- inflammation in favour of regulatory T cells, 
promoting a protective role during DSS-induced and autoimmune models of colitis and fully MHC-
incompatible cardiac allograft rejection [52].  Accordingly, mice treated with HDACi show acetylated 
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Foxp3, which increases its DNA-binding capacity, enhancing Treg differentiation [18]. HDAC9-deficient 
mice display HSP70 acetylation, which prevents its degradation by proteasome and results in its 
accumulation, enhancing HSP70-Foxp3 interaction that stabilizes Foxp3 [53]. Both observations could 
be also extended to HDAC6-deficient mice. Interestinglly, HSP90 acetylation impairs its binding to Aryl 
Hydrocarbon Receptor (AHR), which affects the AHR ability to recognize ligands and the subsequent 
activation of AHR signalling [110]. Activation of AHR signalling pathways, enhances in vitro Th17 
polarization [62]. Hence, Th17 response might be decreased in HDAC6 absence. 
1.5.2. Role of HDAC6 during viral infections 
  Through acetylation, HDAC6 controls microtubule stability and consequently the kinesin and dynein-
dependent transport of various cargoes. Cargo movement mechanisms are co-opted by different types 
of pathogens, including viruses and intracellular bacteria. Thus, HDAC6 becomes a crucial intermediary 
involved in viral fusion, entry, nuclear shuttling, replication, assembly and egress [249,165,93]. 
Likewise, HDAC6 controls the mechanisms involved in the elimination of these pathogens. For 
example, HDAC6 is involved in CD4+ T lymphocytes function during the human immunodeficiency virus 
(HIV) infection [243].  The binding of the viral envelope glycoprotein gp120 to permissive CD4+ T cells 
increases acetylated tubulin. HDAC6 overexpression inhibits tubulin acetylation, preventing viral 
envelop-mediated cellular fusion and infection, without affecting the expression and co-distribution 
of viral receptors. Consequently, the diminished enzymatic activity of HDAC6 favours HIV-1 infection 
and syncytia formation [243]. However, the activity of this protein in the case of influenza A virus (IAV) 
seems to play a dual role. On one hand, it has been described that viral capsids mimic unfolded-protein 
aggregates to take advantage of the host cell aggresome formation to disassemble and successfully 
eliminate viral capsids to continue the infection [15]. On the other hand, it has been observed that 
microtubules deacetylated by HDAC6 hamper the viral cycle, preventing trafficking of viral components 
through the cytoskeleton, which is necessary for viral assemble sites in the host plasma membrane 
and their posterior spreading to neighbouring cells [93]. Besides, caspase-3 cleaves HDAC6 in IAV-
infected cells, removing its BUZ domain, although the consequence in IAV infection remains unknown 
[94]. 
  Other HDAC6 substrates different from cytoskeletal proteins participate in viral pathogenesis like the 
HIV-1 transactivator of transcription protein (Tat) and the Retinoic acid Inducible Gene-I (RIG-I) 
[49,137,92,226]. HDAC6 regulates HIV viral replication by the deacetylation of Tat at transcriptional 
level, imparing the binding of Tat to cyclin T1, which inhibits viral transactivation [92,226]. In addition, 
HDAC6/”apolipoprotein B m-RNA-editing enzyme-catalytic, polypeptide-like 3G” (A3G) complex 
interacts with Viral infectivity factor (Vif) for its autophagic degradation, inhibiting HIV-1 spreading 
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[245]. Recognizion of 5´ppp-dsRNA by RIG-I induces its self-oligomerization via repressor domain (RD) 
of two RIG-I molecules, initiating a conformational change. RIG-I specific deacetylation at residues K858 
and K909 by HDAC6 induces RIG-I “signalling on” conformation, an essential step to engage 
Mitochondrial anti-viral-signalling protein (MAVS) and to activate the anti-viral response through 
Interferon responding factor 3 (IRF-3)-Interferon-β (IFN-β) axis [137,49] (Figure 1.5).  Protein kinase C-
α (PKC-α) is activated by calcium changes, phosphorylating HDAC6 during SeV infection [271]. This PTM 
enhances HDAC6 enzymatic activity and thereby, mediating deacetylation of β-catenin, which works 
as co-activator of IRF-3 transcription [271] (Figure 1.5)  
  Protein kinase C-β (PKC-β) is also able to phosphorylate HDAC6 and enhaces its enzymatic function 
over β-catenin, promoting the transcriptional activation of IRF-3 and the subsequent production of 
type-I IFN in response to Toll-like receptors 3 and 4 (TLR-3 and 4) agonists [46].HDAC6, through its BUZ 
Figure 1.5. Proposed model of HDAC6 functions in pathogen sensing. (1) Calcium changes triggered by viral 
entry activates PKCα, which phosphorylates HDAC6, increasing its deacetylase activity on β-catenin. This protein 
is imported in the nucleus together with IRF-3 to activate the interferon response. (2) After RNA viral infection, 
5´ppp-dsRNA alerts to an unknown kinase, which activates HDAC6 by phosphorylation. HDAC6 deacetylates K858 
and K909 residues of RIG-I, promoting its dimerization and binding of 5´ppp-dsRNA, which is necessary for the 
activation of MAVS signalling pathway. Then, IRF-3 and Nuclear factor-κB (NF-κB) initiate the interferon-β genetic 
transcription to alert the anti-viral host response. Adapted from Zheng et al 2017 [270]. 
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domain, directly associates with ubiquitinated NOD-like receptor (NLR) family, pyrin domain-
containing 3 (NLRP3), down-regulating the activation of NLRP3 inflammasome independently of 
deacetylase activity [95]. Finally, the observation that HDAC6-deficient mice are more susceptible to 
RNA virus infections is in accordance with the observed increased resistance of overexpressing-Hdac6tg 
mice to avian H5N1 virus, highlighting the role of HDAC6 as a new regulator of the innate immune 
defence [249,93,165].  
1.5.3. Role of HDAC6 during bacterial infections and TLR-activation 
  Recent evidence supports a role of HDAC6 in bacterial infections. Hence, bladder-infiltrating 
neutrophils of HDAC6-deficient mice during uropathogenic Escherichia coli (UPEC) infection display 
higher bacteria titres [132]. Recently, new molecular mechanisms have been characterized to be 
involved in inflammatory processes caused by bacterial TLR-agonists such as LPS, suggesting a wider 
implication of HDAC6 in innate immunity [171,261,46]. HDAC6-deficient mice are protected from LPS-
induced septic shock compared to wild-type mice, due to a defective pro-inflammatory response in 
the absence of HDAC6 [46]. Inhibition of HDAC6 expression and HDAC6-deficiency cells reduce pro-
inflammatory cytokines after TLR-stimulation, although it is not clear whether deacetylase activity is 
directly involved in all cases [171,261,46,137,49]. However, it has been observed that HDAC6 hampers 
the formation of MyD88-TRAF6 signalling complex, suppressing TLR-4 mediated activation [97]. Tat 
protein in primary mouse astrocytes induces a severe neuroinflammation, and the silencing of HDAC6 
reduces levels of chemokines, cytokines and adhesion molecules, diminishing the activation of NF-κB 
and AP-1 Transcription Factors (TF) responsible of pro-inflammatory response [226]. Therefore, 
increased expression of HDAC6 protein after TLRs activation and viral infections could serve as a 
protective cellular strategy to deacetylate microtubules and actin networks for avoiding microbial 
spreading [249,226].  
2. Listeria monocytogenes 
  Lm was identified in Cambridge in 1926 as a lethal disease which displayed a pronounced 
monocytosis, an increased number of monocytes in circulating blood, in rabbits and guinea pigs caused 
by a Gram-positive bacterium referred to as Bacterium monocytogenes [163]. Another report in South 
Africa described also a Gram-positive bacterium responsible of Tiger River Disease in wild gerbils. 
Prominent necrotic lesions in liver were described and the microorganism was called Listerella 
hepatolytica, in honour to the surgeon Joseph Lister. New studies concluded both pathogens were the 
same, and the final name was designated as Listeria monocytogenes. 
  The genus Listeria contains 17 species which are able to grow at low temperatures and are very 
resistant to environmental stresses, such as low pH and hight salt concentrations, remarking the 
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concerns for the food industry [181]. Besides, Listeria spp. thrives in a huge range of environments, 
can survive in water, soil and detritus and is able to infect mammalian hosts due to a particular 
adaptability to cross several host barriers, mediated by a vast number of regulatory factors. Lm is a 
non-spore-forming facultative anaerobic rod-shaped bacterium, which can be flagellated under 30°C. 
The systematic sequencing of the bacterial genome of Lm has revealed a genome size of 2,944528 base 
pairs coding for 2,853 proteins [161,73]. However, the most important virulence factors of this 
pathogen has been characterized using biochemical and molecular genetic tools. Besides, murine 
listeriosis has been widely used as a forefront model for the study of host-pathogen interaction and 
innate and adaptive immune responses to intracellular bacterial infection over the past 20 years 
[185,80,175,242]. 
2.1. Listeria monocytogenes pathogenesis 
  Although Lm was first reported to infect rabbits and gerbils, this bacterium has an unusually broad 
host range, infecting almost every mammals, including humans [33]. This intracellular Gram-positive 
bacterium causes listeriosis, a self-limiting gastroenteritis in healthy individuals, but can cause severe 
and systemic infection in immunocompromised individuals, the elderly, pregnant women and new-
borns due to its ability to cross the blood-brain barrier and placenta [185,214]. Immunocompromised 
individuals suffer septicaemia and meningitis, pregnant women in third trimester develop 
chorioamnionitis and infectious of the foetus which can lead to septic abortion [12]. Humans are 
exposed to the infection of this bacterium by ingesting contaminated food, usually unpasteurized or 
incompletely cooked meats [214]. Although Lm is considered a food-borne intracellular bacteria that 
causes a moderately low number of infections per year (listeriosis to 23.150 people worldwide in 
2010), the mortality among infected individuals is strikingly high (30%) being responsible of 
approximately 6,900 deaths every year [50]. 
2.2. Infective cycle of Listeria monocytogenes 
2.2.1. Bacterial entry 
  Despite most studies have used intravenous or intraperitoneal inoculation of L. monocytogenes, the 
natural route of infection is through the gastrointestinal tract [125]. Lm can replicate in the cytosol of 
several host cell types such as epithelial cells and macrophages [194]. The efficiency of bacteria uptake 
can vary depending of cellular type, e.g. macropahges and other phagocytic cells internalize up to 20 
bacteria per cell, whereas fibroblast cell lines internalize less than one bacterium [33]. Lm co-opts the 
cellular receptor-mediated endocytosis machinery to entry into non-phagocytic cells, while Lm entry 
in phagocytic cells is actively mediated by immunoglobulin receptor-mediated engulfment of 
opsonized bacteria [43]. After the ingestion of this pathogen, intestinal epithelial cells are infected by 
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the interaction of the surface bacterial protein internalin A (InlA) with the extracellular domain of the 
epithelial E-cadherin of the host cell through a zipper-like mechanism [69,188]. The ability of this 
bacterium to infect intestinal epithelial cells is quite variable among mammals [111]. For example, mice 
have a limited susceptibility to intestinal infection due to a single amino-acid difference between 
human and mouse E-cadherin [124]. Upon this interaction, Lm is able to traverse the epithelial cell 
layer and disseminate in the bloodstream towards other organs. This bacterium has tropism in 
particular for spleen and liver, where not only is internalized by splenic and hepatic macrophages, but 
also by hepatocytes using the bacterial protein internalin B (InlB) to interact with the hepatocyte 
growth factor receptor (HGFR), mediating the internalization via Phosphatidyl Inositol 3-phosphate 
(PI3)-kinase activation [42,221]. Hence, internalins A and B are considered strategic tools of Lm for 
adhesion and invasion of host cells, increasing the level of bacteria internalization by non-professional 
phagocytic cells. The family of internalins is composed of 25 members, can be anchored to the cell 
wall, associated or secreted for regulating a vast number of virulence-related function [22]. InlC seems 
to affect the rigidity of the cytoskeleton and innate immune signalling, InlP is implicated in placental 
invasion and InlJ has unknown function and is only expressed in vivo [201,211,68]. In addition to InlA 
and B, both fibroblasts and monocytes use the high affinity immunoglobulin gamma Fc receptor I 
(FCGR1A or CD64) as Lm entry receptor without the opsonisation step [189]. 
2.2.2. Bacterial tools to evade the autophagy system 
  From the first hours of infection, professional phagocytic cells trap bacteria in the blood and target 
organs, spleen and liver, exerting a degree of control on bacterial growth [236]. Liver macrophages and 
hepatocytes are the preferential hosts for Lm, although other cell types are also infected such as 
epithelial cells and other phagocytic cells. Upon entry, bacterium is internalized inside a phagocytic 
vacuole and Lm is eliminated by fusion of the phagosome with lysosomes. Interestingly, phagosome-
contained bacteria are also eliminated by the action of reactive oxygen species (ROS) and nitric oxide 
(NO), respectively produced by NADPH oxidase 2 (NOX2) and inducible NO synthase (iNOS) [144] 
[222](Figure 1.6). However, the majority of bacteria escape from the phagosome into the cytoplasm 
through the action of the cholesterol dependent family of cytolysine listeriolysin O (LLO) and two other 
phospholipases C (PLCs), a phosphatidylinositol-specific PLC (PlcA) and a broad spectrum one (PlcB), 
which causes vacuolar rupture [17,71,148,35,23]. In HeLa cell line, escape from the vacuole is 
exclusively mediated by both phospholypases [148].  
  Lm is able to replicate in spacious Lm-containing phagosomes (SLAPs) in some macrophages [23]. The 
formation of SLAPs depends on microtubule associated protein light-chain 3 (LC3)-mediated 
phagocytosis combined with intermediate levels of LLO expression, which dampen the phagosome 
acidification, resulting in Lm proliferation without phagosomal rupture [120]. ActA is also an essential 
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bacterial protein to evade the cell host autophagy. In this regard, ΔactA bacteria is ubiquitinated and 
subsequently recognized by ubiquitin-binding receptors p62 and nuclear dot protein 52 (NDP52) and 
incorporated in LC3+-compartments [266,160]. Indeed, cellular factors that alter ActA localization on 
the bacterial surface could dampen cell-to-cell spreading of Lm, such as the case of type I IFN receptor 
1 (IFNAR1)-deficient mice, which display lower bacterial burden [63,8,230,182]. Cell host Major Vault 
protein (MVP) is hijacked by bacterial InlK to avoid ubiquitination and the subsequent autophagy [60]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3. Lm-induced cellular changes 
  In the cytoplasm, Lm replicates in a more benign and nutrient-rich environment and is able to infect 
neighbouring cells [193,28,178]. Lm is able to replicate and survive in cell host cytosol without causing 
Figure 1.6. Overview of infective cycle of Lm in a phagocytic cell. Lm enters the cell by membrane vesicle 
phagocytosis. Using LLO is able to escape from the vesicle to the cytoplasm. 1. Once in the cytosol, bacteria are 
rapidly ubiquitinated and consequently recognized by autophagy proteins, such as LC3, p62, ATG family. These 
proteins are required  to initiate the phagophore formation, a double-membrane vesicle where ubiquitinated 
bacteria are engulfed. Inside phagosome, the action of ROS, Reactive Nitrogen Species (RNS) and lytic enzymes 
of the lysosome constribute to bacterial degradation in a continuous process of phagosome-lysosome pH 
acidification. However, a percentage of bacteria can avoid this process by the expression of LLO and two 
phospholypases C (PlcA and B), which are activated with the lower pH, allowing Lm to form a pore in the 
phagosome membrane to evade its degradation. By the use of ActA, Lm travels through the cytosol polymerizing 
cellular actin, drawing characteristic acting comets. 2. Besides, this bacterium can avoid the autophagy by 
another mechanism, expressing InlK, which recruit the mammalian MVP to block bacteria ubiquitination. The 
use of ActA protein is also responsible of the formation of actin cage, to avoid autophagy. Once in the cytosol, 
Lm proliferates due to permissive environmental conditions. 3. Moreover, actin-polymerizing bacteria are able 
to infect neighbouring cells without leaving the cytoplasm, making long actin rockets in a process named 
paracytophagy.  
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Figure 1.7. Lm infective cycle in a non-phagocytic cell and in some macrophages. Lm enters epithelial cells 
throught receptor-mediated endocytosis and the majority of bacteria scape from the vacuole. By trancytosis, 
vacuole-contained Lm can pass across the cell in globet cells, whereas Lm can replicate in spacious Lm-containing 
phagosomes (SLAPs) in some macrophages. Potent virulent factors as LLO, PlcA and PlcB  are involved in vacuolar 
escape. Upon vacuolar escape, Lm is able to polymerize actin by using the actin-assembly-inducing protein ActA, 
enhancing the spreading to neighbour cells. The pore-forming activity of LLO triggers numerous changes in host 
cell, such as histone modifications, desumoylation, mitochondrial fission, ER stress and lysosomal 
permeabilization. Host gene expression is controlled by LntA of Lm, which interacts with BAHD1 complex to 
derepress ISGs. This provokes Sirt2 shuttle into the nucleus to deacetylate histone 3 at K18, that changes 
chromatin packing and the subsequent gene expression and DNA damage. The host cell fights against infection 
by upregulating antibacterial effectors, such as ISG15 and its covalent incorporation to ER and Golgi proteins (a 
process namely ISGylation), which modulates cytokine secretion. From Radoshevich et al 2018 [198]. 
 
cell death because of its unique intracellular lifestyle. This hallmark is due to additional functions of 
LLO, different from its pore-forming activity, which cause multiple changes in organelle morphology 
and function before LLO plasma membrane entry and after its cellular internalization [83] (Figure 1.7). 
LLO causes a non-cannonical mitochondrial fission, independent of dynamin-related protein 1 (DRP1) 
and accompained by smaller and rounded mitochondria, which seems to enhance bacterial division 
[227-229]. Upon infection, this cytolysin induces Endoplasmic Reticulum (ER) stress and Unfolded 
Protein Response (UPR), responsible for upregulating chaperones, blocking translation into the ER and 
increasing ER folding capacity [192]. Animals with a defective UPR succumb to Lm infection [106]. 
Finally, LLO alters lysosomal membrane permeability and homeostasis, causing a release of cathepsins 
into cytosol [146].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  However, the host cell fights against infection by upregulating IFNs, cytokines and antibacterial 
effectors, such as IFN-stimulated genes (ISGs) [189]. In this regard, an ubiquitin-like protein, called IFN-
stimulated gene 15 (ISG15), is induced during Lm infection and its covalent incorporation to newly-
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synthesized proteins of ER and Golgi (namely ISGylation), increases cytokine secretion to counteract 
infection [200]. Lm dampens sumoylation of host cell proteins by degradation of SUMO-conjugating 
enzyme UBC9 required for this kind of PTM [204,96]. Lm is able to mimic receptor-mediated 
endocytosis engagement, promoting the phosphorylation and ubiquitination of the cytosolic domain 
of receptors E-cadherin and Met and their subsequent internalization, co-opting the clathrin 
machinery of the host cell [248,26]. Lm also promotes changes in histone PTMs, which changes the 
chromatin packaging and the subsequent access of transcription factors [81,82]. For instance, cell host 
sirtuin-2 is shuttled to the nucleus to deacetylase histone 3 at K18 [67]. A nucleomodulin-type of 
bacterial virulence factor namely nuclear-targeted protein A (LntA), controls host gene expression 
throught its interaction with the bromo adjacent homology domain-containing 1 protein (BAHD1) 
complex to derepress ISGs [122,123]. 
3.2.4. Intracellular and extracelular motility 
  Wiskott Aldrich Syndrome protein (WASP) is a nucleation promoting factor that interacts with the 
actin-related protein 2/3 (ARP2/3) complex to induce actin polimeryzation on host cell. Lm contains a 
surface-anchored protein, called actin-assembly inducing protein (ActA), which mimicks WASP to 
enable bacterial propulsion to neighbouring cells through the directional assembly of actin filaments 
(actin rockets) [113,121,37,28,225]. The canonical ARP2/3 complex is formed by 7 subunits: ARP2 and 
3 and ARPC1-5, and Lm co-opt different combinations of these subunits depending on the type of actin 
polymerization or branching required in every step, such as bacterial entry or actin comet tail 
formation [117]. However, vacuole-contained Lm can pass across the cell cytoplasm in globet cells by 
trancytosis, acting as a vacuolar bacterium for avoiding cytosolic immune detection [174]. Lm can also 
spread from cell to cell elongating filopods to adjacent cells without exiting the intracellular 
compartment by a process called paracytophagy, which exploits host cell efferocytosis for evading 
immune detection [157]. LLO induces membrane damage in actin protrusions, exposing 
phosphatidylserine, which is usually found in the inner membrane of the host cells, therefore adjacent 
macrophages capture protrusion-containing Lm [44]. 
3.2.5. Cellular immune response to infection 
  During food-borne infection, the majority of Lm is extracellularly attached to the surface of activated 
monocytes, although these cells are not a proliferation niche for bacteria [100]. However, monocytes 
increase CD64 expression during their transition to macrophages, which Lm uses as an entry receptor, 
thereby allowing intracellular bacteria to spread to the liver and spleen [101,41]. Resident Kupffer cells 
phagocytose Lm in the liver and the posterior necroptosis of these macrophages generates specific 
inflammatory mediators that activate liver repair processes, the mobilization of bone-marrow-derived 
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monocytes and awake the immune system [25]. Nevertheless, the early control of Lm burden largely 
depends on the innate immune response occurring in the spleen, which relies on two main cell 
populations of dendritic cells (DCs). On one hand, a subset of monocyte-derived DCs namely 
TNF/iNOS–producing DCs (Tip-DCs) has the ability to produce TNF-α and NO [219,236]. On other hand,  
CD8α+splenic conventional DCs (cDCs) are responsible for the final resolution of Lm infection through 
the presentation of bacterial-derived antigens to specific CD8+T cells to induce cytotoxicity 
[86,65,102]. Moreover, it has been reported that CD8α+ cDCs are the first splenic population 
responsible for the phagocytosis of bacteria in vivo [170]. However, the host cell of cytosolic Lm is able 
to develop a specific CD8+T cell response, which is crucial for the control of infection [40,154,79,10]. It 
has been reported that mutant LLO Lm strains are unable to develop CD8+ T cell adaptive response 
and, accordingly, CD8+ T cell memory against this pathogen [154,79,10]. 
3.2.6. Innate immune sensing of Lm 
  The response of dendritic cells (DC) to live Lm is mediated by Toll-like receptors (TLRs), nucleotide-
binding oligomerization domain (NODs)-like receptors (NLRs), and other cytosolic receptors and 
involves two signalling pathways: TLR-dependent and independent signalling [198,199].  Lm pathogen-
associated molecular patterns (PAMPs) are sensed on the cellular surface by TLRs 1, 2 and 6, whereas 
phagosomal-contained bacteria activate endosomal TLRs 2, 3, 7, 8 and 9.  TLR-3 mediates TRIF-
dependent signalling pathways and the rest of TLRs mediates a MyD88-dependent response. Both 
cellular pathways activate NF-κB signalling for the initiation of anti-bacterial host response. After 
phagosomal scape, Lm activates the inflammasome and cyclic GMP-AMP synthase (cGAS), which 
produces a host-specific cyclic dinucleotide (CDN) called cGAMP, that also activates the sensor 
stimulator of interferon (IFN) genes (STING) [237]. Passive release or active secretion by Lm of the 
bacterial 5´triphosphate RNA (5´-pppRNA) is sensed by retinoic acid-inducible gene I protein (RIG-I), 
which triggers the mitochondrial and peroxisomal forms of anti-viral-signalling protein (MAVs) [1,77]. 
These synergic pathways upregulate IFNs, cytokines and anti-bacterial effectors such as IFN-stimulated 
genes (ISGs). At early stage of infection, bacterial DNA is sensed by the cytosolic surveillance pathway, 
that includes STING, the serine/threonine-protein kinase TBK1 and the IFN regulatory factors (IRFs) 3 
and 7 [4,199]. This pathway induces the expression of ubiquitin-like protein ISG15, independently of 
IFN, and the conjugation of ISG15 to newly synthetized Endoplasmic Reticulum (ER) and Golgi proteins 
as a cellular mechanism for tagging proteins after infection [200]. Besides, Lm secretes a small 
dinucleotide namely cyclic di-AMP (c-di-AMP) that directly triggers STING pathway, leading to IFNβ 
production and activation of downstream signals that control the transcription of IFN target genes 
essential for antiviral and antibacterial responses [255,89,4,257]. However, the activation of innate 
immune pathways by c-di-AMP negatively activates T cell-mediated responses, reducing the clearance 
49 
 
of Lm after a reinfection [4]. Additionally, the liver enzyme called aldo-keto reductase family 1 member 
C13 (AKR1C13 or RECON) binds to c-di-AMP with higher affinity than STING. STING affinity for host 
CDNs is stronger than for c-di-AMP, balancing the signalling pathways triggered by c-di-AMP on favour 
of RECON [152]. Although TLR-1 and 2 and NOD1 are activated by Lm PAMPs to stimulate NF-κB 
signalling, RECON negatively regulates this pathway [152]. However, after bacterial CDN-RICON 
binding, the enzyme is inactivated, recovering the NF-κB signalling and Nitric Oxide (NO) production 
[152]. The complete molecular innate immune response to Lm is summarized in Figure 1.8. 
 
 
Although, the function of HDAC6 has been described in autoimmune, inflammatory and viral disease 
models, there is not much information about its role in the regulation of innate immunity during the 
infectious processes by non-viral pathogens, such as bacteria and protozoan. For this reason, this 
doctoral thesis is focused in the study of the role of HDAC6 in the innate immune host defence 
against Listeria monocytogenes infection and tentative molecular mechanisms involved. 
 
Figure 1.8. Innate immune sensing of Lm. Lm is sensed by TLRs 1, 2 and 6 in the plasma membrane and by TLRs 
2,3,7,8, and 9 in endosomes, triggering the TLR-signalling pathway and the nuclear import of NF-κB to induce 
genetic transcription of IFNs, cytokines and ISGs. Upon vacuolar escape of Lm, the cytosolic surveillance pathway 
is activated by bacterial DNA, 5´pppRNA and c-di-AMP, inducing STING, TBK1, RIG-I, mitochondrial and 
peroxisomal MAVs, IRFs 3 and 7 and RECON. From Radoshevich et al 2018 [198]. 
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2. OBJECTIVES  
 
  The general objective of this thesis aims to investigate the functions of HDAC6 during the 
innate immune response to the intracellular bacteria Listeria monocytogenes (Lm). The 
specific objectives are the following: 
 
1. Analysis of HDAC6 contribution to cellular mechanisms that eliminate intracellular 
bacteria by phagocytic cells 
1.1. Effect of HDAC6 absence in the intracellular pathogen clearance of dendritic cells  
1.2. Measurement of Lm load in HDAC6-deficient myeloid cells 
1.3. Determination of in vivo bacterial burden  
1.4. Evaluation of cellular clearance mechanisms of Lm  
1.5. Consequence of the lack of HDAC6 in the autophagy of Lm 
1.6. Effect of HDAC6 absence in the accumulation of autophagy marker p62  
1.7. Mechanism by which HDAC6 regulates autophagy of Lm 
 
2. Study of the role of HDAC6 in the activation of dendritic cell functions by bacterial 
infection and stimulation of TLRs 
2.1. Determination of pro-inflammatory gene expression  
2.2. Effect of HDAC6 in pro-inflammatory cytokine secretion after Lm infection 
2.3. Influence of HDAC6 in the microbicidal activity of iNOS 
2.4. Study of the expression of MHC co-stimulatory molecules on the membrane 
2.5. Function of HDAC6 in the activation of MAPK- and mTOR-signalling pathways 
2.6. Pro-inflammatory cytokine secretion after stimulation with TLR agonists 
2.7. Consequence of HDAC6 defect in the activation of TLR-signalling pathway  
2.8. Evaluation of the HDAC6 role in the in vivo TLR-dependent inflammatory response 
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3. MATERIAL AND METHODS 
1. Ethical Statement 
1.1. Mice procedures 
  Mice were housed under specific pathogen-free conditions at the Centro Nacional de Investigaciones 
Cardiovasculares Carlos III (CNIC), and experiments were approved by the CNIC Ethical Committee for 
Animal Welfare and by the Spanish Ministry of Agriculture, Food, and the Environment. Animal care 
and animal procedures license were reviewed and approved by the local Ethics Committee for Basic 
research at the CNIC Ethical Committee for Animal Welfare and the Órgano Encargado del Bienestar 
Animal (OEBA) del Gabinete Veterinario de la Universidad Autónoma de Madrid (UAM). This 
committee approved the document with an associated identification number PROEX 158/15 (CNIC 
04/15). 
1.2. Human samples 
  Buffy coats of healthy donors were received from the Blood Transfusion Center of Comunidad de 
Madrid, and all donors signed their consent for the use of samples for research purposes. All the 
procedures using primary human cells were approved by the Ethics Committee of the Hospital 
Universitario de la Princesa (HUP). 
2. Mice 
  Hdac6-/- mice were generated through targeting of exons from 10 to 13 by inserting a neomycin (Neo) 
and zeocin (Zeo) cassette, resulting in the disruption of the first catalytic domain of HDAC6 [70]. These 
mice were intercrossed on a C57BL/6 background to generate sex and age matched wild-type (wt) and 
knockout (KO). Mice used in this work were generously donated by Dr. Tso-Pang Yao (Department of 
Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, USA) in a mixed 
background Sv129-C57BL/6. After that, mice were inter-crossed on a C57BL/6 background 8 times 
more to ensure a purer C57BL/6 background. F8 inter-crossed on C57BL/6 background ensures over 
90% of the latter background. 
3. Genotyping of mice 
  In order to genotype these mice and check the homozygousity of the deletion of the first catalytic 
domain of HDAC6,  a PCR was performance with the two pairs of primers of the Table 3.1. 
 
 
                                                                                                    Material & Methods 
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Table 3.1. Genotyping primers. Table of primers used to genotype mice disclosed by gene name, sequence 5´-
3´ and size of the amplification product. (bp: base pair). 
Gene Sequence (5´-3´) Amplification product 
Int-9 CTGGTTCGTCTGAAG 350 bp 
Exo-10 GTGGACCAGTTAGAAGCC 
Zeo-1 CCATGACCGAGATCGGCGAGC 250 bp 
Zeo-3 CGTGAATTCCGATCATATTCAAT 
 
  The pair of primers Int-9/Exo-10 amplifies the wt allele (350 bp), whereas the pair of primers Zeo-
1/Zeo-3 amplifies the knockout allele (250 bp). These two pairs of primers were employed in PCR 
reactions using the genomic DNA from mouse tails as template DNA. Genomic DNA was obtained from 
mouse tails using the protocol of the reactive REDExtractc-N-Amp tissue PCR kit (Sigma). As controls, 
genomic DNA from wt, heterozygous and homozygous mice were used. The amplification protocol is 
showed in the Table 3.2.  
Table 3.2. PCR amplification protocol. Table of PCR cycles for genotyping mice disclosed by phase, temperature, 
time and number of cycles. 
Phase Temperature (°C) Time (min, s) Cycles 
1 95 3 min 1x 
 
2 
 
95 30 s 
55 30 s 30x 
72 1 min 
3 72 10 min 1x 
 
4. Bacteria strains 
4.1. Listeria monocytogenes strains 
  We used the Listeria monocytogenes EGD (BUG 600) strain, provided by Dr. Esteban Veiga (Centro 
Nacional de Biotecnología, CNB, Madrid). Red Fluorecent Protein-expressing Listeria monocytogenes 
(RFP-Lm) was provided by Dr Carlos Ardavín´s laboratory (Centro Nacional de Biotecnología, CNB, 
Madrid). BUG600 strain was grown in Brain Herat Infusion (BHI) broth. 
4.2. Salmonella enterica strain 
   Salmonella enterica serovar Thyphimurium strain SL1344 was provided by Dr. J. Garaude (Centro 
Nacional de Investigaciones Cardiovasculares, CNIC, Madrid). SL1344 strain was grown in Luria-Bertani 
(LB) broth supplemented with 50 μg/ml streptomycin (Sigma). 
4.3. Staphylococcus aureus strain 
  Staphylococcus aureus 132 (S. aureus) was purchased from Invitrogen. S. aureus strain was grown in 
BHI broth. 
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4.4. Escherichia coli K12 strain 
  Escherichia coli K12 strain DH5α (E. coli) was purchased from Invitrogen. DH5α strain was grown in LB 
broth supplemented with 50 μg/ml streptomycin (Sigma). 
  For phagocytosis experiments, Lm and S. aureus were grown overnight in BHI broth and E. coli and S. 
Thyphimurium in LB broth with shaking, diluted 1/50, and grown until log-phase (optical density 0.8-
1.2 at 600 nm) without shaking. Bacteria were washed with phosphate-buffered saline (PBS) to remove 
LB and BHI salts before addition to cells.  
5. Cell culture 
5.1. HEK293T cell line 
  The HEK293T cell line came from human embryonic kidney transformed with the large T antigen of 
SV40. The HEK293T cell line (ATCC) was cultured in Dulbecco´s Modified Eagle medium (MEM) (Sigma) 
containing 10% FBS (Invitrogen), 2 mM L-glutamine, 100 mg/ml penicillin and 100 mg/ml streptomycin.  
5.2. HEK Blue hTLR2 cell line 
  HEK Blue hTLR2 cell line (Invivogen), the HEK293 cell line expressing human TLR2, CD14 and NF-κB-
SEAP (secreted embryonic alkaline phosphatase) reporter gene was cultured in DMEM medium 
(Sigma) containing 10% FBS (Invitrogen), 2 mM L-glutamine, 100 µg/ml Normocin (Invivogen) and 1X 
HEK-Blue Selection (Invitrogen). 
6. Generation of Bone Marrow-Derived Dendritic Cells (GM-CSF) and Macrophages (M-
CSF) 
  Mouse primary bone marrow-derived dendritic cells (BMDCs) and macrophages (BMDMs) were 
obtained from bone marrow cell suspensions after culture on non-treated 150-mm Petri dishes in 
complete Roswell Park memorail institute-1640 medium (RPMI 1640) supplemented with 10% FBS, 2 
mM L-glutamine, 100 mg/ml penicillin, 100 mg/ml streptomycin, 50 mM 2-ME, and 20 ng/ml 
granulocyte-macrophage colony-stimulating factor (GM-CSF, PeproTech, London, U.K.) for BMDCs and 
macrophage colony-stimulating factor (30% mycoplasma-free L929 cell supernatant, NCBI Biosample 
accession number SAMN00155972) for BMDMs. BMDCs were collected at day 9 and BMDCs were 
characterized as CD11c+MHC-II+Gr-1- cells by flow cytometry. BMDMs were collected at day 6 and 
BMDMs were characterized as CD11b+F4/80+ or CD11b+CD64+ cells. 
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7. Generation of Bone Marrow-Derived Dendritic Cells (FLT3L) 
  Bone marrow cell suspensions were culture on treated 6 well plates in complete RPMI 1640 
supplemented with 10% FBS, 2 mM L-glutamine, 100 mg/ml penicillin, 100 mg/ml streptomycin, 50 
mM 2-ME, and 150 ng/ml Fms-related tyrosine kinase 3 ligand dendritic cells (FLT3L, PeproTech, 
London, U.K.). After 9-11 days of differentiation cells were collected to be characterized by flow 
cytometry as CD11c+B220-CD11b+CD24- (60% of the culture) and CD11c+B220-CD11b+CD24+(40%).  
8. Obtainment of Thioglycollate-Elicited Macrophages (TEMs) 
  Mice received peritoneal injections with 1ml 4% thioglycollate (TG). The peritoneal exudate was 
collected after 4 days and cultured in complete RPMI 1640 supplemented with 10% FBS, 2 mM L-
glutamine, 100 mg/ml penicillin, 100 mg/ml streptomycin, and 50 mM 2-ME. To enrich the culture for 
macrophages, non-adherent cells were eliminated after a few hours by washing five times with warm 
PBS and gentle swirling. These cells expressed CD64 macrophage marker in more than 90% after this 
enrichment.  
9. Obtainment of human monocyte-derived Dendritic Cells (moDCs) 
  Peripheral blood mononuclear cells (PBMCs) from Buffy coats of healthy donors were isolated using 
Biocoll separating solution (Millipore) by centrifugation at 700 g 30 min at RT.  Monocytes were 
purified from peripheral blood mononuclear cells (PBMCs) by an adhesion step at 37ºC in incomplete 
RPMI 1640 medium during 1 h. Non-adherent cells were removed and adherent monocytes were 
washed three times with warm 1x PBS to remove residual PBMCs. Monocytes were cultured in 
complete RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 mg/ml penicillin, 100 mg/ml 
streptomycin, 500 U/ml IL-4 (R&D) and 500 U/ml GM-CSF (Immunotools) for 6 days. Fresh medium 
and cytokines were added every 48 h to differentiate monocytes to immature human dendritic cells. 
Cells were characterized by flow cytometry as HLA-DR+CD3-DC-SIGN+CD14-CD11c+. Activation of 
dendritic cells was induced with Pam2GSK4, Pam3GSK4 and HKLM for 30 min (Invivogen). 
10. In vitro Lm-infection of BMDCs, BMDMs and TEMs 
  Cells were incubated with Lm and assessed for survival to gentamicin exposure [247]. Detailed, cells 
were infected with Lm at a multiplicity of infection (MOI) of 10 for 30 min at 37°C and 5% CO2. Lm is a 
facultative pathogen able to growth in culture medium. To prevent extracellular replication, the 
aminoglycoside antibiotic gentamicin was added to the medium after bacterial internalization. This 
antibiotic is bactericidal for extracellular bacteria at high concentrations and does not have any 
significant effect in intracellular ones during the first 8 hpi [247]. Hence, to determine the number of 
bacteria entering the cells, extracellular bacteria were killed by treatment with 100 µg/ml gentamicin 
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(Sigma-Aldrich, St. Louis, MO) for an additional 30 min at 37°C. Then, infected cells were washed with 
PBS three times and lysed with 0.05% Triton X-100 (Sigma-Aldrich, St. Louis, MO) in distilled water. 
Serial dilutions were seeded on brain-heart infusion (BHI) agar plates and colony-forming units (CFUs) 
were counted after 36-48 h. Quantification method of intracellular live bacteria is represented in the 
the following scheme (Figure 3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
11. In vivo Lm systemic infections 
  Hdac6+/+ and Hdac6-/- mice were intravenously injected with Listeria monocytogenes EGD (125,000 
CFUs/mouse resuspended in 200 μl of PBS 1x) using a 29-gauge needle. For survival experiments mice 
were monitored twice a day in order to detect casualties during 15 days of infection. 
  After 12, 24, 48 and 72 hpi, mice were perfused with 1X PBS to clean blood from organs and spleens 
and livers were weighted. To determine bacterial load, spleens and livers were digested with 0.1 mg/ml 
type IV collagenase and 0.5 mg/ml DNAse I (Roche, Mannheim, Germany) for 30 min at 37°C. After 
digestion, organs were homogenized in 70 µm filters and red blood cells were lysed with ammonium 
chloride potassium lysis buffer (ACK, Sigma). Splenic cell suspensions were resuspended in PBS and 
cells were counted. Serial dilutions were grown on BHI agar plates. CFUs were counted after 36-48 h 
of incubation at 37°C. CFUs were calculated by cell number and by gram per organ. The model of 
quantification of intracelular bacteria in mouse target organs is illustrated in Figure 3.2. 
Figure 3.1. Quantification of intracellular live bacteria in myeloid cells. Myeloid cells are infected with Lm using 
a MOI of 10 during 30 min, followed by the addition of gentamicin during other 30 min. Cells are washed with 
PBS to eliminate the antibiotic and lysed with detergent at diferent experimental points (e.g. 0 and 6 hpi). Serial 
dilutions and not diluited sample are grown in BHI-agar plates for 36-38 h. At this time colony-foming units (CFUs) 
can be counted. 
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12. Antibodies and reagents 
  Rapamycin, bafilomycin A1, 3-MA, cloroquine, NH4Cl, 1400W and DPI were from Sigma-Aldrich and 
are illustrated in Table 3.3.  
Table 3.3. Table of Autophagy inhibitors. Table of inhibitors used in experimental procedures. Concentration 
and function of experimental use are indicated. 
  
  
Poly-L-lysine (PLL) was purchased from Sigma. Phalloidin-Alexa488 and 647 were from BD Biosciences. 
Zenon Alexa Fluor 488 rabbit IgG labelling kit, DAPI and Prolong Gold anti-fade mounting medium were 
from Thermofisher Scientific. Anti-human CD3 antibody (T3b hybridoma) was grown in Dr. F. Sánchez-
Madrid laboratory (Hospital Universitario de la Princesa, HUP, Madrid) [158].  
  TLR agonists used for the activation of DCs are listed in Table 3.4, indicating their specific TLR 
activation, the used concentration and the brand.  
 
 
 
Inhibitors Concentraiton Function 
1400W dihydrochloride 10 μM Specific inhibitor of inducible nitic oxide synthase (iNOS) 
3-methyladenine (3-MA) 0,5 mM Inhibitor of the formation of phagosome by inhibition of classs III 
phosphatidylinositol-3 phosphate (PI3P) 
Bafilomycin A1 20 nM Inhibits vacuolar H+ATPase dampening the fusion of 
autophagosome with lysosome 
Cloroquine diphosphate 50 μM Cystein proteases inhibitor which impairs acidification of 
lysosome and late endosomes 
Diphenyleneiodonium 
chloride (DPI) 
5 μM Inhibitor of the NADPH oxidase 
NH4Cl 50 mM Inhibit the acidification of lysosome and late endosomes 
Rapamycin 4 μM Inhibitor of mTOR.  Increase autophagy flux 
Figure 3.2. Quantification of intracellular live bacteria in mouse target organs. Mice are infected with Lm by 
intravenous injection of 125.000 CFUs/mouse. Organs are extracted and homogenizated using enzymatic 
digestion in combination with mechanical force on 70 μm with the piston of a siringe. Cell suspensions are lysed 
with detergent and serial dilutions are perfomed. Serial dilutions and not diluited sample are grown in BHI-agar 
plates for 36-38 hours. At this time Colony-foming units (CFUs) can be counted. 
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 Table 3.4. TLR agonists. Table of TLR agonists used in experimental procedures disclosed by target TLR, 
concentration and brand. 
 
13. Gene overexpression and silencing 
  HEK293 cells were co-transfected with plasmids encoding human MyD88 fused to the influenza 
hemmagglutinin (HA)-tag (Addgene plasmid #12287) together with plasmids encoding HDAC6-WT or 
double mutant deacetylase domain DD (mutated human HDAC6-H216A/H611A) fused to the 
enhanced Green Fluorescent protein (eGFP) tag (HDAC6-WT and HDAC6-DD previously described 
[220]). When indicated, cells were co-transfected with the appropriate small harping RNA plasmid 
pLVX-IRES-ZsGreen1, where shHDAC6-2049 (TRCN0000004842) was cloned between BamH1 and 
EcoR1 sites. Cells were transfected using Lipofectamine 2000 (Invitrogen). Experiments were 
performed 24 h after transfection. 
14. RNA isolation  
  RNA from mouse GM-CSF- derived DCs was isolated with the QIAGEN RNeasy Kit (Qiagen). Residual 
DNA contamination was removed with the Turbo DNA-free Kit (Ambion). RNA purity and concentration 
was analysed in a Nanodrop-1000 Spectrophotometer /Thermo Scientific). RNA integrity was assessed 
by etidium bromide labelling on a 1.5% agarose gel. 
15. Reverse transcription and quantitative real-time-PCR 
  Total RNA (1-2 µg) was reverse transcribed to cDNA with a Reverse Trancription Kit (Applied 
Biosystems). Quantitative PCR was then performed in an AB7900-384 thermocycler (Applied 
Biosystem) using SYBR Green master mix (Applied Biosystems, Warrington, UK) as the reporter. PCR 
reactions were performed by triplicate in 10 µl volumes in 384-well plates. Expression levels of target 
genes were normalized to the expression of housekeeping genes β-actin, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), β2-microglobulin and Ywhaz (tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, ζ) for presentation of relative mRNA levels. Data were analysed 
with Biogazelle qBasePlus version 2.3 (Biogazelle) and graphs are represented as a normalized 
expression scaled to average of all samples. Gene-specific primers used are listed in Table 3.5.  
Agonist TLR activation Concetration Brand 
Lm various MOI=10 EGD strain 
Heat killed Lm (HKLM) various MOI=50 InvivoGen 
Heat killed S. Thyphimurium  (HKST) various MOI=50 InvivoGen 
Palmitoyl-2-cysteine-serine-(lysine)-4 (Pam2GSK4) TLR-2/6 10 μg/ml InvivoGen 
Palmitoyl-3-cysteine-serine-(lysine)-4 (Pam3GSK4) TLR-1/2 10 μg/ml InvivoGen 
Polyinosinic-polycytidylic acid (Poly(I:C)) HMW TLR-3 20 μg/ml InvivoGen 
Lipopolysaccharide (LPS) TLR-4 1 mg/ml Sigma-Aldrich 
Flagellin TLR-5 100 μg/ml InvivoGen 
Imiquimod TLR-7 1 mg/ml InvivoGen 
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Table 3.5. qPCR primers. Table of qPCR primers used in experimental procedures disclosed by gene name and 
sequence 5´-3´.(Fw: Forward, Rv: Reverse). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Sequence (5´-3´) 
Atg12 Fw: AACAAAGAAATGGGCTGTGGAGCG  Rv: TTCCGAGGCCACCAGTTTAAGGAA 
Atg2 Fw: CCACCTCTGCAAATCGGCA Rv: CCAGTTGTCCTGATACCTCCA 
Atg5 Fw: GACAAAGATGTGCTTCGAGATGTG Rv: GTAGCTCAGATGCTCGCTCAG 
Atg7 Fw:  ATGCCAGGACACCCTGTGAACTTC Rv: ACATCATTGCAGAAGTAGCAGCCA 
Beclin-1 Fw: GGCCAATAAGATGGGTCTGA Rv: CACTGCCTCCAGTGTCTTCA 
CXCL10 Fw: CCAAGTGCTGCCGTCATTTTC Rv: TCCCTATGGCCCTCATTCTCA 
CXCL5 Fw: TGCGTTGTGTTTGCTTAACCG Rv: CTTCCACCGTAGGGCACTG 
CXCR1 Fw: TCTGGACTAATCCTGAGGGTG Rv: GCCTGTTGGTTATTGGAACTCTC 
GAPDH Fw: AGCTTGTCATCAACGGGAAG Rv: TTTGATGTTAGTGGGGTCTCG 
HDAC1 Fw: CAGTCATGTCCAAAGTAAT Rv: GTCCTTTGATGGTCAGATTG 
HDAC10 Fw: ACAGCCACTCGACTGCTCT Rv: GATGCCTCACAAGCTGACAAA 
HDAC11 Fw: GTGTACTCACCACGTTACAACA Rv: GCTCGTTGAGATAGCGCCTC 
HDAC2 Fw: TGAAATTCCCAATGAGTTGC Rv: GTTCTGGTTTGTCATGTTTG 
HDAC3 Fw: GTGACATGTATGAAGTTGGAG Rv: AAAAGGTGCTTGTAACTCTG 
HDAC4 Fw: CTACTGGTATGGGAAGACAC Rv: TTTCCTAAGAGGGAAGTCA 
HDAC5 Fw: AAGACCTAGAAGAGGAGGAG Rv: GCGAACAACTTTTTGTAACC 
HDAC6 Fw: TCCACCGGCCAAGATTCTTC Rv: CAGCACACTTCTTTCCACCAC 
HDAC6b Fw: TCGCTGTCTCATCCTACCTGCT Rv: GTCAAAGTTGGCACCTTCACGG 
HDAC6-Ex12 Fw: CTGGCTAAGGGAGTCAGTGC Rv: TAGCACGGCTTCTTCCACTT 
HDAC7 Fw: GAACTCTTGAGCCCTTGGACA Rv: GGTGTGCTGCTACTACTGGG 
HDAC8 Fw: ACTATTGCCGGAGATCCAATGT Rv: CCTCCTAAAATCAGAGTTGCCAG 
HDAC9 Fw: GCGGTCCAGGTTAAAACAGAA Rv: GCCACCTCAAACACTCGCTT 
IFIT3 Fw: GTGGACTGAGATTTCTGAACTGC Rv: CAGAGATTCCCGGTTGACCT 
IFN-β Fw: TCAGAATGAGTGGTGGTTGC Rv: GACCTTTCAAATGCAGTAGATTCA 
IL12p40 Fw: GGAAGCACGGCAGCAGAAT Rv: AACTTGAGGGAGAAGTAGGAATGG 
IL-1β Fw: GCAACTGTTCCTGAACTCAACT Rv: ATCTTTTGGGGTCCGTCAACT 
ISG15 Fw: GGTGTCCGTGACTAACTCCAT Rv: TGGAAAGGGTAAGACCGTCCT 
LAMP-1 Fw: AGCATACCGGTGTGTCAGTG Rv: GTTGGGGAAGGTCCATCCTG 
LAMP-2a Fw: TGGCTAATGGCTCAGCTTTC Rv: ATGGGCACAAGGAAGTTGTC 
LC3A Fw: TTGGTCAAGATCATCCGGC Rv: GCTCACCATGCTGTGCTGG 
LC3B Fw:  CCCACCAAGATCCCAGTGAT Rv: CCAGGAACTTGGTCTTGTCCA 
Mx1 Fw: GACCATAGGGGTCTTGACCAA Rv: AGACTTGCTCTTTCTGAAAAGCC 
p62 Fw: ATGTGGAACATGGAGGGAAGA Rv: GGAGTTCACCTGTAGATGGGT 
PanIFN-α Fw: CCTGAGARAGAAGAAACACAGCC Rv: GGCTCTCCAGAYTTCTGCTCT 
Sirtuin-1 Fw: ATGACGCTGTGGCAGATTGTT Rv: CCGCAAGGCGAGCATAGAT 
Sirtuin-2 Fw: ATCGTGTTTTTCGGTGAGAACC Rv: TTCCTTGTTAATGAGCAGCCG 
Sirtuin-3 Fw: CTTCCGCTAAACTTCTCCCG Rv: ACAGAGGGATATGGGCCTTCT 
Sirtuin-4 Fw: TCTGACGATTTGGCTTGCCT Rv: TTCAGAGTTGGAGCGGCATT 
Sirtuin-5 Fw: CTCCGGGCCGATTCATTTCC Rv: GCGTTCGCAAAACACTTCCG 
Sirtuin-6 Fw: ATGTCGGTGAATTATGCAGCA Rv: GCTGGAGGACTGCCACATTA 
Sirtuin-7 Fw: AGCATCACCCGTTTGCATGA Rv: GGCAGTACGCTCAGTCACAT 
TLR-1 Fw: TGAGGGTCCTGATAATGTCCTAC Rv: AGAGGTCCAAATGCTTGAGGC 
TLR-2 Fw: GCAAACGCTGTTCTGCTCAG Rv: AGGCGTCTCCCTCTATTGTATT 
TLR-6 Fw: TGAGCCAAGACAGAAAACCCA Rv: GGGACATGAGTAAGGTTCCTGTT 
TNF-α Fw: CCCTTCCTCCGATGGCTAC Rv: CGCCTCCTTCTTGTTCTGG 
Ywhaz Fw: CGTTGTAGGAGCCCGTAGGTCAT Rv: TCTGGTTGCGAAGCATTGGG 
β2-M Fw: TTCTGGTGCTTGTCTCACTGA Rv: CAGTATGTTCGGCTTCCCATTC 
β-actin Fw: CAGAAGGAGATTACTGCTCTGGCT Rv: TACTCCTGCTTGCTGATCCACATC 
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  Primers HDAC6-Ex12 were designed to amplify the exon 12 of Hdac6 gene and were included in 
experiments as a control to check Hdac6-/- mice (deletion of the fragment corresponding to exons 10-
13). Amplification after cycle 30-35 was observed in Hdac6-/- DCs, indicating the absence of exon 12. 
HDAC6 and HDAC6b primer pairs were designed to amplify exons before 10-13 fragment, so they were 
used as positive controls of amplification in Hdac6+/+ and Hdac6-/- GM-CSF DCs. 
16. Soluble embryonic alkaline phosphatase (SEAP)-NF-κB detection  
  Transfected HEK-Blue hTLR2 cells (50.000 per well) with different HDAC6 constructions were placed 
in bottom p96 well plates resuspended in HEK-Blue Detection medium (Invivogen) without stimulus 
(negative control) and with TLR-2 agonists (HKLM stimulus, MOI=10). After 8-12 h of incubation, SEAP 
activity was measured by optical density at 620 nm with a microplate reader. To calculate the NF-κB 
induction, the signal obtained from each mutant condition without stimuli (background) was depleted 
of the signal of each condition of activation with Pam2GSK4, Pam3GSK4 or HKLM. 
17. ELISAs and nitrite measurement 
  Cytokine and Nitric Oxide (NO) production was analysed in the supernatants of BMDC cultures at 6, 
12 and 24 h after stimulation with Lm, heat-killed Listeria monocytogenes (HKLM), heat-killed 
Salmonella Typhimurium (HKST), Pam3CSK4, Flagellin, Imiquimod, polyinosinic-polycytidylic acid 
(Poly(I:C)) (InvivoGen, San Diego, CA), or LPS from Escherichia coli (Sigma-Aldrich). TNF-α and IL12p70 
were analysed with OptEIA Enzyme-Linked Immunosorbent Assay (ELISA) kits (BD Biosciences, San 
Diego, CA), IL-1β and IL-6 with the mouse ELISA Ready-SET-Go! kit from eBioscience (Affymetrix, San 
Diego, CA) and Interferon-β was measured with Legend max mouse IFN-β ELISA kit (Biolegend). The 
detection was based on colorimetric quantification of absorbance at 450 nm, corrected with 
subtraction at 570 nm measured in a microplate reader (Bio-Rad Model 550). Nitric oxide (NO) was 
estimated from the nitrite concentration measured with a Griess reagent kit at 548 nm (Molecular 
Probes/Life Technologies, Thermo Fisher Scientific). Results were expressed as the means of duplicate 
wells. 
18. Immunoblotting 
  Total cell extracts from GM-CSF DCs stimulated with Lm, HKLM or the indicated TLR ligands for the 
indicated times were prepared in lysis buffer (0.5% Triton X100, 25 mM Tris-HCl pH 7.5, 0.5 mM EGTA, 
0.5 mM EDTA, 25 mM NaF, 0.5 sodium glycerol-phosphate, 2.5 mM pyrophosphate, 0.135 M sacarose) 
with a cocktail of protease and phosphatase inhibitors (Roche). Cell lysates were cleared of nuclei by 
centrifugation at 15,000 g for 15 min. Protein extracts were quantified using Bio-Rad Protein Assay Dye 
Reagent Concentrate (Bio-Rad) and sample buffer Laemmli were added to protein lysates.  
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  Protein extracts were separated by 8-15% SDS-PAGE using acrylamide/bisacrylamide 29:1 reactive 
(Biorad) following the Laemmli method with Tris-glycine buffer. Proteins were transferred to a PVDF 
membrane (Biorad) or 0.45 μm pore-size nitrocellulose membranes (Biorad). Membranes were 
blocked with TBS-Tween20 5% BSA. Proteins were visualized with LAS-3000 using Luminata Forte and 
Luminata Crescendo Western horseradich peroxidase (HRP) substrate (Millipore) after membrane 
incubation with specific antibodies (Table 3.6) and peroxidase-conjugated secondary antibodies (using 
5 μg ml−1 approximately) (Table 3.7). Band intensities were quantified using Image Gauge software 
(Fuji Photo Film, Co., Ltd) and results are expressed relative to loading controls. For quantification of 
western-blots, phosphorylated/total ratios were divided by loading control signal. Non-infection (NI) 
time was considered as 100%, and following times were relativized to it. 
Table 3.6. Primary antibodies for WB. Table of antibodies used in WB experimental procedures disclosed by 
reference, brand, host and dilution (WB: Western blot). 
 
 
Table 3.7. Secondary antibodies for WB. Table of antibodies used in WB experimental procedures disclosed by 
reference, brand, host and dilution (WB: Western blot). 
      
  Membrane strippings were performed using BlotFresh Western Blot Stripping reagent (SigmaGen 
Laboratories), followed by several Tris-buffered saline (TBS)-Tween 1% washes and TBS-Bovine serum 
albumin (BSA) 5% blockade previously to other primary antibody incubation. 
Primary Antibodies Reference Brand Host Dilution 
AKT #9272 Cell Signaling rabbit WB (1:1000) 
ERK1/2 #9102 Cell Signaling mouse WB (1:1000) 
HDAC6 C0226 Assay bioTech rabbit WB (1:500) 
iNOS # 2982S Cell Signaling rabbit WB (1:500) 
LC3b # 2775S Cell Signaling rabbit WB (1:500) 
MyD88 D80F5 #4283 Cell Signaling rabbit WB (1:500) 
MyD88 sc-11356 (HFL-296) Santa Cruz rabbit WB (1:500) 
MyD88 sc-136970 (B-1) Santa Cruz mouse WB (1:500) 
MyD88 MA5-15762 (2E9C2) TermoFisher Scientific mouse WB (1:500) 
p62 P0067 Sigma-Aldrich rabbit WB (1:1000) 
p70S6K #2703 Cell Signaling rabbit WB (1:1000) 
phAKT (Ser473) #9271 Cell Signaling rabbit WB (1:1000) 
phERK1/2 
(Thr202/Thr204) 
#9101 Cell Signaling rabbit WB (1:1000) 
php70S6K #9205 Cell Signaling rabbit WB (1:1000) 
phS6 (Ser235/236) #2211 Cell Signaling rabbit WB (1:1000) 
S6 #2717 Cell Signaling rabbit WB (1:1000) 
tubulin T9026 (DH1A) Sigma-Aldrich mouse WB (1:2000) 
β-actin A2228 (AC-74) Sigma-Aldrich mouse WB (1:2000) 
Secondary Antibodies Reference Brand Host Dilution 
Goat anti-mouse-HRP #31430 Thermofisher Scientific goat WB (1:5000) 
Goat anti-rabbit-HRP #31460 Thermofisher Scientific goat WB (1:5000) 
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19. Immunoprecipitation of MyD88 and HDAC6 proteins  
19.1. From human monocyte-derived dendritic cells (moDCs) 
  Human moDCs (1 × 107 per condition) were lysed (10 mM Tris pH 7.4, 150 mM NaCl, 5% glycerol, 1mM 
EDTA, 1mM MgCl2, 1mM CaCl2, 1% CHAPS (Sigma) and protease and phosphatase inhibitors (Roche)) 
for 1 h at 4°C. Lysates were incubated for pre-clearing with pre-washed Protein G Dynabeads 
(Invitrogen; 50 μl per condition; 2 h, 4 °C). Pre-cleared lysates were incubated with 6 μg rabbit anti-
MyD88 antibody (Cell Signaling) or 6 μg rabbit anti-HDAC6 antibody (Assay BioTech) per condition O/N 
at 4 °C. Similar μg of control isotype antibody for rabbit were used. Fifty microlitres of Dynabeads per 
condition were washed three times in wash buffer (10 mM Tris pH 7.4, 150 mM NaCl, 5% glycerol, 
1mM EDTA, 1mM MgCl2, 1mM CaCl2, 0.1% CHAPS) and added to antibody-conjugated lysates for 2 h 
4C. Antibody-conjugated Dynabeads were washed six times with wash buffer and transferred to clean 
tubes.  
19.2. From HEK cell lines 
  HEK293T cells or HEK-Blue hTLR2 (1 × 107 per condition) were lysed (25 mM Tris pH 8, 150 mM NaCl, 
0.5% NP-40 and protease and phosphatase inhibitors) and incubated for pre-clearing with pre-washed 
Protein G Dynabeads (Invitrogen; 50 μl per condition; 3 h, 4 °C). Fifty μg of Dynabeads per condition 
were washed three times in wash buffer (25 mM Tris pH 8, 150 mM NaCl, 0.05% NP-40) and re-
suspended in 600 μl of wash buffer containing 1-2 μg mouse anti-HA antibody (Roche) per condition 
and incubated 3 h at 4 °C. Similar μg of control isotype antibody for mouse were used. Pre-cleared 
lysates were incubated with antibody-conjugated Dynabeads (O/N, 4 °C). Antibody-conjugated 
Dynabeads were washed six times with lysis buffer and transferred to clean tubes. Then, were washed 
twice with wash buffer. Protein loading buffer was added, samples were boiled at 95 °C for 5 min and 
processed for immunoblotting. 
  Antibodies used for IP approach are listed in Table 3.8 indicating the reference, brand, host and 
concentration of use. 
 Table 3.8. Primary antibodies for IP. Table of antibodies used in IP experimental procedures disclosed by 
reference, brand, host and dilution (IP: Immunoprecipitation). 
Primary Antibodies Reference Brand Host Dilution 
Anti-HA 000000011583816001 
(12CA5) 
Roche ( Sigma-Aldrich) mouse IP (5 µg/point) 
Anti-HA A190-108A Bethyl rabbit IP (5 µg/point) 
Control isotype of 
mouse 
sc-2025 Santa Cruz rat IP (1-5 µg/point) 
Control isotype of 
rabbit 
sc-2027 Santa Cruz rabbit IP (5 µg/point) 
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20. Flow cytometry  
  Cells were stained in ice-cold PBS containing FBS (0.5%) and EDTA (5 mM) using appropriate antibody-
fluorophore conjugates. Multiparameter analysis was performed on a FACSCANTO II flow cytometer 
(BD Biosciences) and analysed with FlowJo software (Tree Star). Prior to fixing, cells were resuspended 
in PBS/0.5% BSA/5 mM EDTA solution containing yellow fluorescent reactive dye to exclude dead cells 
(Life Technologies). For intracellular staining, cells were fixed and permeabilized using the 
CytoFix/Cytoperm kit (BD). Human cells were blocked with human gamma-globulin from human blood 
(Sigma), whereas mouse cells were blocked using Fc-Block (CD16/32) (Tombo biociencies). Complete 
primary and secondary antibody used for FC are listed in Table 3.9 and Table 3.10. 
 Table 3.9. Primary antibodies for FC. Table of antibodies used in FC experimental procedures disclosed by 
reference, brand, host and dilution (FC: Flow cytometry). 
 
Table 3.10. Secondary antibodies for FC. Table of antibodies used in FC experimental procedures disclosed by 
reference, brand, host and dilution (FC: Flow cytometry). 
 
 
 
 
Primary Antibodies Reference Brand Host Dilution 
B220-PerCP-cyanine5.5 65-0452-U100 (RA 3-
6B2) 
Tombo biociences rat FC (1:200) 
CD11b-FITC 553310 (M1/70) BD Pharmingen rat FC (1:200) 
CD11c-PE 557401 (HL3) BD Pharmingen hamster FC (1:200) 
CD11c-PE 555392 (B-ly6) BD biociences mouse FC (1:200) 
CD11c-PeCy7 558079 (HL3) BD Pharmingen hamster FC (1:200) 
CD11c-PeCy7 55079 BD Pharmingen hamster FC (1:200) 
CD14-FITC 14F-100T (47-3D6) Immunostep mouse FC (1:200) 
CD16/32 Fc-block (clone 2.4G) BD Pharmingen rat FC (1:200) 
CD19-VioletFluor450 75-0193-U100 (1D3) Tombo biociences rat FC (1:200) 
CD24-PE 12-0241-82 (30-F1) ebiocience rat FC (1:200) 
CD3e T3b hybridoma [158] mouse FC (5 µg/ml) 
CD3-VioletFluor450 75-0032-U100 (17A2) Tombo biociences rat FC (1:200) 
CD40-APC 558695 BD Pharmingen rat FC (1:200) 
CD86-biotinylated 553690 (GL1) BD Pharmingen rat FC (1:200) 
CD8-APC 558079 (HL3) BD Pharmingen rat FC (1:200) 
DC-SIGN (CD209) sc-59157 (MR-1) Santa Cruz mouse FC (1:200) 
DX5 (CD49b)-V450 561638 BD biociences rat FC (1:200) 
Gr-1-APC 553129 (RB6-8C5) BD Pharmingen rat FC (1:200) 
HLA-DR-PerCP 560652 (G46-6) BD biociences mouse FC (1:200) 
Lm 0400-0030 AbDSerotec rabbit FC (1:200) 
Ly6C-PerCP-Cy5.5 560525 Becton Dickinson rat FC (1:200) 
Ly6G-PE 551461 (1A8) BD biociences rat FC (1:200) 
MHC-II I-A/I-E-APC 17-5321-81 
(145/1/4.15.2) 
ebiocience rat FC (1:200) 
MHC-II I-A/I-E-FITC 553623 (2G9) BD Pharmingen rat FC (1:500) 
p62 P0067 Sigma-Aldrich rabbit FC (1:200) 
Secondary Antibodies Reference Brand Host Dilution 
Chicken anti-mouse 647 A-21463 Life technologies chicken FC (1:500) 
Chicken anti-rabbit 647 A-21443 Life technologies chicken FC (1:500) 
Streptavidin-APC 554067 BD Pharmingen - FC (1:300) 
Streptavidin-BV421 563259 BD biociences - FC (1:300) 
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21. Fluorescence confocal microscopy 
  For immunofluorescence assays, cells were plated onto slides coated with poly-L-lysine (50 μg ml−1) 
and incubated for 1 h at 37ºC. Infection experiments were carried out at the indicated times. Cells 
were then fixed, blocked and stained with the indicated primary antibodies (5 μg ml−1) (Table 3.11) 
followed by Alexa488- or Rhodamine Red X-labelled secondary antibodies highly cross-adsorbed (Hx)(5 
μg ml−1) (Table 3.11 and Table 3.10).  
Table 3.11. Primary antibodies for IF. Table of antibodies used in IF experimental procedures disclosed by 
reference, brand, host and dilution (IF: Immunofluorescence). 
 
 
  
Table 3.12. Secondary antibodies for IF. Table of antibodies used in IF experimental procedures disclosed by 
reference, brand, host and dilution (IF: Immunofluorescence). 
 
  Samples were examined under a Leica SP5 confocal microscope (Leica) fitted with a 63X objective. 
Images were acquired with sequential xyz acquisition mode scans with laser ranges of 418-473 nm for 
DAPI, 502-548 nm for Alexa-488, 584-644 nm for Rhodamine Red-X and 737-779 nm for Alexa-647. Z-
stacks of 2-5 µm were obtained using a maximum z-step size of 0.3 µm.   
22. Imaris quantification 
  Images were processed and assembled using Image J 1.51p (Fiji). Confocal 3D images assembled with 
Imaris 7.7.2 (Bitplane) using the ImarisCell module. Every cell and its corresponding intracellular 
bacteria were calculated in each image. Surfaces corresponding to bacteria were used to calculate the 
maximal fluorescence intensity of the channels to co-localize with bacteria. Two-channel co-
localization was quantified in at least 10 images per genotype, corresponding to 10 biological samples. 
Each image contains from 60 to 80 cells. 
23. In-gel protein digestion 
  Proteins were in-gel digested using a previously described protocol [27]. Briefly, the 
coimmunoprecipitate was heated at 95 °C for 5 min, after which the magnetic beads were removed 
using a magnet. The resulting solution was added sample buffer and loaded in 0.5-cm-wide wells of an 
SDS-PAGE gel. The run was stopped as soon as the front entered into the resolving gel. The protein 
band was visualized by Coomassie Blue staining, excised, and digested overnight at 37 °C with 60 ng/l 
Primary Antibodies Reference Brand Host Dilution 
Acetylated cortactin 09-881 Millipore rabbit IF (1:100) 
p62 P0067 Sigma-Aldrich rabbit IF (1:200) 
K63 polyUb chain 05-1308 (clone Apu3) Merk-Millipore rabbit IF (1:100) 
Secondary Antibodies Reference Brand Host Dilution 
Goat anti-rabbit A488 Hx A-11008 Thermofisher Scientific goat IF (1:500) 
Goat anti-rabbit Rhodamin Red-X Hx 111-295-144 Jackson goat IF (1:500) 
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sequencing-grade modified trypsin (Promega) at 10:1 protein:enzyme (w/w) ratio in 50 mM 
ammonium bicarbonate, pH 8.8, containing 10% acetonitrile. The resulting tryptic peptides were 
desalted onto C18 OMIX tips (Agilent), dried down and kept at -80 °C until further use. 
24.  Mass spectrometry  
  The resulting peptides were analyzed by liquid chromatography coupled to tandem mass 
spectrometry (LC-MS/MS) on an Easy nLC-1000 nano-HPLC apparatus (Thermo Scientific, San Jose, CA, 
USA) coupled to a hybrid quadrupole-orbitrap mass spectrometer (Q Exactive HF, Thermo Scientific). 
The dried peptides were taken up in 0.1% (v/v) formic acid and then loaded onto a PepMap100 C18 LC 
pre-column (75 μm I.D., 2 cm, Thermo Scientific) and eluted on line onto an analytical NanoViper 
PepMap 100 C18 LC column (75 μm I.D., 50 cm, Thermo Scientific) with a continuous gradient 
consisting of 8-31% B in 240 min (B = 80% ACN, 0.1% formic acid) at 200 nL/min. Peptides were ionized 
using a Picotip emitter nanospray needle (New Objective). Each MS run consisted of enhanced FT-
resolution spectra (120,000 resolution) in the 400–1,200 m/z range followed by data-dependent 
MS/MS spectra of the 20 most intense parent ions acquired along the chromatographic run. The AGC 
target value in the Orbitrap for the survey scan was set to 1,000,000. Fragmentation in the linear ion 
trap was performed at 30% normalized collision energy with a target value of 10,000 ions. The full 
target was set to 30,000, with 1 microscan and 50 ms injection time, and the dynamic exclusion was 
set to 0.5 min.  
25.  Peptide identification 
  For peptide identification the MS/MS spectra were searched with the Sequest algorithm 
implemented in Proteome Discoverer 1.4 (Thermo Scientific). Database searching against human 
protein sequences from the UniProt database (March 2017, 158,382 entries) was performed with the 
following parameters: trypsin digestion with 4 maximum missed cleavage sites; precursor and 
fragment mass tolerances of 800 ppm and 0.02 Da, respectively; Cys carbamidomethylation as static 
modifications; and Met oxidation and Lys acetylation as dynamic modifications. The results were 
analyzed using the probability ratio method [149] and a false discovery rate (FDR) for peptide 
identification was calculated based on the search results against a decoy database using the refined 
method [168]. 
26.  Statistical analysis 
  Data were analysed with GraphPad prism software (La Jolla, CA) for normality (Kolmogorov-Smirnov 
test for small samples). Normal data were analysed by Student t-test, non-normal data by Mann-
Whitney test, and grouped data by 2-tailed One-way ANOVA with a Bonferroni post-test. Graphs show 
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the distribution of every sample and the mean of all samples ± the standard deviation of the mean 
(SEM).  
  For western blot quantification, the sample with the maximum signal was assigned a value of 100%, 
and signals in other samples were expressed as a percentage of this; significance was determined by a 
one-sample test.  
  Long-rank (Mantel-Cox) test and Cehan-Breslow-Wilcoxon test were used for the analysis of the 
Kaplan-Meier curve (survival curve).  
  Statistical significant differences were considered when p≤0.05, expressed as *, whereas ** was used 
for differences p≤0.01 and *** for differences p≤0.001. Non-significant differences were designed as 
ns (p>0.05). 
 
 
 
  
 
 
Results 
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4. RESULTS  
4.1. Analysis of HDAC6 contribution to cellular mechanisms that eliminate intracellular 
bacteria by phagocytic cells 
4.1.1. Effect of HDAC6 absence in the intracellular pathogen clearance of dendritic 
cells  
  To assess the possible role of HDAC6 in innate immune responses during bacterial pathogenesis, we 
performed a time-course infection with Lm in bone marrow (BM)-derived granulocyte and monocyte 
colony-stimulating factor (GM-CSF)-derived dendritic cells (DCs) from Hdac6+/+ and Hdac6-/- mice. 
Increasing levels of HDAC6 expression were detected in the Hdac6+/+ DCs as the infection progressed, 
reaching a peak at 4 hpi (Figure 4.1). 
 
  However, GM-CSF-derived DC differentiation was not noticeably affected in the absence of HDAC6, 
since there are the same levels of CD11c+MHC-II+, CD11c+MHC-II- and Gr-1+ populations between 
Hdac6+/+ and Hdac6-/- DCs at day 11 of in vitro differentiation (Figure 4.2). 
 
 
 
 
 
Figure 4.1. HDAC6 protein induction during Lm infection. Left: Western blot analysis of HDAC6 in a time-course 
of infection of GM-CSF DCs with Lm. Samples of non-infected (NI) cells and 0, 1, 2, 4 and 6 hpi cells are displayed. 
Tubulin was used as a loading control. Right: HDAC6 levels were quantified and are expressed relatively to its 
respective tubulin signal. Two-tailed t-test, ***p≤0.001, ** p≤0.01, *p≤0.05; n=5. 
                                                                                                                         Results 
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  Next, Hdac6+/+ and Hdac6-/- BMDCs were infected for different times with Gram-negative bacteria 
(Salmonella Typhimurium and Escherichia coli DH5α) and Gram-positive bacteria (Listeria 
monocytogenes and Staphylococcus aureus) at a multiplicity of infection (MOI) of 10, with colony-
formed units (CFUs) corresponding to intracellular live bacteria (Figure 4.3). Bacterial entry was similar 
in Hdac6+/+ and Hdac6-/- DCs at 0 h post-infection (hpi), while bacterial proliferation, measured at 6 hpi, 
was significantly higher in Hdac6-/- DCs for both types of intracellular pathogens, Lm and S. 
Typhimurium (Figure 4.3. A). 
 
 
 
 
 
 
Figure 4.2. Differentiation of GM-CSF-derived DCs at day 11 of culture. Left: Dot-plots showing CD11c and MHC-
II markers, with gating for CD11c+MHC-II+ and CD11c+MHC-II- populations (percentages indicated). Middle: Dot-
plots on differentiation day 11 showing FSC-H versus Gr-1, gating the Gr-1+ population corresponding to 
neutrophil contamination in GM-CSF-derived DC cultures. Right: Charts show the percentages of CD11c+MHC-
II+, CD11c+MHC-II- and Gr-1+ populations. ns>0.05 non-significant; n=6. 
 
Figure 4.3. Intracellular bacteria entry and proliferation in GM-CSF-DCs infected with various types of bacteria. 
CFUs obtained at 0 and 6 hpi from DCs infected with (A) intracellular pathogens (L. monocytogenes, S. 
Typhimurium), and (B) extracellular pathogenes (E. coli DHDα, and S. aureus) at a MOI of 10. Data from 0 hpi 
are shown as bacteria entry control. Two-tailed t-test, ***p≤0.001, ns>0.05 non-significant; n=6.  
  
A B  
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Figure 4.4. Viability of GM-CSF-DCs after Lm infection and HKLM stimuli at different times. Percentage viability 
of GM-CSF-DCs before and after (A) the infection with Lm MOI=10 or (B) HKLM stimuli MOI=50 at different 
times, NI: non-infected, 6, 12 and 24 h. Two-tailed t-test, **p≤0.01, ns>0.05 non- significant; n=6. 
 
B A 
 
  This was not due to differences in cell viability after 6 hpi (Figure 4.4. A). However, cell viability of 
Hdac6+/+ DCs is lower than Hdac6-/- ones at 24 hpi (Figure 4.4. A). No-significant differences were 
observed between Hdac6+/+ and Hdac6-/- DCs after the addition of Heat Killed Lm (HKLM) at any time 
(Figure 4.4. B). These data indicate a phenotype in cell viability only with live bacteria at 24 hpi. In 
contrast, no significant difference was observed in the proliferation of the non-intracellular pathogens 
S. aureus and E. coli, indicating that HDAC6 is an important component of cellular mechanisms for the 
clearance of intracellular pathogens (Figure 4.3. B). 
 
 
 
 
 
 
 
4.1.2. Measurement of Lm load in HDAC6-deficient myeloid cells 
  Time-course analysis showed that differences between Lm infection in Hdac6+/+ and Hdac6-/- DCs CFUs 
peaked at 6 hpi and were sustained until 24 hpi (Figure 4.5. A). This effect was clearly observed at a 
MOI of 10, which did not affect cell viability (Figure 4.5. B and Figure 4.4).  
 
 
 
 
 
 
  The lack of difference in bacterial load at 32 hpi between both genotypes is indicating that Hdac6-/- 
DCs do not succumb to the infection (Figure 4.5).  This result suggests that other HDACs can be 
  
Figure 4.5. Time-course of Lm infection in GM-CSF-DCs and multiplicity of infection. (A) CFUs of Lm-infected 
GM-CSF DCs obtained at 0, 6, 24 and 32 hpi with a MOI=10. ***p≤0.001, *p≤0.05, ns>0.05 non-significant; n=6. 
(B) CFUs of Lm-infected DCs obtained at 0, 2, 4 and 6 hpi with a MOI=10 and 1. Two-tailed t-test, ***p≤0.001, 
*p≤0.05, ns>0.05 non-significant; n=6. 
 
A B 
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compensating HDAC6 function during the ellimination of intracellular Lm at long times of infection. To 
address this question, qPCRs of every mouse deacetylase, HDACs (1-5 and 7-11) and sirtuins (1-7), were 
performed in Lm infected DCs at 6 and 24 hpi (Figure 4.6, Figure 4.7, Figure 4.8 and Figure 4.9).  
 
 
 
 
 
 
 
 
 
 
  In this regard, higher expression levels of HDAC5 were detected in Hdac6-/- DCs at 24 hpi, whereas 
similar results were obtained for HDAC9 at 6 hpi (Figure 4.6 and Figure 4.7).  
 
 
 
 
 
 
 
 
 
Figure 4.6. Expression of HDACs in DCs after Lm infection at 6 hpi. PCR analysis of HDACs (HDAC1, 2, 3, 4, 5, 7, 
8, 9, 10 and 11) in Hdac6+/+ and Hdac6-/- GM-CSF DCs infected with Lm at 6 hpi (AU: arbitrary units). Two-tailed 
t-test, * p≤0.05, ns>0.05 non-significant; n=5. 
Figure 4.7. Expression of HDACs in DCs after Lm infection at 24 hpi. PCR analysis of HDACs (HDAC1, 2, 3, 4, 5, 7, 
8, 9, 10 and 11) in Hdac6+/+ and Hdac6-/- GM-CSF DCs infected with Lm at 24 hpi (AU: arbitrary units). Two-tailed 
t-test, * p≤0.05, ns>0.05 non-significant; n=5. 
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  However, no significant differences were observed in sirtuins expresion between Hdac6+/+ and Hdac6-
/- DCs at any time (Figure 4.8 and Figure 4.9). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  A similar pattern was observed with macrophage colony-stimulating factor (M-CSF)-derived 
macrophages, demonstrating the lineage independence of the role of HDAC6 in bacterial clearance 
(Figure 4.10). Although the difference between Hdac6+/+ and Hdac6-/- cells was observed in both 
macrophages and DCs, the clearance capacity of macrophages was ten-fold higher than that of DCs at 
6 hpi (Figure 4.10).  
Figure 4.9. Expression of Sirtuins in DCs after Lm infection at 24 hpi. PCR analysis of Sirtuins (1, 2, 3, 4, 5, 6 and 
7) in Hdac6+/+ and Hdac6-/- GM-CSF DCs infected with Lm at 24 hpi (AU: arbitrary units). Two-tailed t-test, * 
p≤0.05, ns>0.05 non-significant; n=5. 
Figure 4.8. Expression of Sirtuins in DCs after Lm infection at 6 hpi. PCR analysis of Sirtuins (1, 2, 3, 4, 5, 6 and 
7 )in Hdac6+/+ and Hdac6-/- GM-CSF DCs infected with Lm at 6 hpi (AU: arbitrary units). Two-tailed t-test, * p≤0.05, 
ns>0.05 non-significant; n=5. 
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  Bacterial load was also determined by flow cytometry using two strategies: a specific antibody against 
Lm, and RFP-expressing bacteria. Both approaches showed that Hdac6-deficient DCs contained more 
bacteria at 6 hpi (Figure 4.11).  
 
 
 
 
 
 
 
 
  Higher numbers of bacteria in Hdac6-/- GM-CSF DCs were also detected by confocal fluorescence 
microscopy at 6 hpi (Figure 4.12). Some bacteria co-localized with filamentous actin, showing clear 
actin rockets (Figure 4.12. A and B). Image quantification confirmed that Hdac6-/- DCs contained more 
bacteria per cell and more total bacteria, remarking a higher percentage of cells hosting a large number 
of bacteria in Hdac6-/- cells (see distribution of bacteria per cell, 6-7) (Figure 4.12. C and D). ImarisCell 
Figure 4.11. GM-CSF DCs 
were infected with Lm-RFP or 
Lm for 6 h and the bacterial 
signal was determined by 
flow cytometry.  Top panel: 
The panel shows 
representative histograms of 
Lm-RFP and Lm antibody 
signals. Bottom panel: Graphs 
show geometric mean of the 
Lm signals. Each dot 
represents the number of 
samples and the mean with 
SEM is indicated in colour. 
Two-tailed t-test, 
***p≤0.001, ** p≤0.01; n=6. 
 
Figure 4.10. Comparison of 
intracellular bacteria in GM-
CSF-derived DCs and M-CSF-
derived macrophages over the 
time-course of Lm-infection. 
CFUs of DCs and macrophages 
are shown at 0, 6, 12 and 24 
hpi. In both cases Hdac6-/- cells 
display higher intracellular 
bacterial load. Two-tailed t-
test,  ***p≤0.001, ** p≤0.01, 
ns>0.05 non-significant; n=6. 
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Module view of images showed the number of bacteria per cell using actin transparency to easily 
visualize individual bacteria (Figure 4.12. B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D 
 
Figure 4.12. Confocal microscopy determination of bacterial load at 6 hpi. (A) Maximum intensity z-projections 
of confocal microscopy images of Lm-infected Hdac6+/+ and Hdac6-/- GM-CSF DCs at 6 hpi. The panel shows DAPI 
(blue), Lm (red), β-actin (green), merged views of three channels, and magnified views of the boxed areas from 
the merged view. Yellow indicates Lm and β-actin co-localization. Scale bars 20 µm (main panels) and 10 µm 
magnified views). (B) Confocal microscopy determination of bacterial load of Figure 4.12.A. Maximum intensity 
z-projections of confocal microscopy images of Lm-infected Hdac6+/+ and Hdac6-/- DCs at 6 hpi. ImarisCell Module 
view of the number of nucleus and bacteria per cell. Actin transparency is used to visualize bacteria (number 
indicated on the right). Images show DAPI (blue), Lm (red), β-actin (green). Scale bars 20 µm. (C) ImarisCell 
Module analysis of the number of cells and the number of bacteria per cell in all pictures (10 pictures per 
genotype). The graph shows the distribution of cells with a specific number of bacteria per cell. The number of 
cells with 6 and 7 bacteria differed significantly between the Hdac6+/+ and Hdac6-/- genotypes. Two-way Anova, 
* p≤0.05; n=10 . (D) Graphs show statistical analysis of Imaris quantification of total bacteria and bacteria per cell 
in Hdac6+/+ and Hdac6-/- DCs. Two-tailed t-test, ***p≤0.001, ** p≤0.01; n=10. 
A 
B C 
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4.1.3. Determination of in vivo bacterial burden  
  To ascertain whether Hdac6-/- cells display higher bacterial burden than Hdac6+/+ cells in vivo, Hdac6+/+ 
and Hdac6-/- mice were intravenously injected with Lm and total CFUs per gram of liver and spleen 
were determined at 6 hpi.  In agreement with the higher numbers of Lm observed in GM-CSF-DCs and 
M-CSF-Macrophages, we observed increased bacterial titres in spleen and liver cell suspensions (Figure 
4.13).  
 
 
 
 
  Next, to determine the specific cell populations underlying this phenotype, a multicolour gating 
strategy was used to identify the myeloid cell compartment, including monocytes, neutrophils, Tips 
DCs, total cDCs, CD8- cCDs and CD8+ cDCs (Figure 4.14).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Deficient intracellular bacteria 
clearance in target organs of Hdac6-/- mice. 
Quantification of bacterial load in target 
organs (spleen and liver) at 6 hpi in Hdac6+/+ 
and Hdac6-/- mice injected with a lethal dose 
of Lm. Bacterial load is expressed by CFUs 
per gram of liver (left graph) and per gram of 
spleen (right graph). Two-tailed t-test, 
**p≤0.01, n=6. 
 
Figure 4.14. Gating strategy of myeloid populations of the spleen. Dot-plots showing the gating of myeloid 
populations of spleen. Dot-plots showing SSC-A versus FSC-A indicates p1, FSC-H versus FSC-W and SSC-H versus 
SSC-W were used to avoid doublets and FSC-H versus viability shows live and dead cells. Singlets and live cells 
were used to choose CD3-CD19-DX5-Ly6G+ cell population. From this population, neutrophils were gated as 
Ly6G+Ly6C+ cells, monocytes as CD11b+CD11clo, Tips DCs as intermedium levels of CD11b and CD11c, 
conventional dendritic cells (cDCs) as CD11chi; inside this population CD8- cDCs were distinguished as 
CD11chiCD11b+ and CD8- cDCs as CD11chiCD11blo.   
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  Non-significant differences were detected in the total number of myeloid splenic populations 
between Hdac6+/+ and Hdac6-/-genotypes at 6 hpi of Lm-infection (Figure 4.15). 
 
 
 
 
 
 
 
 
 
 
  However, higher numbers of Lm were observed in different myeloid cells at 6 hpi (Figure 4.16). These 
data highlight the impairment of intracellular Lm clearance in Hdac6-/- myeloid cells.  
 
 
 
 
 
 
 
 
 
Figure 4.15. Comparison of myeloid populations of the spleen between Hdac6+/+ and Hdac6-/- genotypes. The 
charts show percentage of cells of the different splenic populations (monocytes, neutrophils, Tips DCs, total 
cDCs, CD8- cDCs and CD8+cDCs) gated in the live CD3-CD19-DX5- population of Hdac6+/+ and Hdac6-/- mice 
injected with a lethal dose of Lm at 6 hpi. Two-tailed t-test, ns>0.05 non-significant; n=6. 
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Figure 4.16. Deficient intracellular bacteria clearance in Hdac6-/- splenic myeloid populations. (A) The charts 
show geometric means (GM) of Lm of different splenic populations (monocytes, neutrophils, Tips DCs, total cDCs, 
cDCs CD8- and cDCs CD8+) gated in the live CD3-CD19-DX5- population of Hdac6+/+ and Hdac6-/- mice injected with 
a lethal dose of Lm at 6 hpi. Two-tailed t-test, **p≤0.01, * p≤0.05; n=6. (B) Representative histograms of different 
splenic populations (monocytes, neutrophils, Tips DCs, total cDCs, CD8- cDCs and CD8+cDCs) show Lm signal of 
Hdac6+/+ and Hdac6-/- mice injected with a lethal dose of Lm at 6 hpi. A pool of Hdac6+/+ and Hdac6-/- non-infected 
spleens was used as a control sample without infection (NI).   
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4.1.4. Evaluation of cellular clearance mechanisms of Lm  
  To test the involvement of autophagy in the mechanism by which HDAC6 regulates Lm infection, we 
treated GM-CSF-derived DCs with 3-methyladenine (3-MA), an inhibitor of autophagosome formation. 
Treatment with 3-MA increased bacterial load in Hdac6+/+ DCs at 6 hpi, while having no effect on Hdac6-
/- DCs (Figure 4.17. B), suggesting autophagy as the bacterial clearance mechanism impaired in Hdac6-
deficient DCs. A similar result was observed upon treatment of DCs with bafilomycin A1, an inhibitor 
of vacuolar proton pump that indirectly inhibits phagosome-lysosome fusion, and with the lysosome 
acidification inhibitors chloroquine and NH4Cl (Figure 4.17. B and C). In contrast, increasing autophagy 
flux with rapamycin did not restore the impaired autophagy in Hdac6-/- DCs (Figure 4.17. D). No 
significant effects were observed with control vehicles (Figure 4.17. A). To explore other possible 
mechanisms, we treated DCs with inhibitors of NADPH oxidase (DPI) and iNOS (1400W). These 
treatments did not alter the difference in CFU number at 6 hpi between treated and non-treated 
Hdac6+/+ and Hdac6-/- DCs, indicating that the activity of either enzyme is not accounting for the existing 
phenotype (Figure 4.17. E).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 4.17. Intracellular bacteria after treatment with different inhibitors of principal clearance mechanisms 
of the cell. (A) Total CFUs at 0 and 6 hpi in Lm-infected GM-CSF DCs (MOI of 10) treated with different control 
vehicles (H2O, DMSO and ethanol). Total CFUs in Lm-infected DCs treated with inhibitors. CFUs were detected 
at entry (0 hpi) and 6 hpi (bacterial proliferation) using: (B) the autophagy inhibitors (3-MA and bafilomycin A1, 
(C) the lysosome acidification inhibitors (NH4Cl and cloroquine), and (D) the autophagy activator (rapamycin), 
(E) the NADPH oxidase inhibitor (DPI) and the iNOS inhibitor (1400W). Two-tailed t-test, ***p≤0.001, ns>0.05 
non-significant; n=6. Specification of control vehicles: H2O were the control vehicle used for NH4Cl and 
cloroquine, DMSO for 3-MA, bafilomycin A1, DPI and 1400W and ethanol for rapamycin. Time 0 hpi is included 
as a bacterial entry control.   
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4.1.5. Consequence of the lack of HDAC6 in the autophagy of Lm 
  The defective autophagy phenotype of Hdac6-/- GM-CSF-derived DCs was not due to transcriptional 
alterations of autophagy or lysosome components, since Lm-infected Hdac6+/+ and Hdac6-/- DCs 
showed no mRNA expression differences at 6 hpi in the autophagy components LC3 A and B, p62, 
ATG2, 5, 7 and 12, and Beclin-1 or in the lysosome components LAMP-1 and 2 (Figure 4.18). 
 
 
 
 
 
 
 
 
 
 
  To determine whether these findings can be extended to other phagocytic cells, we carried out CFU 
assays with macrophages obtained from Hdac6+/+ and Hdac6-/- mice four days after intraperitoneal 
thioglycollate injection. Higher bacterial load was observed only in Hdac6-/- macrophages at 6 hpi, and 
this difference was abrogated by treatment with bafilomycin A1 (Figure 4.19).  
 
 
 
 
   
Figure 4.18. Expression of relevant autophagy and lysosome markers in Lm-infected GM-CSF-DCs at 6 hpi. PCR 
analysis of autophagy markers (ATG-2, 5, 7 and 12, LC3A and B, p62 and Beclin-1) and lysosome markers (LAMP-
1 and 2) (AU: arbitrary units) after 6 hpi with Lm. Two-tailed t-test, ns>0.05 non-significant; n=5. 
 
 
Figure 4.19. Intracellular bacteria in peritoneal macrophages. (A) Total CFUs at 0 and 6 hpi in Lm-infected 
thioglycollate-elicited macrophages. (B) Total CFUs at 0 and 6 hpi in Lm-infected TEMs treated with bafilomycin 
A1. Two-tailed t-test, ***p≤0.001, ns>0.05 non-significant; n=6. 
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  These data indicate that the phenotype observed in DCs is also extendable to other Hdac6-deficient 
phagocytic cells such as peritoneal macrophages, indicating a widespread defect in intracellular killing 
ability due to lack of HDAC6. Moreover, the killing ability shown by peritoneal macrophages is similar 
to that of M-CSF-derived macrophages and higher than GM-CSF-derived DCs (Figure 4.19 compared 
with Figure 4.10).   
  To gain further insight into the autophagy mechanism affected by HDAC6, we monitored the 
autophagosome markers p62 and LC3bI and II in Lm-infected GM-CSF DCs (Figure 4.20).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. Western-blot levels of autophagy markers during infection with Lm in GM-CSF DCs treated with 
or without various autophagy inhibitors or an autophagy inducer. Left panels: Western-blot analysis of 
autophagy markers over the time-course of Lm infection in Hdac6+/+ and Hdac6-/- DCs. Left panels: Levels of p62, 
LC3bI and II and HDAC6 were detected in (A) control cells and cells treated with (B) the inhibitor of phagosome 
maturation bafilomycin A1 and (C) the activator of autophagy rapamycin. Tubulin was used as a loading control. 
HDAC6 was used as a genotype check of Hdac6+/+ and Hdac6-/- DCs and to monitor HDAC6 induction during 
infection. Right panels: Accompanying charts show quantification of the p62 percentage of control, bafilomycin 
A1 and rapamycin western blots in non-infected cells (NI) and 0, 1, 2, 4 and 6 hpi. NI time was considered the 
100% point to refer other times as percentage from this sample. Two-tailed t-test, ** p≤0.01, * p≤0.05, ns>0.05 
non-significant; n=5. 
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  Hdac6-/- DCs showed a 2-fold higher accumulation of p62 than Hdac6+/+ cells at 6 hpi and increased 
LC3bII level in Hdac6+/+ cells from 1 to 6 hpi (Figure 4.20. A). However, differences in p62 and LC3b 
levels were not found at early times of Lm infection of Hdac6+/+ and Hdac6-/- DCs, indicating that the 
induction of autophagy is not affected in the absence of HDAC6 (Figure 4.20. A).  
  The treatment with bafilomycin A1 enhances the accumulation of p62 during the infection up to the 
same level in both genotypes, abrogating the deficiency in autophagy observed in Hdac6+/+ DCs (Figure 
4.20. B). Although rapamycin also increased p62 accumulation at early times in Hdac6+/+ and Hdac6-/- 
DCs, only Hdac6+/+ cells are able to diminished p62 at 6 hpi (Figure 4.20. C). This treatment confirmed 
the results obtained in the CFUs functional assays with this inhibitor (Figure 4.20. C compared with 
Figure 4.17. B). The similarity of the autophagy defect detected in Hdac6-/- DCs in control condition to 
that in rapamycin-treated Hdac6-/- cells, suggests an impairment in phagocytic vesicle fusion with the 
lysosome.  
  To show all the information about autophagy drugs in a single Western blot, samples of non-infected 
Hdac6+/+ and Hdac6-/- DCs and Lm-infected at 6 hpi, without inhibitors, and treated with an autophagy 
inhibitor (bafilomycin A1) and an activator of autophagy (rapamycin) were shown (Figure 4.21). In 
accordance with data of the previous figure, an increment in p62 level in control Hdac6-/- DCs can be 
observed at 6 hpi, similar p62 levels in bafilomycin A1-treated Hdac6+/+ and Hdac6-/- DCs at 6 hpi, and 
more p62 signal in rapamycin-treated Hdac6-/- DCs (Figure 4.21). 
 
 
 
 
 
 
 
 
 
Figure 4.21. Western-blot levels of autophagy markers in untreated and treated with bafilomycin A1 and 
rapamycin DCs. Western-blot analysis of autophagy markers during Lm infection in Hdac6+/+ and Hdac6-/- GM-
CSF-derived DCs without treatment and treated with bafilomycin A1 and rapamycin. Levels of p62, LC3bI and II 
and HDAC6 were detected. Tubulin and actin were used as a loading controls. HDAC6 was as a genotype check 
of Hdac6+/+ and Hdac6-/- DCs and to monitor HDAC6 induction during infection.  
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4.1.6. Effect of HDAC6 absence in the accumulation of autophagy marker p62  
  In order to further understand the defective autophagy of Hdac6-/- DCs, the accumulation of p62 was 
studied in more detail. Flow cytometry at 6 hpi revealed significantly higher p62 content in Hdac6-/- 
GM-CSF DCs, indicating accumulation of this phagosome marker due to defective fusion of this 
organelle with the lysosome (Figure 4.22). Bafilomycin A1 treatment completely abrogated this 
difference, suggesting that Hdac6-/- DCs displayed an impairment in the final step of autophagy (Figure 
4.22). More signal of Lm is displayed in Hdac6-/- DCs (Figure 4.22). In this regard, bafilomycin A1 
treatment increased the low Lm signal in Hdac6+/+ DCs to the level observed in Hdac6-/- cells (Figure 
4.22). 
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Figure 4.22. The treatment with 
bafilomycin A1 abolishes differences in 
p62 expression or intracellular bacteria at 
6 hpi. (A) The charts show geometric 
means of p62 and Lm gated in the 
MHCII+CD11c+ population of Hdac6+/+ and 
Hdac6-/- GM-CSF DCs without infection 
(NI) and at 6 hpi, with and without 
bafilomycin A1 treatment. (B) The 
representative histograms show p62 and 
Lm with and without bafilomycin A1. Two-
tailed t-test, ***p≤0.001, ** p≤0.01, * 
p≤0.05, ns>0.05 non-significant; n=6. 
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  Confocal fluorescence analysis of Lm-infected DCs revealed increased levels of p62 in Hdac6-/- GM-
CSF DCs (Figure 4.23). Hdac6-/- DCs also showed a higher percentage of p62-Lm co-localization than 
Hdac6+/+ cells, indicating that Hdac6-/- cells have higher number of phagosome-contained bacteria 
(Figure 4.23 in accordance with p62 accumulation observed in Figure 4.20. A and Figure 4.22).  
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Figure 4.23. Confocal microscopy of the phagosome marker p62 co-localization with Lm. Confocal 
microscopy analysis of p62-Lm co-localization in Lm-infected Hdac6+/+and Hdac6-/- DCs at 6 hpi. Left panel: 
Panels show DAPI (blue), Lm (red), p62 (green), and merged views of the three channels, with magnified views 
of the boxed areas. Yellow indicates p62-Lm co-localization. Scale bars 20 µm (main panels) and 10 µm 
(magnified views). Right panel: The chart shows ImarisCell Module analysis of the number of cells and the 
number of bacteria per cell in all pictures (10 pictures per genotype). Co-localization percentages were 
obtained by measuring the p62 channel on the bacterial surface using a threshold of 100. The statistical 
analysis of Imaris quantifications corresponds to the percentage of p62-Lm co-localization at 6 hpi. Two-tailed 
t-test, *p≤0.05; n=10.   
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  Increase of the autophagosomal marker p62 and the consequent accumulation of post-translational 
modification K63-linked poly-ubiquitin chains have been reported during impaired phagosome-
lysosome fusion. Confocal fluorescence microscopy images of K63-linked poly-ubiquitin chains with Lm 
at 6 hpi reveal a higher accumulation of K63 poly-Ub in Hdac6-/- DCs, consistent with a stronger co-
localization of bacteria tagged with this post-translational modification (PTM) (Figure 4.24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 4.24. Confocal microscopy of K63 poly-ubiquitination co-localization with Lm. Maximum intensity z-
projections of confocal microscopy images of K63 polyUb-Lm co-localization in Lm-infected Hdac6+/+ and Hdac6-
/- DCs at 6 hpi. Left panel: Panels show DAPI (blue), Lm (red), K63 polyUb (green), and merged views of the three 
channels, with magnified views of the boxed areas. Yellow indicates Lm-K63 polyUb co-localization. Scale bars 
20 µm (main panels) and 10 µm (magnified views). Right panel: The chart shows ImarisCell Module analysis of 
the number of cells and the number of bacteria per cell in all pictures (10 pictures per genotype). Co-localization 
percentages were obtained by measuring the K63 polyUb channel on the bacterial surface using a threshold of 
82. The statistical analysis of Imaris quantifications corresponds to the percentage of K63 polyUb-Lm co-
localization at 6 hpi. Two-tailed t-test, *** p≤0.001; n=10. 
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Figure 4.25. Confocal microscopy of β-actin co-localization with Lm. Confocal microscopy analysis of actin-Lm 
co-localization in Lm-infected Hdac6+/+ and Hdac6-/- DCs at 6 hpi. Left panel: Panels show DAPI (blue), Lm 
(green), β-actin (red), and merged views of the three channels, with magnified views of the boxed areas. Yellow 
indicates Lm-β-actin co-localization. Scale bars 20 µm (main panels) and 10 µm (magnified views). Right panel: 
The chart shows ImarisCell Module analysis of the number of cells and the number of bacteria per cell in all 
pictures (10 pictures per genotype). Co-localization percentages were obtained by measuring the actin channel 
on the bacterial surface using a threshold of 40.6. The statistical analysis of Imaris quantifications corresponds 
to the percentage of actin-Lm co-localization at 6 hpi. Two-tailed t-test, *** p≤0.001; n=10. 
 
  Confocal fluorescence microscopy study of actin and Lm revealed more frequent co-localization in 
Hdac6-/- than in Hdac6+/+ DCs, indicating that more bacteria are at the cytoplasm to form actin rockets 
in Hdac6-deficient cells (Figure 4.25). 
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4.1.7. Mechanism by which HDAC6 regulates autophagy of Lm 
  More signal of acetylated-cortactin is detected in Hdac6-/- DCs and also higher percentage of 
acetylated-cortactin-Lm co-localization (Figure 4.26).  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 These data could explain the accumulation of p62 and the delay in phagocytic vesicle fusion observed 
in Hdac6-/- DCs, necessary to degrade phagocytosed Lm. 
 
Figure 4.26. Confocal microscopy of acetylated cortactin co-localization with Lm. Confocal microscopy 
analysis of acetylated cortactin-Lm co-localization in Lm-infected Hdac6+/+ and Hdac6-/- DCs at 6 hpi. Left panel: 
Panels show DAPI (blue), Lm (red), acetylated cortactin (green), and merged views of the three channels, with 
magnified views of the boxed areas. Yellow indicates Lm-acetylated cortactin co-localization. Scale bars 20 µm 
(main panels) and 10 µm (magnified views). Right panel: The chart shows ImarisCell Module analysis of the 
number of cells and the number of bacteria per cell in all pictures (10 pictures per genotype). Co-localization 
percentages were obtained by measuring the acetylated cortactin channel on the bacterial surface using a 
threshold of 184. The statistical analysis of Imaris quantifications corresponds to the percentage of acetylated 
cortactin-Lm co-localization at 6 hpi. Two-tailed t-test, *** p≤0.001; n=10. 
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4.2. Study of the role of HDAC6 in the activation of dendritic cell functions by bacterial 
infection and stimulation of TLRs 
4.2.1. Determination of pro-inflammatory genes expression  
  The effect of HDAC6 on the response of DCs to Lm was evaluated by measuring pro-inflammatory 
cytokine gene induction. The relative mRNA levels of type I interferons (interferons α and β) were 
lower in Hdac6-/- DCs at 6 hpi (Figure 4.27. A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27. Expression of Type I interferons, interferon down-stream proteins, pro-inflammatory cytokines, 
chemokine receptor and chemokines in DCs after Lm infection at 6 hpi. PCR analysis of (A) Type-I interferons 
(PanIFN-α and IFN-β), (B) interferon downstream proteins (Mx1, IFIT3 and ISG15), (C) pro-inflammatory cytokines 
(TNF-α, IL-1β and IL-12p40), (D) chemokine receptor (CXCR1) and chemokines (CXCL5 and CXCL10) of Hdac6+/+ 
and Hdac6-/- DCs non-infected (NI) and infected with Lm at 6 hpi (AU: arbitrary units). Two-tailed t-test, 
***p≤0.001, ** p≤0.01, * p≤0.05; n=5-6. 
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  Accordingly, expression of downstream interferon-response genes such as Mx1, IFN-induced protein 
with tetratricopeptide repeats 3 (IFIT3), and ISG15 was also lower in Hdac6-/- DCs (Figure 4.27. B). Lack 
of HDAC6 also decreased the relative mRNA levels of the pro-inflammatory cytokines TNFα, IL-1β and 
IL12p40, indicating impaired cytokine activation after infection (Figure 4.27. C). Similarly, Hdac6-/- DCs 
expressed lower levels than their Hdac6+/+ counterparts of the chemokine receptor CXCR1 and 
chemokines CXCL5 and CXCL10 (Figure 4.27. D). These data demonstrate that Hdac6-deficient DCs 
have a weakened activation response to Lm infection at 6 hpi, which suggests a defect in bacterial 
clearance, consistent with the increased bacterial load in these cells. 
4.2.2. Effect of HDAC6 in pro-inflammatory cytokine secretion after Lm infection 
  To confirm these data, we monitored pro-inflammatory cytokines and IFN-β in the supernatants of 
Lm-infected DCs. Early after infection, TNFα, IL-1β, IL-6, IL12p70 and IFN-β levels were lower in 
supernatants from Hdac6-/- cells than in those from Hdac6+/+ cells, and this difference held at 12 and 
24 hpi (Figure 4.28).  
 
 
 
 
 
 
 
 
 
   
  To exclude a defect in cytokine secretion, we compared cytokine levels in supernatants (S) with the 
levels in supernatants plus their corresponding cell pellets (S+P). Both analyses showed decreased 
cytokine levels in Hdac6-/- cells, indicating an impaired antibacterial response in Hdac6-deficient DCs 
(Figure 4.29). 
Figure 4.28. Pro-inflammatory cytokines secreted by Lm-infected DCs. ELISA analysis of the pro-inflammatory 
cytokines TNFα, IL1β, IL6 and IL12p70 (pg/ml) and IFN-β in supernatants of Hdac6+/+ and Hdac6-/- DCs at 6, 12 and 
24 hpi with Lm. Two-tailed t-test, ***p≤0.001, ** p≤0.01, * p≤0.05 ns>0.05 non-significant; n=5-6. 
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Figure 4.29. Comparison of secreted versus intracellular+secreted pro-inflammatory cytokines. ELISA detection 
of the pro-inflammatory cytokines IL-1β and IL12p70 (pg/ml) in supernatants (S) and in supernatants plus the 
corresponding cell pellets (S+P) of Lm-infected Hdac6+/+ and Hdac6-/- DCs at 6, 12 and 24 hpi. Two-tailed t-test, 
***p≤0.001, ** p≤0.01, * p≤0.05, ns>0.05 non-significant; n=5. 
 
 
 
 
 
 
 
 
 
4.2.3. Influence of HDAC6 in the microbicidal activity of iNOS 
  Measurement of nitrite in supernatants of infected-DCs revealed higher nitric oxide production by 
Hdac6+/+ DCs than in Hdac6-/- DCs at 24 hpi (Figure 4.30. A). 
 
 
 
 
 
 
 
 
 
 
Figure 4.30. Lm activated iNOS activity in DCs. (A) Nitrite levels in supernatants of Lm-infected DCs at 6, 12 and 
24 hpi. Two-tailed t-test, ***p≤0.001; n=5. (B) Top panel: Western-blot analysis of iNOS over the time-course of 
infection. β-actin was used as a loading control. Lower panel: The chart shows quantification of iNOS at 4 and 6 
hpi. Two-tailed t-test, ** p≤0.01, * p≤0.05; n=4 (C) Left: The panel shows representative histograms of iNOS 
expressed by Hdac6+/+ and Hdac6-/- DCs after exposure to live Lm or HKLM for 24 h (left). Right: The chart shows 
the geometric mean of iNOS expression. Non-infected (NI) DCs were used as a control of iNOS induction. Two-
tailed t-test, **p≤0.01; n=6.  
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  In agreement, western blot revealed lower levels of inducible nitric oxide synthase (iNOS) in Hdac6-/- 
DCs at 4 and 6 hpi (Figure 4.30. B), indicating a delay of the enzyme induction in Hdac6-/- DCs. Likewise, 
flow cytometry after exposure of DCs to live or heat-killed Listeria monocytogenes (HKLM) revealed 
higher expression of iNOS in Hdac6+/+ DCs in both cases (Figure 4.30. C). These data support the 
involvement of HDAC6 in the activation of DC-mediated iNOS microbicidal responses to Lm infection 
and in the clearance of this intracellular pathogen. 
4.2.4. Study of the expression of MHC co-stimulatory molecules on the membrane 
  Flow cytometry assay of Lm infected-GM-CSF-DCs at 24 hpi showed higher level of expression of 
membrane CD86 and CD40, both molecules routinely used as markers of co-stimulation of MHC (Figure 
4.31).  
 
 
 
 
 
 
 
 
 
 
 
 
  The MHC-II+CD11c+ population of DCs were gated to check geometric means of CD86 and CD40, and 
non-significant differences in the percentage of this population were detected between Hdac6+/+ and 
Hdac6-/- DCs (Figure 4.32). However, the MHC-II+CD11c+ population express higher levels of MHC-II 
and CD11c molecules on the cell surface in Hdac6+/+ DCs (Figure 4.32). These results are in accordance 
with the observation of iNOS and pro-inflammatory cytokines, supporting the hypothesis of a stronger 
activation of Hdac6+/+ DCs after Lm infection than Hdac6-/- ones. 
Figure 4.31. CD86 and CD40 
membrane expression after Lm 
infection. (A) The charts show 
geometric means of CD86 and CD40 
gated in live MHCII+CD11c+ 
population of Hdac6+/+ and Hdac6-/- 
DCs without infection (NI) and 24 h 
after exposure to Lm. Two-tailed t-
test, ***p≤0.001, ** p≤0.01, ns>0.05 
non-significant; n=6. (B) The 
representative histograms show 
CD86 and CD40. Non-infected NI DCs 
were used as a control of CD86 and 
CD40 induction.  
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4.2.5. Function of HDAC6 in the activation of MAPK- and mTOR-signalling 
pathways 
  The diminished activation response against Lm in Hdac6-/- DCs is consistent with impaired TLR-related 
signalling. To investigate this question, we determined the phosphorylation levels of TLR downstream 
mediators by western blot. Compared with Hdac6+/+ DCs, Hdac6-/- DCs showed weaker phosphorylation 
signals for ERK and AKT after Lm infection (Figure 4.33. A and B).  
 
 
 
 
 
 
 
 
 
 
 A
B 
Figure 4.33. MAPK  and AKT activation after Lm infection. Western-blot analysis of MAPK activation ERK1/2 
and AKT over the time-course of Lm infection in Hdac6+/+ and Hdac6-/- DCs. Left: Total and phosphorylated (A) 
ERK and (B) AKT were detected. Tubulin was used as a loading control. Right: Accompanying charts show 
quantification of (A) phERK/totalERK and (B) phAKT/totalAKT ratios relative to the loading control, ns non-
significant; n=7 (right).  
Figure 4.32. MHC-II and CD11c membrane expression after activation of DCs with Lm infection. (A)The chart 
displays the percentage of live cells of Hdac6+/+ and Hdac6-/- DCs gated as MHC-II+CD11c+.Non-infected (NI) and 
24 hpi Lm-infected conditions were tested. Two-tailed t-test, ns>0.05 non-significant; n=6. (B) The charts show 
geometric means of MHC-II and CD11c gated in live MHCII+CD11c+ population of Hdac6+/+ and Hdac6-/- DCs 
without infection (NI) and 24 h after infection with Lm. Two-tailed t-test, ** p≤0.01, * p≤0.05, ns>0.05 non-
significant; n=6.  
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  We next examined the effect of HDAC6 deficiency on TLR-signalling pathways using other TLR stimuli, 
including HKLM and LPS. AKT phosphorylation in Hdac6-/- DCs was decreased after LPS or HKLM 
treatment compared to Hdac6+/+, confirming defective TLR activation (Figure 4.34. A and B).  
 
 
 
 
 
 
 
 
 
 
 
  These effects are not related to a defect in Lm-induced transcriptional induction since mRNA levels 
of different Lm-related TLRs (TLR1, 2, and 6) were similar in Hdac6+/+ and Hdac6-/- GM-CSF DCs (Figure 
4.35).  
 
 
 
 
 
 
Figure 4.35. mRNA expression of TLRs involved in the detection of Lm PAMPs. RT-q-PCR analysis of TLR-1, 2 
and 6 (AU: arbitrary units) in Hdac6+/+ and Hdac6-/- DCs non-infected (NI) and after Lm-infection at 6 hpi. Two-
tailed t-test, ns>0.05 non-significant; n=6. 
Figure 4.34. Induction of AKT phosphorylation in BMDCs after stimuli with HKLM and LPS. Left: Western-blot 
analysis in Hdac6+/+ and Hdac6-/- DCs over the time-course of (A) HKLM or (B) LPS treatment. Total and 
phosphorylated AKT were detected for both treatments.  Right: Accompanying charts on the right show 
quantification, indicating the percentage of phAKT/total AKT ratio. Two-tailed t-test, ** p≤0.01, * p≤0.05; n=4.    
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  Moreover, Hdac6-/- DCs showed weaker phosphorylation of mammalina target of rapamycin complex 
1 (mTORC1) pathway proteins (mTORC1 downstream substrates p70S6K and S6), consistent with a less 
pronounced pro-inflammatory response after TLR-activation by pathogen-associated molecular 
patterns (PAMPs) (Figure 4.36). 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.6. Pro-inflammatory cytokine secretion after stimulation with TLR agonists 
  To determine whether Hdac6-/- DCs showed a similar defective response to other TLR agonists, we 
first examined secretion of pro-inflammatory cytokines in response to agonists of TLR1-2 (Pam3GSK4), 
TLR-4 (LPS), TLR-7-9 (Imiquimod), and multiple TLRs (heat-killed Salmonella Typhimurium; HKST). 
Hdac6-/- DCs showed a defective cytokine response to these stimuli, determined from the release of 
TNFα, IL-6, IL-1β and IL12p70 (Figure 4.37. A-D). 
 
 
Figure 4.36. mTOR activation after Lm infection. Top panel: Western-blot analysis of mTORC1 pathway 
activation over the time-course of Lm infection in Hdac6+/+ and Hdac6-/- DCs. Levels of phosphorylated and total 
p70S6K and S6 were detected. Tubulin was used as a loading control. Lower panel: Accompanying charts show 
quantification of php70S6K/total70S6K (n=5) and phS6/totalS6 (n=7) ratios relative to the loading control.  Two-
tailed t-test, ** p≤0.01, ns non-significant. 
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Figure 4.37. Pro-inflammatory 
cytokines secreted by DCs after 
stimulation with various TLR 
agonists.  ELISA analysis of the pro-
inflammatory cytokines TNFα, IL-
1β, IL-6 and IL12p70 (pg/ml) in 
supernatants of Hdac6+/+ and 
Hdac6-/- DCs after treatment for 6, 
12 and 24 h with (A) Pam3GSK4, 
(B) LPS (C) Imiquimod and (D) 
HKST. Two-tailed t-test, 
***p≤0.001, ** p≤0.01, * p≤0.05, 
ns>0.05 non-significant; n=5-6.  
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  To assess the pro-inflammatory cytokine response to TLR3 and TLR5 ligands, we generated Fms-
related tyrosine kinase 3 ligand-derived dendritic cells (FLT3L-derived DCs). Differentiation with the 
cytokine FLT3L yielded similar percentages of CD24+ and CD24- subpopulations (CD11c+CD11b+B220-
CD24+ and CD11c+CD11b+B220-CD24-, respectively) from Hdac6+/+ and Hdac6-/- DCs, indicating that 
differentiation is unaffected by HDAC6 absence (Figure 4.38).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  The TLR agonists Pam3GSK4 (TLR1-2), Poly(I:C) (TLR3), LPS (TLR4), flagellin (TLR5), Imiquimod (TLR-7-
9), Lm, HKLM, and HKST (which activates several TLRs simultaneously) elicited similar cytokine 
secretion profiles in GM-CSF DCs and FLT3L-DCs (Figure 4.39. A and Figure 4.39. B compared to Figure 
 
 
Figure 4.38. Characterization of FLT3L-derived DCs at day 11 of differentiation. Left: Dot-plots of FLT3L-derived 
DC cultures at day 11 of differentiation, showing gating for the CD11c+ population (percentages indicated). 
Centre: Dot-plots showing CD11b versus B220 to select two populations: CD11c+CD11b+B220+ (plasmacytoid 
DCs, pDCs) and CD11c+CD11b+B220- (conventional DCs, cDCs) (percentages indicated). Right: Dot-plots showing 
CD11b versus CD24 to select the CD11b+CD24+ and CD11b+CD24- populations (gated from cDCs) (percentages 
indicated). The charts on the right show the percentages of CD11c+, CD11c+CD11b+B220-CD24- and 
CD11c+CD11b+B220-CD24+ populations. Two-tailed t-test, ns>0.05 non-significant; n=6. 
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4.37. A-D). Hdac6-/- DCs of both origins showed an impaired cytokine response to each TLR agonist, 
indicating that HDAC6 likely regulates a common TLR signalling adaptor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.39. Pro-inflammatory cytokines IL-6, IL-1β, IL-12p70 and TNF-α secreted by FLT3L-derived DCs after the 
stimulation with various TLR agonist. ELISA detection of the pro-inflammatory cytokines IL-6, IL-1β, IL-12p70 and 
TNF-α (pg/ml) in supernatants of Hdac6+/+ and Hdac6-/- FLT3L-derived DCs activated with LPS, Imiquimod, 
Pam3GSK4, HKLM, HKST, Lm, Poly(I:C) or flagellin for (A) 6 h and (B) 24 h. Two-tailed t-test, ***p≤0.001, ** p≤0.01, 
* p≤0.05; n=6.  
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4.2.7. Consequence of HDAC6 defect in the activation of TLR-signalling pathway  
  In this view, the TLR adaptor MyD88 participates in the transmission of signals by all TLRs except for 
TLR3. We decided to study MyD88 levels in a time-course infection with Lm by western blot, 
demonstrating that the quantity of this molecule was the same in Hdac6+/+ and Hdac6-/- DCs and 
remained stable during infection (Figure 4.40).  
 
 
 
 
 
 
  
 Remarkably, MyD88-HDAC6 molecular association was observed by co-immunoprecipitations of 
endogenous proteins using human dendritic cells after Pam2GSK4, Pam3GSK4 and HKLM stimulation 
(Figure 4.41).  
 
 
 
 
 
 
 
  Likewise, the MyD88 immunoprecipitation in MyD88- and HDAC6-overexpressing HEK cells was also 
able to co-precipitate HDAC6 (Figure 4.42). 
Figure 4.41. Molecular association of HDAC6 
with the MyD88 adaptor protein. 
Immunoprecipitation of endogenous (A) HDAC6 
and (B) MyD88 followed by western-blot for both 
proteins. Immunoprecipitations were carried out 
using human moDCs after 30 min of stimulation 
with Pam2GSK4, Pam3GSK4 and HKLM. 
Molecular weight of endogenous HDAC6 (130 
KDa) and MyD88 (33 KDa) are indicated at the 
right of western-blot. Similar results were 
obtained in two independent experiments. 
A 
B 
Figure 4.40. Levels of MyD88 adaptor protein during Lm infection.  Left: Western-blot analysis of MyD88 
protein level over the time-course of Lm infection in Hdac6+/+ and Hdac6-/- DCs. Tubulin was used as a load 
control. NI correspond to non-infected cells and infected cells are displayed as 0, 1, 2, 4 and 6 hpi. Right: 
Accompanying charts show quantification of the percentage of MyD88. MyD88 levels were normalized with its 
corresponding tubulin and expressed as percentage in arbitrary units. NI sample is considered as 100% of signal 
and the rest of samples are relativized to it. Two-tailed t-test, ns non-significant; n=5. 
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  These results were corroborated by mass spectrometry analysis of MyD88 immunoprecipitates; 
which in addition detected two acetylated peptides corresponding to MyD88 (Figure 4.42. B and Figure 
4.43).  
 
 
 
 
 
 
 
 
 
Figure 4.43. Acetylated lysines on MyD88 adaptor protein. MS2 fragmentation spectra from the peptides 
showing at 1217.0699 (Top), and 599.3803 (Bottom). Ion adscription to carboxy- (y ions, blue) and amino-
terminal (b ions, red) fragmentation series is indicated. Kac denotes acetylated lysine and Ccm indicates 
carbamidomethylated cysteine. Fragment ion sequence coverage is schematically indicated. Similar results were 
obtained in three independent experiments. 
 
 
Figure 4.42. Molecular association of HDAC6 and MyD88 adaptor protein. (A) Immunoprecipitation of HA 
(MyD88) followed by western-blot for HDAC6 and MyD88. Immunoprecipitations were carried out using 
different HDAC6-eGFP plasmids co-transfected with MyD88-HA in HEK cell line. Over-expressed (HDAC6-eGFP, 
160 kDa) is indicated at right of western-blot. Similar results were obtained in three independent experiments. 
(B) Immunoprecipitation of HA (MyD88) followed by mass spectrometry analysis. Immunoprecipitations were 
carried out using different HDAC6-eGFP plasmids co-transfected with MyD88-HA in HEK cell line. The number 
of unique MyD88 and HDAC6 peptides identified is indicated. (*) indicates the presence of acetylated MyD88 
peptides. Similar results were obtained in three independent experiments.  
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  The same approach was used to determine MyD88-HDAC6 molecular association after TLR-2 
activation with HKLM using a constitutively expressed human TLR-2 HEK cell line, rendering the same 
result (Figure 4.44). This association is also maintained using a double-deacetylase domain mutant of 
HDAC6 (H216A:H611A), called HDAC6-DD, indicating that HDAC6-MyD88 interaction is independent of 
its catalytic activity (Figure 4.42 and Figure 4.44). The knock-down of HDAC6 expression using a small 
hairpin plasmid (sh-HDAC6) blocked this interaction (Figure 4.42 and Figure 4.44). 
   However, no acetylated peptides could be detected in the mass spectrometry analysis of the MyD88 
immunoprecipitation from HKLM-stimulated TLR-2 HEK cell line (Figure 4.44. B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Moreover, assessment of Nuclear factor-κB (NF-κB) induction in TLR-2-expressing HEK cells after 
HKLM, Pam2GSK4 and Pam3GSK4 stimulation shows lower activation only in shHDAC6 transfected 
cells, without affecting the activity of HDAC6-DD-transfected cells (Figure 4.45). 
 
 
Figure 4.44. Molecular interaction of HDAC6 with the MyD88 adaptor protein. (A) Immunoprecipitation of HA 
(MyD88) followed by western-blot for HDAC6 and MyD88. Immunoprecipitations were carried out using 
different HDAC6-eGFP plasmids co-transfected with MyD88-HA in HEK-Blue hTLR2 cell line after 30 min of 
stimulation with HKLM. Over-expressed (HDAC6-eGFP, 160 KDa) and endogenous HDAC6 (130 KDa) are 
indicated at right of western-blot. Similar results were obtained in four independent experiments. (B) 
Immunoprecipitation of HA (MyD88) followed by mass spectrometry analysis. Immunoprecipitations were 
carried out using different HDAC6-eGFP plasmids co-transfected with MyD88-HA in HEK-Blue hTLR2 cell line 
after 30 min of stimulation with HKLM. The number of unique MyD88 and HDAC6 peptides is indicated. No 
acetylated peptides from MyD88 were detected in any sample. Similar results were obtained in four 
independent experiments. 
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  Taking into account all these data, we concluded that HDAC6 associates with the TLR-adaptor 
molecule MyD88, and the absence of HDAC6 in DCs seems to diminish the TLR-response after a variety 
of stimuli, underlining the scaffold role of HDAC6 in determining the ability of MyD88 to mediate TLR 
signalling. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.45. NF-κB induction after TLR-2 activation. Graph of NF-κB induction in transfected HDAC6-WT, HDAC6-
DD and shHDAC6 HEK-Blue hTLR2 cell line after activation with HKLM, Pam2GSK4 and Pam3GSK4 during 8 h. NF-
κB induction was calculated by the ratio of the signal of stimulated cells with its corresponding transfected cells 
in basal condition (without stimuli). Two-tailed t-test, ***p≤0.001, ** p≤0.01, * p≤0.05, ns>0.05 non-significant; 
n=6.  
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4.2.8. Evaluation of the HDAC6 role in the in vivo TLR-dependent inflammatory 
response  
  To ascertain the defective TLR-dependent inflammatory response in vivo due to the molecular 
MyD88-HDAC6 association, Hdac6+/+ and Hdac6-/- mice were intravenously injected with a lethal dose 
of Lm (Figure 4.46. A) [150]. A protective effect against Lm-induced septic shock was observed from 3 
to 10 days post-infection (dpi) (Figure 4.46. A). Accordingly, lower levels of the pro-inflammatory 
cytokine IL-6 were detected in the serum of Hdac6-/- mice at 72 hpi, highlighting a reduced systemic 
cytokine-driven inflammatory response after Lm infection in these mice (Figure 4.46. B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  No significant differences in spleen and liver bacterial load were found between Hdac6+/+and Hdac6-
/- from 12 to 48 hpi (Figure 4.47). However, higher bacterial burden was distinguished in target organs 
of Lm-induced septic shock Hdac6+/+ mice at 72 hpi (Figure 4.47). This observation is in accordance 
with the increased IL-6 level in Hdac6+/+ mice sera at 72 hpi, suggesting an impairment of the anti-
bacterial clearance response in these animals (Figure 4.47 and compared with Figure 4.46. B). 
Figure 4.46. Inflammatory response of Hdac6-/- mice to Lm. (A) Survival curve to intravenous injection with a 
lethal dose of Lm in Hdac6+/+ and Hdac6-/- is showed. This curve corresponds to two different experiments of 
survival to Lm with a n=24-21. Long-rank (Mantel-Cox) test and Cehan-Breslow-Wilcoxon test, ***p≤0.001. (B) 
Pro-inflammatory cytokine IL-6 was measured in sera of Hdac6+/+ and Hdac6-/- mice intravenously injected with 
a lethal dose of Lm at 12, 24, 48, 72 and 96 hpi and NI (non-infected). Two-tailed t-test, *p≤0.05, n=5. 
 
B  
 
 
A 
109 
 
 
Figure 4.47. Bacterial burden in target organs of Hdac6-/- mice. Quantification of bacterial load in target organs, 
(A) spleen and (B) liver, at 12, 24, 48 and 72 hpi in Hdac6+/+ and Hdac6-/- mice injected with a lethal dose of Lm. 
Bacterial load is expressed by CFUs per gram of spleen and per gram of liver. Two-tailed t-test, **p≤0.01, n=6. 
A B 
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5. DISCUSSION   
  Here we present evidence suggesting a critical role for HDAC6 in the regulation of innate immune 
responses. Our results underscore a fundamental role of HDAC6 in almost every step of dendritic 
cell functions against the intracellular bacteria Lm, starting with the control of bacterial degradation 
by autophagy, cytokine production and regulation of the outcome of anti-bacterial host response. 
By regulating the fusion of autophagosomes with lysosomes, HDAC6 is able to degrade invading 
pathogens and reduce bacterial burden, which is critical to efficiently initiate the signalling pathways 
involved in anti-bacterial response. In addition, our results on the functional regulation of HDAC6 
during TLR stimulation of pro-inflammatory cytokine production after Lm infection demonstrate the 
scaffold role of HDAC6 in the TLR-signalling pathway as a MyD88-interacting protein, providing a 
novel role of HDAC6 in the activation of innate immune responses against intracellular bacteria 
infection. Finally, we present evidence indicating a major role of HDAC6 in the context of pro-
inflammatory cytokine production, which is associated with the exhacerbated inflammatory 
cytokine storm found during septic shock caused by Gram-positive bacteria. These results open a 
new field for the application of HDAC6 specific inhibitors in septic shock cases to avoid exacerbated 
inflammation.  
5.1. Analysis of HDAC6 contribution to cellular mechanisms that eliminate intracellular 
bacteria by phagocytic cells 
  Recent studies have revealed the involvement of HDAC6 in the innate immune response against 
Influenza Virus A (IVA), Sendai virus (SeV), and vesicular stomatitis virus (VSV) [243,271,15,93]. Given 
the similarities between the innate responses to viruses and intracellular bacteria, this prompted us to 
investigate the role of HDAC6 in a model of Listeria monocytogenes infection. In this work, we 
demonstrate a dual role of HDAC6 in the innate response against Lm, not only due to its enzymatic 
activity but also dependent of its function as a scaffold protein (Figure 5.1 and Figure 5.3).   
5.1.1. Effect of HDAC6 absence in the intracellular pathogen clearance of dendritic 
cells  
  Our results describe an internalization up to 20 bacteria per DC as it has been previously described in 
phagocytic cells [195]. The significant median bacterial uptake by GM-CSF DCs was observed in cases 
of 6-7 bacteria per cell, although the distribution of the number of phagocyted bacteria per cell 
indicates that Hdac6-/- DCs display higher Lm titres than Hdac6+/+ DCs independently of the number of 
bacteria per cell. Our data clearly demonstrate that Hdac6-/- DCs have an impaired immune response 
against Lm and S. Typhimurium infection in vitro. Moreover, higher Lm titres observed in Hdac6-/- DCs, 
                                                                                                                 Discussion 
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M-CSF-derived macrophages and peritoneal macrophages were corroborated during in vivo Lm 
infection at 6 hpi in various myeloid subsets of the spleen, including monocytes, neutrophils, cDCs, and 
TipDCs. The absence of this effect during DC in vitro infection by the non-intracellular bacteria S. aureus 
and E. coli DH5α indicates that Hdac6-/- DCs are specifically unable to efficiently clear intracellular 
pathogens.  
5.1.2. Evaluation of cellular clearance mechanisms of Lm  
  Intracellular pathogens have developed specialized tools to evade cellular clearance mechanisms. For 
instance, S. Typhimurium uses a type-III secretion system to escape form Salmonella-containing 
vacuoles (SCVs), whereas Lm uses the pore-forming enzyem LLO and two phospholypases, PlcA and 
PlcB, to reach the host cell cytosol.  
  Additionaly, HDAC6 is involved in two of the most important cellular clearance systems, autophagy 
and ubiquitin-proteasome pathway (UPP) [127,186]. In the case of Lm and S. Typhimurium, the main 
molecular mechanism for degradation of vesicle-contained bacteria is fusion with lysosomes in a 
process called autophagy [205,197,24]. In agreement with this, our data show that impaired 
phagosome-lysosome fusion underlies the phenotype observed in Hdac6-/- DCs. 
  It has been previously reported that unsuccessful phago-lysosomal fusion depends on acetylated-
cortactin in Hdac6-deficient cells [127]. This mechanism was first described in Hdac6-deficient mouse 
embryonic fibroblasts (MEFs) during quality-control autophagy [127]. Quality-control autophagy is a 
selective autophagy as well as the specific autophagy of Lm that we have observed in this work, which 
is commonly known as xenophagy. We demonstrate here that in Hdac6-/- DCs co-localize higher levels 
of acetylated-cortactin with intracellular Lm. The delay in vesicle fusion caused by the acetylation of 
cortactin, impairs the phagosome-lysosome fusion and provides more opportunities for phagosome-
containing bacteria to escape to the cytosol, resulting in the higher bacterial load detected in Hdac6-/- 
DCs. Based on this experimental evidence, it is conceivable to postulate that the enzymatic activity of 
HDAC6 on its substrate cortactin controls autophagy of intracellular bacteria for their efficient 
clearance (Figure 5.1 part 1 and Figure 5.3 part 1). Hence, Hdac6-/- DCs displays higher levels of 
acetylated cortactin and consequently more Lm burden. 
5.1.3. Consequence of the lack of HDAC6 in the autophagy of Lm 
  Pharmacological autophagy inhibitors erased the observed differences between Hdac6+/+ and Hdac6-
/- DCs, remarking the impaired autophagy detected in Hdac6-/- DCs. Conversely, rapamycin did not 
overcome the Hdac6-/- autophagy defect. Rapamycin inhibits mTOR activity, causing an increment of 
the autophagic flux. Increased p62 levels were observed after rapamicyn treatment, although Hdac6-
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/- DCs accumulated higher p62 levels at 6 hpi compared to Hdac6+/+ DCs, indicating a defect in the last 
step to autophagy, the phagosome-lysosome fusion. Accordingly, similar results were obtained after 
the treatment with inhibitors  of acidification of lysosomal enzymes, such as NH4Cl and cloroquine, 
further sopporting this observation. However, other authors have reported opposite observations 
using pan-HDAC inhibitors (HDACi) or specific inhibitors of HDAC6 (HDAC6i) during infection of human 
macrophages with the Gram-negative intracellular pathogens S. Typhimurium and E. coli [5]. These 
inhibitors, when added at the time of infection, increase mitochondrial ROS production [5]. Overnight 
pre-treatment with HDACi before infection hampers bacterial clearance and reduces phagocytosis [5]. 
These data indicate that specific HDAC6 chemical inhibitors can have side-effects, including effects on 
other HDAC members, potentially interfering with the acetylation of other substrates upstream of 
cortactin that also have a role during bacterial infection. We have not observed any significant 
difference during bacterial entry between Hdac6-/- and Hdac6-/- DCs. Results obtained afterovernight 
pre-treatment with HDAC6i in phagocytosis indicate additional acetylations on cytoskeleton proteins 
that do not occur in Hdac6-/- DCs. Hence, our genetic approach unequivocally assigns a specific role to 
HDAC6 in innate cells during bacterial infection.  
5.1.4. Effect of HDAC6 absence in the accumulation of autophagy marker p62   
  Although we observed an impairment in phagosome-lysosome fusion, we cannot rule out an 
involvement of HDAC6 in the anti-microbial response through its BUZ domain, with a contribution from 
ubiquitin. The characterized interaction between p62 and HDAC6 through their ubiquitin-binding 
domains provides a clue about the possible role of ubiquitin in the activation of innate immunity 
through the recognition of ubiquitinated-molecules [262]. For example, the ubiquitin-binding regions 
of HDAC6 and p62 are both essential for MyD88 aggregation and the downstream activation of MyD88-
dependent signal transduction [97]. Furthermore, ubiquitin-binding platforms formed by HDAC6 and 
p62 are able to interact with interferon stimulated gene 15 (ISG15) to eliminate ISGylated proteins 
tagged after interferon stimulation by autophagy [166]. These ubiquitin-binding platforms also bind 
protein aggregates tagged by lysine 63 (K63)-linked polyubiquitin (polyUb) chains and degrade them 
by autophagy. HDAC6 is able to bind to either mono- and poly-Ub proteins, but shows a preference for 
proteins modified with K63-linked polyUb chains, which share structural similarities with ISG15 
[180,179]. S. Typhimurium is decorated with this kind of ubiquitin topology for recognition by host 
cells, and can be recovered with phagosome proteins to initiate autophagy [210]. Nevertheless, we 
were not able to detect K63 polyUb signal at early times of infection in our Lm-infected DC samples 
(data not shown). Consequently, our data demonstrate that autophagy induction does not differ 
between Hdac6+/+ and Hdac6-/- DCs, indicating that this phenotype is due to p62 accumulation in 
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Hdac6-/- BMDCs as a consequence of impaired phagosome-lysosome fusion. Intact autophagy 
activation in Hdac6-/- DCs could be explained by compensatory p62 binding to ubiquitinated bacteria 
in the absence of HDAC6. However, higher K63 polyUb signal detected in in Hdac6-/- DCs at late time 
of infection (about 6 hpi) is clearly in accordance with the observation of higher p62 levels co-localizing 
with Lm in these DCs. Besides, it has been previously reported that an impaired autophagy results in 
the accumulation of the p62 autophagy marker and the subsequent increased amount of polyUb 
proteins.  Together, these data indicates that HDAC6-deficient cells display an altered accumulation of 
p62 and K63 polyUb proteins due to the impared phagolysosomal fusion. 
5.2. Study of the role of HDAC6 in the activation of dendritic cell functions by bacterial 
infection and stimulation of TLRs 
  Our data also underscore another different function of HDAC6 in the innate immune response to 
intracellular bacteria and various TLR stimuli, independent of its enzymatic activity on cortactin  (Figure 
5.1 and Figure 5.3). Upon infection, the activation of pro-inflammatory responses to alert immune 
system cells is an essential step for the elimination of intracellular pathogens. 
5.2.1. Impaired inflammatory response 
  We provide evidence for a dampened inflammatory response in the absence of HDAC6, as shown by 
lower RNA levels of pro-inflammatory cytokines, chemokines, type-I interferons, and interferon-
related proteins in Hdac6-/- DCs than in Hdac6+/+ cells at 6 hpi, as well as the lower pro-inflammatory 
cytokine production of IL-1β, IL-6, IL-12p70 and TNF-α by Lm infected Hdac6-/- DCs from 6 to 24 hpi. 
This global diminished production of pro-inflammatory cytokines could reflect a defect in the TLR-
signalling pathway. 
   Whole pathogens and their constituents contain Pathogen-asssociated molecular patterns (PAMPs) 
that activate TLRs, NLRs and other cytosolic receptors in host cells [108,162]. These receptors 
recognize general molecular patterns of microbes to rapidly activate the immune response. Upon Lm 
entry, heterodimers of TLR-2/6 and TLR-1/2 recognize respectively di-acyl- and tri-acyl-lipopeptides of 
Lm. Then, a receptor-signalling complex is triggered upon TLR activation where signalling proteins are 
modified by PTMs such as phosphorylation and ubiquitinaiton [234,198]. Both are reversible PTMs that 
allow transient protein-protein interactions occurring during signal transduction.  
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Figure 5.1. Dual role of HDAC6 during Lm infection in DCs. The figure shows two HDAC6 functions in Lm-infected 
DCs, the autophagy and the TLR signalling. (1) Autophagy: The deacetylation of cortactin by HDAC6 allows the 
correct phago-lysosomal fusion and the subsequent clearance of Lm. However, this bacterium is able to avoid 
autophagic degradation by the expression of LLO protein. Besides, Lm spread through the cytosol using ActA 
protein to polymerize cell host actin. (2) TLR-signalling pathway: Di- and tri-acyl lipopeptides and peptidoglycan 
(PGN) of Lm are recognized by TLR-2/6 and TLR-1/2, flagellin by TLR-5 and CpG DNA by TLR-9 upon Lm entry. 
HDAC6 interacts with the TLR-adaptor protein MyD88, enhancing down-stream TLR-signalling, (increasing NF-κB 
and MAPK activation). This stronger activation seems to be independent of HDAC6 enzymatic activity and causes 
higher pro-inflammatory cytokine production and more iNOS induction, necessary for the correct activation of 
anti-bacterial transcription program. Note that both processes occur during Lm infection and the pro-
inflammatory cytokines and iNOS induction can impact on the autophagic process. The images in the figure are 
not scaled. 
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  The TLR universal adaptor protein MyD88 is also activated, together with other adaptor protein called 
TIRAP  (Toll/Interleukin-1 receptor domain containing adapter protein) or MAL (MyD88-adapter-like), 
followed by Interleukin-1 receptor-associated kinases (IRAK) 1, 2 and 4, TNF receptor-associated factor 
6 (TRAF-6), finally transducing nuclear signals through Activator Protein 1 (AP-1) and NF-κB TFs leading 
to pro-inflammatory cytokine secretion [172]. In this regard, the E3-ubiquitin protein ligase TRAF-6 
catalizes the formation of K63-linked polyUb chains and participates in the canonical NF-κB activation 
pathway, ubiquitinating Transforming growth factor-β (TGF-β) Activated Kinase 1 (TAK1): TAK-1 
binding proteins 1, 2 and 3 (TAB1-3) and NF-κB essential modulator (NEMO):IκB kinase (IKK) complexes 
[48,105,139]. The canonical IKK complex is formed by two kinases, IKKα and IKKβ and their regulatory 
protein NEMO, which has an ubiquitin-binding domain (UBD) that recognizes K63-linked polyUb 
chains, an essential step for the activation of the NF-κB pathway [64,258]. In this case, K63-Ub chains 
function as molecular scaffolds for the recruitment of both IKK and TAK1 complexes, enhancing the 
TAK1-dependent activation of the IKKs [64,258]. Hence, ubiquitination of proteins belonging to the TLR 
signalling complex can fine tune innate immune responses to pathogens [142].  
  It has been also described that the expression of HDAC6 in the nucleus deacetylates p65 subunit of 
NF-κB, reducing its capacity to bind the Matrix metalloproteinase 2 (MMP2) promoter thereby causing 
the inhibition of tumour invasion [263]. Hence, deacetylation of NF-κB by HDAC6 adds more complexity 
to signalling regulation. Moreover, a suppressed activation of NF-κB and AP-1 pathways has been 
observed in HDAC6-silenced cells after HIV-1 Tat-stimulation [226]. Moreover, Lm-derived lipoteichoic 
acids and LLO induce NF-κB signalling during infection, which seems to be MyD88-independent 
[87,109]. TAB2 and TAB3 are receptors which preferentially bind K63-linked polyUb chains through a 
highly conserved zinc finger domain (ZnF), very similar to the HDAC6 BUZ domain [105]. PolyUb-
binding domains represent a new class of signaling structures that regulate protein kinase activity 
through a nonproteolytic mechanism. This issue may suggest a specific role of HDAC6 as an Ub-binding 
receptor in the NF-κB pathway, and this is in accordance with the lower phosphorylation observed in 
downstream MAPK signalling pathway in Hdac6-/- DCs. The Figure 5.2 summarizes the tentative model 
of HDAC6 regulation of MyD88-dependent TLR-signalling pathway during Lm infection. 
  Moreover, during TLR-signalling MAPKs are also activated and the microbicidal activity of iNOS is 
induced [108]. For instance, HIV-1 Tat-induced activation in HDAC6-silenced cells shows a reduced 
induction of MAPKs, including ERK, c-Jun N-terminal kinase (JNK) and p38 signalling pathways [226]. In 
fact, Hdac6-/- DCs show diminished iNOS induction at 6 hpi associated with low nitrite production and 
iNOS expression at longer times of Lm infection (24 hpi). These results are in accordance with a lower 
phosphorylation of the MAPK pathway after Lm infection in Hdac6-/- DCs, controlling the activation of 
the AP-1 family of TFs, which is necessary to switch-on pro-inflammatory responses [108]. 
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  In addition, the lower phosphorylation of mTORC1 pathway components in Hdac6-/- DCs is consistent 
with a lower pro-inflammatory response, as reported in trained macrophages and dendritic cells, in 
which a metabolic switch to glycolysis has been described [169]. These data may indicate that HDAC6 
also appears to play a role in the activation of the mTOR pathway upon Lm infection to initiate the 
anti-bacterial transcriptional response to combat this pathogen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Lower IFN-β secretion was detected in Lm-infected Hdac6-/- DCs from 6 to 24 hpi. Upon vacuolar 
escape of Lm, the cytosolic surveillance pathway of host cell is activated [199]. Bacterial c-di-AMP and 
DNA mediate the activation of STING, whereas 5´pppRNAs are sensed by RIG-I, mediating the 
aggregation of mitochondrial and peroxisomal MAVS and the subsequent nuclear signalling of IRF-3 
and 7 [1,77]. Aditionally, RIG-I deacetylation at K858 and K909 by HDAC6 is essental to engage MAVs for 
the activation of anti-viral response through IRF-3-IFN-β signalling [49,137]. The lack of RIG-I cytosolic 
response to Lm in Hdac6-/- DCs can partially explain the diminished pro-inflammatory production of 
IFN-β observed in this work.  
Figure 5.2. Proposed model of HDAC6 functions in Lm sensing. Activation of membrane TLR1/2, TLR2/6 or TLR5 
or endosomal TLR-9 by Gram-positive bacteria as Listeria monocytogenes initiates the TLR-signalling complex.  
HDAC6 binds to MyD88 independently of its deacetylases domains, suggesting a scaffold role of HDAC6 in this 
signalling complex, likely mediated by K63-polyUb chain recognition through HDAC6 ubiquitin binding domain 
(BUZ domain). Other molecules of the TLR-signalling complex, like TAB2, TAB3 and IKK proteins,  have been 
described to be modified with K63-polyUb chains by TRAF-6 and other E3-ubiquitin ligases. NF-κB promotes the 
transcription of pro-inflammatory genes, whereas IRF-7 activates the transcription of type I IFNs to enhance the 
cell microbicidal capacity against intracellular bacteria. The images in the figure are not scaled. 
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  Regarding the lower levels of RNA expression of some chemokines in Hdac6-/- DCs, a reduced 
expression of CXCL10 was also detected in HDAC6-silenced cells after HIV-1 Tat-activation [226]. 
However, further experiments are necessary to unveil the molecular mechanism by which HDAC6 
could regulate this chemokine. In summary, our results reveal a defect in DC activation after Lm entry. 
5.2.2. Pro-inflammatory cytokine secretion after stimulation with TLR agonists 
  The impaired anti-inflammatory response in Hdac6-/- DCs was also observed with other TLR-agonists 
such as LPS, Imiquimod, poly(I:C) and Pam3GSK4, highlighting HDAC6 as an important player in TLR 
signalling activation. This result remarks the possible involvement of HDAC6 in both MyD88-dependent 
and independent TLR-signalling pathways, because TLR-3 and non-cannonical TLR-4 pathway use TIR-
domain containing adapter-inducing IFN-β (TRIF) adaptor instead of MyD88 [234].  
  Broad-spectrum HDAC inhibitors such as TSA exert immunosuppressive effects in TLR-2 and TLR-4 
signalling pathways [208]. Genome-wide expression profiling arrays have revealed that 60% of genes 
transcriptionally increased by TLR-2 or TLR-4 stimulation are inhibited in TSA-treated cells, whereas 16 
% of genes are potentiated [208]. However, these observations do not provide any demonstrative 
evidence for a specific role of HDAC6, since other HDACs may also be involved. At this point, our results 
with the genetic ablation of HDAC6 inequivocally endorse a specific role for this deacetylase in TLR-
mediated cytokine secretion. 
5.2.3. TLR-signalling pathway 
  Because GM-CSF-derived DCs express low levels of TLR-3 and TLR-5 in the membrane, we stimulated 
FLT3-L-derived DCs with poly(I:C) and flagellin to measure pro-inflammatory cytokines [55,260], noting 
maintained failure in the inflammatory response in Hdac6-/- cells. Moreover, we detected impaired 
responses to PAMPs activation in GM-CSF-derived and FLT3L-derived Hdac6-/- DCs. In addition, all TLRs 
except for TLR-3 signal through the adaptor MyD88, and the result obtained with the TLR-3 ligand 
poly(I:C) was similar to that showed for the rest of TLR stimuli, thereby indicating that the TLR3-
response is also affected by absence of HDAC6. In this regard, these data are in agreement with a 
recent study showing that acetylated retinoic-acid-inducible gene-1 (RIG-1) makes Hdac6-/- cells less 
sensitive to the presence of RNA viruses, resulting in a higher viral titre [49]. While this mechanism 
could explain the difference between the response of Hdac6+/+ and Hdac6-/- FLT3L-DCs to TLR-3 
stimulation, the deficient activation by other TLRs in Hdac6-/- DCs also requires an explanation. 
  However, it has been observed that HDAC6 hampers the formation of MyD88-TRAF6 signalling 
complex, suppressing TLR-4 mediated activation in mouse macrophage cell line Raw 264.7 [97]. In this 
work, both p62 and HDAC6 are required for MyD88 aggregation and mediate the suppression of IL-6 
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and iNOS after TLR-ligand interaction [97]. However, these data are not in agreement with data 
obtained by other authors and our work [46,226,49,137]. 
5.2.4. HDAC6-MyD88 molecular association 
 Since the diminished pro-inflammatory reponse after TLR agonists in Hdac6-/- DCs can be explained by 
RIG-I acetylation, with the exception of poly(I:C), we decided to focus our mechanistic study in the 
general TLR-adaptor protein MyD88. In this respect, we demonstrate the molecular association of 
HDAC6 with MyD88 studing the endogenous proteins and an overexpression system. Conceivably, the 
depletion of HDAC6 and therefore the prevention of HDAC6-MyD88 binding, could inhibit TLR-2-
signalling pathway activation, which is in accordance with a lower NF-κB induction measured in Hdac6-
/- cells after stimulation with various TLR-2 agonists. A diminished NF-κB induction in Hdac6-/- cells could 
explain a reduced initiation of the pro-inflammatory response observed in Hdac6-/- DCs, needed to 
alert the innate and adaptive immune response to Lm. However, NF-κB activity of HDAC6-DD-
transfected HEK cell line after different TLR-2 stimuli (HKLM, Pam2GSK4 and Pam3GSK4) did not display 
any significant change compared to HDAC6-WT-transfected cells, supporting that enzymatic activity of 
HDAC6 is not involved in this signalling pathway. Interestingly, we have assessed the acetylation of 
MyD88 by mass spectrometry, detecting acetylation of this molecule in two residues different to the 
one described previously [171]. The basal MyD88 IP detected “MVVVVSDDYLQSAcK231ECDFQTK” 
sequence in shHDAC6+MyD88-HA and HDAC6-DD+MyD88-HA samples, and “LLELLTAcK95LGR” 
sequence in MyD88-HA contruction. The acetylated peptides detected in basal condition correspond 
to the MyD88 sequences “MVVVVSDDYLQSAcK231ECDFQTK” and “LLELLTAcK95LGR”, different from the 
residue described by New et al. “LAcK132QQQEEAEKPL”. In fact, the peptide described in New et al is 
surrounded by leucine residues, instead lysine or arginine, both produced by the trypsin digestion 
[171].  
Our data suggest that the acetylation status of MyD88 does not appear to be regulated by HDAC6, as 
acetylation was detected not only in the shHDAC6+MyD88-HA sample, but also in the HDAC6-
DD+MyD88-HA and MyD88-HA samples without any TLR stimuli. However, no changes in the 
acetylation marks on MyD88 were detected after HKLM incubation, highlighting the scaffold role of 
HDAC6 in the proper activation of TLR-signalling pathway (Figure 5.1 part 2 and Figure 5.3 part 2). 
Therefore, we cannot assign the defect observed in TLR-signalling in Hdac6-/- DCs to this post-
translational modification of MyD88, as it appears to be independent of the enzymatic activity of 
HDAC6.  
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Figure 5.3. Graphical summary of HDAC6 role during DC response to Lm infection. The scheme shows the 
involvement of HDAC6 in two different functions of DC during Lm infection, the autophagy and the TLR signalling. 
(1) The fusion of phagosomes with lysosomes is dependent on cortactin and F-actin. The deacetylation of 
cortactin by HDAC6 allows the correct fusion, followed by an autophagic clearance of Lm. The absence of this 
enzyme delays the fusion of phagosome and lysosome, facilitating Lm to escape from phagosome leading to an 
increased bacterial load. (2) Di- and tri-acyl lipopeptides and peptidoglycan (PGN) of Lm are recognized by TLR1/2 
or TLR2/6, activating the TLR pathway. HDAC6 is able to interact with the TLR-adaptor protein MyD88 which 
causes an enhanced down-stream signalling of the TLR pathway, increasing NF-κB and MAPK activation. This 
stronger activation (independent on HDAC6 enzymatic activity) results in higher pro-inflammatory cytokine 
production and iNOS induction, reinforcing the ability of the DC to combat against this intracellular pathogen. 
Although the absence of HDAC6 does not fully abolish DC activation, a lower induction of NF-κB and MAPK 
pathways promotes a lower activation of the anti-bacterial transcriptional program of the DCs. Note that both 
processes occur during Lm infection and the pro-inflammatory cytokines and iNOS induction can impact on the 
autophagic process. The images in the figure are not scaled. 
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    It is conceivable that HDAC6 plays a scaffold role in the initial MyD88 complex in order to maintain 
the TLR-signalling the time necessary to achieve a proper TLR down-stream signalling. This scaffold role 
was previously described for HDAC6 in cell migration by Cabrero et al [36]. Comparison of induction of 
NF-𝜅B with TLR-2 agonists in HEK-hTLR2 cells transfected with HDAC6-WT, HDAC6-DD and sh-HDAC6 
constructs demonstrate differences for silencing HDAC6 protein, but not for the double deacetylase 
mutant (DD), further supporting the scaffold role for HDAC6 in the maintenance of the TLR-signalling. 
However, we can not rule out that other PTMs regulate the function of MyD88 such as ubiquitination, 
because this molecule can be ubiquitinated at 95, 119, 231 and 262 K residues [131]. K48-linked 
polyubiquitinated-MyD88 seems to be degraded by Smad6-Smurf pathway after TLR-2 and TLR-4 
stimulation [131]. Nevertheless, there are many types of ubiquitination and further studies are 
required to understand what kind of ubiquitin topology could be involved in MyD88-mediated TLR 
activation [114,233].  
5.2.5. Evaluation of the HDAC6 role in the in vivo TLR-dependent inflammatory response  
  Unexpectedly, a protective effect against systemic infection to a lethal dose of Lm was observed in 
Hdac6-/- mice. The reduced level of the inflammatory cytokine IL-6 detected in Hdac6-/- mice are in 
accordance with its higher resistance to Lm infection. The defective systemic inflammatory response 
after Lm infection of Hdac6-/- mice may indicate an impaired TLR-response in the absence of HDAC6 
and might therefore be attributed to the absence of the molecular association between MyD88 and 
HDAC6.  In this regard, mice resistance to Lm infection can be mediated by sequential MyD88-
independent and -dependent responses [217,66,239,218]. However, the role of TLR-2 during Lm 
infection does not appear to be clear enough [66,239]. On one hand, Tlr-2-/- mice display a deficit in 
circulating TNF-α and IL-12p40 production during intravenously injected Lm infection combined with 
a lower mice survival and increased bacterial burden in the liver [217,239]. Other authors have 
obtained similar resistance to intraperitoneal-injected Lm infection between Tlr-2-/- and Tlr-2+/+ mice, 
indicating that different inoculation routes of bacteria may result in different immune outcomes [66].  
  Although handling and direct killing of Lm by activated macrophages can be mediated by TLR-2- and 
MyD88-independent mechanisms, the role of TLR-signalling has been found necessary for nitric oxide 
and cytokine production [217,239]. In fact, MyD88 not only works as TLR-adaptor protein, but also as 
adaptor of IL-1 and IL-18 receptors, both cytokine responses affected in Lm-infected Myd88-/- mice 
[66,239,6]. Although Myd88-/- mice are more suceptible to Lm infection,  mice that lack caspase-1, 
which is responsible for the processing of immature forms of IL-1 and IL-18 into secreted forms, are 
only slightly more sensitive to infection than wt mice [66,241,217]. These data indicate that the 
protective immune response of MyD88 is mainly mediated through TLR-dependent signalling, rather 
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than IL-1 and IL-18 receptors. The recruitment of monocytes to Lm-infected spleens is mediated by 
MCP-1, which is MyD88-independent [218]. Hence, MyD88 deficiency does not impair monocyte 
recruitment, but prevents monocyte activation due to TNF-α and IL12p70 cytokine secretions are 
MyD88-dependent [218]. However, the protective CD8+ T-cell response to Lm is maintained in Myd88-
/- mice [252]. 
  The apparently contradictory results obtained using Tlr-2-/- mice can be explained by different 
inoculation routes of Lm. On one hand, Torres et al. reported an increased susceptibility of these 
animals to intravenous injection of Lm, whereas Edelson et al did not observe any difference compared 
to wt mice using intraperitoneal injection [66,239]. Moreover, Lm is not only recognized by TLR-2, but 
also by other TLRs such as TLR-9. In the case of MyD88, it does not appear to be necessary to clear 
bacteria in in vitro infections of macrophages, but this adaptor is essential for cytokine and nitric oxide 
production, particularly during in vivo infections [66,239]. Hence, MyD88 is required for early Lm 
resistance and for proper activation of innate immune responses [66]. 
  Innate immune responses against Lm are essential for host survival, because the lack of various innate 
immunity molecules increase the suceptibility to this pathogen [242]. The fundamental role of innate 
immunity to combact Lm is hihlighted in studies carried out with severe combined immunodeficient 
(SCID) and nude mice, which display a remarkable resitance to early time points of Lm-infection, but 
are unable to clear bacteria in the long term [14,173]. Further works have demonstrated that the IFN-
γ produced by natural killer cells is responsible for macrophage activation at early times of infection 
[240,34,191,209,85]. Besides, mice lacking IFN-γ and TNF-α rapidly succumb to Lm-infection, 
remarking the importance of both cytokines in the control of the early infection [34,88,191,209]. 
However, mice that lack the receptor for type I IFNs (IFNAR1) or IRF-3 are more resistant to Lm-
infection due to an increased apoptosis of T lymphocytes and the loss of TNF-α-producing cells 
[8,177,38]. Moreover, the lower suceptibility to Lm infection displayed by Ifnar1-/- mice was associated 
to a lack of cell-to-cell spreading of bacteria in in vitro infections of macrophages and in vivo, which is 
due to an alteration of actin-polymerization of ActA protein on the surface of Lm [8,230,182]. However, 
the existence of cellular factors that alter ActA localization of enclosing bacteria, or altered bacterial 
regulation mechanisms remains unknow. In this regard, HDAC6 could differently modulate host cell 
factors necessary for bacterial infection such as in the case of IFNARI absence. 
  Interestingly, here we detected decreased levels of the inflammatory cytokine IL-6 in Hdac6-/- mice 
serum at 72 and 96 hpi, indicating higher inflammation of Hdac6+/+ animals in response to a lethal dose 
of Lm. Similar observations regarding lower inflammation in Hdac6-/- mice have been reported by other 
authors [46]. Hdac6-/- mice were more resistant to LPS injection, a model typically used to trigger a 
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septic shock [46]. Similarly, together the results reported in Chattopadhyay et al. and our Lm survival 
curves indicate that Hdac6-/- mice display a defect in inflammation that could protect Hdac6-/- mice 
from systemic pro-inflammatory cytokine response.  
  Although, the opposite results were expected based on the in vitro and in vivo data showing increased 
bacterial burden at early times in Hdac6-/- myeloid cells, a comparative of this short time with the in 
vivo response after various days of infection is hard to be interpret. Besides, HDAC6 overall effect on 
the inflammatory response to lethal dose of Lm should be taken into account when analyzing animal 
survival at long time points after a septic shock model. In this context, the defective response of 
inflammatory mediators in Hdac6-/- mice may be responsible for their higher survival. It has been 
described that MyD88 and TLR responses contribute to inflammation during infection [239]. Tlr-2-/- 
mice not only show a reduced production of TNF-α and IL-12, but also lower induction of iNOS, and 
the costimulatory molecules CD40 and CD86, necessary for the control of infection [239]. In this regard, 
Lm-infected Hdac6-/- GM-CSF DCs not only express lower CD86 and CD40 markers, but also a reduced 
nitrite production, fewer induction of iNOS and a reduced secretion of TNF-α and IL-12p70. However, 
bacterial burden can be controlled by other processes as well, e.g. macrophages directly kill Lm by 
autophagy, independently of TLR-2- and MyD88-mechanisms [66]. In this regard, the impared 
autophagy observed in Hdac6-/- GM-CSF DCs and peritoneal macrophages at 6 hpi is not maintained 
during the lethal dose of Lm-septic shock model. This issue could be explained by a compensatory 
activity of HDAC5 during the absence of HDAC6 as we have observed in GM-CSF DCs after 24 hpi of 
Lm-infection. Moreover, the in vivo quantification of bacterial burden in target organs from 12 to 48 
hpi, did not display any significant results between Hdac6+/+ and Hdac6-/-mice, indicating that 
compensatory mechanisms are playing at these times or perhaps, the inflammatory cytokine storm is 
impairing the bacterial clearance at 72 hpi. Upon Lm infection, host cell Sirt-2 is shuttled to the nucleus 
to deacetylase histone 3, changing the chromatin packaging and the access of TFs. This step seems to 
be required for effective Lm infection because Sirt-2-deficient mice display decreased bacterial burden 
in target organs [67]. The molecular association between Sirt-2 and HDAC6 has been previously 
reported. Although HDAC6 is able to bind to both phosphorylated and non-phosphorylated forms of 
Sirt-2, the ability of Sirt-2 to bind tubulin can only be mediated when it forms a complex with HDAC6 
[164]. HADC6-Sirt-2 interaction could mediate also a role in the nucleus by deacetylating  histone 3, 
and the absence of HDAC6 may alter Lm adaptation in the host cell. This could explain why Hdac6-/- 
mice are protected from Lm infection as well as Sirt-2-/- mice. 
  The results obtained with in vivo long-term infection experiments may seem contradictory 
compared to in vitro assays and to short-term in vivo ones. Hence, further studies will be needed to 
uncover the consequences of HDAC6 deficiency in other mouse cell populations, in other kind of 
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bacterial inoculation, like intraperitoneal or oral infection models, or in other contexts of bacterial 
infection, such as Gram-negative bacteria.  
  Taking together, our data support a dual role for HDAC6 in the regulation of innate immunity 
against intracellular bacteria. An increased bacterial load in different Hdac6-/- myeloid cells can be 
explained by the autophagy mechanism, where a permanently acetylated cortactin may impair the 
phagosome-lysosome fusion, necessary for the clearance of this pathogen. Our experiments also 
show the importance of HDAC6 in DC activation, uncovering a novel mechanism of HDAC6 action 
mediated by the appropriate signalling via the TLR pathway, due to the association of HDAC6 with 
the TLR-adaptor protein MyD88. This molecular association seems to be required for a response to 
TLR stimuli to initiate the inflammatory response of an activated DC. Taken together, both HDAC6 
functions described in this work, reinforce the importance of this molecule to combat the 
intracellular bacteria Lm by autophagy and to completely activate the inflammatory response after 
TLR activation. Overall, this work identifies for the first time part of the TLR regulatory machinery of 
the proinflammatory response after Lm infection. Moreover, the results obtained demonstate the 
importance of HDAC6 in the control of intracellular bacterial infection by innate immune system. 
  
  
 
  
Conclusions 
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6. CONCLUSIONS 
 
The findings presented herein support the following conclusions:  
 
1. HDAC6 protein expression is increased during Lm infection in DCs. 
2. Hdac6-/- myeloid cells display defective clearance of intracellular bacteria due to an impaired 
autophagy. 
3. Hdac6-/- DCs display higher titres of Lm due to delayed fusion of autophagosome with lysosome, 
likely mediated by the acetylation state of cortactin. 
4. Hdac6-/- DCs show impaired pro-inflammatory cytokine production in response to Lm infection 
and TLR agonist stimulation. 
5. Hdac6-/- DCs exhibit weaker iNOS microbicidal activity after Lm infection and HKLM stimulation. 
6. Hdac6-/- DCs show lower induction of MAPK and mTOR signalling pathways after Lm infection 
and TLR activation, indicating a defective anti-bacterial response. 
7. There is a molecular association between HDAC6 and MyD88 responsible of a proper 
inflammatory response after TLR stimulation, which is independent of HDAC6 enzymatic activity. 
8. The impaired TLR-signalling pathway observed in the absence of HDAC6 can explain the Hdac6 -
/- mice protection against septic shock model based in lethal dose-Lm infection. 
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7. CONCLUSIONES  
 
Los resultados presentados en esta tesis doctoral son respaldados con las siguientes conclusiones: 
 
1. La expression de la proteína HDAC6 se induce durante la infección de DCs con Lm. 
2. Las células mieloides de ratones Hdac6-/- muestran un defecto en la eliminación de bacterias 
intracelulares debido a un defecto en la autofagia.  
3. Las DCs de ratones Hdac6-/- contienen una mayor carga bacteriana debido a un retraso en la 
fusion del autophagosoma con el lisosoma, probablemente mediada por la acetilación de la 
cortactina.  
4. En las DCs de ratones Hdac6-/- se detecta una producción de citoquinas proinflamatorias 
disminuida en respuesta a la infección por Lm y a la estimulación con ligandos de TLRs. 
5. En las DCs de ratones Hdac6-/- DCs se observa una menor inducción de la actividad microbicida 
de la enzima iNOS tras la infección con Lm y la estimulación con HKLM. 
6. Las DCs de ratones Hdac6-/- DCs tienen una menor inducción de las rutas de señalización de 
MAPK y mTOR por la infección de Lm y la activación de los TLR, lo que indica que la respuesta 
anti-bacteriana está afectada.   
7. La asociación molecular existente ente HDAC6 y MyD88 es responaible de la correcta 
respuesta inflamatoria después de la estimulación de los TLRs, que parece ser independiente 
de la actividad enzimática de HDAC6. 
8. La ruta de señalización de los TLRs afectada que se observa en la ausencia de la proteina 
HDAC6, podría explicar la protección de los ratones Hdac6 -/- frente al modelo de shock séptico 
usando una dosis letal infectiva de Lm. 
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Abstract
Recent evidence on HDAC6 function underlines its role as a key protein in the innate
immune response to viral infection. However, whether HDAC6 regulates innate immunity
during bacterial infection remains unexplored. To assess the role of HDAC6 in the regulation
of defence mechanisms against intracellular bacteria, we used the Listeria monocytogenes
(Lm) infection model. Our data show that Hdac6-/- bone marrow-derived dendritic cells
(BMDCs) have a higher bacterial load than Hdac6+/+ cells, correlating with weaker induction
of IFN-related genes, pro-inflammatory cytokines and nitrite production after bacterial infec-
tion. Hdac6-/- BMDCs have a weakened phosphorylation of MAPK signalling in response to
Lm infection, suggesting altered Toll-like receptor signalling (TLR). Compared with Hdac6+/+
counterparts, Hdac6-/- GM-CSF-derived and FLT3L-derived dendritic cells show weaker
pro-inflammatory cytokine secretion in response to various TLR agonists. Moreover,
HDAC6 associates with the TLR-adaptor molecule Myeloid differentiation primary response
gene 88 (MyD88), and the absence of HDAC6 seems to diminish the NF-κB induction after
TLR stimuli. Hdac6-/- mice display low serum levels of inflammatory cytokine IL-6 and corre-
spondingly an increased survival to a systemic infection with Lm. The impaired bacterial
clearance in the absence of HDAC6 appears to be caused by a defect in autophagy. Hence,
Hdac6-/- BMDCs accumulate higher levels of the autophagy marker p62 and show defective
phagosome-lysosome fusion. These data underline the important function of HDAC6 in den-
dritic cells not only in bacterial autophagy, but also in the proper activation of TLR signalling.
These results thus demonstrate an important regulatory role for HDAC6 in the innate
immune response to intracellular bacterial infection.
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Author summary
Listeria monocytogenes (Lm) is a food-borne intracellular bacterium that causes listeriosis
to 1.600 people each year, being responsible of approximately 260 deaths. This pathogen
mostly affects immunocompromised individuals and pregnant women. It is particularly
dangerous for the later due to its ability to pass across the placenta and the blood-brain
barrier. Lm is extensively used as a Gram positive infection model in the laboratory to
study innate and adaptive immune responses. HDAC6 is an important regulatory enzyme
of the tubulin and actin cytoskeletons. Its inhibition or deficiency quells the immune
response against different virus infections. Previous work has shown its involvement in
the regulation of viral RNA-sensing activity and in interferon signalling. In this study, we
report that HDAC6 is an essential component of the innate immune response to fight
against intracellular bacterial infections. Genetic ablation of HDAC6 impairs activation of
the pertinent Toll-like receptor pathway to induce the pro-inflammatory transcriptional
program of the cell. Moreover, this enzyme controls cytoskeletal proteins that mediate the
fusion of phagosome-contained bacteria with the lysosome during pathogen degradation.
Introduction
Histone deacetylase 6 (HDAC6) is a cytoplasmic deacetylase involved in the regulation of
several biological processes, including migration, transport, angiogenesis, and tumour pro-
gression [1–5]. This enzyme is able to deacetylate α-tubulin and cortactin, regulating not
only the microtubule cytoskeleton, but also actin [6, 7]. Both cytoskeletal interactions under-
line a crucial role of HDAC6 in many cellular functions such as phagosome-lysosome fusion,
cargo transport through microtubules, and cell motility [8–10]. The role of HDAC6 has also
been described in two of the main cellular degradation mechanisms: autophagy, through
interaction with the autophagy marker p62; and the proteasome, mediated by deacetylation
of HSP90 and its intersection with the ubiquitin-proteasome system (UPS) [11–15]. In addi-
tion, HDAC6 is involved in the transport of damaged mitochondria (mitophagy) and mis-
folded proteins (aggrephagy) to lysosomes and the proteasome for degradation [16–18]. The
absence of HDAC6 impairs the deacetylation of mitofusin 1, preventing the mitochondrial
fusion induced by glucose deprivation and causing excessive ROS production that provokes
oxidative damage [19].
HDAC6 regulates the replication of human immunodeficiency virus (HIV) by deacetylating
Tat and thus inhibiting viral transactivation [20, 21]. HDAC6 also participates in Sendai virus
infection through the deacetylation of β-catenin, which acts as a co-activator of IRF3-mediated
transcription [22]. During infection with Influenza Virus A (IVA), HDAC6 appears to play a
dual role. IVA capsids mimic misfolded-protein aggregates to take advantage of the host cell
aggresome pathway, thereby achieving disassembly and successful viral uncoating [23]. On the
other hand, HDAC6-mediated microtubule deacetylation impairs the IVA cycle, preventing
trafficking of viral components to the viral assembly site in the host plasma membrane and the
spread of infection to surrounding cells [24]. The role of HDAC6 in the adaptive CD4 + T-cell
response has been studied in several autoimmune and inflammatory situations such as colitis
and cardiac allograft rejection; however, little is known about its role in innate immunity and
bacterial diseases [25, 26].
Listeria monocytogenes (Lm) is a Gram-positive bacteria that causes severe infection in
immunocompromised individuals and is able to cross the blood-brain barrier and the placenta
[27]. Lm is widely used as a model of innate and adaptive immune responses to intracellular
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bacterial infection [27–29]. From the first hours of infection, professional phagocytic cells trap
bacteria in the blood and target organs, exerting a degree of control on bacterial growth [28].
After internalization by phagocytic cells, Lm is eliminated by fusion of the phagosome with
lysosomes; however, some bacteria escape the phagosome into the cytoplasm through the
action of listeriolysin O (LLO). In the cytoplasm, Lm replicates and is able to infect neighbour-
ing cells [30–32]. Interestingly, phagosome-contained bacteria are also eliminated by the
action of reactive oxygen species (ROS) and nitric oxide (NO), produced by NADPH oxidase
2 (NOX2) and inducible NO synthase (iNOS), respectively [33]. Moreover, Lm bacteria con-
tain an ARP2/3-mimicking protein that enables their propulsion to neighbouring cells through
the directional assembly of actin filaments (actin rockets) [34]. Lm can spread from cell to cell
without exiting the intracellular compartment by a process called paracytophagy, which evades
immune detection. However, the host cell is able to develop a specific CD8+T cell response to
cytosolic Lm, which is crucial for the control of infection [35–38].
Early control of Listeria burden largely depends on the innate immune response occurring
in the spleen, which relies on two main cell populations of dendritic cells (DCs). On one hand,
a subset of monocyte-derived DCs namely TNF/iNOS–producing DCs (Tip-DCs) has the abil-
ity to produce TNFα and NO [39]. The other splenic DC subset is CD8α+ conventional DCs
(cDCs), and it is responsible for the final resolution of infection against Listeria through the
antigen presentation of bacterial-derived antigens to specific CD8+T cells to induce cytotoxic-
ity [40, 41]. The response of dendritic cells (DC) to live Lm is mediated by toll-like receptors
(TLRs), nucleotide-binding oligomerization domain (NODs)-like receptors (NLRs), and other
cytosolic receptors and involves two signalling pathways: TLR-dependent and independent
signalling. TLR-dependent signalling, triggered by sensing of cell-surface and endo-phagoso-
mal bacteria, mediating the activation of a MyD88-dependent response; and the cytosolic
pathway, triggered by bacterial DNA after the escape of Lm into the cytosol, is responsible for
the activation of sensor stimulator of interferon (IFN) genes (STING). STING activation leads
to IFN regulatory factor (IRF)3–dependent production of IFN-β and activation of downstream
signals that control the transcription of IFN target genes essential for antiviral and antibacterial
responses [42, 43].
To determine the role of HDAC6 in the innate response to bacterial infection, we explored
the impact of HDAC6 deficiency on the response of myeloid cells to Lm. Our results reveal
that Hdac6-/- BMDCs are less efficient than Hdac6+/+ at clearing Lm. This is due to defective
maturation of phagosome-contained bacteria. Moreover, Hdac6-/- DCs display lower activa-
tion after Lm infection and TLR stimuli. These data support the view that HDAC6 positively
regulates innate defence mechanisms against Lm and that its absence weakens the pro-inflam-
matory response.
Results
Deficient intracellular bacteria clearance in Hdac6-/- BMDCs
To assess the possible role of HDAC6 in innate immune responses during bacterial pathogene-
sis, we performed a time-course infection with Lm in granulocyte and monocyte colony-stim-
ulating factor (GM-CSF)-derived BMDCs from Hdac6+/+ and Hdac6-/- mice. Increasing levels
of HDAC6 expression were detected in the Hdac6+/+ DCs as the infection progressed (Fig 1A).
However, BMDC differentiation was not noticeably affected in the absence of HDAC6 (S1 Fig
part A). Next, Hdac6+/+ and Hdac6-/- BMDCs were infected for different times with Gram-neg-
ative bacteria (Salmonella Typhimurium and Escherichia coli DH5α) and Gram-positive bacte-
ria (Listeria monocytogenes and Staphylococcus aureus) at a multiplicity of infection (MOI) of
10, with colony-formed units (CFUs) corresponding to intracellular live bacteria. Bacterial
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Fig 1. Deficient intracellular bacteria clearance in Hdac6-/- BMDCs. A) Western blot analysis of HDAC6 in a time-course of infection of BMDCs
with Lm. Tubulin was used as a loading control. HDAC6 levels were quantified in five independent experiments. p0.001,  p0.01p0.05. B)
CFUs obtained at 0 and 6 hpi from BMDCs infected with L. monocytogenes, S. Typhimurium, E. coli DHDα, and S. aureus at a MOI of 10. Data from
0 hpi are shown as a bacteria entry control. p0.001, ns>0.05 non-significant; n = 6. C) CFUs of Lm-infected BMDCs obtained at 0, 6, 24 and 32
hpi with a MOI = 10. p0.001, p0.05, ns>0.05 non-significant; n = 6. D) CFUs of Lm-infected BMDCs obtained at 0, 2, 4 and 6 hpi with a
MOI = 10 and 1. p0.001, p0.05, ns>0.05 non-significant; n = 6. E) BMDCs were infected with Lm or Lm-RFP for 6 h and the bacterial signal
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entry was similar in Hdac6+/+ and Hdac6-/- DCs at 0 h post-infection (hpi), while bacterial pro-
liferation, measured at 6 hpi, was significantly higher in Hdac6-/- BMDCs for both types of
intracellular pathogens, Lm and S. Typhimurium (Fig 1B). This was not due to differences in
cell viability at 6 hpi (S1 Fig part B). In contrast, no significant difference was observed in the
proliferation of the non-intracellular pathogens S. aureus and E. coli, indicating that HDAC6 is
an important component of cellular mechanisms for the clearance of intracellular pathogens
(Fig 1B).
Time-course analysis showed that differences between Lm infection in Hdac6+/+ and
Hdac6-/- BMDCs CFUs peaked at 6 hpi and were sustained until 24 hpi (Fig 1C). This effect
was clearly observed at a MOI of 10, which did not affect cell viability (Fig 1D and S1 Fig part
B). A similar pattern was observed with macrophage colony-stimulating factor (M-CSF)-
derived macrophages, demonstrating the lineage independence of the role of HDAC6 in bacte-
rial clearance (S1 Fig part C). Although the difference between Hdac6+/+ and Hdac6-/- cells was
observed in both macrophages and DCs, the clearance capacity of macrophages was ten-fold
higher than that of DCs at 6 hpi (S1 Fig part C).
Bacterial load was also determined by flow cytometry using two strategies: a specific anti-
body against Lm, and RFP-expressing bacteria. Both approaches showed that Hdac6-deficient
DCs contained more bacteria at 6 hpi (Fig 1E). Higher numbers of bacteria in Hdac6-/- BMDCs
were also detected by confocal fluorescence microscopy at 6 hpi (Fig 1F). Some bacteria co-
localized with filamentous actin, showing clear actin rockets (Fig 1F). Image quantification
confirmed that Hdac6-/- BMDCs contained more bacteria per cell and more total bacteria,
remarking a higher percentage of cells hosting a large number of bacteria in Hdac6-/- cells (see
distribution of bacteria per cell, 6–7) (S1 Fig part D). ImarisCell Module view of Fig 1F images
showed the number of bacteria per cell using actin transparency to easily visualize individual
bacteria (S1 Fig part E).
To ascertain whether Hdac6-/- cells display higher bacterial burden than Hdac6+/+ cells in
vivo, Hdac6+/+ and Hdac6-/- mice were intravenously injected with Lm and total CFUs per
gram of liver and spleen were determined at 6 hpi. In agreement with the higher numbers of
Lm observed in GM-CSF-DCs and M-CSF-Macrophages, we observed increased bacterial
titres in spleen and liver cell suspensions (Fig 2A). Next, to determine the specific cell popula-
tions underlying this phenotype, a multicolour gating strategy was used to identify the myeloid
cell compartment, including monocytes, neutrophils, Tips DCs, total cDCs, cCDs CD8- and
cDCs CD8+ (S2 Fig part A). Higher numbers of Lm were observed in different myeloid cells at
6 hpi (Fig 2B and S2 Fig part B). These data highlight the impairment of Hdac6-/- myeloid cells
to clear intracellular Lm.
Impaired bacterial clearance in Hdac6-/- BMDCs is caused by a defect in
autophagy
To test the involvement of autophagy in the mechanism by which HDAC6 regulates Lm infec-
tion, we treated DCs with 3-methyladenine (3-MA), an inhibitor of autophagosome formation.
Treatment with 3-MA increased bacterial load in Hdac6+/+ BMDCs at 6 hpi, while having no
was determined by flow cytometry. The panel shows representative histograms and the geometric mean of the Lm signal. p0.001,  p0.01;
n = 6. F) Confocal microscopy determination of bacterial load at 6 hpi. Left panel: Maximum intensity z-projections of confocal microscopy images
of Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at 6 hpi. The panel shows DAPI (blue), Lm (red), β-actin (green), merged views of three channels,
and magnified views of the boxed areas from the merged view. Yellow indicates Lm and β-actin co-localization. Scale bars 20 μm (main panels) and
10 μm magnified views). Right panel: ImarisCell Module analysis of the number of cells and the number of bacteria per cell in all pictures (10
pictures per genotype). Statistical analysis of Imaris quantification of total bacteria and bacteria per cell in Hdac6+/+ and Hdac6-/- BMDCs.
p0.001,  p0.01; n = 10.
https://doi.org/10.1371/journal.ppat.1006799.g001
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effect on Hdac6-/- BMDCs (Fig 3A), suggesting autophagy as the bacterial clearance mecha-
nism impaired in Hdac6-deficient DCs. A similar result was observed upon treatment of
BMDCs with bafilomycin A1, an inhibitor of vascular proton pump that indirectly inhibits
phagosome-lysosome fusion, and with the lysosome acidification inhibitors chloroquine and
NH4Cl (Fig 3A). In contrast, increasing autophagy flux with rapamycin did not restore the
impaired autophagy in Hdac6-/- BMDCs (Fig 3B). No significant effects were observed with
control vehicles (S3 Fig part A). To explore other possible mechanisms, we treated BMDCs
with inhibitors of NADPH oxidase (DPI) and iNOS (1400W). These treatments did not alter
the difference in CFU number at 6 hpi between treated and non-treated Hdac6+/+ and Hdac6-/-
BMDCs, indicating that the activity of either enzyme is not accounting for the existing pheno-
type (Fig 3B).
The defective autophagy phenotype of Hdac6-/- BMDCs was not due to transcriptional
alterations to autophagy or lysosome components, since Lm-infected Hdac6+/+ and Hdac6-/-
BMDCs showed no mRNA expression differences at 6 hpi in the autophagy components
LC3A and B, p62, ATG2, 5, 7 and 12, and Beclin-1 or in the lysosome components LAMP-1
and 2 (S3 Fig part B).
To determine whether these findings can be extended to other phagocytic cells, we carried
out CFU assays with macrophages obtained from Hdac6+/+ and Hdac6-/- mice four days after
intraperitoneal thioglycollate injection. Higher bacterial load was observed only in Hdac6-/-
Fig 2. Deficient intracellular bacteria clearance in Hdac6-/- splenic myeloid populations. A) Quantification of
bacterial load in target organs (spleen and liver) at 6 hpi in Hdac6+/+ and Hdac6-/- mice injected with a lethal dose of
Lm. Bacterial load is expressed by CFUs per gram of liver (left graph) and per gram of spleen (right graph). p0.01,
n = 6. B) The charts show geometric means of Lm of different splenic populations (monocytes, neutrophils, Tips DCs,
total cDCs, cDCs CD8- and cDCs CD8+) gated in the live CD3-CD19-DX5- population of Hdac6+/+ and Hdac6-/- mice
injected with a lethal dose of Lm at 6 hpi. p0.01; n = 6.
https://doi.org/10.1371/journal.ppat.1006799.g002
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Fig 3. Impaired bacterial clearance in Hdac6-/- BMDCs is caused by a defect in autophagy. A) Total CFUs in Lm-
infected BMDCs treated with inhibitors. CFUs were detected at entry (0 hpi) and 6 hpi (bacterial proliferation) using the
autophagy inhibitors (3-MA and bafilomycin A1 and the lysosome acidification inhibitors (NH4Cl and cloroquine),
ns>0.05 non-significant; n = 6. B) Total CFUs at 0 and 6 hpi in Lm-infected BMDCs treated with the autophagy activator
(rapamycin), the NADPH oxidase inhibitor (DPI) and the iNOS inhibitor (1400W). p0.001; n = 6. C) Total CFUs at 0
and 6 hpi in Lm-infected thioglycollate-elicited macrophages treated with or without bafilomycin A1. p0.001, ns>0.05
non-significant; n = 6. D) Western-blot analysis of autophagy markers over the time-course of Lm infection in Hdac6+/+
and Hdac6-/- BMDCs. Left panels: Levels were detected of p62, LC3bI and II and HDAC6 in control cells and cells treated
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macrophages at 6 hpi, and this difference was abrogated by treatment with bafilomycin A1
(Fig 3C). These data indicate that the phenotype observed in BMDCs is also extendable in
other Hdac6-deficient phagocytic cells such as peritoneal macrophages, indicating a wide-
spread defect in intracellular killing ability due to lack of HDAC6. Moreover, the killing ability
shown by peritoneal macrophages is similar to that of M-CSF-derived macrophages and
higher than GM-CSF-derived DCs (Fig 3C compared with S1 Fig part C).
To gain further insight into the autophagy mechanism affected by HDAC6, we monitored
the autophagosome markers p62 and LC3bI and II in Lm-infected BMDCs. Hdac6-/- BMDCs
showed a 2-fold higher accumulation of p62 than Hdac6+/+ cells at 6 hpi and increased LC3bII
level in Hdac6+/+ cells from 1 to 6 hpi (Fig 3D). However, differences in p62 and LC3b levels
were not noticed at early times of Lm infection of Hdac6+/+ and Hdac6-/- BMDCs, indicating
that the induction of autophagy is not affected in the absence of HDAC6 (Fig 3D). The treat-
ment with bafilomycin A1 enhances the accumulation of p62 during the infection at the same
level in both genotypes, abrogating the deficiency in autophagy observed in Hdac6+/+ BMDCs
(Fig 3D). Although rapamycin also increased p62 accumulation at early times in Hdac6+/+ and
Hdac6-/- BMDCs, only Hdac6+/+ cells are able to diminished p62 at 6 hpi (Fig 3D). This treat-
ment confirmed the results obtained in the CFUs functional assays with this inhibitor (Fig 3D
compared with Fig 3B). The similarity of the autophagy defect detected in Hdac6-/- BMDCs in
control condition to that in rapamycin-treated Hdac6-/- cells, suggests an impairment in
phagocytic vesicle fusion with the lysosome.
Hdac6-/- BMDCs accumulate p62
In order to further understand the defective autophagy of Hdac6-/- BMDCs, the accumulation
of p62 was studied in more detail. Flow cytometry at 6 hpi revealed significantly higher p62
content in Hdac6-/- BMDCs, indicating accumulation of this phagosome marker due to defec-
tive fusion of this organelle with the lysosome (Fig 4A). Bafilomycin A1 treatment completely
abrogated this difference, suggesting that Hdac6-/- BMDCs displayed an impairment in the
final step of autophagy (Fig 4A). More signal of Lm is displayed in Hdac6-/- DCs (Fig 4A). In
this regard, bafilomycin A1 treatment increased the low Lm signal in Hdac6+/+ DCs to the
level observed in Hdac6-/- cells (Fig 4A).
Confocal fluorescent analysis of Lm-infected DCs revealed increased levels of p62 in
Hdac6-/- BMDCs (Fig 4B). Hdac6-/- BMDCs also showed a higher percentage of p62-Lm co-
localization than Hdac6+/+ cells, indicating that Hdac6-/- cells have more number of phago-
some-contained bacteria (Fig 4B in accordance with p62 accumulation observed in Figs 3D
and 4A). Confocal fluorescent microscopy study of actin and Lm revealed more frequent co-
localization in Hdac6-/- than in Hdac6+/+ BMDCs, indicating that more bacteria are at the
cytoplasm to form actin rockets in Hdac6-deficient cells (Fig 4C). Moreover, more signal of
acetylated-cortactin is detected in Hdac6-/- BMDCs and also higher percentage of acetylated-
cortactin-Lm co-localization (Fig 4D). These data could explain the accumulation of p62
and the delay in phagocytic vesicle fusion observed in Hdac6-/- BMDCs, necessary to degrade
phagocytosed Lm.
with bafilomycin A1 and rapamycin. Tubulin was used as a loading control. HDAC6 was as a genotype check of Hdac6+/+
and Hdac6-/- BMDCs and to monitor HDAC6 induction during infection. Right panels: Accompanying charts show
quantification of the p62 percentage of control, bafilomycin A1 and rapamycin western blots.  p0.01,  p0.05, ns>0.05
non-significant; n = 5.
https://doi.org/10.1371/journal.ppat.1006799.g003
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Fig 4. Hdac6-/- BMDCs accumulate higher levels of p62. A) Left panels: The charts show geometric means of p62 and
Lm gated in the MHCII+CD11c+ population of Hdac6+/+ and Hdac6-/- BMDCs without infection (NI) and at 6 hpi, with
and without bafilomycin A1 treatment. The representative histograms on the right show p62 and Lm with and without
bafilomycin A1. p0.001,  p0.01, ns>0.05 non-significant; n = 6. B) Confocal microscopy analysis of p62-Lm co-
localization in Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at 6 hpi. Panels show DAPI (blue), Lm (red), p62 (green), and
merged views of the three channels, with magnified views of the boxed areas. Yellow indicates p62-Lm co-localization.
Role of HDAC6 in bacterial infection
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Defective pro-inflammatory cytokine response to Lm in Hdac6-/- BMDCs
The effect of HDAC6 on the response of BMDCs to Lm was evaluated by measuring pro-
inflammatory cytokine gene induction. The relative mRNA levels of type I interferons (inter-
ferons α and β) were lower in Hdac6-/- BMDCs at 6 hpi (Fig 5A). Accordingly, expression of
downstream interferon-response genes such as Mx1, IFIT3, and ISG15 was also lower in
Hdac6-/- BMDCs (Fig 5A). Lack of HDAC6 also decreased the relative mRNA levels of the pro-
inflammatory cytokines TNFα, IL-1β and IL12p40, indicating impaired cytokine activation
after infection (Fig 5A). Similarly, Hdac6-/- DCs expressed lower levels than their Hdac6+/+
counterparts of the chemokine receptor CXCR1 and chemokines CXCL5 and CXCL10 (Fig
5A). These data demonstrate that Hdac6-deficient DCs have a weakened activation response
to Lm infection at 6 hpi, which suggests a defect in bacterial clearance, consistent with the
increased bacterial load in these cells. To confirm these data, we monitored pro-inflammatory
cytokines and IFN-β in the supernatants of Lm-infected DCs. Early after infection, TNFα,
IL-1β, IL-6, IL12p70 and IFN-β levels were lower in supernatants from Hdac6-/- cells than in
those from Hdac6+/+ cells, and this difference held at 12 and 24 hpi (Fig 5B). To exclude a
defect in cytokine secretion, we compared cytokine levels in supernatants (S) with the levels in
supernatants plus their corresponding cell pellets (S+P). Both analyses showed decreased cyto-
kine levels in Hdac6-/- cells, indicating an impaired antibacterial response in Hdac6-deficient
DCs (S4 Fig).
Measurement of nitrite in supernatants of infected-BMDCs revealed higher nitric oxide
production by Hdac6+/+ DCs than in Hdac6-/- DCs at 24 hpi (Fig 6A). In agreement, western
blot revealed lower levels of inducible nitric oxide synthase (iNOS) in Hdac6-/- BMDCs at 4
and 6 hpi (Fig 6B), indicating a delay of the enzyme induction in Hdac6-/- BMDCs. Likewise,
flow cytometry after exposure of DCs to live or heat-killed L. monocytogenes (HKLM) revealed
higher expression of iNOS in Hdac6+/+ BMDCs in both cases (Fig 6C). These data support the
involvement of HDAC6 in the activation of DC-mediated iNOS microbicidal responses to Lm
infection and in the clearance of this intracellular pathogen.
Hdac6-/- BMDCs show defective activation of Toll-like receptor signalling
pathway
The diminished activation response against Lm in Hdac6-/- BMDCs is consistent with impaired
TLR-related signalling. To investigate this question, we determined the phosphorylation levels
Scale bars 20 μm (main panels) and 10 μm (magnified views). Right panel: The chart shows ImarisCell Module analysis of
the number of cells and the number of bacteria per cell in all pictures (10 pictures per genotype). Co-localization
percentages were obtained by measuring the p62 channel on the bacterial surface using a threshold of 100. The statistical
analysis of Imaris quantifications corresponds to the percentage of p62-Lm co-localization at 6 hpi. p0.05; n = 10. C)
Confocal microscopy analysis of actin-Lm co-localization in Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at 6 hpi. Panels
show DAPI (blue), Lm (green), β-actin (red), and merged views of the three channels, with magnified views of the boxed
areas. Yellow indicates β-actin-Lm co-localization. Scale bars 20 μm (main panels) and 10 μm (magnified views). Right
panel: The chart shows ImarisCell Module analysis of the number of cells and the number of bacteria per cell in all
pictures (10 pictures per genotype). Co-localization percentages were obtained by measuring the actin channel on the
bacterial surface using a threshold of 40.6. The statistical analysis of Imaris quantifications corresponds to the percentage
of actin-Lm co-localization at 6 hpi.  p0.001; n = 10. D) Confocal microscopy analysis of acetylated cortactin-Lm co-
localization in Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at 6 hpi. Panels show DAPI (blue), Lm (red), acetylated
cortactin (green), and merged views of the three channels, with magnified views of the boxed areas. Yellow indicates
acetylated cortactin-Lm co-localization. Scale bars 20 μm (main panels) and 10 μm (magnified views). Right panel: The
chart shows ImarisCell Module analysis of the number of cells and the number of bacteria per cell in all pictures (10
pictures per genotype). Co-localization percentages were obtained by measuring the acetylated cortactin channel on the
bacterial surface using a threshold of 184. The statistical analysis of Imaris quantifications corresponds to the percentage
of acetylated cortactin-Lm co-localization at 6 hpi.  p0.001; n = 10.
https://doi.org/10.1371/journal.ppat.1006799.g004
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Fig 5. Defective pro-inflammatory cytokine response to Lm in Hdac6-/- BMDCs. A) PCR analysis of type-I interferons
(PanIFN-α and IFN-β), interferon downstream proteins (Mx1, IFIT3 and ISG15), pro-inflammatory cytokines (TNF-α, IL-
1β and IL-12p40) chemokine receptor (CXCR1) and chemokines (CXCL5 and CXCL10) of Hdac6+/+ and Hdac6-/- BMDCs
non-infected (NI) and infected with Lm at 6 hpi (arbitrary units). p0.001,  p0.01,  p0.05; n = 5–6. B) ELISA
analysis of the pro-inflammatory cytokines TNFα, IL1β, IL6 and IL12p70 (pg/ml) and IFN-β in supernatants of Hdac6+/+ and
Hdac6-/- BMDCs at 6, 12 and 24 hpi with Lm. p0.001,  p0.01,  p0.05 ns>0.05 non-significant; n = 5–6.
https://doi.org/10.1371/journal.ppat.1006799.g005
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of TLR downstream mediators by western blot. Compared with Hdac6+/+ BMDCs, Hdac6-/-
BMDCs showed weaker phosphorylation signals for ERK and AKT after Lm infection (Fig
7A). We next examined the effect of HDAC6 deficiency on TLR-signalling pathways using
other TLR stimuli, including HKLM and LPS. AKT phosphorylation in Hdac6-/- BMDCs was
decreased after LPS or HKLM treatment compared to Hdac6+/+, confirming defective TLR
activation (S5 Fig part A). These effects are not related to a defect in Lm-induced transcrip-
tional induction since mRNA levels of different Lm-related TLRs (TLR1, 2, and 6) were similar
in Hdac6+/+ and Hdac6-/- BMDCs (S5 Fig part B). Moreover, Hdac6-/- BMDCs showed weaker
phosphorylation of mTORC1 pathway proteins (mTORC1 downstream substrates p70S6K
and S6), consistent with a less pronounced pro-inflammatory response after TLR-activation by
pathogen-associated molecular patterns (PAMPs) (Fig 7B).
To determine if Hdac6-/- BMDCs showed a similarly defective response to other TLR ago-
nists, we first examined secretion of pro-inflammatory cytokines in response to agonists of
TLR1-2 (Pam3GSK4), TLR-4 (LPS), TLR-7-9 (Imiquimod), and multiple TLRs (heat-killed
Salmonella Typhimurium; HKST). Hdac6-/- BMDCs showed a defective cytokine response to
these stimuli, determined from the release of TNFα, IL-6, IL-1β and IL12p70 (Fig 8A–8D).
To assess the pro-inflammatory cytokine response to TLR3 and TLR5 ligands, we gener-
ated Fms-related tyrosine kinase 3 ligand dendritic cells (FLT3L-DCs). Differentiation
with the cytokine FLT3L yielded similar percentages of CD24+ and CD24- subpopulations
(CD11c+CD11b+B220-CD24+ and CD11c+CD11b+B220-CD24-, respectively) from Hdac6+/+
Fig 6. Defective iNOS response to Lm in Hdac6-/- BMDCs. A) Lm-activated iNOS activity. Nitrite levels in supernatants of Lm-infected BMDCs at 6,
12 and 24 hpi. p0.001; n = 5. B) Western-blot analysis of iNOS induction over the time-course of Lm infection. β-actin was used as a loading
control (top panel). The chart shows quantification of iNOS at 4 and 6 hpi.  p0.01,  p0.05; n = 4 (lower panel). C) The panel shows representative
histograms of iNOS expressed by Hdac6+/+ and Hdac6-/- BMDCs after exposure to live Lm or HKLM for 24 h (left). The right chart shows the geometric
mean of iNOS expression. Non-infected (NI) BMDCs were used as a control of iNOS induction. p0.01; n = 6.
https://doi.org/10.1371/journal.ppat.1006799.g006
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and Hdac6-/- DCs, indicating that differentiation is unaffected by HDAC6 absence (S6 Fig
part A). The TLR agonists Pam3GSK4 (TLR1-2), Poly(I:C) (TLR3), LPS (TLR4), flagellin
(TLR5), Imiquimod (TLR-7-9), Lm, HKLM, and HKST (which activates several TLRs simul-
taneously) elicited similar cytokine secretion profiles in GM-CSF DCs and FLT3L-DCs (Fig
9A and S6 Fig part B compared to Fig 8A–8D). Hdac6-/- DCs of both derivations showed an
impaired cytokine response to each TLR agonist, indicating that HDAC6 likely regulates a
common TLR signalling adaptor.
Fig 7. Hdac6-/- BMDCs show defective activation of the Toll-like receptor signalling pathway. A) Western-blot analysis of MAPK activation over the
time-course of Lm infection in Hdac6+/+ and Hdac6-/- BMDCs. Total and phosphorylated ERK and AKT were detected. Tubulin was used as a loading
control (left). Accompanying charts show quantification of phERK/totalERK and phAKT/totalAKT ratios relative to the loading control, ns non-
significant; n = 7 (right). B) Western-blot analysis of mTORC1 pathway activation over the time-course of Lm infection in Hdac6+/+ and Hdac6-/-
BMDCs. Levels of phosphorylated and total p70S6K and S6 were detected. Tubulin was used as a loading control (top panel). Accompanying charts
show quantification of php70S6K/total70S6K (n = 5) and phS6/totalS6 (n = 7) ratios relative to the loading control.  p0.01, ns non-significant;
(lower panel).
https://doi.org/10.1371/journal.ppat.1006799.g007
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Fig 8. Hdac6-/- BMDCs show defective inflammatory cytokine response to Toll-like receptor stimuli. A) ELISA
analysis of the pro-inflammatory cytokines TNFα, IL-1β, IL-6 and IL12p70 (pg/ml) in supernatants of Hdac6+/+ and
Hdac6-/- BMDCs after treatment for 6, 12 and 24 h with Pam3GSK4. p0.001,  p0.01,  p0.05, ns>0.05 non-
significant; n = 5–6. B) ELISA analysis of the pro-inflammatory cytokines TNFα, IL-1β, IL-6 and IL12p70 (pg/ml) in
supernatants of Hdac6+/+ and Hdac6-/- BMDCs after treatment for 6, 12 and 24 h with LPS. p0.001,  p0.01,
ns>0.05 non-significant; n = 5–6. C) ELISA analysis of the pro-inflammatory cytokines TNFα, IL-1β, IL-6 and IL12p70
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In this view, the TLR adaptor MyD88 participates in the transmission of signals by all TLRs
except for TLR3. We decided to study MyD88 levels in a time-course infection with Lm by
western blot, demonstrating that the quantity of this molecule was the same between Hdac6+/+
and Hdac6-/- DCs and remaining stable during infection (S6 Fig part C). Remarkably, MyD88-
HDAC6 molecular association was observed by co-immunoprecipitations of endogenous pro-
teins using human dendritic cells after Pam2GSK4, Pam3GSK4 and HKLM stimulation (Fig
9B). Likewise, the MyD88 immunoprecipitation in MyD88- and HDAC6-overexpressed HEK
cell line was also able to co-precipitate HDAC6 (S6 Fig part D). These results were corrobo-
rated by mass spectrometry analysis of MyD88 immunoprecipitates; which in addition
detected two acetylated peptides corresponding to MyD88 (S6 Fig parts E and F). The same
approach was used to determine MyD88-HDAC6 molecular association after TLR-2 activation
with HKLM using a constitutively expressed human TLR-2 HEK cell line, rendering the same
result (Fig 9C). This association is also maintained using a double-deacetylase domain mutant
of HDAC6 (H216A:H611A), called HDAC6-DD, indicating that HDAC6-MyD88 interaction
is independent of its catalytic activity (Fig 9C and S6 Fig part D). The knock-down of HDAC6
expression using a small harping plasmid (sh-HDAC6) blocked this interaction (Fig 9C and S6
Fig part D). However, no acetylated peptides could be detected in the mass spectrometry anal-
ysis of the MyD88 immunoprecipitation from HKLM-stimulated TLR-2 HEK cell line (Fig
9D). Moreover, assessment of NF-κB induction in TLR-2-expressing HEK cell line after
HKLM, Pam2GSK4 and Pam3GSK4 stimulation shows lower activation only in shHDAC6
transfected cells, without affecting the activity of HDAC6-DD-transfected ones (Fig 9E).
Taking into account all these data, HDAC6 associates with the TLR-adaptor molecule
MyD88, and the absence of HDAC6 in DCs seems to diminish the TLR-response after a vari-
ety of stimuli, underlining the scaffold role of HDAC6 in determining the ability of MyD88 to
mediate TLR signalling.
To ascertain the defective TLR-dependent inflammatory response in vivo due to the molec-
ular association of MyD88-HDAC6, Hdac6+/+ and Hdac6-/- mice were intravenously injected
with a lethal dose of Lm (Fig 9F) [44]. A protective effect against Lm-induced septic shock was
observed from 3 to 10 days post-infection (dpi) (Fig 9F). Accordingly, lower levels of the pro-
inflammatory cytokine IL-6 were detected in the serum of Hdac6-/- mice at 72 hpi, highlighting
a reduced systemic cytokine-driven inflammatory response after Lm infection in these mice
(Fig 9G).
Discussion
Recent studies have revealed the involvement of HDAC6 in the innate immune response
against Influenza Virus A (IVA), Sendai virus (SeV), and vesicular stomatitis virus (VSV) [21–
24]. Given the similarities between the innate responses to viruses and intracellular bacteria,
this prompted us to investigate the role of HDAC6 in a model of Lm infection. In this work,
we demonstrated a dual role of HDAC6 in the innate response against Lm, not only due to its
enzymatic activity but also dependent of its function as a scaffold (Fig 10). Our data clearly
demonstrate that Hdac6-/- BMDCs have an impaired immune response against Lm and S.
Typhimurium infection in vitro. Moreover, higher Lm titres observed in Hdac6-/- dendritic
cells, M-CSF-derived macrophages and peritoneal macrophages were corroborated during in
(pg/ml) in supernatants of Hdac6+/+ and Hdac6-/- BMDCs after treatment for 6, 12 and 24 h with Imiquimod.
p0.001,  p0.05, ns>0.05 non-significant; n = 5–6. D) ELISA analysis of the pro-inflammatory cytokines TNFα, IL-
1β, IL-6 and IL12p70 (pg/ml) in supernatants of Hdac6+/+ and Hdac6-/- BMDCs after treatment for 6, 12 and 24 h with
HKST. p0.001,  p0.01, ns>0.05 non-significant; n = 5–6.
https://doi.org/10.1371/journal.ppat.1006799.g008
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Fig 9. Association of HDAC6 with TLR-adaptor MyD88 and its contribution to the inflammatory response to Lm. A)
ELISA analysis of the pro-inflammatory cytokines TNFα, IL-1β, IL-6 and IL12p70 (pg/ml) in supernatants of Hdac6+/+ and
Hdac6-/- FLT3L-DCs activated with LPS, Imiquimod, Pam3GSK4, HKLM, HKST, Lm, Poly(I:C) and flagellin for 24 h.
p0.001,  p0.01,  p0.05; n = 6. B) Immunoprecipitation of endogenous HDAC6 and MyD88 followed by western-
blot for both proteins. Immunoprecipitations were carried out using human moDCs after 30 min of stimulation with
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vivo Lm infection at 6 hpi in various myeloid subsets of the spleen. The absence of this effect
during BMDC in vitro infection by the non-intracellular bacteria S. aureus and E. coli DH5α
indicates that Hdac6-/- BMDCs are specifically unable to efficiently clear intracellular patho-
gens. HDAC6 is involved in two of the most important cellular clearance systems, autophagy
and ubiquitin-proteasome system (UPS) [9, 13]. In the case of Lm and S. Typhimurium, the
main molecular mechanism for degradation of vesicle-contained bacteria is fusion with lyso-
somes in a process called autophagy [45–47]. In agreement with this, our data show that
impaired phagosome-lysosome fusion underlies the phenotype observed in Hdac6-/- BMDCs.
Unsuccessful fusion depends on acetylated-cortactin in Hdac6-deficient cells [9]. A similar
mechanism has been described in Hdac6-deficient MEFs during quality-control autophagy
[9]. We demonstrated that in Hdac6-/- BMDCs co-localized higher levels of acetylated-cortac-
tin with intracellular Lm. The delay in vesicle fusion caused by the acetylation of cortactin,
impairs the phagosome-lysosome fusion and provides more opportunities for phagosome-
containing bacteria to escape to the cytosol, resulting in the higher bacterial load detected in
Hdac6-/- BMDCs. Based on this experimental evidence, it is conceivable to postulate that the
enzymatic activity of HDAC6 on its substrate cortactin controls autophagy of intracellular bac-
teria for their efficient clearance (Fig 10).
Pharmacological autophagy inhibitors erased the observed differences between Hdac6+/+
and Hdac6-/- BMDCs. Conversely, rapamycin did not overcome the Hdac6-/- autophagy defect,
indicating a defect in phagosome-lysosome fusion. However, other authors have reported
opposite observations using pan-HDAC inhibitors or specific inhibitors of HDAC6 during
infection of human macrophages with the Gram-negative intracellular pathogens S. Typhi-
murium and E. coli [48]. These inhibitors, when added at the time of infection, increase mito-
chondrial ROS production [48]. However, overnight pre-treatment before infection hampered
bacterial clearance and reduced phagocytosis [48]. These data indicate that specific HDAC6
chemical inhibitors can have side-effects, including effects on other HDAC members, poten-
tially interfering with the acetylation of other substrates upstream of cortactin that also have a
role during bacterial infection. Our genetic approach unequivocally assigns a specific role to
HDAC6 in innate cells during bacterial infection.
Although we observed an impairment in phagosome-lysosome fusion, we cannot rule out
an involvement of HDAC6 in the anti-microbial response through its BUZ domain, with
a contribution from ubiquitin. The characterized interaction between p62 and HDAC6
through their ubiquitin-binding domains provides a clue about the possible role of ubiquitin
in the activation of innate immunity through the recognition of ubiquitinated-molecules [15].
For example, the ubiquitin-binding regions of HDAC6 and p62 are both essential for MyD88
Pam2GSK4, Pam3GSK4 and HKLM. Endogenous HDAC6 (130 KDa) and MyD88 (33 KDa) are indicated at right of
western-blot. Similar results were obtained in two independent experiments. C) Immunoprecipitation of HA (MyD88)
followed by western-blot for HDAC6 and MyD88. Immunoprecipitations were carried out using different HDAC6-eGFP
plasmids co-transfected with MyD88-HA in HEK-Blue hTLR2 cell line after 30 min of stimulation with HKLM. Over-
expressed (HDAC6-eGFP, 160 KDa) and endogenous HDAC6 (130 KDa) are indicated at right of western-blot. Similar
results were obtained in four independent experiments. D) Immunoprecipitation of HA (MyD88) followed by mass
spectrometry analysis. Immunoprecipitations were carried out using different HDAC6-eGFP plasmids co-transfected with
MyD88-HA in HEK-Blue hTLR2 cell line after 30 min of stimulation with HKLM. The number of unique MyD88 and
HDAC6 peptides is indicated. No acetylated peptides from MyD88 were detected in any sample. Similar results were
obtained in four independent experiments. E) Graph of NF-κB induction in transfected HDAC6-WT, HDAC6-DD and
shHDAC6 HEK-Blue hTLR2 cell line after activation with HKLM, Pam2GSK4 and Pam3GSK4 during 8 h. NF-κB induction
was calculated by the ratio of the signal of stimulated cells with its corresponding transfected cells in basal condition (without
stimuli), p0.001,  p0.01,  p0.05, ns>0.05 non-significant; n = 6. F) Survival curve to intravenous injection with a
lethal dose of Lm in Hdac6+/+ and Hdac6-/- is showed. This curve corresponds to two different experiment of survival to Lm
with a n = 24–21. p0.001. G) Pro-inflammatory cytokine IL-6 was measured in sera of Hdac6+/+ and Hdac6-/- mice
intravenously injected with a lethal dose of Lm at 12, 48 and 72 hpi. p0.05, n = 5.
https://doi.org/10.1371/journal.ppat.1006799.g009
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aggregation and the downstream activation of MyD88-dependent signal transduction [49].
Furthermore, ubiquitin-binding platforms formed by HDAC6 and p62 are able to interact
with interferon stimulated gene 15 (ISG15) to eliminate ISGylated proteins tagged after
interferon stimulation by autophagy [50]. HDAC6 is able to bind to either mono- and poly-
Fig 10. Dual role of HDAC6 during Lm infection in dendritic cells. The scheme shows the involvement of HDAC6
in two different functions of dendritic cell during Lm infection, the autophagy and the TLR signalling. (1) The fusion of
phagosome with lysosome is dependent on cortactin and F-actin. The deacetylation of cortactin by HDAC6 allows the
correct fusion, followed by an autophagic clearance of Lm. The absence of this enzyme delays the fusion of phagosome
and lysosome, facilitating Lm to escape from phagosome leading to an increased bacterial load. (2) Di- and tri-acyl
lipopeptides and peptidoglycan (PGN) of Lm are recognized by TLR1/2 or TLR2/6, activating the TLR pathway.
HDAC6 is able to interact with the TLR-adaptor protein MyD88 which caused an enhanced down-stream signalling of
TLR pathway, increasing NF-κB and MAPK activation. This stronger activation (independent on HDAC6 enzymatic
activity) results in higher pro-inflammatory cytokine production and iNOS induction, reinforcing the ability of the DC
to combat against this intracellular pathogen. Although the absence of HDAC6 does not fully abolish the activation of
the DC, a lower induction of NF-κB and MAPK pathways promotes a lower activation of the anti-bacterial
transcriptional program of the DCs. Note that both processes occur during Lm infection and the pro-inflammatory
cytokines and iNOS induction can impact on the autophagic process. The images in the figure are not scaled.
https://doi.org/10.1371/journal.ppat.1006799.g010
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ubiquitinated proteins, but shows a preference for proteins modified with k63-linked ubiquitin
chains, which share structural similarities with ISG15 [51]. S. Typhimurium is decorated with
this kind of ubiquitin chain for recognition by host cells, and can be recovered with phago-
some proteins to initiate autophagy [52, 53]. Nevertheless, our data demonstrate that autop-
hagy induction does not differ between Hdac6+/+ and Hdac6-/- BMDCs, indicating that this
phenotype is due to p62 accumulation in Hdac6-/- BMDCs as a consequence of impaired pha-
gosome-lysosome fusion. Intact autophagy activation in Hdac6-/- BMDCs could be explained
by compensatory p62 binding to ubiquitinated bacteria in the absence of HDAC6.
Our data also underscore other different function of HDAC6, independent of its enzymatic
activity, in innate immune response to intracellular bacteria and various TLR stimuli (Fig 10).
Hence, we provide evidence for a dampened inflammatory response in the absence of
HDAC6, as shown by lower RNA levels of pro-inflammatory cytokines, chemokines, type-I
interferons, and interferon-related proteins in Hdac6-/- BMDCs than in Hdac6+/+ cells at 6 hpi,
as well as the lower pro-inflammatory cytokine production and IFN-β secretion by infected
Hdac6-/- BMDCs from 6 to 24 hpi. Moreover, Hdac6-/- BMDCs showed diminished iNOS
induction at 6 hpi associated with low nitrite production and iNOS expression at longer times
of Lm infection (24 hpi). These results agree with a lower phosphorylation of the MAPK path-
way after Lm infection in Hdac6-/- dendritic cells, controlling the activation of AP-1 family
transcription factors, which is necessary to switch inflammatory responses on [54]. In addi-
tion, the lower phosphorylation of mTORC1 pathway components in Hdac6-/- DCs is consis-
tent with a lower pro-inflammatory response, as reported in trained macrophages and
dendritic cells, in which a metabolic switch to glycolysis has been described [55]. These data
may indicate that HDAC6 also appears to play a role in the activation of mTOR pathway after
Lm infection to initiate the antibacterial transcriptional response to combat this pathogen. In
summary, our results reveal a defect in DC activation after Lm entry.
Remarkably, this impaired anti-inflammatory response in Hdac6-/- BMDCs was also
observed with other TLR-agonists such as LPS, Imiquimod, poly(I:C) and Pam3GSK4,
highlighting HDAC6 as an important player in TLR signalling activation. Broad-spectrum
HDAC inhibitors such as TSA exert immunosuppressive effects [56]. Genome-wide expres-
sion profiling arrays have revealed that 60% of genes transcriptionally increased by TLR2 or
TLR4 stimulation are inhibited in TSA-treated cells, whereas 16% of genes are potentiated
[56]. However, these observations do not provide any demonstrative evidence for a specific
role of HDAC6, since other HDACs may also be involved.
Because GM-CSF-derived DCs express low levels of TLR3 and 5 in the membrane, we stim-
ulated FLT3-L-derived DCs with poly(I:C) and flagellin to measure pro-inflammatory cyto-
kines [57, 58], noting maintained failure in the inflammatory response in Hdac6-/- cells.
Moreover, we detected impaired responses to PAMPs activation in GM-CSF-derived and
FLT3L-derived Hdac6-/- DCs. In addition, all TLRs except for TLR3 signal through the adaptor
MyD88, and the result obtained with the TLR3 ligand poly(I:C) was similar to that showed for
the rest of TLR stimuli, thereby indicating that the TLR3-response is also affected by absence
of HDAC6. In this regard, these data are in agreement with a recent study showing that acety-
lated retinoic-acid-inducible gene-1 (RIG-1) makes Hdac6-/- cells less sensitive to the presence
of RNA viruses, resulting in a higher viral titre [59]. While this mechanism could explain the
difference between the response of Hdac6+/+ and Hdac6-/- FLT3L-DCs to TLR3 stimulation,
the deficient activation by other TLRs in Hdac6-/- DCs also requires an explanation. In this
respect, we demonstrate the molecular association of HDAC6 with MyD88 with endogenous
proteins and in an overexpression system. Conceivably, the depletion of HDAC6 and therefore
prevention of HDAC6-MyD88 binding, could inhibit TLR-2-signalling pathway activation,
which is in accordance with a lower NF-κB induction measured in Hdac6-/- cells after various
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TLR-2 agonist stimulation. A diminished NF-κB induction in Hdac6-/- cells could explain a
reduced initiation of the pro-inflammatory response observed in Hdac6-/- dendritic cells,
needed to alert the innate and adaptive immune response to Lm. However, NF-κB activity of
HDAC6-DD-transfected HEK cell line after TLR-2 stimuli did not display any significant
change compared to HDAC6-WT-transfected ones, supporting that enzymatic activity of
HDAC6 is not involved in this signalling pathway. Two acetylated peptides corresponding
to MyD88 have been found in basal condition in HEK transfected with HDAC6-DD and
shHDAC6 constructions, which are different from the residue previously described in MyD88
[60]. However, no changes in the acetylation marks on MyD88 were detected after HKLM
incubation, highlighting the scaffold role of HDAC6 in the proper activation of TLR-signalling
pathway (Fig 10). Unexpectedly, a protective effect against systemic infection to a lethal dose
of Lm were observed in Hdac6-/- mice. The reduced level of the inflammatory cytokine IL-6
detected in Hdac6-/- mice are in accordance with its higher resistance to Lm infection. The
defective systemic inflammatory response after Lm infection of Hdac6-/- mice may indicate an
impaired TLR-response in the absence of HDAC6 and might therefore be attributed to the
absence of the molecular association of MyD88 and HDAC6. In this regard, mice resistance to
Lm infection can be mediated by sequential MyD88-independent and -dependent responses
[61–64]. However, the role of TLR-2 during Lm infection does not appear to be clear enough
[62, 63]. On one hand, Tlr-2-/- mice display a deficit in circulating TNF-α and IL-12p40 pro-
duction during intravenously injected Lm infection combined with a lower mice survival and
increased bacterial burden in the liver [61, 63]. Other authors have obtained similar resistance
to intraperitoneal-injected Lm infection between Tlr-2-/- and Tlr-2+/+ mice, indicating that dif-
ferent inoculation routes of bacteria may render different immune outcomes [62]. Although
handling and direct killing of Lm by activated macrophages can be mediated by TLR-2- and
MyD88-independent mechanisms, the role of TLR-signalling has been observed necessary for
nitric oxide and cytokine production [61, 63]. In fact, MyD88 not only works as TLR-adaptor
protein, but also as adaptor of IL-1 and IL-18 receptors, both cytokine responses affected in
Lm-MyD88-/- mice [62, 63, 65].
Overall, our data support a dual role for HDAC6 in the regulation of innate immunity
against intracellular bacteria. An increased bacterial load in different Hdac6-/- myeloid cells
can be explained by the autophagy mechanism, where a permanently acetylated cortactin may
impair the phagosome-lysosome fusion, necessary for the clearance of this pathogen. Our
experiments also show the importance of HDAC6 in DC activation, uncovering a novel mech-
anism of HDAC6 action mediated by the appropriate signalling via the TLR pathway, due to
the association of HDAC6 with the TLR-adaptor protein MyD88. This molecular association
seems to be required for a response to TLR stimuli to initiate the inflammatory response of an
activated dendritic cell. Taken together, both HDAC6 functions described in this manuscript,
reinforce the importance of this molecule to combat intracellular bacteria as Lm by autophagy
and to completely activate the inflammatory response after TLR activation.
Materials and methods
Ethical statement
Mice were housed under specific pathogen-free conditions at the Centro Nacional de Investi-
gaciones Cardiovasculares Carlos III (CNIC), and experiments were approved by the CNIC
Ethical Committee for Animal Welfare and by the Spanish Ministry of Agriculture, Food, and
the Environment. Animal care and animal procedures license were reviewed and approved by
the local Ethics Committee for Basic research at the CNIC Ethical Committee for Animal Wel-
fare and the O´rgano Encargado del Bienestar Animal (OEBA) del Gabinete Veterinario de la
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Universidad Auto´noma de Madrid (UAM). This committee approved the document with an
associated identification number PROEX 158/15 (CNIC 04/15).
Buffy coats of healthy donors were received from the Blood Transfusion Center of Comuni-
dad de Madrid, and all donors signed their consent for the use of samples for research pur-
poses. All the procedures using primary human cells were approved by the Ethics Committee
of the Hospital Universitario de la Princesa.
Mice
HDAC6-/- mice were generated through targeting of exons from 10 to 13 by inserting a neomy-
cin (Neo) and zeocin (Zeo) cassette, resulting in the disruption of the first catalytic domain of
HDAC6 [66]. These mice were intercrossed on a C57BL/6 background to generate sex and age
matched wild-type (wt) and knockout.
Bacteria strains
We used the Listeria monocytogenes EGD (BUG 600) strain, provided by Dr. Esteban Veiga
(Centro Nacional de Biotecnologı´a, CNB, Madrid). Staphylococcus aureus 132 and Escherichia
coli K12, strain DH5α, were purchased from Invitrogen. BUG600 and S. aureus bacteria were
grown in BHI broth. RFP-expressing Listeria monocytogenes (RFP-Lm) was provided by Dr
Carlos Ardavı´n´s laboratory (Centro Nacional de Biotecnologı´a, CNB, Madrid). Salmonella
enterica serovar Thyphimurium strain SL1344 was provided by Dr. J. Garaude (Centro Nacio-
nal de Investigaciones Cardiovasculares, CNIC, Madrid). SL1344 and DH5α bacteria were
grown in LB broth supplemented with 50 μg/ml streptomycin (Sigma). For phagocytosis
experiments, Lm and S. aureus were grown overnight in Brain Herat Infusion (BHI) broth and
E. coli and S. Thyphimurium in Luria-Bertani (LB) broth with shaking, diluted 1/50, and
grown until log-phase (optical density 0.8–1.2 at 600 nm) without shaking. Bacteria were
washed with phosphate-buffered saline (PBS) to remove LB salts before addition to cells.
Cell culture
The HEK293T cell line (ATCC) was cultured in DMEM medium (Sigma) containing 10% FBS
(Invitrogen), 2 mM L-glutamine, 100 mg/ml penicillin and 100 mg/ml streptomycin. HEK
Blue hTLR2 cell line (Invivogen), the HEK293 cell line expressing human TLR2, CD14 and
NF-κB-SEAP (secreted embryonic alkaline phosphatase) reporter gene was cultured in
DMEM medium (Sigma) containing 10% FBS (Invitrogen), 2 mM L-glutamine, 100 μg/ml
Normocin (Invivogen) and 1X HEK-Blue Selection (Invitrogen).
Generation of bone marrow-derived dendritic cells (GM-CSF) and
macrophages (M-CSF)
Mouse primary dendritic cells (BMDCs) and macrophages (BMDMs) were obtained from
bone marrow cell suspensions after culture on non-treated 150-mm Petri dishes in complete
RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 100 mg/ml penicillin, 100 mg/
ml streptomycin, 50 mM 2-ME, and 20 ng/ml granulocyte-macrophage colony-stimulating
factor (GM-CSF, PeproTech, London, U.K.) for BMDCs and macrophage colony-stimulating
factor (30% mycoplasma-free L929 cell supernatant, NCBI Biosample accession number
SAMN00155972) for BMDMs. BMDCs were collected at day 9 and BMDCs were characterized
as CD11c+MHC-II+Gr-1- cells by flow cytometry. BMDMs were collected at day 6 and
BMDMs were characterized as CD11b+F4/80+ or CD11b+CD64+ cells.
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Generation of bone marrow-derived dendritic cells (FLT3L)
Bone marrow cell suspensions were culture on treated 6 well plates in complete RPMI 1640 sup-
plemented with 10% FBS, 2 mM L-glutamine, 100 mg/ml penicillin, 100 mg/ml streptomycin,
50 mM 2-ME, and 150 ng/ml (FLT3L, PeproTech, London, U.K.). After 9–11 days of differenti-
ation cells were collected to be characterized by flow cytometry as CD11c+B220-CD11b+CD24-
(60% of the culture) and CD11c+B220-CD11b+CD24+(40%).
Obtainment of thioglycollate-elicited macrophages (TEMs)
Mice received peritoneal injections with 1ml 4% TG. The peritoneal exudate was collected
after 4 days and cultured in complete RPMI 1640 supplemented with 10% FBS, 2 mM L-gluta-
mine, 100 mg/ml penicillin, 100 mg/ml streptomycin, and 50 mM 2-ME. To enrich the culture
for macrophages, non-adherent cells were eliminated after a few hours by washing five times
with warm PBS and gentle swirling.
Obtainment of human monocyte-derived dendritic cells (moDCs)
Peripheral blood mononuclear cells (PBMCs) from Buffy coats of healthy donors were isolated
using Biocoll separating solution (Millipore) by centrifugation at 700 g 30 min at RT. Mono-
cytes were purified from peripheral blood mononuclear cells (PBMCs) by an adherence step at
37˚C in incomplete RPMI 1640 medium during 1 h. Non-adherent cells were removed and
adherent monocytes were washed three times with warm 1xPBS to remove residual PBMCs.
Monocytes were cultured in complete RPMI 1640 supplemented with 10% FBS, 2 mM L-gluta-
mine, 100 mg/ml penicillin, 100 mg/ml streptomycin, 500 U/ml IL-4 (R&D) and 500 U/ml
GM-CSF (Immunotools) for 6 days. Fresh medium and cytokines were added every 48 hours
to differentiate monocytes to immature human dendritic cells. Cells were characterized by
flow cytometry as HLA-DR+CD3-DC-SIGN+CD14-CD11c+. Activation of dendritic cells was
induced with Pam2GSK4, Pam3GSK4 and HKLM for 30 min (Invivogen).
In vitro Lm-infection of BMDCs, BMDMs and TEMs
Cells were incubated with Lm and assessed for survival to gentamicin exposure [67]. Cells
were infected with Lm at a multiplicity of infection (MOI) of 10 for 30 min at 37˚C. To deter-
mine the number of bacteria entering the cells, extracellular bacteria were killed by treatment
with 100 μg/ml gentamicin (Sigma-Aldrich, St. Louis, MO) for an additional 30 min at 37˚C.
Then, infected cells were washed with PBS three times and lysed with 0.05% Triton X-100
(Sigma-Aldrich, St. Louis, MO) in distilled water. Serial dilutions were seeded on brain-heart
infusion (BHI) agar plates and CFUs were counted after 36 hours.
In vivo Lm systemic infections
Hdac6+/+ and Hdac6-/- were intravenously injected with Listeria monocytogenes EGD (125.000
CFUs/mouse) using a 29-gauge needle. For survival experiments mice were monitored twice a
day in order to detect casualties during 15 days of infection.
Determination of CFUs in target organs
After 12, 24, 48 and 72 hpi, mice were perfused with 1X PBS to clean blood form organs and
spleens and livers were weight. To determine bacterial load, spleens and livers were digested
with 0.1 mg/ml type IV collagenase and 0.5 mg/ml DNAse I (Roche, Mannheim, Germany)
for 30 min at 37˚C. After digestion, organs were homogenized in 70 μm filters and red blood
cells were lysed with ammonium chloride potassium lysis buffer (ACK, Sigma). Splenic cell
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suspensions were resuspended in PBS and cells were counted. Serial dilutions were grown on
BHI agar plates. CFUs were counted after 36 hours of incubation at 37˚C. CFUs were calcu-
lated by cell number and by gram per organ.
Antibodies and reagents
Antibodies were used in western blotting, flow cytometry and immunofluorescence; detailed
information is available in S1 Table. Poly-L-lysine (PLL) was purchased from Sigma. Phalloi-
din-Alexa488 and 647 were from BD Biosciences. Zenon Alexa Fluor 488 rabbit IgG labelling
kit, DAPI and Prolong Gold anti-fade mounting medium were from Thermofisher Scientific.
Anti-human CD3 antibody (T3b hybridoma) was generated in Dr. F. Sa´nchez-Madrid labora-
tory (Hospital Universitario de la Princesa, HUP, Madrid) [68]. Rapamycin, bafilomycin A1,
3-MA, cloroquine, NH4Cl, 1400W and DPI were from Sigma-Aldrich.
Gene overexpression and silencing
HEK293 cells were co-transfected with plasmids encoding human MyD88 fused to the HA-tag
(Addgene plasmid #12287) together with plasmids encoding HDAC6-WT or double deacety-
lase domain mutant DD (mutated human HDAC6-H216A/H611A) fused to the eGFP tag
(HDAC6-WT and HDAC6-DD have been previously described [26]. When indicated, cells
were co-transfected with the appropriate small harping RNA plasmid pLVX-IRES-ZsGreen1,
where shHDAC6-2049 (TRCN0000004842) was cloned between BamH1 and EcoR1 sites. Cells
were transfected using Lipofectamine 2000 (Invitrogen). Experiments were performed after 24
h after transfection.
RNA extraction and real-time quantitative PCR
RNA from mouse BMDCs was isolated with the QIAGEN RNeasy Kit (Qiagen). Residual
DNA contamination was removed with the Turbo DNA-free Kit (Ambion). Total RNA (1–
2 μg) was reverse transcribed to cDNA with a Reverse Trancription Kit (Applied Biosystems).
Quantitative PCR was then performed in an AB7900-384 thermocycler (Applied Biosystem)
using SYBR Green master mix (Applied Biosystems, Warrington, UK) as the reporter. Expres-
sion levels of target genes were normalized to the expression of housekeeping genes β-actin,
GAPDH, β2-microglobulin and Yhwaz (tyrosine 3-monooxygenase/tryptophan 5-monooxy-
genase activation protein, z) for presentation of relative mRNA levels. Data were analysed
with Biogazelle qBasePlus version 2.3 (Biogazelle) and graphs are represented as a normalized
expression scaled to average of all samples. Gene-specific primers used are listed in S2 Table.
Soluble embryonic alkaline phosphatase (SEAP)-NF-κB detection
50.000 transfected HEK-Blue hTLR2 cells with different HDAC6 constructions were place in
bottom p96 well plates resuspended in HEK-Blue Detection medium (Invivogen) without
stimulus (negative control) and with TLR-2 agonists (HKLM stimulus, MOI = 10). After 8–12
h of incubation, SEAP activity was measured by optical density at 620 nm with a microplate
reader. To calculate the NF-κB induction, the signal obtained from each mutant condition
without stimuli (background) was depleted of the signal of each condition of activation with
Pam2GSK4, Pam3GSK4 or HKLM.
ELISAs and nitrite measurement
Cytokine and NO production was analysed in the supernatants of BMDC cultures at 6, 12
and 24 h after stimulation with Lm, heat-killed Listeria monocytogenes (HKLM), heat-killed
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Salmonella Typhimurium (HKST), Pam3CSK4, Flagellin, Imiquimod, polyinosinic-polycy-
tidylic acid (Poly(I:C)) (InvivoGen, San Diego, CA), or LPS from Escherichia coli (Sigma-
Aldrich). TNF-α and IL12p70 were analysed with OptEIA ELISA kits (BD Biosciences, San
Diego, CA), IL-1β and IL-6 with the mouse ELISA Ready-SET-Go! kit from eBioscience (Affy-
metrix, San Diego, CA) and Interferon-β was measured with Legend max mouse IFN-β ELISA
kit (Biolegend). The detection was based on colorimetric quantification of absorbance at 450
nm, corrected with subtraction at 570 nm measured in a microplate reader (Bio-Rad Model
550). NO was estimated from the nitrite concentration measured with a Griess reagent kit
at 548 nm (Molecular Probes/Life Technologies, Thermo Fisher Scientific). Results were
expressed as the means of duplicate wells.
Immunoblotting
Total cell extracts from BMDCs stimulated with Lm, HKLM or the indicated TLR ligands for
the indicated times were prepared in lysis buffer (0.5% Triton X100, 25 mM Tris-HCl pH 7.5,
0.5 mM EGTA, 0.5 mM EDTA, 25 mM NaF, 0.5 sodium glycerol-phosphate, 2.5 mM pyro-
phosphate, 0.135 M sacarose) with a cocktail of protease and phosphatase inhibitors (Roche).
Cell lysates were cleared of nuclei by centrifugation at 15,000 g for 15 min. Protein extracts
were separated by 8–15% SDS-PAGE and transferred to a PVDF membrane (Biorad). Proteins
were visualized with LAS-3000 after membrane incubation with specific antibodies (see S1
Table) and peroxidase-conjugated secondary antibodies (5 μg ml−1). Band intensities were
quantified using Image Gauge software (Fuji Photo Film, Co., Ltd) and results are expressed
relative to loading controls. For quantification of western-blots, phosphorylated/total ratios
were divided by loading control signal. Non-infection (NI) time was considered as 100%, and
following times were relativized to it.
Immunoprecipitation of MyD88 and HDAC6 proteins
Human moDCs (1 × 107 per condition) were lysed (10 mM Tris pH 7.4, 150 mM NaCl, 5% glyc-
erol, 1mM EDTA, 1mM MgCl2, 1mM CaCl2, 1% CHAPS (Sigma) and protease and phosphatase
inhibitors (Roche)) for 1 h at 4˚C. Lysates were incubated for pre-clearing with pre-washed Pro-
tein G Dynabeads (Invitrogen; 50 μl per condition; 2 h, 4˚C). Pre-cleared lysates were incubated
with 6 μg rabbit anti-MyD88 antibody (Cell Signaling) or 6 μg rabbit anti-HDAC6 antibody
(Assay bioTech) per condition O/N at 4˚C. Similar μg of control isotype antibody for rabbit
were used. Fifty microlitres of Dynabeads per condition were washed three times in wash buffer
(10 mM Tris pH 7.4, 150 mM NaCl, 5% glycerol, 1mM EDTA, 1mM MgCl2, 1mM CaCl2, 0.1%
CHAPS) and added to antibody-conjugated lysates for 2 h 4C. Antibody-conjugated Dynabeads
were washed six times with wash buffer and transferred to clean tubes.
HEK293T cells or HEK-Blue hTLR2 (1 × 107 per condition) were lysed (25 mM Tris pH 8,
150 mM NaCl, 0.5% NP-40 and protease and phosphatase inhibitors) and incubated for pre-
clearing with pre-washed Protein G Dynabeads (Invitrogen; 50 μl per condition; 3 h, 4˚C).
Fifty microlitres of Dynabeads per condition were washed three times in wash buffer (25 mM
Tris pH 8, 150 mM NaCl, 0.05% NP-40) and re-suspended in 600 μl of wash buffer containing
1–2 μg mouse anti-HA antibody (Roche) per condition and incubated 3 h at 4˚C. Similar μg of
control isotype antibody for mouse were used. Pre-cleared lysates were incubated with anti-
body-conjugated Dynabeads (O/N, 4˚C). Antibody-conjugated Dynabeads were washed six
times with lysis buffer and transferred to clean tubes. Then, were washed twice with wash
buffer. Protein loading buffer was added, samples were boiled at 95˚C for 5 min and processed
for immunoblotting.
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Flow cytometry
Cells were stained in ice-cold PBS containing FBS (0.5%) and EDTA (5 mM) using appropriate
antibody-fluorophore conjugates. Multiparameter analysis was performed on a FACSCANTO
II flow cytometer (BD Biosciences) and analysed with FlowJo software (Tree Star). Prior to fix-
ing, cells were resuspended in PBS/0.5% BSA/5 mM EDTA solution containing yellow fluores-
cent reactive dye to exclude dead cells (Life Technologies). For intracellular staining, cells were
fixed and permeabilized using the CytoFix/Cytoperm kit (BD).
Fluorescence confocal microscopy
For immunofluorescence assays, cells were plated onto slides coated with poly-L-lysine (50 μg
ml−1) and incubated for 1 h at 37˚C. Infection experiment were carried out at the indicated
times. Cells were then fixed, blocked and stained with the indicated primary antibodies (5 μg
ml−1) followed by alexa488- or Rhodamine Red X-labelled secondary antibodies (5 μg ml−1).
Samples were examined under a Leica SP5 confocal microscope (Leica) fitted with a 63X
objective. Images were acquired with sequential xyz acquisition mode scans with laser ranges
of 418–473 nm for DAPI, 502–548 nm for Alexa-488, 584–644 nm for Rhodamine X and 737–
779 nm for Alexa-647. Z-stacks of 2–5 μm were obtained using a maximum z-step size of
0.3 μm.
Imaris quantification
Images were processed and assembled using Image J 1.51p (Fiji). Confocal 3D images assem-
bled with Imaris 7.7.2 (Bitplane) using the ImarisCell module. Every cell and its corresponding
intracellular bacteria were calculated in each image. Surfaces corresponding to bacteria were
used to calculate the maximal fluorescence intensity of the channels to co-localize with bacte-
ria. Two-channel co-localization was quantified in at least 10 images per genotype, corre-
sponding to 10 biological samples.
In-gel protein digestion
Proteins were in-gel digested using a previously described protocol [69]. Briefly, the coimmu-
noprecipitate was heated at 95˚C for 5 min, after which the magnetic beads were removed
using a magnet. The resulting solution was added sample buffer and loaded in 0.5-cm-wide
wells of an SDS-PAGE gel. The run was stopped as soon as the front entered into the resolving
gel. The protein band was visualized by Coomassie Blue staining, excised, and digested over-
night at 37˚C with 60 ng/μl sequencing-grade modified trypsin (Promega) at 10:1 protein:
enzyme (w/w) ratio in 50 mM ammonium bicarbonate, pH 8.8, containing 10% acetonitrile.
The resulting tryptic peptides were desalted onto C18 OMIX tips (Agilent), dried down and
kept at -80˚C until further use.
Mass spectrometry
The resulting peptides were analyzed by liquid chromatography coupled to tandem mass spec-
trometry (LC-MS/MS) on an Easy nLC-1000 nano-HPLC apparatus (Thermo Scientific, San
Jose, CA, USA) coupled to a hybrid quadrupole-orbitrap mass spectrometer (Q Exactive HF,
Thermo Scientific). The dried peptides were taken up in 0.1% (v/v) formic acid and then
loaded onto a PepMap100 C18 LC pre-column (75 μm I.D., 2 cm, Thermo Scientific) and
eluted on line onto an analytical NanoViper PepMap 100 C18 LC column (75 μm I.D., 50 cm,
Thermo Scientific) with a continuous gradient consisting of 8–31% B in 240 min (B = 80%
ACN, 0.1% formic acid) at 200 nL/min. Peptides were ionized using a Picotip emitter
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nanospray needle (New Objective). Each MS run consisted of enhanced FT-resolution spectra
(120,000 resolution) in the 400–1,200 m/z range followed by data-dependent MS/MS spectra
of the 20 most intense parent ions acquired along the chromatographic run. The AGC target
value in the Orbitrap for the survey scan was set to 1,000,000. Fragmentation in the linear
ion trap was performed at 30% normalized collision energy with a target value of 10,000 ions.
The full target was set to 30,000, with 1 microscan and 50 ms injection time, and the dynamic
exclusion was set to 0.5 min.
Peptide identification
For peptide identification the MS/MS spectra were searched with the Sequest algorithm imple-
mented in Proteome Discoverer 1.4 (Thermo Scientific). Database searching against human
protein sequences from the UniProt database (March 2017, 158,382 entries) was performed
with the following parameters: trypsin digestion with 4 maximum missed cleavage sites; pre-
cursor and fragment mass tolerances of 800 ppm and 0.02 Da, respectively; Cys carbamido-
methylation as static modifications; and Met oxidation and Lys acetylation as dynamic
modifications. The results were analyzed using the probability ratio method [70] and a false
discovery rate (FDR) for peptide identification was calculated based on the search results
against a decoy database using the refined method [71].
Statistical analysis
Data were analysed with GraphPad prism software (La Jolla, CA) for normality (Kolmogorov-
Smirnov test for small samples). Normal data were analysed by Student t-test, non-normal
data by Mann-Whitney test, and grouped data by 2-tailed One-way ANOVA with a Bonferroni
post-test. For western blot quantification, the sample with the maximum signal was assigned a
value of 100%, and signals in other samples were expressed as a percentage of this; significance
was determined by a one-sample test. Long-rank (Mantel-Cox) test and Cehan-Breslow-Wil-
coxon test were used for the analysis of the Kaplan-Meier curve (survival curve).
Supporting information
S1 Fig. Differentiation of GM-CSF-derived DCs, their viability at 6 hpi, comparison of
CFUs of GM-CSF- and M-CSF-derived cells and fluorescent confocal microscopy of Lm.
A) Left: Dot-plots showing CD11c and MHC-II markers, with gating for CD11c+MHC-II+
and CD11c+MHC-II- populations (percentages indicated). Right: Dot-plots on differentia-
tion day 11 showing FSC-H versus Gr-1, gating the Gr-1+ population corresponding to neu-
trophil contamination in GM-CSF-derived DC cultures. Charts show the percentages of
CD11c+MHC-II+, CD11c+MHC-II- and Gr-1+ populations. ns>0.05 non-significant; n = 6.
B) Percentage viability of BMDCs before infections and at 6 hpi with Lm, ns>0.05 non-
significant; n = 6. C) Comparison of CFUs in GM-CSF-derived DCs and M-CSF-derived
macrophages over the time-course of Lm infection. p0.001,  p0.01, ns>0.05 non-sig-
nificant; n = 6. D) ImarisCell Module analysis of the number of cells and the number of bac-
teria per cell in all pictures (10 pictures per genotype). The graph shows the distribution
of cells with a specific number of bacteria per cell. The number of cells with 6 and 7 bacteria
differed significantly between the Hdac6+/+ and Hdac6-/- genotypes.  p0.05, n = 10. E)
Confocal microscopy determination of bacterial load of the Fig 1F. Maximum intensity z-
projections of confocal microscopy images of Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at
6 hpi. ImarisCell Module view of the number of nucleus and bacteria per cell. Actin transpar-
ency is used to visualize bacteria (number indicated on the right). Images show DAPI (blue),
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Lm (red), β-actin (green). Scale bars 20 μm.
(TIF)
S2 Fig. Gating strategy of myeloid populations of the spleen. A) Dot-plots showing the gat-
ing of myeloid populations of spleen. Dot-plots showing SSC-A versus FSC-A indicates p1,
FSC-H versus FSC-W and SSC-H versus SSC-W were used to avoid doublets and FSC-H
versus viability shows live and dead cells. Singlets and live cells were used to choose
CD3-CD19-DX5-Ly6G+ cell population. From this population, neutrophils were gated as Ly6G
+Ly6C+ cells, monocytes as CD11b+CD11clo, Tips DCs as intermedium levels of CD11b and
CD11c, conventional dendritic cells (cDCs) as CD11chi; inside this population cDCs CD8-
were distinguish as CD11chiCD11b+ and cDCs CD8- as CD11chiCD11blo. B) Representative
histograms of different splenic populations (monocytes, neutrophils, Tips DCs, total cDCs,
cDCs CD8- and cDCs CD8+) show Lm signal of Hdac6+/+ and Hdac6-/- mice injected with a
lethal dose of Lm at 6 hpi. A pool of Hdac6+/+ and Hdac6-/- spleens non-infected was used as a
control sample without infection (NI). p0.01,  p0.05; n = 6.
(TIF)
S3 Fig. Control vehicles and autophagy markers. A) Total CFUs at 0 and 6 hpi in Lm-
infected BMDCs (MOI of 10) treated with different control vehicles (H2O, DMSO and etha-
nol). H2O were the control vehicle used for NH4Cl and cloroquine, DMSO for 3-MA, bafilo-
mycin A1, DPI and 1400W and ethanol for rapamycin. Time 0 is included as a bacterial entry
control. p0.001, ns>0.05 non-significant; n = 6. B) PCR analysis of autophagy markers
(ATG-2, 5, 7 and 12, LC3A and B, p62 and Beclin-1) and lysosome markers (LAMP-1 and 2)
(arbitrary units) after 6 hpi with Lm, ns>0.05 non-significant; n = 5.
(TIF)
S4 Fig. Pro-inflammatory cytokine secretion. ELISA detection of the pro-inflammatory
cytokines IL-1β and IL12p70 (pg/ml) in supernatants (S) and in supernatants plus the corre-
sponding cell pellets (S+P) of Lm-infected Hdac6+/+ and Hdac6-/- BMDCs at 6, 12 and 24 hpi.
p0.001,  p0.01,  p0.05, ns>0.05 non-significant; n = 5.
(TIF)
S5 Fig. TLR expression and TLR-signalling pathway activation by LPS and HKLM. A)
Western-blot analysis in Hdac6+/+ and Hdac6-/- BMDCs over the time-course of LPS or
HKLM treatment. Total and phosphorylated AKT were detected for both treatments. Accom-
panying charts on the right show quantification, indicating the percentage of phAKT/total
AKT ratio.  p0.01,  p0.05; n = 4. B) PCR analysis of TLR-1, 2 and 6 (arbitrary units) in
Hdac6+/+ and Hdac6-/- BMDCs non-infected (NI) and after Lm-infection at 6 hpi. ns>0.05
non-significant; n = 6.
(TIF)
S6 Fig. Differentiation of FLT3-L DCs, their pro-inflammatory cytokine secretion at 6
hpi and association of HDAC6 with TLR-adaptor MyD88. A) Left: Dot-plots of FLT3-L
DC cultures at day 11 of differentiation, showing gating for the CD11c+ population (percent-
ages indicated). Centre: Dot-plots showing CD11b versus B220 to select two populations:
CD11c+CD11b+B220+ (plasmacytoid DCs, pDCs) and CD11c+CD11b+B220- (conventional
DCs, cDCs) (percentages indicated). Right: Dot-plots showing CD11b versus CD24 to select
the CD11b+CD24+ and CD11b+CD24- populations (gated from cDCs) (percentages indi-
cated). The charts on the right show the percentages of CD11c+, CD11c+CD11b+B220-CD24-
and CD11c+CD11b+B220-CD24+ populations, ns>0.05 non-significant; n = 6. B) ELISA
detection of the pro-inflammatory cytokines IL-1β and IL-6 (pg/ml) in supernatants of
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Hdac6+/+ and Hdac6-/- FLT3L-DCs activated with LPS, Imiquimod, Pam3GSK4, HKLM,
HKST, Lm, Poly(I:C) or flagellin for 6 h. p0.001,  p0.01,  p0.05; n = 6. C) MyD88
adaptor protein in Hdac6+/+ and Hdac6-/- BMDCs. Western-blot analysis of MyD88 over the
time-course of Lm infection in Hdac6+/+ and Hdac6-/- BMDCs (left). Accompanying charts on
the right show quantification of the percentage of MyD88; ns non-significant; n = 5. D) Immu-
noprecipitation of HA (MyD88) followed by western-blot for HDAC6 and MyD88. Immuno-
precipitations were carried out using different HDAC6-eGFP plasmids co-transfected with
MyD88-HA in HEK cell line. Over-expressed (HDAC6-eGFP, 160 kDa) is indicated at right of
western-blot. E) Immunoprecipitation of HA (MyD88) followed by mass spectrometry analy-
sis. Immunoprecipitations were carried out using different HDAC6-eGFP plasmids co-trans-
fected with MyD88-HA in HEK cell line. The number of unique MyD88 and HDAC6 peptides
identified is indicated. () indicates the presence of acetylated MyD88 peptides. Similar results
were obtained in three independent experiments. F) MS2 fragmentation spectra from the pep-
tides showing at 1217.0699 (Top), and 599.3803 (Bottom). Ion adscription to carboxy- (y ions,
blue) and amino-terminal (b ions, red) fragmentation series is indicated. Kac denotes acety-
lated lysine and Ccm indicates carbamidomethylated cysteine. Fragment ion sequence coverage
is schematically indicated. Similar results were obtained in three independent experiments.
(TIF)
S1 Table. Antibody table. Table of antibodies used in experimental procedures disclosed by
reference, brand, host, application and dilution.
(PDF)
S2 Table. qPCR primers. Table of qPCR primers used in experimental procedures disclosed
by gene name and sequence 5´-3´.
(PDF)
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Abstract
HDAC6 is a tubulin deacetylase involved in many cellular functions related to cytoskeleton 
dynamics including cell migration and autophagy. In addition, HDAC6 affects antigen-dependent 
CD4+ T cell activation. In this study, we show that HDAC6 contributes to the cytotoxic function of 
CD8+ T cells. Immunization studies revealed defective cytotoxic activity in vivo in the absence of 
HDAC6. Adoptive transfer of wild-type or Hdac6-/- CD8+ T cells to Rag1-/- mice demonstrated 
specific impairment in CD8+ T cell responses against vaccinia infection. Mechanistically, 
HDAC6-deficient cytotoxic T lymphocytes (CTLs) showed defective in vitro cytolytic activity 
related to altered dynamics of lytic granules, inhibited kinesin 1 – dynactin mediated terminal 
transport of lytic granules to the immune synapse and deficient exocytosis, but not to target cell 
recognition, T cell receptor (TCR) activation or interferon (IFNγ) production. Our results establish 
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HDAC6 as an effector of the immune cytotoxic response that acts by affecting the dynamics, 
transport and secretion of lytic granules by CTLs.
Introduction
Cytotoxic T Lymphocytes (CTLs) are a specialized population of CD8+ T cells that provides 
defense against virus-infected cells and tumors. Naïve CD8+ T cells differentiate into CTLs 
upon antigen recognition, a process involving the synthesis and storage of cytotoxic 
mediators into lysosomal-derived lytic granules (LG) (Williams and Bevan, 2007). CTLs 
eliminate target cells by different mechanisms, including secretion of pro-inflammatory 
cytokines, e.g. tumor necrosis factor (TNF)α or interferon (IFN)γ (de Saint Basile et al., 
2010), FAS-L (FAS ligand) ligation to its receptor as well as granule-mediated apoptosis 
upon cell-cell contact and immune synapse (IS) formation (Ritter et al., 2013). LG fuse with 
the plasma membrane and release granzymes, cathepsins and perforins (Prf) (Lopez et al., 
2013; Pardo et al., 2009). The IS acts as a focal point for exocytosis of LG. LG polarization 
towards the target cell depends on T cell receptor (TCR) engagement, driven by the 
relocation of the centrosome to IS. The LG degranulate at a secretory domain adjacent to the 
TCR-enriched region within the IS (de Saint Basile et al., 2010; Ritter et al., 2013).
Histone deacetylase 6 (HDAC6) is an ubiquitous, cytosolic protein from the class II HDACs 
family with X-linked inheritance, that binds to and deacetylates α-tubulin at lys40 (Hubbert 
et al., 2002; Valenzuela-Fernandez et al., 2008). HDAC6 also modulates other substrates, 
e.g. cortactin or hsp90. HDAC6 controls cell migration (Zhang et al., 2007), T-regulatory 
functions (de Zoeten et al., 2011) and CD4+ T cell activation (Serrador et al., 2004). 
Consistent with this, HDACs inhibitors impair some immune functions (Mosley et al., 2006; 
Tsuji et al., 2015). However, the precise contribution in vivo (by using Hdac6-/- mice) has 
not been assessed, and the mechanisms involved remain unsolved. HDAC6 also functions as 
a scaffold protein in T cell migration (Cabrero et al., 2006) and the transport of misfolded 
proteins (Kawaguchi et al., 2003). In this report, we describe the impaired killing capacity of 
Hdac6-/- CTLs. The molecular mechanism underlying this defect involves a scaffold role 
that positions HDAC6 as a protein that oversees the proper movement of LG, their transport 
to the IS and secretion towards the target cell.
Results and Discussion
HDAC6 deficiency reduces the cytolytic capacity of CD8+ T lymphocytes
We examined the ability of cytotoxic T cells from Hdac6-/- mice to kill target cells in vitro. 
CD8+ T cells from wild-type (WT) and Hdac6-/- mice expressing the transgenic ovalbumin 
(OVA)-specific TCR (OT-I) were activated in vitro and cultured to generate CTLs. Cell 
cytotoxicity was subsequently analyzed by survival of dye-labeled EL4 target cells pulsed or 
not with OVA257-264 peptide (SIINFEKL). Hdac6-/- CTLs showed decreased killing activity 
(Fig. 1A), consistent with reduced expression of CD107a (also known as Lamp1) in Hdac6-/- 
CTLs upon degranulation (Fig. 1B). Likewise, CTLs from OT-I mice treated treated with 
tubastatin A, a potent HDAC6 inhibitor, displayed a reduced killing ability (Suppl. Fig. 1A). 
We also detected decreased Prf1 secretion from activated (i.e. induced by anti-CD3 and anti-
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CD28 monoclonal antibodies) Hdac6-/- CTLs (Fig. 1C, left). Next, we assessed the secretion 
promoted by phorbol-12-myristate-13-acetate (PMA), to bypass TCR stimulation. Both 
cathepsins D and Prf1 decreased in supernatants from activated Hdac6-/- CTLs (Fig. 1C, 
right). Taken together, our data demonstrate that Hdac6-/- CTLs show reduced cytotoxic 
activity, and suggest that HDAC6 controls exocytosis.
We next tested IFN-γ production; the frequency of CTLs producing IFNγ and its secretion 
was unaffected in activated Hdac6-/- CTLs (Fig. 1D-E), in contrast to what has been 
described when cells are treated with ACY-1215, a recently described inhibitor that is ten-
fold more selective for HDAC6 than for HDAC1, HDAC2 and HDAC3 and that shows slight 
activity against HDAC8 (Tsuji et al., 2015). Likewise, treatment of CTLs from OT-I mice 
with tubastatin A had no significant effect (Suppl. Fig. 1B). Importantly, T-cell signaling 
induced by anti-CD3/anti-CD28 mAbs in Hdac6-/- was comparable to control, as determined 
by assessing PLCγ1 and erk1/2 (Erk1/2; also known as MAPK3 and MAPK1, 
respectively)phosphorylation (Fig. 1F). Likewise, the increase in intracellular calcium 
remained unchanged upon activation (Fig. 1G). As expected, tubulin acetylation at Lys40 
was increased in Hdac6-/- CTLs (Fig. 1F). These results suggest that the killing defect 
observed does not result from a general impairment of CTLs function.
Defective in vivo and ex vivo killing in HDAC6 knockout mice
The effector activity of Hdac6-/- CD8+ T cells was tested in vivo following mouse 
immunization using SIINFEKL-pulsed dendritic cells. The in vivo killing activity against 
the injected target cells (pulsed or not with SIINFEKL) was analyzed upon recovery by 
peritoneal lavage. Notably, Hdac6-/- mice showed reduced specific killing of target cells 
(Fig. 2A, left panel). However, the proportion of SIINFEKL-specific CD8+ T cells from the 
endogenous repertoire was not affected in Hdac6-/- mice (Fig. 2A, right panel), suggesting 
that the cytotoxic function rather than the number of antigen-specific CTLs could underlie 
the defect. Next, we examined whether the decreased cytotoxic function of the CTLs 
resulted in an impaired ability to prevent morbidity and/or mortality during a viral infection. 
To restrict HDAC6 deficiency to CD8+ T cells, we adoptively transferred Rag1-/- mice with 
WT or Hdac6-/- naïve CD8+ T cells and subsequently challenged with a fully replicative 
vaccinia virus (VACV) WR strain. This infection model mimics the immunological and 
clinical features of smallpox vaccination in humans (Mota et al., 2011). CD8+ T cell 
proliferation was comparable, or even increased (division 4) in Hdac6-/- (Fig. 2B). Rag1-/- 
mice passively transferred with Hdac6-/- CD8+ T cells showed increased morbidity at 9 and 
11 days post-infection (p.i.) (Fig. 2C). Virus titration from the lesion tissue demonstrated 
that Hdac6-/- immune cells exerted a less-efficient virus clearance (Fig. 2D). Consistent with 
our findings on the lack of effect in endogenous antigen-specific CD8+ T cell numbers, CTL 
expansion tracked at 13 d.p.i. was not affected in Hdac6-/- (Fig. 2E, left). The proportion of 
activated CD8+ T cells (CD44high) at early (5 d.p.i) and late stages (13-30 d.p.i.) of the 
disease were similar for WT and Hdac6-/- mice (tested in peripheral blood and spleen, 
respectively; Fig. 2E, right). These in vivo results emphasize the role of HDAC6 in the CD8+ 
T cell-dependent protection against VACV infection without affecting effector CD8+ CTLs 
differentiation.
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HDAC6 drives the terminal transport of LG to the target cell
CTL killing is limited to target cells (and not neighbor cells) by the confinement of secretion 
to the immune synapse established between the CTL and the target cell (de Saint Basile et 
al., 2010). Interestingly, the intracellular colocalization between cathepsinD and lamp1 
(CD107a) was affected in Hdac6-/- CTLs conjugated with target cells, pointing to the 
mislocalization of lytic mediators in these cells (Fig. 3A; images and middle graphs). The 
decreased secretion of lytic proteins from Hdac6-/- CTLs suggests that HDAC6 regulates 
exocytosis of LG (Fig. 1C). Indeed, the translocation of the centrosome to the contact area 
with the target cell was even more pronounced in Hdac6-/- CTLs than in WT cells (Fig. 3A, 
right graph), in accordance with the effect described with the HDAC inhibitor Trichostatin A 
on the centrosomal polarization in CD4+ T cells (Serrador et al., 2004). This suggests that 
the defective exocytosis might rely on the movement of LG themselves.
We thus monitored the dynamics of LG at the subcortical immune synapse cytoskeleton and 
their release by Total Internal Reflection Fluorescence microscopy (TIRFm). CTLs were 
loaded with a pH-dependent, lysosomal tracker which allows the visualization of the LG and 
settled on to a stimulating surface to form an IS-like structure (Fig. 3B). These experiments 
revealed significant changes in the distribution of the LG and their dynamics, with a marked 
decrease in the number of LG detected at the immune synapse-like structure in Hdac6-/-, 
suggesting alterations to the active transport of the granules from the centrosomal region to 
the plasma membrane. Indeed, the mean fluorescence intensity detected for Hdac6-/- 
granules was lower, which suggests a higher pH and therefore a different degree of 
maturation, although the LG displayed similar sizes in WT and Hdac6-/- cells (Fig. 3C). The 
most remarkable difference pertained to the x-y distribution of the LG, which was wider 
(diffusion surface) in the Hdac6-/- CTLs, with a higher diffusion coefficient, although 
maintaining similar duration times and path lengths (Fig. 3D). These data suggest that the 
LG from Hdac6-/- CTLs are not properly targeted and/or that they dock inefficiently at the 
immune synapse.
Tubulin motors control the delivery of LG to the plasma membrane. Whereas dynein 
controls LG targeting to the centrosome (Burkhardt et al., 1993; Mentlik et al., 2010), the 
kinesin-1/Slp3/Rab27a (Slp3 is also known as SYTL3) complex directs terminal transport to 
the plasma membrane for exocytosis (Kurowska et al., 2012). Dynactin might also be part of 
this complex, linking the cargo to kinesin-1 motor (Haghnia et al., 2007; Hendricks et al., 
2010). We then hypothesized that HDAC6 regulates the movement and delivery of the LG at 
the IS through kinesin-1. Using a biochemical approach, we observed that HDAC6 formed a 
complex with kinesin-1 light chain (KLC1) upon triggering with anti-CD3 and anti-CD28 
monoclonal antibodies (Fig. 3E). Moreover, interaction of the kinesin-activator complex 
dynactin subunits p150-glued (also known as DCTN1) and p50-dynamitin (also known as 
DCTN2) was impaired in Hdac6-/- (Fig. 3F).
In summary, our data support a specific role for HDAC6 in the intracellular localization of 
lytic mediators and, particularly, in their exocytosis. Therefore, the catalytic and scaffold 
activities of HDAC6 might act at multiple levels in the control of cytotoxic-related 
pathways, making HDAC6 a potential candidate that could be targeted to modulate CTLs in 
specific diseases.
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Materials and Methods
Mice
Hdac6-/- mice were generated through targeting of exons 10 to 13 (Gao et al., 2007). They 
were intercrossed in a C57BL/6 background to generate wild-type and knockout littermates. 
Mice presenting transgenic inserts for mouse Tcra-Variable 2 and Tcrb-Variable 5 genes, 
which TCR recognizes ovalbumin257-264 peptide in the context of H2Kb MHC-I (OT-I), 
were crossed to female Hdac6+/-mice to generate WT and KO littermates; males were used 
for in vivo experimentation since Hdac6 is a X-linked gene. Rag1-/- mice were used for 
adoptive transfer experiments. These studies were approved by the local Ethics Committee 
for Basic Research at the CNIC and the Comunidad Autónoma de Madrid.
Cell culture
Cytotoxic cells were produced by culturing cells upon stimulation with SIINFEKL peptide 
(0.5 µM, 24h) or concanavalin A (2.5 µg/ml, 36 h) and cultured in presence of IL-2 (50-100 
IU/ml) for at least 7 days. All other cells were cultured and treated as described previously 
(Cascio et al., 2015; Martin-Cofreces et al., 2006; Sancho et al., 2008).
Immunoprecipitation, CTL signaling and immunoblotting
Experimentation was performed as described (Martin-Cofreces et al., 2012; Martin-Cofreces 
et al., 2008; Martin-Cofreces et al., 2006). ); KLC1 antibody was from Merck Millipore (5 
µg/ml for Immunoprecipitation and 1 µg/ml for Western blot; Darmstadt, Germany; KLC), 
anti-HDAC6 from Assay Biotech (0.1 µg/ml for Western blot; Sunnyvale, California, US) 
and anti-p50 (0.25 µg/ml for Western blot) and -p150 (1 µg/ml for Immunoprecipitation and 
0.25 µg/ml) for Western blot from BD Pharmingen (Franklin Lakes, New Jersey,US).
Measurement of intracellular variations in Calcium ions by flow cytometry
The method used for intracellular calcium influx is described (June and Moore, 2004). In 
particular, 5x106 purified CD8+ CTLs generated in vitro were loaded with 2 µg.ml-1 
INDO-1 AM (Invitrogen Corporation) and stimulated with anti-CD3 and anti-CD28 
monoclonal antibodies (BD Biosciences; Franklin Lakes, New Jersey, US) plus goat anti-
Armenian-hamster IgG antibodies (Jackson Immunoresearch Laboratories; West Grove, PA, 
US. 6, 3 and 6 µg/ml, respectively).
In vitro degranulation assay
CD107a expression was monitored with anti-CD107a-Alexa647 antibody (BD Biosciences) 
in monensin-pretreated CD8+ OTI cells (5 mM) stimulated with SIINFEKL-pulsed EL4 (1 
μM; 3 h, 37 ºC). Cells were stained with anti-CD8-PE and anti-CD44-FITC, analyzed by 
FACS and data were processed with FlowJo 7.6.5 (TreeStar Inc; Ashland, Oregon; US).
Confocal and Total Internal Reflection Fluorescence Microscopy analysis
Cell conjugates between CTLs and EL4 cells were allowed to form (15 min) and processed 
as described (Cascio et al., 2015; Martin-Cofreces et al., 2006) under a Leica SP5 confocal 
microscope (Leica Microsystems; Manheim, Germany) mounted on an inverted DMI6000 
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microscope fitted with a HCX PL APO 63x/1.40-0.6 oil objective. Images were processed 
using Imaris software (Bitplane; Zurich, Switzerland), Image J software (http://
rsbweb.nih.gov/ij/) and assembled with Photoshop 6 software. 3D distance from the 
centrosomal centre of mass to the target cell-edge was measured by generating image masks 
from fluorescence with Imaris Software. TIRFm imaging was performed with a Leica AM-
TIRF-MC-M system mounted on a Leica DMI-6000B microscope coupled to an Andor-
DU8285_VP-4094 camera (Andor; Belfast, UK) fitted with a HCX-PL-APO 100.0x1.46 
OIL objective as described (Baixauli et al., 2011; Martin-Cofreces et al., 2012). The laser 
penetrance used was 90 nm (561 nm laser). The LG mechanical properties were determined 
with a user-customized routine developed in Python. The software can be freely downloaded 
from: https://dl.dropboxusercontent.com/u/4050954/VesiclesAnalyser.zip. For more 
information, see the tutorial included.
Vaccinia virus (VACV) infection and virus titration
Tails were scarified with VACV (2x106 PFU/mouse) by gently scratching (x25) with a 28 
1/2 G needle. For virus titration, tails were mechanical disaggregated (1ml of PBS), 
subjected to freeze-thaw cycles and sonication. Serial dilutions of the homogenates were 
added to monolayers of CV-1 cells seeded in 24 well plates. Cells were stained with Cristal 
violet 24 h later. We observed a detection limit of 5 PFU/tail, the number of plaques was 
multiplied by the reciprocal of sample dilution and converted to p.f.u./g of tissue.
In vitro and in vivo cytotoxicity assay
For in vitro experiments, EL4 target cells were incubated with 1 μM Cell Violet pulsed with 
1 μM SIINFEKL or with 0.1 μM Cell Violet and no SIINFEKL, washed extensively, mixed 
(1:1), pooled with different dilutions of effectors, plated in a 96-well U-bottom plate for 5 h 
(37ºC) by triplicate and analyzed by FACS. Dead cells were excluded on the basis of 
propidium iodide staining. The mean percentage of survival in antigen-loaded targets was 
calculated relative to antigen-negative internal controls in each sample. Specific lysis was 
calculated using the following equation: percentage specific lysis = 100 * (1 - (percentage of 
cells staining for Cell Violet 1µM/percentage of cells staining for Cell Violet 0,1µM). All 
data were normalized to the basal specific lysis in absence of effector cells. For in vivo 
assays, WT and Hdac6-/- mice were immunized by i.p. injection of bone marrow dendritic 
cells pulsed with 1 µM of SIINFEKL and LPS (1 µgml-1) for 1 h. After 7 days, CD45.1 
splenocytes were prepared as targets as described above and injected i.p. into recipients. 
Cells were recovered 24 h later by peritoneal lavage and in vivo killing measured (Hermans 
et al., 2004; Iborra et al., 2012; Sancho et al., 2008; Schulz et al., 2005).
Statistical analysis
Data were analyzed with GraphPad Prism software (La Jolla, California, US) for normality 
(D’Agostino-Pearson or the Kolmogorov-Smirnov test for small sAMples). Student’s t-tests 
or Mann-Whitney tests were used for normal or non-normal data, respectively and two-tailed 
ANOVA for grouped data (Bonferroni post-test).
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Figure 1. HDAC6 modulates the efficiency of target cell killing and degranulation of lytic 
mediators.
(A) Graph showing in vitro cytotoxic assay for specific lysis of SIINFEKL-pulsed EL4 
target cells by OT-I-WT or -Hdac6-/- CTLs. Mean ± SEM of specific lysis for 5 h are shown 
at the indicated target to effector ratios. All killing assay where performed by triplicate. *, P 
< 0.05; **, P < 0.01; ***, P < 0.001. Unpaired T-test (n=5 mice for each genotype). 
Histograms, representative FACS profile. (B) Degranulation is shown as the percentage of 
CD107a+ cells detected by FACS in activated vs non-stimulated WT and Hdac6-/- CD8+ 
CTLs. Results are mean±s.e.m. n=5 for each genotype. (C) Exocytosis of lytic mediators 
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upon T cell activation. Left, Perforin content in culture cell supernatants was determined by 
ELISA. CTLs were stimulated with anti-CD3 and anti-CD28 monoclonal antibodies and 
'goat' anti-Armenian-hamster 'IgG' anyibodies (5 h). Graphs show mean±s.e.m. (n=6 mice 
for each genotype). *P<0.05 (unpaired t-test). Middle panel, representative Western blot 
showing exocytosis. PMA stimulation (1 h). Normalization was performed against cell 
fractions. Right graphs, Mean +/-SEM (3 independent experiments). (D) Graph, IFNγ 
secretion supernatants from anti-CD3/anti-CD28 mAbs activated WT and Hdac6-/- CTLs by 
ELISA. Results are mean±s.e.m. n=3 for each genotype. Mann-Whitney test. (E) Percentage 
of IFNγ+ cells in WT and Hdac6-/- CTLs activated with anti-CD3 and anti-CD28 
monoclonal antibodies. Results are mean±s.e.m. n=6 (0 and 6 h) and n= 3 (4 h) for each 
genotype. Mann-Whitney test. (F) Effector CD8+ CTLs isolated from WT and Hdac6-/- mice 
were activated (anti-CD3/anti-CD28 mAbs), lysed and blotted against PLCγ1 (pY783) and 
erk1/2 (pT202/Y204) phosphorylation and tubulin acetylation. (G) Calcium flux. WT and 
Hdac6-/- purified CTLs pre-loaded with the INDO-1 AM probe were analyzed for free and 
bound Ca2+ by flow cytometry. Left graphs, time course ratiometric variation (left Y axis). 
Black line, Median function normalized to basal (0%) and total activation by ionomycin 
treatment (100%; right Y axis). Stimuli are indicated. A representative experiment is shown. 
Right graph, Mean of the increase in the ratio +/-SD (WT, n=7; Hdac6-/- n=6. Mann 
Whitney test).
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Figure 2. In vivo function of CTLs is impaired in HDAC6 knockout mice.
(A) WT and Hdac6-/- were immunized against SIINFEKL peptide. 7 days after 
immunization, cell violet-labelled, SIINFEKL-pulsed or not target cells (1 μM) were 
injected i.p., recovered through intraperitoneal lavage (24 h) and cell survival assessed by 
FACs (left panel). Data represent mean±s.e.m. (n= 12 for each genotype from three 
independent experiments). *P<0.05, Mann-Whitney test. Relative percentage of CD8+ 
H-2Kb+ was determined to control avidity towards SIINFEKL (right panel, results are mean
±s.e.m. (WT, n= 10; Hdac6−/−, n= 9 from three independent experiments. Mann-Whitney’s 
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test). (B) Proliferation of CD8+ cells in VACV-OVA infected WT and Hdac6-/- mice. Results 
are means±s.e.m. (n= 5 for each genotype). **P<0.01 (Mann-Whitney test). (C) Rag1-/- 
mice inoculated i.v. with 0.8x106 CD8+ naïve cells and infected with VACV-WR by tail 
scarification were weighted every 2 days. Results are means±s.e.m. (n=10 for each 
genotype). **P<0.01 (Mann-Whitney test). (D) Titration of viral particles from scarified 
tails (13 d.p.i). The colonies of CV-1 cells infected in vitro with different dilutions of tail 
extracts were counted, and normalized to the tail tissue weight. Results are means±s.e.m. 
(WT, n= 13; Hdac6−/− n= 14). *P<0.05 (Mann-Whitney test). (E) Percentage of CD8+ 
expansion and CD44 expression by FACs analysis in peripheral blood (5 d.p.i) and in spleen 
populations (13 and 30 d.p.i.). CD11b was used as negative control. Results are means
±s.e.m. (n= 5) (Mann-Whitney test).
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Figure 3. HDAC6 drives the terminal transport of LG to the target cell.
(A) Confocal microscopy images of WT and Hdac6-/- OT-I-derived CTLs conjugated with 
CMAC-loaded, OVA pre-pulsed target cell EL4 (500 nM SIINFEKL, Cyan) for 15 min. 
Green, CD107a. Red, CathepsinD. Magenta, α-tubulin. Bright-field (BF) images correspond 
to a unique plane and fluorescence images, to maximal projections from Z-stacks. Middle 
graphs, Mander’s coefficient for co-localization of Lamp1 and CathepsinD. Results are 
mean±???? (WT, n=39; Hdac6−/−, n=35). ***P<0.001 (Mann–Whitney test). Right graph, 
quantification of MTOC translocation. Results are mean±s.e.m. (n>270, from 3 independent 
experiments); *P<0.05 (unpaired t-test). (B) Representative TIRFm images of Lysotracker 
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Red-loaded WT and Hdac6-/- CTLs in glass-bottom chambers coated with anti-CD3 and 
anti-CD28 monoclonal antibodies. Video recording was initiated upon cell adhesion (37ºC 
and 5% CO2). Images were acquired for 5 min every 0.5 s. (C-D) Quantification for LG 
parameters at the IS-like was performed for each cell Results are means±s.e.m. (n=28 for 
each genotype, 3 independent experiments). *P<0.05; **P<0.01. Mann-Whitney test. (E-F) 
Western blots showing immunoprecipitates from resting or activated WT and Hdac6-/- CTLs 
(15 min) from a representative experiment out of three. Antibodies anti-KLC1 (E) or anti-
p150 glued (p150) were used (F). Samples were blotted against indicated antibodies. Ab, 
pre-immune control antibody. Scale bars: 4 μm.
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The PDZ-adaptor protein syntenin-1 regulates 
HIV-1 entry
Mónica Gordón-Alonsoa, Vera Rocha-Peruginib, Susana Álvarezc, Olga Moreno-Gonzaloa, 
Ángeles Ursaa, Soraya López-Martínd, Nuria Izquierdo-Userose, Javier Martínez-Picadoe, 
Maria Ángeles Muñoz-Fernándezc, María Yáñez-Mód, and Francisco Sánchez-Madrida,b
aServicio de Inmunología, Instituto de Investigación Sanitaria de la Princesa, Hospital Universitario de la Princesa, 
28006 Madrid, Spain; bCentro Nacional de Investigaciones Cardiovasculares, 28029 Madrid, Spain; cServicio de 
Inmunobiología Molecular del Hospital Universitario Gregorio Marañon, 28007 Madrid, Spain; dInstituto de Investi-
gación Sanitaria de la Princesa, Hospital Santa Cristina, 28007 Madrid, Spain; eInstitut de Recerca de la SIDA IrsiCaixa, 
University Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, 08916 Badalona, Spain
ABSTRACT Syntenin-1 is a cytosolic adaptor protein involved in several cellular processes 
requiring polarization. Human immunodeficiency virus type 1 (HIV-1) attachment to target 
CD4+ T-cells induces polarization of the viral receptor and coreceptor, CD4/CXCR4, and cel-
lular structures toward the virus contact area, and triggers local actin polymerization and phos-
phatidylinositol 4,5-bisphosphate (PIP2) production, which are needed for successful HIV in-
fection. We show that syntenin-1 is recruited to the plasma membrane during HIV-1 attachment 
and associates with CD4, the main HIV-1 receptor. Syntenin-1 overexpression inhibits HIV-1 
production and HIV-mediated cell fusion, while syntenin depletion specifically increases HIV-1 
entry. Down-regulation of syntenin-1 expression reduces F-actin polymerization in response 
to HIV-1. Moreover, HIV-induced PIP2 accumulation is increased in syntenin-1–depleted cells. 
Once the virus has entered the target cell, syntenin-1 polarization toward the viral nucleo-
capsid is lost, suggesting a spatiotemporal regulatory role of syntenin-1 in actin remodeling, 
PIP2 production, and the dynamics of HIV-1 entry.
INTRODUCTION
The adaptor protein syntenin-1 was originally described in relation 
to its association with the syndecan receptor and its recycling 
(Grootjans et al., 1997; Zimmermann et al., 2005). It was also termed 
melanoma differentiation-associated gene-9 (mda-9) for its up-reg-
ulated expression in several types of tumors, which correlates with 
high invasiveness (Sarkar et al., 2004, 2008). Structurally, syntenin-1 
contains a regulatory N-terminal region and two tandem postsyn-
aptic density protein, Drosophila disk large, and zonula occludens-1 
(PDZ) domains. The N-terminal region is composed of two Tyr-
based domains: one ITIM and one ITAM domain, the ITIM domain 
being important for CXCR4-mediated T-cell migration (Sala-Valdes 
et al., 2012). PDZ domains are involved in the formation of macro-
molecular complexes that often link transmembrane proteins to the 
actin cytoskeleton, mediating their clustering and polarized subcel-
lular distribution (Fanning and Anderson, 1999; Brone and Egger-
mont, 2005; Hirbec et al., 2005; Ludford-Menting et al., 2005). PDZ 
domains interact with short amino acid sequences at the C-terminal 
end of plasma membrane proteins. Three consensus sequences 
bind PDZ domains: class I ([S/T]-X-Φ), class II (Φ-X-Φ), and class III 
([D/E]-X-Φ), where X is any amino acid and Φ is a hydrophobic resi-
due (Chimura et al., 2011). Through its PDZ domains, syntenin-1 
binds to transmembrane proteins, such as CD6 (Gimferrer et al., 
2005) and the tetraspanin CD63 (Latysheva et al., 2006); signaling 
proteins, such as the tyrosine kinase Src (Boukerche et al., 2008); 
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of syntenin-1 recruitment, we assessed CD45 distribution and ob-
served that it did not accumulate at virus-induced capping areas 
(Figure 1, B and E). In addition, to assess that syntenin-1 recruitment 
was Env-mediated, target CEM-T4 cells were incubated with a Jur-
kat clone expressing the T-tropic HIV-1 envelope HxB (Env+ HxBc2 
cells). Syntenin-1 was found at the Env-driven cell contacts, together 
with CD4 (Figure 1, C and E). We also cocultured target CEM-T4 
cells with T-cells directly infected with HIV–green fluorescent protein 
(GFP) virus (MT4-HIV-GFP). In these cocultures, syntenin-1 accumu-
lated at cell–cell contacts, areas in which viral synapses are estab-
lished (Figure 1, D and E), but not at unspecific Env-independent 
cell–cell contacts (Figure1E, right-hand white bar; exemplified in 
Supplemental Figure S1). Quantification confirmed significant ac-
cumulation of syntenin-1 at contacts with HIV-1 viral particles and 
infected cells, in comparison with CD45 (Figure 1E).
Syntenin-1 associates with the cytoplasmic tail of CD4
PDZ domains usually bind to specific consensus sequences at the 
C-terminal ends of transmembrane proteins (Chimura et al., 2011). 
To determine whether syntenin-1 forms part of the CD4/CXCR4 
complex at the capping areas, we first searched the CD4 and CXCR4 
cytoplasmic domain sequences for potential PDZ-binding motifs. A 
class I PDZ-binding consensus sequence (Ser-Pro-Ile) was detected 
at the C-terminal end of CD4, suggesting potential direct interac-
tion with syntenin-1 via its PDZ domains. To test this, we immobi-
lized glutathione S-transferase (GST)-fused hemagglutinin (HA)- or 
Myc-tagged syntenin-1 on Sepharose beads, and incubated them 
with human primary lymphoblast lysates. GST-syntenin-HA and GST-
syntenin-Myc, but not GST alone, precipitated CD4 (Figure 2A). 
Confirming this interaction, anti-CD4 antibody immunoprecipitated 
endogenous syntenin-1 from CEM T-cell lysates; syntenin-1 was de-
tected with anti–syntenin-1 antibody as a double band of around 
32 kDa (Figure 2B). To demonstrate the occurrence of CD4–syn-
tenin-1 association in the context of HIV-1 infection, we performed 
reverse immunoprecipitation assays with Jurkat T-cells previously 
incubated with free viral particles. Immunoprecipitation of syn-
tenin-1, followed by immunodetection of CD4, detected constitu-
tive CD4–syntenin-1 interaction that was maintained during HIV-1 
contact (Figure 2C). Together, these data suggest that syntenin-1 
interacts with CD4 before and during HIV-1 infection.
Syntenin-1 overexpression inhibits HIV-1–induced cell 
fusion and viral production
To assess the specific role of syntenin-1 during HIV-1 infection, target 
T-cells were transfected with GFP-tagged, wild-type syntenin-1 (syn-
tenin-GFP) or a mutated protein, syntenin-Y1-GFP (Synt-Y1-GFP), 
which carries a Y4>F point mutation in the ITIM motif of the regula-
tory N-terminal region. Phosphorylation of endogenous syntenin-1 
at this tyrosine residue has been shown to be essential for CXCR4-
induced chemotaxis (Sala-Valdes et al., 2012). Syntenin-GFP and 
Synt-Y1-GFP showed a similar distribution to endogenous syn-
tenin-1, being enriched at Env-driven cell–cell contacts (Figure 3A) 
and HIV-induced capping areas (Figure 3B and data not shown). Tar-
get J77 cells overexpressing these GFP-tagged proteins were in-
fected with free HIV-1 particles, and viral production was measured 
3 d later by p24 enzyme-linked immunosorbent assay (ELISA). Cells 
overexpressing syntenin-GFP produced lower viral titers than control 
cells (transfected with GFP alone). In contrast, overexpression of the 
mutated syntenin-1 had no effect on HIV-1 production (Figure 3C).
To investigate the potential effect of syntenin-1 plasma mem-
brane recruitment on HIV-1–induced cell fusion, we measured 
Env-mediated cell fusion by flow cytometry. Env+ HxBc2 cells 
and the actin-linker protein merlin (Jannatipour et al., 2001). Re-
cruitment of syntenin-1 to the plasma membrane is also regulated 
through its PDZ-mediated interaction with the lipid second mes-
senger phosphatidylinositol 4,5-bisphosphate (PIP2; Zimmermann, 
2006).
Syntenin-1 has a cytosolic distribution, being enriched in vesicles 
and F-actin structures (Zimmermann et al., 2001). It is implicated in 
several actin-polarized processes, such as cell migration, immune 
synapse formation, intracellular trafficking, cell-surface targeting, 
axonal outgrowth, and synaptic transmission (Gimferrer et al., 2005; 
Hirbec et al., 2005; Zimmermann et al., 2005; Beekman and Coffer, 
2008; Sarkar et al., 2008). We recently reported the involvement of 
syntenin-1 in CXCR4-mediated T-chemotaxis and T-APC antigen 
presentation, in which it regulates Rac-triggered actin polymeriza-
tion (Sala-Valdes et al., 2012).
CD4/CXCR4-derived signaling and Rac-induced actin remodel-
ing are also important for human immunodeficiency virus type 1 
(HIV-1) infection (Pontow et al., 2004; Carter et al., 2009). Soon after 
HIV-1 contact with CD4+ T-cells, the viral envelope glycoprotein 
complex gp120/gp41 (Env) engages with CD4 and CXCR4, inducing 
several signaling pathways that trigger receptor clustering (Jimenez-
Baranda et al., 2007; Barrero-Villar et al., 2009) in a structure called 
“cap” (Dianzani et al., 1995; Nguyen et al., 2005), local actin polym-
erization (Iyengar et al., 1998; Jolly et al., 2004), T-cell activation 
(Popik et al., 1998; Hiscott et al., 2001), and HIV-1 replication (Popik 
and Pitha, 2000; Mettling et al., 2008). These rearrangements en-
hance viral entry (Wu and Yoder, 2009; Juno and Fowke, 2010) by 
supplying an optimal density of CD4/CXCR4 complexes through 
actin-mediated surface reorganization (Iyengar et al., 1998; Doms, 
2000; Jolly et al., 2004). Thus the actin-binding proteins moesin and 
filamin-A accumulate at the F-actin–enriched capping areas and in-
fluence CD4/CXCR4 clustering (Jimenez-Baranda et al., 2007; 
Barrero-Villar et al., 2009). Moreover, we previously showed that 
HIV-1 gp120, through its interaction with CD4, induces local produc-
tion of PIP2 by activating PI4P5K-Iα (Barrero-Villar et al., 2008).
After viral attachment to the plasma membrane, the local F-actin 
accumulation can constitute a physical barrier for entry of the viral 
nucleocapsid (Vasiliver-Shamis et al., 2009). In this regard, CXCR4-
gp120 interaction was recently shown to activate cofilin, which pro-
motes actin clearance, facilitating nucleocapsid entry into the cyto-
plasm (Yoder et al., 2008).
In this study, we assessed the possible role of syntenin-1 as a 
mediator of CD4/CXCR4 clustering and actin remodeling during 
HIV-1 infection. Our data indicate that syntenin-1 associates with 
CD4 and negatively regulates HIV-1 infection by affecting the 
dynamic reorganization of actin cytoskeleton and PIP2 production 
triggered upon HIV-1 contact, specifically at the viral entry step.
RESULTS
Syntenin-1 is recruited to the plasma membrane 
by HIV-1 Env
PDZ proteins commonly determine the polarization of cellular events 
(Fanning and Anderson, 1999; Brone and Eggermont, 2005; 
Ludford-Menting et al., 2005). Because HIV-1 contact with target 
cells triggers the polarization of cellular components (Dianzani et al., 
1995; Nguyen et al., 2005), we investigated whether the PDZ pro-
tein syntenin-1 was recruited upon HIV-1 contact with target CD4+ 
T-cells (CEM-T4). In the absence of HIV-1 virus, syntenin-1 displayed 
a diffuse cytosolic pattern with low clustering at the plasma mem-
brane (Figure 1A). In contrast, after incubation of T-cells with free 
HIV-1 particles, syntenin-1 was clearly recruited toward the CD4/
CXCR4 capping area (Figure 1, A and E). To confirm the specificity 
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were labeled with red intracellular tracker 
(CMTMR; 5-(and-6)(((4chloromethyl)benzoyl)-
amino) tetramethylrhodamine) and cocul-
tured with target T-cells transfected with 
each GFP-tagged syntenin-1 construct. Env-
driven cell fusion leads to syncytia forma-
tion, detected as double-fluorescence 
positive events of higher size and complex-
ity. As a control of specificity, syncytia for-
mation was blocked with the HIV-1 fusion 
inhibitor T-20 (Figure 3D). Quantification of 
these events showed that overexpression 
of wild-type syntenin-1 reduced Env-medi-
ated cell fusion, whereas the Y4>F mutant 
had no significant effect (Figure 3D). These 
data suggest that syntenin-1 negatively 
regulates HIV-1–mediated membrane fu-
sion through a mechanism requiring phos-
phorylation of tyrosine 4 in the ITIM motif. 
To assess whether the Y4>F point mutant 
was able to interact with CD4, cells were 
transfected with syntenin-GFP or Synt-
Y1-GFP, immunoprecipitated with an anti-
GFP, and blotted for CD4. As shown in 
Figure 3E, Synt-Y1-GFP also associated 
with CD4.
Knockdown of syntenin-1 expression 
increases HIV-1 cell fusion and viral 
entry
To further study syntenin-1 function during 
HIV-1 infection, we knocked down endoge-
nous syntenin-1 expression using small inter-
fering RNA (siRNA). Control cells were trans-
fected with an siRNA sequence that does 
not hybridize with any eukaryotic mRNA. 
Syntenin-1 down-regulation was assessed 
for each experiment (Figure 4A and data not 
shown). Membrane expression levels of CD4 
and CXCR4 were also routinely assessed to 
confirm that they were not affected by syn-
tenin depletion (Figure 4B). To assess Env-
driven cell fusion, silenced T-cells loaded 
with green cell tracker were cocultured with 
FIGURE 1: Syntenin-1 is recruited by HIV-1 envelope glycoproteins. (A) CEM-T4 cells incubated 
with or without HIV-1 particles for 30 min were fixed and immunostained for syntenin-1 and CD4 
(HP2/6). Summative projections of confocal stack images are shown. Scale bars: 5 μm. Surface 
plots show fluorescence distribution and intensity for corresponding images. (B) CEM-T4 cells 
incubated with HIV-1 particles for 30 min were fixed and immunostained for CD4 (CD4v4-FITC) 
and CD45 (D3/9). Summative projections of confocal stack images are shown. Scale bar: 5 μm. 
Surface plots show fluorescence distribution and intensity for corresponding images. 
(C) Immunofluorescence microscopy images of target CEMT4 cells incubated for 2 h with Env+ 
HxBc2 cells (CMAC stained, blue) and stained for syntenin-1 and CD4 (HP2/6). Scale bars: 5 μm. 
(D) Target J77 cells were incubated for 2 h 
with HIV-1–infected T-cells (MT4-HIV-GFP) 
and immunostained for syntenin-1 and CD4 
(HP2/6). Projections of confocal stack images 
are shown. Scale bar: 5 μm. (E) Quantification 
of syntenin-1 accumulation at HIV-1-induced 
capping areas (HIV-wt), contacts between 
target cells and HIV-infected cells (MT4-J77), 
or contacts between target cells and Env+ 
cells (HxB-J77). The control (white bars) for 
HIV wild-type and MT4-J77 represent the 
recruitment of CD45. The control (white bar) 
for HxB-J77 corresponds to the recruitment 
of syntenin at Env-independent cell–cell 
contacts (between two target J77 cells). The 
chart represents the mean ± SD of three 
independent experiments; more than 100 
conjugates were counted in each condition.
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Higher luciferase levels were found in X4-Luc–infected syntenin-1–si-
lenced cells, confirming that syntenin-1 knockdown specifically in-
creases viral entry (Figure 5B). VSV infection was similar in silenced 
and control cells, demonstrating that the effect observed is HIV-1 
Env-dependent (Figure S2). These results indicate that syntenin-1 
negatively regulates HIV-1 entry without affecting viral attachment.
To study the behavior of syntenin-1 during viral attachment and 
entry in more detail, we incubated Gag-GFP fluorescent virus-like 
particles (VLPs) with T-cells at 4°C or 37°C. At 4°C, VLPs attached 
preferentially to one pole of the target cell (Figure S3; see Supple-
mental Movie S1 for three-dimensional reconstruction), which sug-
gests that the capping area behaves as the main site for viral entry, 
as has been proposed (Doms, 2000; Nguyen et al., 2005). At 37°C, 
VLPs could be observed inside target cells, usually accumulated at 
one pole of the cytoplasm (Figure S3; see Movie S2 for three-dimen-
sional reconstruction).
We next examined the localization of endogenous syntenin-1 by 
confocal immunostaining of T-cells exposed to VLPs. To avoid false 
positives due to fortuitous superposition, we only analyzed planes 
in which VLPs were detected (usually one to two planes distanced 
by 0.25 μm). Syntenin-1 was enriched at VLP attachment sites in 
cells kept at 4°C (Figure 5, C and F), whereas barely any syntenin-1 
localized at the internalized VLPs in cells incubated at 37°C (Figure 
5, D and F). However, syntenin-1 did accumulate near VLPs posi-
tioned at cell–cell contacts at 37°C (Figure 5, E and F). Quantifica-
tion of syntenin-1 accumulation at VLPs at each temperature and 
location confirmed that association of syntenin-1 with VLPs occurs 
only on the plasma membrane, and not once the particles are 
already internalized (Figure 5F).
Thus syntenin-1 is recruited to the plasma membrane by HIV-1 
Env during the attachment and entry steps but affects only the 
effectiveness of viral entry, and it is released from the viral complex 
once the nucleocapsid has entered the cytoplasm.
Syntenin-1 regulates actin polymerization and PIP2 
accumulation upon HIV-1 contact
Syntenin-1 was recently found to regulate F-actin polymerization via 
Rac GTPase in T-cells during CXCR4-induced chemotaxis and su-
perantigen presentation (Sala-Valdes et al., 2012). This syntenin-1–
mediated activation of Rac depends on phosphorylation of tyrosine 4 
(Sala-Valdes et al., 2012). Moreover, Rac-mediated actin reorganiza-
tion is known to be essential for HIV-1 entry (Iyengar et al., 1998; 
Pontow et al., 2004; Harmon et al., 2010). To analyze the relation 
between syntenin-1 and F-actin during HIV-1 infection, we incubated 
target cells with VLPs, stained them for syntenin-1 and F-actin, and 
analyzed them with confocal microscopy. Syntenin-1 clusters at the 
plasma membrane corresponded with the VLP contact area and par-
tially overlapped with F-actin accumulation (Figure 6A; see Figure S4 
for F-actin staining in noninfected target cells). Given that HIV-1 at-
tachment to CD4 and CXCR4 triggers local actin polymerization (Jolly 
et al., 2004), we analyzed this process in syntenin-1–depleted cells. A 
similar percentage of VLPs colocalized with F-actin in control and 
syntenin-1–depleted cells (Figure 6A). However, when actin polymer-
ization after HIV-1 contact was monitored at different time points, 
control cells showed a marked increase in F-actin content 30 min after 
HIV-1 contact, whereas F-actin polymerization was markedly lower in 
syntenin-1–depleted cells (Figure 6B). These data indicate that syn-
tenin-1 is required for HIV-1–triggered F-actin polymerization at early 
stages, when most virus particles are observed at the plasma mem-
brane. Moreover, F-actin accumulation at cell–cell contacts between 
target and infected MT4 cells was reduced in cells knocked down for 
syntenin in comparison with control cells (Figure 6C).
Env+ HxBc2 cells labeled with red cell tracker. Syntenin-1–depleted 
cells exhibited enhanced cell fusion with Env+ cells compared with 
control cells (Figure 4C). Furthermore, syntenin-1–depleted cells 
produced higher viral titers than control cells upon infection with free 
HIV-1 virions (Figure 4D). Importantly, this effect could be rescued by 
syntenin-GFP overexpression in silenced T-cells (Figure 4E). Taken 
together, these results confirm the inhibitory role of syntenin-1 in 
HIV-1 infection.
Syntenin-1 restricts HIV-1 entry
Syntenin-1 recruitment at the plasma membrane suggested its in-
volvement during HIV-1 attachment or entry steps. To distinguish 
between these possibilities, we incubated syntenin-1–depleted cells 
with HIV-1 particles for 2 h at 4°C, a temperature that does not allow 
Env-induced membrane fusion, thus arresting the virus at the attach-
ment step, or at 37°C, a permissive temperature for membrane fu-
sion and consequently for viral entry. For both conditions a low infec-
tion rate was used to avoid superinfection and cooperative virion 
entry. The amount of p24 in the lysates was measured by ELISA 
(Figure 5A) and Western blot (data not shown); HIV-1 attachment was 
estimated from the p24 level at 4°C, and HIV entry was estimated 
from the difference between the levels at 37 and 4°C. Syntenin-1 si-
lencing enhanced virus entry without affecting viral attachment (4°C), 
suggesting that syntenin-1 specifically impairs HIV entry (Figure 5A). 
To confirm these observations, we infected target cells with a one-
cycle luciferase virus displaying a T-tropic envelope (X4-Luc), or the 
vesicular stomatitis virus (VSV) envelope (VSV-Luc) as a control. 
FIGURE 2: Syntenin-1 interacts with CD4 during HIV infection of 
T-cells. (A) T-lymphoblast cell lysates (Lys) were pulled down with GST, 
GST-syntenin-Myc, or GST-syntenin-HA, and blotted with anti-CD4 
mAb MEM241. (B) CEM T-cell lysates were immunoprecipitated with 
anti-CD4 mAb OKT4 (IP-OKT4) and anti-syntenin pAb (IP-Synt), and 
then blotted for syntenin-1 (pAb) and CD4 (mAb MEM241). Total 
lysates (Lys) and Sepharose beads incubated with lysates (Seph+Lys) 
are shown. (C) Jurkat J77 T-cells incubated with or without HIV-1 
particles were lysed, immunoprecipitated with anti–syntenin-1 pAb, 
and blotted with anti-CD4 mAb MEM241.
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local production of PIP2. Control or syntenin-1–depleted cells were 
incubated with MT4-HIV-GFP cells for 2 h and then fixed and stained 
for PIP2 with anti-PIP2 mAb. Syntenin-1–depleted T-cells showed in-
creased accumulation of PIP2 at contacts with HIV-1–infected T-cells 
(Figure 6D). To confirm that this effect was related to HIV-1 Env-
dependent contacts, we quantified PIP2 accumulation in target cells 
Interaction of the HIV-1 envelope with CD4 triggers PIP2 produc-
tion (Barrero-Villar et al., 2008), and this lipid has been found to regu-
late not only syntenin-1 recruitment to the plasma membrane 
(Zimmermann et al., 2005) but also many other actin-related proteins 
(Saarikangas et al., 2010). We therefore assessed whether syntenin-
1–dependent actin polymerization upon HIV-1 contact was related to 
FIGURE 3: Overexpression of wild-type syntenin-1, but not a phosphorylation-defective mutant, in target T-cells impairs 
HIV-1 infection. (A) CEM-T4 cells overexpressing syntenin-GFP or Synt-Y1-GFP (containing the Y4>F point mutation) 
were incubated with Env+ HxBc2 cells (tracked with CMAC, blue) for 2 h, fixed, and stained for CD4 (HP2/6 mAb). 
Summative projections of confocal stack images are shown. Scale bars: 5 μm. (B) CEM-T4 cells overexpressing wild-type 
syntenin-1 (syntenin-GFP) were incubated for 30 min with or without HIV-1 particles, fixed, and stained for CD4 (HP2/6 
mAb). Projections of confocal stack images are shown. Scale bars: 5 μm. (C) HIV-1 infection is inhibited by syntenin-GFP 
but not by Synt-Y1-GFP. Infection was measured as viral production, quantified as p24 viral protein content in 
supernatants (ELISA). Data are the fold induction relative to control cells transfected with GFP alone (mean ± SD of four 
experiments performed in triplicate; p = 0.0058). (D) Cell fusion triggered by HIV-1 envelope is reduced in cells 
overexpressing syntenin-GFP. As a control, syncytia formation was blocked by incubation with the fusion inhibitor 
T20 (10 nM). Data are the fold induction relative to GFP-transfected cells (mean ± SD of four experiments performed in 
duplicate; p = 0.031). (E) Cells were transfected with GFP, syntenin-GFP, or Synt-Y1-GFP; immunoprecipitated with pAb 
anti-GFP; and blotted for CD4 (MEM241) and GFP (mAb).
2258 | M. Gordón-Alonso et al. Molecular Biology of the Cell
To assess whether syntenin-1 depletion 
increases PIP2 accumulation in virus–cell con-
tacts, we transfected control and syntenin-
1–depleted cells with PLCδ-PH-GFP (pleck-
strin homology domain of PLC-delta tagged 
to GFP), a biosensor that binds to PIP2-en-
riched membranes (Varnai and Balla, 1998), 
and incubated them with Cherry-fluorescent 
VLPs expressing HxB (T-tropic) envelope. 
Patches of PLCδ-PH-GFP were frequently 
observed on the target cell surface at sites of 
VLP attachment (a representative image is 
shown in Figure 6F). The frequency of these 
events was higher in syntenin-1–depleted 
cells (Figure 6F). Taken together, these data 
indicate that syntenin-1 depletion increases 
PIP2 accumulation at Env-driven contacts 
both of cell–cell and of virus–cell interac-
tions, correlating with lower F-actin polymer-
ization and higher viral entry.
DISCUSSION
In this study we show that syntenin-1 is re-
cruited toward HIV-1 Env-driven virus–cell 
and cell–cell contacts, associates with CD4, 
limits HIV-1–induced cell fusion and viral en-
try, and modulates Env-triggered F-actin re-
modeling and PIP2 production.
HIV-1 binding to CD4/CXCR4 complexes 
at the T-cell surface activates several signal-
ing pathways and triggers local actin poly-
merization (Iyengar et al., 1998; Jolly et al., 
2004), which is essential for receptor clus-
tering at the plasma membrane (Iyengar 
et al., 1998; Jolly et al., 2004, 2007; Pontow 
et al., 2004). The actin-binding proteins fil-
amin-A and ERMs are known to favor CD4/
CXCR4 clustering during HIV-1 attachment 
(Jimenez-Baranda et al., 2007; Barrero-Villar 
et al., 2009). Filamin-A is needed for a tran-
sient cofilin inactivation through a RhoA-
ROCK–dependent mechanism that stabi-
lizes F-actin during HIV-1 attachment 
(Jimenez-Baranda et al., 2007). ERMs are 
activated by phosphorylation upon HIV-1 
contact and are essential for F-actin polar-
ization and CD4/CXCR4 clustering (Barrero-
Villar et al., 2009). In contrast with these 
actin-binding proteins, syntenin-1 does not 
affect HIV-1 attachment and therefore does 
not seem to be involved in HIV-1–induced 
CD4/CXCR4 clustering.
Instead, syntenin-1 binding to CD4 might 
block Lck activation or other CD4-derived 
pathways, thus hampering HIV-1 entry. How-
ever, since syntenin-1 depletion reduces ac-
tin polymerization soon after HIV-1 contact, the most plausible expla-
nation for its inhibitory effect is that it induces an actin accumulation 
at the viral attachment site that hinders viral nucleocapsid entry at the 
cell surface. Localized actin clearance during HIV-1 entry has been 
proposed as a mechanism for overcoming this physical restriction 
(Yoder et al., 2008; Liu et al., 2009; Vasiliver-Shamis et al., 2009), and 
cocultured with Env+ HxBc2 cells (heterotypic, Env-driven contacts) 
or cultured alone (homotypic, Env-independent contacts between 
target cells; Figure 6E and see Figure S5 for an example image). 
Syntenin-1 knockdown specifically increased PIP2 accumulation at 
Env-driven contacts, while having no effect on Env-independent con-
tacts (Figure 6E).
FIGURE 4: Knockdown of syntenin-1 expression increases HIV-1 entry and syncytia formation. 
(A) Representative Western blot showing silencing of endogenous syntenin-1 expression using 
oligonucleotide J-008270-08 in T-cells 48 h after siRNA transfection. Numbers below the blot 
show band intensity ratios between cells transfected with control siRNA and syntenin-1 siRNA, 
expressed relative to tubulin. (B) Bar chart showing surface expression levels (mean fluorescence 
intensity) of CD4 and CXCR4 in control and syntenin-depleted cells measured by flow cytometry. 
(C) Syntenin-1 silencing in target T-cells favors syncytia formation induced by Env+ HxBc2 cells. 
Syncytia formation was quantified by flow cytometry detection of double-positive fluorescent 
cells and is presented as the fold induction relative to cells transfected with control siRNA (mean 
± SD of four independent experiments performed in duplicate; p = 0.017). As a control, syncytia 
formation was blocked by incubation with the fusion inhibitor T20 (10 nM). (D) Effect of 
syntenin-1 silencing on HIV-1 infection. Infection was measured as viral production (p24 viral 
protein content in supernatants [ELISA]) and depicted as the mean fold induction relative to cells 
transfected with control siRNA (mean ± SD of four experiments performed in triplicate; 
p = 0.025). (E) Syntenin-1-GFP overexpression on cells knocked down for the endogenous 
syntenin-1 rescues the level of HIV-1 infection. Infection was measured as p24 viral protein 
content in supernatants (ELISA) and quantified as the mean fold induction relative to cells 
transfected with control siRNA + GFP (mean ± SD of two experiments performed in triplicate).
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cofilin activation and its actin-severing func-
tion have been linked to enhanced HIV entry 
(Yoder et al., 2008). Thus a reduced F-actin 
structure after HIV-1 attachment renders cells 
more susceptible to subsequent HIV-1 nucle-
ocapsid entry, as occurs in syntenin-depleted 
cells.
Higher HIV-1–mediated cell fusion and 
viral entry in syntenin-1–depleted target 
T-cells also correlates with increased PIP2 
production at Env-mediated cell–cell con-
tacts. PIP2 is an important second messen-
ger that targets proteins to the plasma 
membrane and regulates many actin-related 
proteins, such as ERMs, filamin, cofilin, and 
α-actinin (Saarikangas et al., 2010). Genera-
tion of PIP2 triggers local actin cytoskeleton 
changes by activating ERMs (Nakamura 
et al., 1999), recruiting cofilin (van Rheenen 
et al., 2009), and inhibiting α-actinin bun-
dling activity (Corgan et al., 2004). Overall, 
these pathways might favor HIV-1 mem-
brane fusion by facilitating receptor cluster-
ing and subsequent actin clearance (Liu 
et al., 2009). Remarkably, although PIP2-
associated cofilin is inactive in tumor cells, 
cofilin activation in leukocytes is mainly 
regulated by dephosphorylation (van 
Rheenen et al., 2009), which is in fact in-
duced upon HIV-1 contact through CXCR4-
derived signaling (Yoder et al., 2008). Thus 
PIP2 might switch the association of mem-
brane receptors and their cytosolic partners 
(Zimmermann et al., 2005; Saarikangas 
et al., 2010), modulating the links between 
transmembrane proteins and the subcorti-
cal actin cytoskeleton, and subsequently 
altering the association of proteins belong-
ing to the same signaling pathway. In this 
FIGURE 5: Syntenin-1 specifically inhibits viral entry and coclusters with fluorescent VLPs at the 
plasma membrane. (A) Effect of syntenin-1 silencing on HIV-1 attachment (4°C) and entry 
(37–4°C) into target T-cells. Data present the fold induction relative to control cells (mean ± SD 
of three experiments performed in triplicate; p = 0.016). (B) HIV-1 entry in syntenin-silenced cells 
measured by infection with one-cycle viral particles carrying a luciferase reporter gene. Data 
present the fold induction of luciferase-HIV-1-envelope virus relative to control cells and 
normalized to values obtained with luciferase-VSV-envelope virus (mean ± SD from four 
independent experiments performed in triplicate; p = 0.038). (C) Confocal images showing the 
recruitment of endogenous syntenin-1 toward attached VLPs (Gag-GFP) at 4°C. Images are 
projections of the planes in which each individual VLP is observed. Scale bar: 5 μm. Syntenin-1 
staining is shown in pseudocolor intensity-coding format next to the confocal image. The small 
panels are zoomed views of VLP contacts from pseudocolor syntenin-1 and merged 
immunostaining images (×3). Note that the 
maximum intensity of syntenin-1 staining 
(white on the pseudocolor scale images) 
overlaps the VLP attachment site. 
(D) Confocal images showing endogenous 
syntenin-1 distribution in target T-cells with 
internalized VLPs (37°C). Two VLPs are 
shown: one with low syntenin-1 clustering 
and another with no clustering. Scale bar: 
5 μm. Small panels as in (C). (E) Confocal 
images showing endogenous syntenin-1 
distribution in target T-cells forming cell–cell 
contacts with cells infected with VLPs. 
Contacts are productive sites for viral transfer 
and also recruit syntenin-1. Scale bar: 5 μm. 
Small panels as in (C). (F) Quantification of 
the number of VLPs that cluster syntenin-1 at 
the surface of target T-cells (4°C, attached 
particles), in the cytoplasm (37°C, intracellular 
particles) or at cell–cell contacts (37°C). 
Results are from at least three independent 
experiments and more than 100 VLPs were 
quantified for each condition.
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FIGURE 6: Actin polymerization is reduced in syntenin-1–depleted T-cells. (A) J77 T-cells were incubated with fluorescent 
VLPs (Gag-GFP) for 30 min, fixed, and stained for syntenin-1 and F-actin. The panels show projections of selected 
confocal planes in which a VLP was observed, with corresponding pseudocolor images below. Scale bar: 5 μm. The 
zoomed image shows the particle site (boxed region in merged image) together with orthogonal sections. Quantification 
of VLPs that colocalized with F-actin in cells silenced or not for syntenin-1 is shown at the right. No significant difference 
was observed. (B) Time profile of F-actin content upon contact with HIV-1 particles, measured by flow cytometry in 
control or syntenin-depleted cells. Data are means ± SD of four independent experiments. (C) F-actin accumulation at 
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Research and Reference Reagent Program and were cultured ac-
cording to NIH instructions. The chronically infected MT4-NL4.3-GFP 
cell line (MT4-HIV-GFP) was generated by Nuria Izquierdo-Useros at 
the laboratory of Martinez-Picado (IrsiCaixa, Barcelona, Spain).
The biotinylated monoclonal anti-CXCR4 antibody was from BD 
PharMingen. Mouse monoclonal anti–α-tubulin was from Sigma-
Aldrich (Saint Louis, MO). Anti-CD4 monoclonal antibodies used 
were HP2/6 (Gordon-Alonso et al., 2006), OKT4 (eBioscience), RPA-
T4 (eBioscience, San Diego, CA), CD4v4-FITC (BD PharMingen, 
Franklin Lakes, NJ), and MEM 241 (Abcam, Cambridge, UK). Rabbit 
polyclonal anti–syntenin-1 was from Synaptic Systems (Göttingen, 
Germany). The anti-CD45 mAb was clone D3/9, previously de-
scribed (Gordon-Alonso et al., 2006). Anti-PIP2 mAb was from Santa 
Cruz Biotechnology (clone 2C11; Santa Cruz, CA). Anti-GFP anti-
bodies (pAb for IP and mAb for WB) were from Living colors (Clon-
tech, Mountain View, CA). HRP-conjugated secondary antibodies 
were from Pierce (Rockford, IL).
The intracellular fluorescent trackers CMAC, Calcein-AM, and 
CM-TMR and all fluorochrome-conjugated secondary antibodies 
and phalloidins were from Molecular Probes (Camarillo, CA). The 
HIV-1-specific fusion inhibitor T20 (Enfuvirtide) was from Roche 
Diagnostics.
Cell transfection, DNA and siRNA
J77 cells (2 × 107) were electroporated in cold Optimem (Life Technol-
ogies-BRL, Camarillo, CA) with DNA (20 mg) or with siRNA (1.25 mM) 
using a Bio-Rad GenePulser II electroporator (240 V; 950°F). Fluores-
cent protein expression and siRNA knockdown were tested respec-
tively by flow cytometry (24 h) and Western blot analysis (48 h).
The syntenin-1 GFP fusion proteins Psrα-HAGFP-syntenin-1 and 
syntenin-1-Y1-GFP have been described previously (Sala-Valdes 
et al., 2012). PIP2-enriched plasma membranes were monitored 
during Env-mediated membrane fusion or VLP attachment by 
transfecting cells with the biosensor PLCδ-PH-GFP (Varnai and 
Balla, 1998). GST-syntenin-1-HA and GST-syntenin-1-Myc were 
kindly donated by F. Lozano (Hospital Clinic, Barcelona, Spain).
Negative control siRNA was from Eurogentec (Serain, Belgium) 
and the specific siRNAs against syntenin-1 were from Thermo Scien-
tific Dharmacon (oligonucleotides J-008270-08 and J-008270-06).
Preparation and production of HIV-1 and virus attachment 
and entry assay
Preparation of HIV-1 NL4.3 and measurement of viral replication 
were as previously described (Valenzuela-Fernandez et al., 2005). 
Gag-GFP and Gag-Cherry fluorescent VLPs were produced as previ-
ously described (Izquierdo-Useros et al., 2009) by cotransfecting 
293T cells with the HIV Gag-eGFP/Cherry plasmids and the enve-
lope plasmid pHXB2.
regard, in a preliminary attempt to assess syntenin-1 partners, we 
have observed its association with ERMs and PI4P5K-I (Gordon-
Alonso et al., unpublished data). One possibility is that syntenin-1 
may be able to prevent ERMs from fulfilling their role of in facilitat-
ing HIV-1 entry but without affecting CD4/CXCR4 clustering. A 
second option is that syntenin-1 is limiting PI4P5K-I PIP2 produc-
tion, and therefore, inhibiting HIV-1 entry (Barrero-Villar et al., 
2008). The complexity of syntenin-1 relationships deserves further 
investigation. Alternatively, depletion of syntenin-1 might simply 
allow a higher pool of free PIP2 to accumulate at the plasma mem-
brane after HIV-1 attachment, where it could mediate the recruit-
ment of proteins, such as, ERMs, that facilitate HIV entry (Barrero-
Villar et al., 2008, 2009).
The fact that syntenin-1 clustering around the virus-like particle 
vanishes after viral entry is consistent with participation of syntenin-1 
at the plasma membrane during HIV-1 entry, probably as a conse-
quence of its association with CD4 or its recruitment through PIP2. 
We therefore propose a dynamic model in which syntenin-1 is first 
recruited to the viral attachment site through CD4 and/or PIP2. At 
this location, syntenin-1 would trigger F-actin polymerization via Rac 
GTPase, as has also been suggested for other processes mediated 
by this GTPase (Sala-Valdes et al., 2012). This is consistent with the 
fact that Rac is the Rho GTPase specifically activated during HIV-1 
entry (Pontow et al., 2004; Harmon et al., 2010). Because syntenin-1 
regulates Rac-triggered F-actin polymerization through the adaptor 
protein M-Rip during T chemotaxis (Sala-Valdes et al., 2012), it is 
conceivable that this or a similar signaling axis could be involved 
during HIV-1 entry. Indeed, syntenin-1 Tyr-4 is essential for Rac-me-
diated T-cell chemotaxis and superantigen presentation (Sala-Valdes 
et al., 2012) and seems also to be crucial for syntenin-mediated in-
hibition of HIV infection. Subsequently, F-actin must be locally de-
polymerized to facilitate the nucleocapsid entry (Yoder et al., 2008; 
Vasiliver-Shamis et al., 2009), which is favored (F-actin depolymeriza-
tion) in the absence of syntenin-1. In this context, PIP2 induction by 
HIV-1 might be the signal that shuts down local F-actin polymeriza-
tion while activating F-actin clearance.
In summary, our results have unveiled a critical regulatory role for 
syntenin-1 in controlling HIV-1 entry into target T-cells through alter-
ing actin polymerization, most likely in a PIP2-regulated manner.
MATERIALS AND METHODS
Cell lines and reagents
The Jurkat-derived human T-cell line J77 Vβ8+ J77cl20 was grown in 
RPMI 1640 medium supplemented with 10% fetal bovine serum 
(FBS; Cambrex Bioscience, Charles City, IA). The CEM-T4 human 
T-lymphoblast–like cell line (courtesy of Paul Clapman), and the 
HxBc2 Jurkat-derived T-cell line (courtesy of Joseph Sodrowski) 
were obtained from the National Institutes of Health (NIH) AIDS 
contacts between infected MT4-HIV-GFP cells and silenced or control target cells was quantified using the synapse-
measure plug-in of Image J. The medians and interquartile ranges are shown. More than 100 conjugates were counted 
for each condition in two independent experiments (p = 4.08 × 10−31). (D) MT4-HIV-GFP infected T-cells were incubated 
with control or syntenin-depleted target T-cells for 2 h, fixed, and stained for PIP2 with anti-PIP2 mAb. Quantified PIP2 
labeling at Env-mediated cell contacts is presented as the percentage of PIP2 accumulated at cell contacts. More than 
100 conjugates were counted for each condition (p = 1.1 × 10−5). (E) Env+ HxBc2 T-cells were incubated with control or 
syntenin-depleted target T-cells for 2 h and then fixed, and the conjugates were stained for PIP2 with anti-PIP2 mAb. 
Quantified PIP2 labeling at cell contacts is presented as the percentage of PIP2 accumulated at heterotypic Env-driven 
cell–cell contacts and at homotypic Env-independent contacts (between two target T-cells). More than 100 conjugates 
were counted for each condition (p = 2.1 × 10−4). (F) Control or syntenin-depleted cells expressing PLCδ-PH-GFP were 
incubated with fluorescent VLPs (Gag-Cherry) for 30 min, fixed, and analyzed by confocal microscopy. The bar chart 
shows quantification of PIP2 enrichment at VLP contacts, presented as the percentage of PIP2 recruited to VLP–cell 
contacts. More than 100 VLP contacts were counted for each condition (p = 0.038). The right panel shows a sample 
confocal image in which several VLPs are attached to one pole of the target T-cell (arrows). Scale bar: 5 μm.
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ples were permeabilized for 5 min with 0.5% Triton X-100 in TBS, 
stained and mounted in Prolong (Invitrogen, Camarillo, CA). Images 
were obtained with a photomicroscope (DMR; Leica, Germany) fit-
ted with an HCX PL APO 63×/1.32-210.6 oil-immersion objective 
(Leica; Germany) and coupled to a COHU 4912–5010 charge-cou-
pled camera.
Confocal images were obtained with a Leica TCS-SP5 confocal 
scanning laser microscope fitted with either an HCX PL APO lambda 
blue 63×/1.4 or an HCX PL APO lambda blue 100×/1.4 oil-immer-
sion objective and analyzed with Image J. For clustering quantifica-
tion, staining intensities were transformed with the pseudocolor-in-
tensity look-up-table (LUT). Yellow-white patches at VLP locations 
were considered positive for clustering. For analyzing F-actin accu-
mulation at cell–cell contacts, Image J software was used as previ-
ously described (Calabia-Linares et al., 2011).
Western blotting
J77 T-cells were lysed in 1% NP-40 in TBS supplemented with a 
cocktail of protease inhibitors and phosphatase inhibitors. Lysates 
were centrifuged at 11,000 rpm for 10 min at 4°C, and supernatants 
were mixed with reducing Laemmli buffer and boiled for 5 min. 
Lysates were separated by SDS–PAGE and immunoblotted with 
specific antibodies. Protein bands were analyzed using the LAS-
1000 CCD system and Image Gauge 3.4 software (Fuji Photo Film, 
Tokyo, Japan).
Flow cytometry
Cells were incubated with TBS 5% BSA for 30 min at 4°C and then 
with primary monoclonal antibody (30 min at 4°C). After being 
washed, cells were incubated with a fluorescein isothiocyanate 
(FITC)-conjugated secondary antibody and analyzed in a FACScali-
bur flow cytometer (Becton Dickinson, Franklin Lakes, NJ). Data were 
analyzed with Cell-Quest Pro (Becton Dickinson).
F-actin quantification
Cells were stimulated with HIV NL4.3 free virions (100 ng/million 
cells), fixed with 4% formaldehyde at different time points, permea-
bilized with TBS 0.5% Triton X-100 (5 min), and stained with Phalloi-
din-Alexa647 (Molecular Probes, Camarillo, CA). Mean fluorescence 
intensity of F-actin staining was analyzed on a FACScalibur cytometer 
(BD Biosciences, Franklin Lakes, NJ).
Statistical analysis
Statistical significance was calculated using Student’s t test or the 
parametric one-way analysis of variance with Bonferroni’s post hoc 
multiple-comparison test. Significant differences are labeled 
(*, p < 0.05; **, p < 0.01; ***, p < 0.001).
For p24 production, T-cells were infected with 100 ng of HIV-1 
NL4.3 per million cells for 2 h at 37°C (which is equivalent to 1–2 
multiplicity of infection or viral particles per cell), and then exten-
sively washed with medium to remove nonattached viral particles. 
Infected T-cells were kept in culture for 3 d, at which time superna-
tants were harvested and p24 concentration measured by ELISA 
(Innotest HIV-1 antigen mAb; Innogenetic, Ghent, Belgium).
For HIV attachment and entry measurements, T-cells were in-
fected with 20 ng of HIV-1 NL4.3 per million cells for 2 h at 4°C 
(attachment) or 37°C (attachment + entry), and then extensively 
washed to remove viral input and lysed with RIPA buffer (50 mM Tris 
HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS). p24 was measured by ELISA (Innotest HIV-1antigen 
mAb; Innogenetic).
Luciferase virus assay
Replication-deficient luciferase-HIV-1 particles were kindly provided 
by Suryaram Gummuluru (Boston University, Boston, MA). Replica-
tion-deficient viral particles were produced by cotransfecting 293T 
cells with the luciferase-expressing reporter virus, HIV/Δnef/Δenv/
luc+, which contains the luciferase gene inserted into the nef 
open reading frame and does not express env glycoprotein 
(Yamashita and Emerman, 2004), and a CXCR4-tropic (Lai) env 
glycoprotein or non–T-tropic VSV glycoprotein. Virus stocks were 
generated by PolyFect transient cotransfection of HEK293T cells 
(Gummuluru et al., 2002). Two days after transfection, cell-free virus-
containing supernatants were clarified of cell debris and concentrated 
by centrifugation (16,000 × g, 1 h at 4°C) and stored at −80°C until 
required. HIV-1 virus preparations were titrated by p24-ELISA. T-cells 
were infected with 200 ng of luciferase-based virus with X4-tropic 
HIV-1 envelope or VSV envelope per million cells for 2 h. Cells were 
washed extensively and luciferase activity was measured at 48 h after 
infection with a luciferase assay kit (Promega Corporation, Madison, 
WI) on a 1450 Microbeta Luminescence Counter (Walax, Trilux).
Env-induced cell fusion assay
A dual-fluorescence cell-fusion assay was performed as described 
previously (Gordon-Alonso et al., 2006). Briefly, CMTMR-loaded 
Env+ Jurkat-Hxbc2 cells were mixed with calcein-AM–loaded paren-
tal or transfected CEM-T4 cells. Fluorescence events were detected 
14 h later by flow cytometry. Fusion was quantified as the ratio of 
double-positive events to single-positive target cells.
Immunoprecipitation
T lymphoblasts and CEM T-cells were lysed in 1% NP-40, 1 mM 
MgCl2, 1 mM CaCl2 in Tris-buffered saline (TBS) supplemented with 
protease and phosphatase inhibitor cocktails. J77 T-cells (4 × 107) 
were lysed in 1% NP-40 in TBS supplemented with a protease in-
hibitor cocktail. Lysates were centrifuged at 11,000 rpm for 10 min 
at 4°C, and cell lysate supernatants were incubated for 2 h at 4°C 
with cyanogen bromide (CNBr) beads (Amersham, Uppsala, Swe-
den) blocked with bovine serum albumin (BSA). Supernatants were 
then incubated with the indicated antibody covalently coupled to 
CNBr beads for 2 h at 4°C. Pellets were washed with lysis buffer, 
resuspended in reducing Laemmli buffer, and processed for West-
ern blotting with the indicated antibodies.
Immunofluorescence and confocal microscopy
T-cells incubated with viral particles, Env+ cells (HxBc2), or HIV-1 in-
fected cells (MT4-HIV-GFP) were seeded on 50 μg/ml poly-l-lysine 
for 30 min and fixed with 3% paraformaldehyde. For staining of in-
tracellular proteins (endogenous syntenin-1, F-actin, and PIP2), sam-
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ISGylation controls exosome secretion by
promoting lysosomal degradation of MVB
proteins
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Exosomes are vesicles secreted to the extracellular environment through fusion with the
plasma membrane of speciﬁc endosomes called multivesicular bodies (MVB) and mediate
cell-to-cell communication in many biological processes. Posttranslational modiﬁcations are
involved in the sorting of speciﬁc proteins into exosomes. Here we identify ISGylation as a
ubiquitin-like modiﬁcation that controls exosome release. ISGylation induction decreases
MVB numbers and impairs exosome secretion. Using ISG15-knockout mice and mice
expressing the enzymatically inactive form of the de-ISGylase USP18, we demonstrate in vitro
and in vivo that ISG15 conjugation regulates exosome secretion. ISG15 conjugation triggers
MVB co-localization with lysosomes and promotes the aggregation and degradation of MVB
proteins. Accordingly, inhibition of lysosomal function or autophagy restores exosome
secretion. Speciﬁcally, ISGylation of the MVB protein TSG101 induces its aggregation and
degradation, being sufﬁcient to impair exosome secretion. These results identify ISGylation as
a novel ubiquitin-like modiﬁer in the control of exosome production.
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xosomes are vesicles secreted to the extracellular
environment by most cell types. They are key mediators
of cell-to-cell communication in many different contexts,
including the immune response1,2 and tumour progression3,4.
Exosomes originate in endosomal compartments called
multivesicular bodies (MVBs), which are late endosomes
containing multiple intraluminal vesicles (ILVs) formed by the
invagination of the endosomal membrane. When MVBs fuse with
the plasma membrane, ILVs are released as exosomes5.
Alternatively, MVBs can fuse with the lysosomal compartment,
resulting in degradation of their content.
Exosome composition is not a mere copy of cytosolic content;
rather, speciﬁc proteins and nucleic acids are selectively sorted
into exosomes. The amount and content of exosomes can
moreover change in response to different stimuli6,7. Such changes
in exosome composition determine the ﬁnal outcome of
exosome-mediated communication8,9.
The mechanisms that control exosome composition and
content are still not well understood10. Posttranslational
modiﬁcations such as ubiquitination may play an important
role in the sorting of proteins into exosomes11–13. The endosomal
sorting complex required for transport (ESCRT) recognizes
ubiquitinated proteins and sorts them into ILVs14. The ESCRT
complex is essential for the sorting of proteins such as epidermal
growth factor receptor into MVBs that are degraded through
fusion with lysosomes15, but is also involved in the regulation of
exosome composition and secretion16,17. Another ubiquitin-like
protein (UBL) that can modify exosomal proteins is SUMO,
whose conjugation to hnRNPA2B1 is essential for the sorting of
microRNAs into exosomes18, and enhances the secretion of
a-synuclein into extracellular vesicles (EVs) in an ESCRT-
dependent manner19.
ISG15 is an interferon (IFN)-a/b-induced UBL20, which exerts
its functions in two distinct states: as a free molecule (intracellular
and extracellular)21 or conjugated to target proteins
(ISGylation)22,23. Analogous to ubiquitin, ISG15 conjugation is
mediated by the consecutive action of an E1-activating enzyme
(Ube1L), an E2-conjugating enzyme (UbCH8) and E3 ligases
(mHERC6/hHERC5)24–26, and counteracted by the speciﬁc
isopeptidase USP18 (ref. 27). ISGylation was shown to occur in
a co-translational process favouring modiﬁcation of viral proteins
in infected cells, which, in turn, interferes with virus assembly or
function28–30. Furthermore, cellular proteins involved in antiviral
defense or export of viral particles have been shown to be
ISGylated, supporting the antiviral function of ISG15 (ref. 28).
Studies in mice have demonstrated a role for ISG15 in antiviral
immunity. Hence, mice lacking ISG15 exhibit a higher
susceptibility to several pathogens including virus31 and
bacteria32, and this is reverted in USP18-mutant mice, in which
high levels of ISG15 conjugation are observed33. However,
human ISG15 seems to have critical immune functions but
not in antiviral immunity; unlike mice, ISG15 deﬁciency
increased viral resistance in humans34. Speciﬁcally, free
extracellular human ISG15 is important in IFN-g-dependent
anti-mycobacterial immunity21, whereas free intracellular ISG15
is involved in USP18-mediated downregulation of IFN-a/b
signalling35.
ISG15 expression blocks the process of virus-budding by
different mechanisms such as the blockage of ESCRT machinery
in HIV-infected cells36, or in the case of Ebola and other
enveloped virus infections, inhibiting the Nedd4 E3 ubiquitin
ligase37. Interestingly, exosomes and viruses share many features,
and some viruses have been shown to exploit exosome and
microvesicle secretion pathways38,39. In addition, exosomes
are enriched in ISGylation targets, such as TSG101 (ref. 40)
and heat-shock proteins41.
Here we show that IFN-I inhibits exosome secretion by inducing
protein ISGylation. We demonstrate that the ISGylation of the
MVB protein TSG101 induces its aggregation and degradation,
and this is sufﬁcient for impairing exosome secretion. Moreover,
the ISGylation-induced defect in exosome secretion is rescued on
inhibition of lysosomal function or autophagy.
Results
ISGylation inhibits exosome secretion. To analyse the role of
ISGylation on exosome production, we ﬁrst treated Jurkat T cells
with IFN-I, to induce ISG15 expression and conjugation
(Supplementary Fig. 1A), and puriﬁed the secreted EVs from
their culture supernatants by a serial ultracentrifugation protocol.
IFN-I treatment inhibited the secretion of the classical exosome
markers CD63, TSG101 and CD81 in the puriﬁed EVs (Fig. 1a).
A concomitant decrease in the exosomal markers on IFN-I
treatment was also observed after an additional puriﬁcation step
by ultracentrifugation in a sucrose gradient (Supplementary
Fig. 1B). Interestingly, the few EVs secreted by IFN-treated cells
were recovered in different fractions than the EVs from non-
treated cells, suggesting that they might be of different nature.
To further investigate the function of ISGylation in controlling
EVs secretion, we next overexpressed ISG15 and the machinery
responsible for ISGylation (E1, E2 and E3) in HEK293 cells,
which mimics the activation of the ISG15 pathway
(Supplementary Fig. 1A)24,28 without activating other pathways
induced by IFN-I treatment. ISGylation induction inhibited the
secretion of EVs containing CD63, TSG101 and CD81 (Fig. 1b).
To dissect whether the inhibition in exosomal markers secretion
was due to ISG15 overexpression itself or to increased ISG15
conjugation to proteins, we overexpressed the ISGylation
machinery together with an ISG15 mutated at the carboxy-
terminal (ISG15MUT), thus disabling protein conjugation. Cells
overexpressing ISG15MUT showed higher levels of exosomal
markers in comparison with ISG15WT (Fig. 1c), demonstrating
that ISG15 conjugation to proteins, but not free ISG15, is
required for the inhibition of exosomal markers secretion.
Nanoparticle tracking analysis (NTA) showed a decrease in the
number of particles secreted on ISG15WT overexpression in
comparison with ISG15MUT-expressing cells (Supplementary
Fig. 1C), indicating that ISGylation is not causing a mere decrease
in the sorting of exosomal markers in EVs, but an actual decrease
in exosome secretion. However, NTA did not reveal any
signiﬁcant decrease in the secretion of nanoparticles on IFN-I
treatment (Supplementary Fig. 1D).
To study the role of ISG15 in exosome secretion in a more
physiological context, we analysed the secretion of exosomes by
primary cells from wild-type (WT), ISG15 knockout (ISG15KO)42
and USP18C61A mice, which have the ISG15 de-conjugating
enzyme USP18 enzymatically inactive and thus show higher levels
of protein ISGylation33. Consistent with the inhibition of
exosome secretion induced by ISGylation, IFN-I treatment
decreased exosome secretion in primary bone marrow-derived
macrophages (BMDMs) from WT mice but not in ISG15-
deﬁcient macrophages (Fig. 1d). Furthermore, BMDMs from
USP18C61A mice secrete less exosomes than either WT or
ISG15KO mice on ISGylation induction by IFN-I, supporting the
role of ISG15 protein conjugation in the regulation of exosome
secretion. Similar results were also obtained with primary
T lymphoblasts (Supplementary Fig. 1E). To assess the role of
ISGylation in vivo, poly (I:C) was injected intraperitoneally
into WT, ISG15KO and USP18C61A mice, to induce ISG15
expression43, and exosomes from blood serum analysed.
Interestingly, there were less exosomes in serum from poly
(I:C)-injected WT than ISG15KO mice, and even less exosomes in
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serum from injected USP18C61A mice (Fig. 1e), demonstrating
the role of ISGylation in the inhibition of exosome secretion
in vivo. Overall, our gain- and loss-of-function experiments
strongly support the role of ISGylation in the regulation of
exosome secretion in vitro and in vivo.
ISGylation decreases MVB numbers. To investigate the
mechanisms by which ISGylation controls exosome secretion,
MVBs were studied. Hepatocyte growth factor-regulated tyrosine
kinase substrate (HRS) is involved in MVB formation and exo-
some secretion17,44, and it has been previously used as a marker
of MVBs, being present in intermediates between early and late
MVBs positive for TSG101 and LBPA44,45. ISGylation induction
resulted in a more perinuclear and clustered localization of HRS,
as shown by the increase in the size of HRSþ structures (Fig. 2a),
and decreased the number of HRSþ spots per cell
(Supplementary Fig. 2A). Similar results were obtained with the
MVB marker CD63 (Fig. 2a and Supplementary Fig. 2A), whereas
the early endosome (EE) marker EEA1 did not show any
apparent alteration (Supplementary Fig. 2B). Electron microscopy
analyses revealed signiﬁcant reduced MVBs numbers and density
on ISGylation induction (Fig. 2b). In accordance, IFN-I treatment
reduced HRSþ spots in WT macrophages but not in ISG15KO
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Figure 1 | ISGylation inhibits exosome secretion. (a) Western blot analysis of EVs puriﬁed by serial ultracentrifugation from cell culture supernatants from
equal numbers of Jurkat T cells untreated (Cont) or treated with 1,000Uml 1 IFN-I for 16 h. Cells and EVs (Exo) were blotted for the exosomal markers
CD63, TSG101, Flotillin and CD81, and for the endoplasmic reticulum marker Calnexin. Right graph: quantiﬁcation of exosomal protein levels in the EVs
obtained from IFN-I-treated and untreated cells in three independent experiments. (b) Western blot analysis of the EVs obtained from equal numbers of
untransfected HEK293 cells (Cont) or co-transfected with ISG15 and the ISGylation machinery; E1, E2, E3 ligases (ISG15). Cells and EVs (Exo) were blotted
for CD63, TSG101, CD81 and Calnexin. Right graph: quantiﬁcation of exosomal protein levels in the EVs obtained from untransfected HEK293 cells or co-
transfected with ISG15 and the ISGylation machinery in three independent experiments. (c) Western blot analysis of the EVs obtained from equal numbers
of HEK293 cells co-transfected with plasmids encoding the ISGylation machinery and the functional (ISG15WT) or mutated ISG15 (ISG15MUT). Cells and
EVs (Exo) were blotted for CD63, CD81 and Calnexin. Right graph: quantiﬁcation of exosomal protein levels in four independent experiments. (d) Western
blot analysis of the EVs obtained from equal numbers of WT, ISG15KO and USP18C61A BMDMs treated 16 h with IFN-I or left untreated. Cells and EVs were
blotted for TSG101 and quantiﬁcation of exosomal protein levels of IFN-I-treated and -untreated cells is shown for three independent experiments.
(e) Western blot analysis of the EVs obtained in blood serum from poly(I:C)-injected WT, ISG15KO and USP18C61A mice. EVs were isolated from 250ml of
serum and blotted for TSG101. Right graphs: quantiﬁcation of exosomal TSG101 protein levels of three mice per genotype; t-test *P-valueo0.05,
**P-valueo0.001 and ***P-valueo0.0001.
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Figure 2 | ISGylation decreases MVB numbers. (a) Confocal microscopy analysis of the endosome markers HRS (red) and CD63 (green) in
non-transfected HEK293 cells or HEK293 cells co-transfected with plasmids encoding the ISGylation machinery and the functional (ISG15WT) or mutated
ISG15 (ISG15MUT). Scale bar, 10mm. Right graph: quantiﬁcation of HRSþ and CD63þ average particle size per cell (n¼ 20). Each dot represents the
average particle size from individual cells and mean is indicated in red lines. (b) Electron microscopy images showing representative ﬁelds with MVBs
(red arrows) and lysosomes/autophagosomes (blue arrows) in HEK293 transfected as in a. Right graph: quantiﬁcation of MVB numbers in more than
25 ﬁelds per condition. Each dot represents the number of MVBs per section and mean is indicated in red lines. Scale bar (insets), 500 nm. (c) Confocal
microscopy analysis of HRS inWTor ISG15KO BMDMs left untreated or treated with 1,000Uml 1 IFN for 16 h. Scale bar, 10mm. Right graph: quantiﬁcation
of the number of HRSþ particles per cell. Each dot represents the number of HRSþ particles from individual cells and mean is indicated in red lines
(n¼ 28). (d) Electron microscopy images showing MVBs (red arrows) in WT or ISG15KO BMDMs treated with 1,000Uml 1 IFN for 16 h. Upper graph,
quantiﬁcation of MVB numbers in 20 ﬁelds per condition. Each dot represents the number of MVBs per section and mean is indicated in red lines. Lower
graph, quantiﬁcation of ILV numbers per MVB. Each dot represents the number of ILVs per MVB and mean is indicated in red lines (nZ24). Scale bar
(insets), 500nm. (e) Confocal microscopy analysis of CD63 (red) in Rab5-Q79L-GFPþ endosomes (green). HEK293 cells were transfected with
Rab5-Q79L-GFP and treated 16 h with 1,000Uml 1 IFN or left untreated. (f) Confocal microscopy analysis of CD63 (red) in Rab5-Q79L-GFPþ endosomes
(green). HEK293 cells were co-transfected with Rab5-Q79L-GFP mutant, the ISGylation machinery and ISG15WTor ISG15MUT. Images from e,f: Scale bar,
10mm. Right graphs: each dot represents the percentage of CD63-ﬁlled endosomes per individual cell and mean is indicated in red lines; t-test;
NS: P-value40.05 and ***P-valueo0.0001.
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macrophages (Fig. 2c), and MVBs were more abundant in
ISG15KO macrophages than in their WT counterparts on IFN-I
treatment (Fig. 2d), overall suggesting a role for ISG15 in
regulating MVB numbers.
To ascertain whether ISGylation decreases MVB numbers
by affecting MVB formation, we transfected HEK293 cells with
the constitutively active Rab5-Q79L-GFP mutant, which forms
large endosomes with a mixed morphology between EE and
MVBs, which facilitates the study of the ﬁrst steps in MVB
biogenesis46,47. ISGylation induction by either IFN-I or ISG15
overexpression did not affect the sorting of the exosomal protein
CD63 into Rab5-Q79L-GFP endosomes (Fig. 2e,f). Furthermore,
quantitative electron microscopy analyses did not show any
signiﬁcant differences in the number of ILVs per MVB on
ISGylation induction (Supplementary Fig. 2C,D). To rule out any
possible side effect derived from the uneven distribution of small
ILVs within enlarged MVBs48, ILV numbers were also quantiﬁed
in the absence of Rab5-Q79L-GFP overexpression. Accordingly,
macrophages from WT and ISG15KO mice also showed similar
levels of ILVs per MVB on ISGylation induction by IFN (Fig. 2d).
Altogether, these data support that ISGylation does not impair
the formation of ILVs, suggesting that it is mainly affecting later
stages on the MVB pathway.
ISGylation induces protein aggregation and degradation. We
then sought to understand how ISGylation regulates MVB
numbers and exosome secretion. For this, we used ISG15 fusion
proteins as models of protein ISGylation, as previously described
for other posttranslational modiﬁcations such as ubiquitin or
other UBLs49–51. Although fusion proteins are not exactly the
same than endogenous ISGylation in lysines, in our ISG15 fusion
proteins the C-terminal glycine of ISG15 is fused to the NH2
group of the target protein in the N-terminal amino acid through
a peptidic bond, which is chemically analogue to the isopeptidic
bond formed between the endogenous ISG15 and the NH2 group
of a target protein lysine.
Confocal analysis showed partial co-localization of ISG15-GFP
fusion protein with the MVB marker HRS and with the
aggresome marker p62 (ref. 52 and Fig. 3a,b), whereas no
co-localization was detected with the EE marker EEA1
(Supplementary Fig. 3A). Notably, ISGylation increased the
co-localization of HRS with the lysosome marker LAMP1
(Fig. 3c), although neither LAMP1 content nor localization were
affected (Supplementary Fig. 3B).
Despite its co-localization with MVB markers, green
ﬂuorescent protein (GFP) was not found in exosomes when
fused to ISG15 (Fig. 3d) but rather promoted its accumulation
in detergent-insoluble cell fractions (Fig. 3e), indicating that
ISGylation promotes protein aggregation. Western blot analysis
of cycloheximide-treated cells showed that when fused to ISG15,
GFP is degraded faster than GFP alone or when fused to the
ubiquitin-like modiﬁer SUMO2, and that this degradation is
delayed by the lysosome inhibitor Baﬁlomycin A1 but not by the
proteasome inhibitor MG132 (Fig. 3f and Supplementary
Fig. 3C–E), thus indicating that ISGylation of proteins promotes
their degradation through the lysosome.
Inhibition of MVB–lysosome fusion rescues exosome secretion.
To assess whether ISGylation inhibits exosome secretion by
inducing MVB lysosomal degradation, we studied whether
inhibition of MVB fusion with lysosomes could recover exosome
secretion. Baﬁlomycin A1 is a proton pump inhibitor that
increases the pH of lysosomes and inhibits trafﬁcking between
MVB and lysosomes53,54. Baﬁlomycin A1 treatment recovered
exosome secretion in HEK293 cells in which ISGylation was
induced by ISG15 overexpression (Fig. 4a), whereas it did not
increase exosome secretion in control cells (Supplementary
Fig. 4A), suggesting that ISGylation inhibits exosome secretion
by re-routing MVB to lysosomes but is not impairing MVB
biogenesis. This is also supported by the detection of ISGylated
proteins in exosomes on secretion recovery (Supplementary
Fig. 4B). Exosome secretion was also recovered despite ISGylation
induction by IFN-I in Jurkat T cells when treated with
Baﬁlomycin A1 (Supplementary Fig. 4C).
To avoid unspeciﬁc effects derived from the use of the
inhibitor, we also studied exosome recovery on Rab7T22N
dominant-negative mutant expression, which inhibits both
endosome–lysosome and autophagosome–lysosome fusion55–58.
Rab7T22N expression rescued exosome secretion in HEK293 cells
despite ISGylation induction by ISG15 overexpression (Fig. 4b),
whereas it did not increase exosome secretion in control cells
(Supplementary Fig. 4D), supporting that the ISGylation-induced
inhibition of exosome secretion is mediated by MVB fusion and
degradation by the lysosome.
Fusion of MVBs with autophagosomes on induction of
autophagy by rapamycin has been reported56. Interestingly, the
secretion of exosomes on ISGylation induction was also recovered
on silencing of the autophagy mediator ATG5 (Fig. 4c),
indicating that autophagy probably contributes to the decreased
exosome release induced by ISGylation. Accordingly, IFN-I
treatment promoted the localization of the autophagy mediator
LC3 in more acidic compartments, presumably lysosomes,
supported by the loss of GFP ﬂuorescent signal in mRFP-GFP-
LC3 tandem reporter (Fig. 4d). Notably, ISGylation induction by
IFN-I treatment or ISG15 overexpression did not induce
general autophagy, as evidenced by unaltered levels of p62
and other autophagy markers (Supplementary Fig. 4E,F),
indicating that ISGylation promotes selective autophagy and
degradation of MVB without inducing a global autophagy
response.
ISG15 impairs exosome secretion by modifying TSG101. To
elucidate the molecular mechanism by which ISGylation regulates
exosome secretion, we focused on TSG101, a component of the
ESCRT machinery involved in exosome biogenesis that has been
shown to be ISGylated and to regulate the secretion of virus40.
To conﬁrm TSG101 ISGylation, we overexpressed the ISGylation
machinery together with WT or mutated ISG15 fused to the
V5 tag and performed V5 immunoprecipitation. Western blot
analysis of TSG101 in V5-ISG15 but not in control or
V5-ISG15MUT immunoprecipitates conﬁrmed endogenous
TSG101 ISGylation (Fig. 5a). Moreover, ISGylation induction
by ISG15 overexpression induced endogenous TSG101
aggregation and accumulation in insoluble fractions (Fig. 5b).
To address whether ISGylation of TSG101 is sufﬁcient to inhibit
exosome secretion, we generated a TSG101-GFP plasmid that
mimics TSG101 ISGylation (referred as ISG15-TSG101-GG), in
which ISG15 terminal glycine is conjugated to TSG101
N-terminal through a peptide bound that can be cleaved by the
USP18 de-ISGylase (Supplementary Fig. 5A). Consequently,
both ISGylated and de-ISGylated TSG101-GFP are detected in
cells transfected with this plasmid (Fig. 5c). Interestingly,
ISGylated TSG101-GFP accumulated in insoluble fractions
and was degraded faster than de-ISGylated TSG101-GFP
(Fig. 5d,e), consistent with ISGylation promoting TSG101
protein aggregation and degradation. The expression of the
ISG15-TSG101-GG plasmid rescued exosome secretion in cells
targeted for endogenous TSG101 (Fig. 5f and Supplementary
Fig. 5B), probably due to the presence of a functional
de-ISGylated form of TSG101. To circumvent this, we
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generated a non-de-ISGylable TSG101 mutant by changing ISG15
terminal glycines into alanines (ISG15-TSG101-AA), thus
preventing TSG101 de-ISGylation (Fig. 5c). In cells devoid of
endogenous TSG101, overexpression of the non-de-ISGylable
TSG101 mutant did not restore the secretion of exosomes (Fig. 5g
and Supplementary Fig. 5C), supporting that ISG15 conjugation
to the ESCRT component TSG101 is sufﬁcient to inhibit the
secretion of exosomes.
Discussion
Cells secrete a variety of EVs including shedding vesicles, coming
from the direct evagination of the plasma membrane, and
exosomes, coming from endosomal compartments called MVBs.
The membrane of MVB invaginates to form ILVs, which are
secreted to the extracellular environment on MVB fusion with the
plasma membrane5. MVBs can also fuse with the lysosomal
compartment for the degradation of their content. There is
evidence that different types of MVB co-exist in cells59, although
the differences in their composition and the mechanisms that
control their biogenesis and ﬁnal fusion with the lysosome or
plasma membrane are not well understood10. In addition, on
speciﬁc stimuli such as starvation or rapamycin treatment, MVBs
can be re-routed to promote their fusion with the lysosomal
compartment and thus avoid their fusion with the plasma
membrane and the concomitant secretion of exosomes56
demonstrating that the ﬁnal fate of MVBs is not immutable but
can change under speciﬁc conditions60.
The role of the ESCRT complex in the sorting of ubiquitinated
proteins into ILVs for their degradation in the lysosome is well
known61 and some of the ESCRT complex components are also
involved in the secretion of exosomes and other EVs12,17,
although their precise role in the biogenesis of the different
types of EVs is not known. Other ubiquitin-like modiﬁers have
been shown to control the composition of EVs, for example,
SUMOylation of hnRNPA2B1 promotes the sorting of speciﬁc
microRNAs into exosomes18, and also controls the sorting of
a-synuclein into EVs19. Here we identify the ubiquitin-like
modiﬁer ISG15 as a novel regulator of the exosome pathway.
We show that ISGylation induction by ISG15 machinery
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Figure 3 | ISG15 conjugation induces protein aggregation and degradation by lysosomes. (a) Confocal co-localization analysis of ISG15-GFP (green) and
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functional (ISG15WT) or mutated ISG15 (ISG15MUT). Nuclei were stained with DAPI. Scale bar, 10mm. Co-localization area per cell was quantiﬁed by
ImageJ (n¼ 16). Each dot represents the percentage of co-localization area per cell surface and mean is indicated in red lines. (d) Western blot analysis of
exogenous ISG15 in HEK293 cells transfected with ISG15-GFP. Cells and EVs (EXO) were blotted for GFP and CD81. (e) Western blot analysis of ISG15-GFP
and GFP in 0.5% NP-40 soluble and insoluble cell fractions in HEK293 transfected with GFP or ISG15-GFP. Right graph: quantiﬁcation of GFP and ISG15-GFP
in the insoluble fraction respect to the soluble fraction in three independent experiments. (f) Western blot analysis of GFP and ISG15-GFP degradation
kinetics in HEK293 cells transfected with GFP or ISG15-GFP and treated with cycloheximide to inhibit protein synthesis during the indicated times. Where
speciﬁed, the medium was supplemented with the lysosome inhibitor Baﬁlomycin A1 (BAF) or the proteasome inhibitor MG132. A representative blot from
two independent experiments is shown. Data from c,e: t-test *P-valueo0.05 and ***P-valueo0.0001.
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overexpression or IFN-I decreases the secretion of exosomal
markers. Importantly, experiments with the non-conjugable
ISG15MUT and with primary cells from mice with defective
function of the speciﬁc ISG15 de-ISGylase USP18 demonstrated
that this effect is mediated by ISG15 conjugation to proteins and
not by free ISG15. ISGylation induction by ISG15 overexpression
induces a decrease in microparticle secretion, indicating that
ISGylation is not merely decreasing the sorting of certain
exosomal markers into ILVs but is actually decreasing exosome
secretion. However, ISGylation induction by IFN-I does not
induce a signiﬁcant decrease in the number of secreted
microparticles. This could be due to the induction of the
secretion of other types of EVs by IFN-I and this is in
agreement with previous reports showing that IFN-I can
promote the secretion of EVs loaded with antiviral components
that are transferred to other cells62. In fact, on ultracentrifugation
in sucrose gradients, the few EVs secreted by IFN-treated cells are
recovered in different fractions than the EVs from non-treated
cells, suggesting that they might have a different nature.
Alternatively, the absence of effect of IFN on global particle
secretion may indicate that only the EVs derived from MVBs are
affected.
We also show that ISGylation decreases the numbers of MVBs,
but does not prevent the formation of ILVs. The secretion of
exosomes is recovered when the fusion of MVB with lysosomes or
autophagosomes is inhibited, indicating that the observed
inhibition of exosome secretion is mainly mediated by the
induction of MVB degradation by the lysosome. In accordance,
we show that ISGylation promotes the aggregation and
degradation of proteins by the lysosome, and this is in agreement
with previous reports in which ISG15-linked proteins associated
with the proteins p62 and HDAC-6 involved in the autophagic
process52. We have observed that ISGylation decreases the
number of HRSþ structures without preventing the formation
of ILVs, possibly reﬂecting an accelerated degradation of
endosomes. In addition, ISGylation increases the co-localization
of the lysosome marker LAMP-1 with HRS, which is usually
absent from LAMP-1-positive structures44. Whether ISGylation
of MVB proteins induces the rapid fusion of MVB with lysosomes
in an earlier stage of maturation, or whether it directly impairs
HRS dissociation from endosomal membranes is not known.
A number of ISG15 target proteins are typically present in
exosomes and MVBs41, including several components of the
ESCRT complex such as TSG101, CHMP2A, CHMP4B and
CHMP6 (refs 40,63,64). It is therefore conceivable that ISG15 is
recruited to MVB by conjugating endosomal proteins. There, it
may promote protein aggregation and enhance MVB degradation
by the autophagosome–lysosome compartment, thus preventing
their fusion with the plasma membrane and the secretion of
exosomes (Fig. 6). We have validated the ISGylation of TSG101,
which has been previously shown to control the secretion of viral
particles40, and we show that TSG101 ISGylation is sufﬁcient to
impair exosome secretion. However, we cannot rule out the
possibility that other endosomal proteins are being ISGylated and
also contribute to the inhibition of exosome secretion induced by
ISG15. TSG101 depletion has been previously shown to inhibit
MVB formation65 or to modify the size of MVBs and/or the
number of ILVs48. However, there are signiﬁcant differences
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Figure 4 | Inhibition of lysosome function upon ISGylation induction rescues exosome secretion. (a) Western blot analysis of exosome secretion in
untransfected HEK293 cells and HEK293 cells co-transfected with plasmids encoding the ISGylation machinery and ISG15, and treated with Baﬁlomycin A1
(BAF), when indicated. Cells and EVs (Exo) were blotted for CD63 and CD81. Right graph: quantiﬁcation of exosomal protein levels in three independent
experiments. (b) Western blot analysis of exosome secretion in HEK293 cells transfected with GFP or co-transfected with plasmids encoding ISG15 and the
ISGylation machinery, and when indicated, with the Rab7T22N dominant-negative mutant. Cells and EVs were blotted for CD63 and CD81. Right graph:
quantiﬁcation of exosomal protein levels in three independent experiments. (c) Western blot analysis of exosome secretion in HEK293 cells transfected
with control small interfering RNAs (siRNAs) or siRNAs targeting ATG5. After 48 h, cells were re-transfected with siRNAs together with plasmids encoding
ISG15 and ISGylation machinery. Cells and EVs (Exo) were blotted for CD63 and CD81. Right: quantiﬁcation of exosomal protein levels in three or four
independent experiments. (d) Confocal analysis of LC3 localization into acidic compartments in HEK293 cells transfected with LC3-RFP-GFP tandem
plasmid and treated 16 h with IFN-I where indicated. Nuclei were stained with DAPI. Scale bar, 10mm. Images were processed by ImageJ and the number of
RFPþ and RFPþGFPþ dots quantiﬁed. Each dot represents the percentage of RFPþGFPþ dots per individual cell and mean is indicated in red lines; t-test;
***P-valueo0.001. Data a,b,c: analysis of variance; *P-valueo0.05, **P-valueo0.001 and ***P-valueo0.0001.
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between depletion and ISGylation of TSG101. ISG15 may be
directed to endosomes in a later stage of their maturation and
here modify MVB proteins such as TSG101, and promote their
aggregation and subsequent degradation by the lysosome without
impairing ILV biogenesis. However, we could not completely rule
out any effect of ISGylation on MVB biogenesis.
ISGylation has been previously shown to exert an antiviral
activity by blocking the exit of viral particles36,40,64,66. The
ISGylation of multiple MVB proteins and the consequent
inhibition of exosome secretion induced by IFN-I would
prevent the spreading of viruses that exploit the MVB
pathway for their way out the cell. In addition, exosomes play
important roles in cell-to-cell communication during the immune
response, tumour progression, neuron survival and many other
contexts1,3,4,67. Therefore, ISGylation induction by different
stimuli such as viral infection, IFN, ischaemia68 or ageing69 can
be an important mechanism to regulate exosome-mediated
communication in many different situations.
Methods
Cell culture. The human Jurkat-derived T-cell line J77cl20 (TCR Val. 2 Vb8) was
cultured in RPMI (Sigma) containing 10% fetal bovine serum (FBS; Invitrogen).
The HEK293T cell line was cultured in DMEM medium (Sigma) containing 10%
FBS (Invitrogen).
Mouse primary macrophages (BMDMs) were obtained from the bone marrow
of C57BL/6 WT, ISG15 knockout42 and USP18C61A mice33 (kindly provided by
K. Knobeloch, Freiburg University, Germany). Cells were cultured RPMI-1640
supplemented with macrophage colony-stimulating factor (30% mycoplasma-free
L929 cell supernatant, NCBI Biosample accession number SAMN00155972) for
6 days, to induce cell differentiation.
Mouse primary T lymphocytes were obtained from cell suspensions prepared
from spleens and peripheral lymph nodes of C57BL/6 WT, ISG15KO USP18C61A
mice. Cells were cultured for 36–48 h in RPMI with 2 mgml 1 concanavalin A
(Sigma) and subsequently 50Uml 1 human recombinant IL-2 (Glaxo) was added
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Figure 5 | ISG15 impairs exosome secretion by modifying TSG101. (a) Western blot analysis of TSG101 immunoprecipitation in HEK293 cells
non-transfected or HEK293 cells co-transfected with plasmids encoding the ISGylation machinery and functional (ISG15WT) or mutated ISG15
(ISG15MUT). Total lysates and V5 immunoprecipitates were blotted for TSG101. (b) Western blot analysis of 0.5% NP-40 soluble and insoluble fractions
from non-transfected HEK293 cells (Cont) or cells transfected with ISG15 and ISGylation machinery (ISG15). Soluble and insoluble fractions were blotted
for TSG101 and GAPDH. Right graph: quantiﬁcation of TSG101 protein levels in insoluble fractions in three independent experiments. (c) Western blot
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Cell lysates were blotted for GFP. Right graph: quantiﬁcation of ISG15-TSG101-GFP/TSG101-GFP ratio in three independent experiments. (d) Western blot
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blot is shown for F4. (e) Western blot analysis of ISG15-TSG101-GFP and TSG101-GFP degradation kinetics in HEK293 cells transfected with ISG15-TSG101-
GFP-GG and treated with cycloheximide during the indicated times. Cell lysates are blotted for GFP. (f) Western blot analysis of HEK293 cells transfected
with control small interfering RNAs (siRNAs) or siRNAs targeting TSG101. When indicated, cells were co-transfected with ISG15-TSG101-GFP-GG. Cells
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Lower graph: quantiﬁcation of exosomal protein levels in three independent experiments. (g) Western blot analysis of HEK293 cells transfected with
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Lower graph: quantiﬁcation of exosomal protein levels in three independent experiments. Data b,c: t-test; NS: P-value40.05 and *P-valueo0.05. Data f,g:
analysis of variance; NS: P-value40.05 and *P-valueo0.05.
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to the medium every 2 days for at least 4–6 days, to obtain differentiated
T lymphoblasts.
Exosome puriﬁcation. Cells were cultured in medium supplemented with 10%
exosome-depleted FBS (bovine exosomes were removed by overnight centrifuga-
tion at 100,000 g). Supernatant fractions were collected from 16 to 20 h cell culture
supernatants and exosomes were obtained by serial centrifugation as follows. Cells
were pelleted (320 g for 10min) and the supernatant was centrifuged at 2,000 g
for 15min, to discard debris and dead cells. The supernatant was collected and
ultracentrifuged at 10,000 g for 30min at 4 C (Beckman Coulter Optima L-100 XP,
Beckman Coulter) and exosomes were pelleted by ultracentrifugation at 100,000 g
for 70min at 4 C. The exosome pellet was washed in PBS and collected by
ultracentrifugation at 100,000 g for 70min (Beckman Coulter Optima L-100 XP,
Beckman Coulter).
Nanoparticle tracking analysis. Exosome numbers and size distribution were
determined by measuring the rate of Brownian motion using a NanoSight LM10
system, which is equipped with fast video capture and particle-tracking software
(NanoSight, Amesbury, UK). Samples were diluted before analysis to between
2 108 and 20 108 particles per ml, and the relative concentration was calculated
according to the dilution factor. Data analysis was performed with NTA 2.1
software (Nanosight). Samples were analysed using manual shutter and gain
adjustments, which resulted in shutter speeds of 15 or 30ms, with camera gains
between 280 and 560. The detection threshold was kept above 2; blur: auto;
minimum expected particle size: 50 nm.
ISGylation induction by overexpression. HEK293 cells were co-transfected
with plasmids encoding human E1, E2 and E3 ligases (kindly provided by
A. Garcı´a-Sastre, Mount Sinai Hospital, NYC) together with plasmids encoding
WT or C-terminal mutated human ISG15 fused to the V5 tag. When indicated,
cells were co-transfected with the appropriate small interfering RNAs or with the
EGFP-Rab7A T22N plasmid (gift from Qing Zhong, Addgene plasmid 28048).
Cells were transfected using Lipofectamine 2000 (Invitrogen). Twenty-four hours
after transfection, cells were cultured in exosome-depleted medium for 20 h and
exosomes were isolated from supernatants as described above. When indicated,
cells were incubated overnight in exosome-depleted medium containing 20 nM
Baﬁlomycin A1 (Merck).
Exosome extraction from blood serum. WT, ISG15KO and USP18C61A mice
were treated with 5 mg g 1 body weight poly (I:C) (InvivoGen) intraperitoneally.
Blood samples were extracted from the heart 24 h after poly (I:C) injection and
allowed to clot 3 h at room temperature. Blood samples were kept 2 h at 4 C and
serum was obtained by centrifugation at 400 g, 10min at 4 C. Cell debris were
removed by centrifugation at 3,000 g, 15min at 4 C and serum samples were
stored at  20 C. Exosomes were extracted from serum as previously described70;
brieﬂy, 125ml of Exoquick reagent were added to 250 ml of serum and incubated
overnight at 4 C. Samples were centrifuged at 1,500 g, 30min and exosome pellets
resuspended in RIPA buffer.
Gene silencing. HEK293 cells were transfected using Lipofectamine 2000
(Invitrogen) with the following small interfering RNAs: control (scrambled), ATG5
and TSG101 (SIGMA). Twenty-four hours after transfection, cells were cultured in
exosome-depleted medium for 20 h and exosomes were isolated from supernatants
as described above.
Western blotting. Cells or exosomes were lysed in RIPA buffer (50mM Tris-HCl
pH 8, 150mM NaCl, 1% Triton X-100, 0.1% sodium deoxycholate and 0.1% SDS)
containing a protease inhibitor cocktail (Complete, Roche). Proteins were separated
on 10% acrylamide/bisacrylamide gels and transferred to a nitrocellulose
membrane. Membranes were incubated with primary antibodies (1:1,000) and
peroxidase-conjugated secondary antibodies (1:5,000), and proteins were visualized
with LAS-3000. The following antibodies were used: rabbit anti-human ISG15
(Proteintech, 15981-1-AP), mouse anti-human CD63 (Calbiochem, OP171), mouse
5A6 anti-human CD81 (Santa Cruz, sc-23962), mouse anti-human TSG101
(Abcam, GTX70255), mouse anti-GFP (Living colors, 632381), rabbit anti-p62
(Sigma, P0067), mouse DM1A anti-tubulin (Sigma, F2168), rabbit anti-Calnexin
(Abcam, ab10286), goat anti-mouse peroxidase (Thermo Scientiﬁc), goat
anti-rabbit peroxidase (Thermo Scientiﬁc) and donkey anti-goat peroxidase
(Thermo Scientiﬁc). Full immunoblots are provided in Supplementary Fig. 6.
Fluorescence confocal microscopy. For immunoﬂuorescence assays, cells were
plated onto slides coated with ﬁbronectin (20 mgml 1), incubated for 16 hmin,
ﬁxed with 2% paraformaldehyde and stained with the indicated primary antibodies
(1:100) followed by secondary antibodies (1:500). When indicated, cells were
previously transfected with GFP-Rab5CA (Q79L) plasmid (gift from Sergio
Grinstein, Addgene plasmid 35140) or LC3-GFP-RFP tandem construct (gift from
Tamotsu Yoshimori, Addgene plasmid 21074). Samples were examined with a
Leica SP5 confocal microscope (Leica) ﬁtted with a  63 objective and images were
processed and assembled using Leica software. The following antibodies were used:
anti-CD63 (clone Tea 3/18, generated in the laboratory), anti-HRS (Abcam,
ab72053), anti-EE1A (Santa Cruz, sc-6415), anti-LAMP1-647 (BioLegend, 328612),
anti-p62 (Sigma, P0067), goat anti-mouse-488 and goat anti-rabbit-RX (Life
Technologies). Images were processed and quantiﬁed using LAS-AF and ImageJ.
Cloning. ISG15-GFP plasmids were generated by excision of ISG15 from the
pCAGG plasmid with XhoI and EcoICRI restriction enzymes, followed by insertion
between the XhoI and AfeI sites of pAcGFP-N1. ISG15 stop codons were mutated
using the QuickChange Site-Directed Mutagenesis kit (Agilent). ISG15-TSG101-
GFP was obtained by inserting TSG101 into ISG15-GFP plasmid with XhoI and
BamHI restriction enzymes. Non-de-ISGylable mutant ISG15-TSG101-GFP-AA
was obtained by mutated terminal glycines into alanines using the QuickChange
Site-Directed Mutagenesis kit (Agilent). Ubiquitin-GFP expressing plasmid was
obtained from Addgene (gift from Nico Dantuma, Addgene plasmid 11928).
Protein aggregation. HEK293 cells were transfected with GFP or ISG15-GFP
plasmids using Lipofectamine 2000 (Invitrogen) and 48 h later lysed in lysis buffer
(10mM Tris-HCl pH 8, 100mM NaCl, 1mM EDTA, 0.5% NP40 and 50mM
iodoacetamide) supplemented with protease inhibitor cocktail (Complete, Roche).
Cells were centrifuged for 5min a 13,000 g, and the supernatant (S1) and pellet (P1)
were saved. P1 was resuspended in lysis buffer containing 2% SDS, sonicated and
centrifuged at 16,000 g for 10min. The pellet (P2) was resupended in lysis buffer
containing 2% SDS and sonicated. S1 and P2 were loaded on a poly-acrylamide gel
and blotted for GFP. Subcellular fractionation was performed with ProteoExctarct
Subcellular Proteome Extraction kit (Calbiochem).
Protein degradation. HEK293 cells were cultured in six-well-plates and
transfected with GFP or ISG15-GFP using Lipofectamine 2000 (Invitrogen).
Cells were treated with 40 mgml 1 cycloheximide (Sigma) to inhibit protein
synthesis and were lysed at the indicated time points. When indicated, the medium
contained 20 nM Baﬁlomycin A1 (Merk) or 40 mM MG132 (Sigma).
Immunoprecipitation. 1 107 HEK293 cells per condition were lysed (25mM
Tris pH 8, 150mM NaCl, 2mM MgCl2, 0.5% NP-40 and protease inhibitors) and
incubated for pre-clearing with pre-washed Protein G Dynabeads (Invitrogen; 50 ml
per condition; 1 h, 4 C). Fifty microlitres of Dynabeads per condition were washed
twice in 0.01% Tween PBS and resuspended in 200ml of 0.01% Tween PBS
containing 5 mg mouse anti-V5 antibody (Life Technologies) per condition and
incubated 1 h at 4 C. Pre-cleared lysates were incubated with antibody-conjugated
Dynabeads (1.5 h, 4 C). Antibody-conjugated Dynabeads were washed six times
with lysis buffer and transferred to clean tubes. Protein loading buffer was added,
samples were boiled at 95 C for 5min and processed for immunoblotting.
Electron microscopy and MVB quantiﬁcation. Cells cultured on dishes were
washed in PBS and ﬁxed for 1 h in 2.5% glutaraldehyde in 0.1M phosphate buffer
at room temperature. Then, cells were slowly and gently scrapped and pelleted in
eppendorf tubes. Pellets were washed in phosphate buffer and incubated with 1%
TSG101 TSG101
ISG15
IFN-I
ISG15-ISGylation
MVBs Autophagosome
Exosomes
Lysosome
Figure 6 | Proposed model for the role of ISGylation in the regulation
of exosome secretion. IFN-I induces ISG15 expression and conjugation
to MVB proteins such as TSG101. ISGylation of MVB proteins promotes
MVB fusion with lysosomes and degradation, thus inhibiting exosome
secretion.
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OsO4 for 90min at 4 C. Then, samples were dehydrated, embedded in Spurr and
sectioned using Leica ultramicrotome (Leica Microsystems). Ultrathin sections
(50–70 nm) were stained with 2% uranyl acetate for 10min and with a
lead-staining solution for 5min and observed using a transmission electron
microscope, JEOL JEM-1010 ﬁtted with a Gatan Orius SC1000 (model 832) digital
camera.
For the calibration of images, quantiﬁcation and analysis ImageJ was used.
MVBs were identiﬁed and counted by morphology, having only discrete ILVs.
Lysosomes contain multilamellar proﬁles. At least 20 MVBs were analysed per
experiment from separate cells. Data were analysed from duplicate or triplicate
separate experiments and two to four grids were used for each condition. The
minimum number of cells scored for each condition was 20. Box scatter plots were
generated using Prism GraphPad software and statistical tests were performed in
Microsoft Excel. Data are means±s.d. and ***P-valueo0.0001.
Data availability. The data that support the conclusions of this study are available
from the corresponding author upon request.
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Introduction
Extracellular vesicles
Extracellular vesicles (EVs) are 50–300 nm-sized nanovesi-
cles secreted to the extracellular milieu by a vast variety 
of cell types to promote inter-cellular communication on 
cells that capture them. Such vesicle exchange is involved 
in many physio-pathological situations such as tumour pro-
gression, metastasis, immunomodulation and the spread-
ing of infections [1]. EVs have a heterogeneous nature, 
thus they are classified according to their origin into three 
groups: exosomes, shedding vesicles and apoptotic bod-
ies [2]. Exosomes are of endosomal origin. Cells release 
them by fusing multivesicular bodies (MVBs)-containing 
intraluminal vesicles (ILVs) with the plasma membrane. 
Shedding vesicles form directly at the plasma membrane. 
Finally, apoptotic bodies are vesicles that result from apop-
tosis and contain cellular waste [3, 4]. EVs are membrane-
covered vesicles that contain proteins, nucleic acids (DNA, 
mRNA and miRNAs), lipids and metabolites [5]. Proteins 
that are enriched in exosomes include tetraspanins (CD9, 
CD63, CD81), cytoskeleton components (Syntenin, Drebrin, 
ERMs), Endosomal Sorting Complexes Required for Trans-
port (ESCRT complex) (TSG101, ALIX), Heat-Shock pro-
teins (HSP70 and 90), Annexins, Rab proteins, among others 
[6]. Exosome membranes are also different from the mem-
brane of their producer cells, mainly enriched in ceramide, 
sphingolipids, glycerophospholipids and cholesterol [7, 8].
Almost every cell, prokaryotic and eukaryotic, can 
secrete EVs. These particles appear in many fluids, includ-
ing urine, amniotic fluid, blood, bile, semen, cerebrospinal 
fluid, breast milk, ascites and cell cultures (reviewed in 
[2]). Moreover, EVs contain specific external and inter-
nal markers, which vary depending on their origin. For 
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instance, CD24 is a marker for urine and amniotic fluid 
exosomes [9]. In addition, a single cell type can simultane-
ously secrete different populations of exosomes [10, 11]. 
For example, polarized cells can deliver different popula-
tions of exosomes through the apical and basolateral poles 
[12].
Regarding cargo sorting, EVs receive cargoes through 
both ESCRT-dependent and independent mechanisms [13, 
14]. The existence of heterogeneous MVBs populations 
becomes apparent when different components of endo-
somal trafficking or the ESCRT pathway are silenced or 
overexpressed, and when exosomal secretion is disturbed 
and not all exosomal markers are affected to the same 
extent [10, 15]. This enables distinguishing between global 
markers, e.g. TSG101, ALIX or HSP70; and cell-specific 
markers, e.g. class II Major Histocompatibility Complex 
(MHC-II) [3]. EV cargo also evolves with global changes 
to the whole cells. For example, oxidative stress modu-
lates MVB biogenesis, endocytosis and consequently EVs 
composition [12].
Post‑translational modifications
Post-translational modifications (PTMs) include a collection 
of add-ons that provide variability to a defined set of pro-
teins that all cells use to enable most biological processes, 
adapting the functionality of those proteins by varying 
their interactive capability, resistance to degradation, etc. 
In this sense, PTMs exponentially increase the level of the 
proteome complexity [16]. These add-ons are molecules of 
diverse nature that attach to specific amino acids. Multiple 
amino acids can receive varied PTMs. The types of added 
molecule include chemical groups, carbohydrates, lipids, 
aminoacids, proteins and nucleotides. This process is con-
trolled by specialized enzymes responsible for the addition 
or removal of each modification [17]. PTMs and their regu-
lation constitute a cellular communication code to respond 
in a fast, versatile and accurate mode. The fulcrum of this 
review is that PTMs can direct exosome loading. Exosomes 
do not mirror the protein composition of their parental cells, 
and some proteins appear enriched in exosomes by selective 
mechanisms of protein cargo sorting controlled by specific 
PTMs [18]. The main PTMs are summarized in Table 1. 
These include addition of chemical groups (phosphorylation, 
acetylation, methylation, oxidation, hydroxylation, S-nitros-
ylation, sulfation or sulfonation, and others), carbohydrates 
[N-glycosylation, O-glycosylation, glycosylphosphati-
dylinositol (GPI)-anchoring], lipids (myristoylation, palmi-
toylation, prenylation) and nucleotides (ADP-rybosylation, 
PARylation). To make this large problem tractable, we focus 
in Ubiquitin and Ubiquitin-like modifiers (UBLs) as major 
controllers of EV protein loading.
Ubiquitination and Ubiquitin‑like modifiers (UBLs)
This group of PTMs represents one of the most important 
regulatory systems of protein location, stability and func-
tion. The C-terminal (C-t) Gly of ubiquitin and most UBLs 
attaches covalently mainly to the ε-amino group of a Lys 
(K) residue of the substrate protein, forming an isopeptide 
bond. The conjugation of ubiquitin and UBLs requires the 
consecutive action of three specific enzymes: Ubl-activating 
enzymes (E1s), Ubl-conjugating enzymes (E2s) and Ubl-
protein ligases (E3s). Specific proteases reverse this process, 
removing ubiquitin from target proteins [19, 20]. Ubiquitin 
is a highly conserved, small protein of 8.5 kDa involved 
in diverse functions, such as protein degradation, endocytic 
trafficking, signal transduction and DNA repair, among oth-
ers. Mono-ubiquitination is the modification of a specific 
Lys in a target protein. The same protein can bear multiple 
mono-ubiquitinated residues simultaneously. Besides, the 
ubiquitin protein itself contains seven Lys (K6, 11, 27, 29, 
33, 48 and 63) in its sequence. These Lys can bind to other 
molecules of ubiquitin, generating seven types of polymeric 
ubiquitin chains, constituting the so called “ubiquitin code”. 
Moreover, M1 chains are polymeric chains formed by ubiq-
uitin N-terminal (N-t) Met. All these chains vary in length, 
ranging from two to more than ten residues. They can be 
homotypic if the same residue is modified during elongation 
as in M1, K11, 48 or 63-linked chains, or heterotypic if the 
same chain displays different linkages [21, 22]. Moreover, 
a single ubiquitin can be modified with multiple chains or 
UBLs (NEDD8, SUMO, ISG15), generating branched chains 
or mixed chains, respectively. Finally, ubiquitin can be acety-
lated or phosphorylated [21–25]. K48-linked ubiquitin was 
the first described poly-ubiquitin chain related to degrada-
tion [21, 26]. On the other hand, K63-linked chains relate to 
many biological processes, and K63-modified proteins play 
important roles in diverse cellular signalling pathways, e.g. 
Toll-like receptor (TLR) cascade and endosomal transport 
[21, 27–30]. However, the specific functions of other mixed, 
branched or heterogeneous chains remain almost unknown 
[28] (Table 1). The consensus is that proteins modified with 
K29 and K48-linked chains are proteasome-bound for deg-
radation. Nevertheless, M1, K6, K11, K27 and K63 chains 
and mono-ubiquitination regulate different cellular processes 
such as DNA repair, translation, inflammation and endocytic 
trafficking [21, 27–33] (Table 1).
UBLs share many features with ubiquitin, including 
their sequence and three-dimensional structure, which is a 
compact β-grasp fold. The main members of this group are 
SUMO1, SUMO2-3, SUMO4, ISG15, NEDD8, ATG12, 
FAT10, MNSFβ, UFM1, URM and UBL5 (reviewed in 
[34–38]). Neural precursor cells-Expressed Developmentally 
Down-regulated protein 8 (NEDD8) is the closest UBL to 
ubiquitin. NEDD8 mainly modifies proteins from the Cullin 
3Post-translational add-ons mark the path in exosomal protein sorting 
1 3
Table 1  Post-translational modifications of proteins
Group Subgroup Molecule (donor)
Protein
residues
Average
mass (Da) Structure Adding Enzyme // Cleaving Enzyme Ref
puorglaci
mehC
Phosphorylaon Phosphate
(γ-phosphate ATP)
Ser/Thr     Tyr    
His   Asp, Arg*,Lys*
94.973 Kinases (phosphotransferases)//
Phosphatases
[155]
Acetylaon Acetate
(Acetyl coenzyme A)
Lys(1,2)
N-t(1,2)
43.045 Acetyl-trasferases (ATs)//
Desacetylases (DACs)
[156,157]
N- Methylaon Methyl group
(S-adenosylmethionine, SAM)
Arg        Lys 15.035 Methyltransferases // Demethylases [158-160]
Oxidaon Reacve Oxygen species (ROS) [161]
Oxidaon Anion superoxide Cys      Met 16.000 - // Superoxide dismutases [161]
Hydroxylaon Hydroxyl group Pro      Asn
Lys       
17.007 Iron-containing monooxygenases  // Pro-
hydroxylase and oxygenases
[162]
Reacve Nitrogen species (RNS) [161]
Tyr-Nitraon Nitro group (NO2)
(Peroxynitrites)
Tyr 46.006 - // Denitrase [163]
S-Nitrosylaon Nitric oxide (NO) Cys(1,2) Met 30.006 Nytrosylases // Denitrosylases, S-
Nitroglutathione reductase (GSNOR)
[164]
Other oxidave compound: hydrogen peroxide (peroxidaon) and nitrate. [161]
Sulfaon Sulphate 
(Phosphoadenosyl-
phosphosulfate)
Tyr 96.064 Tyrosylprotein sulfotransferases // Sulfatase [165]
Amidaon Amide C-tA 16.023 Pepdylglysine α-amid monooxygenase (PAM) [166]
Formylaon Formate Met         Lys 28.010 Methionyl-tRNAMet transformylase [167,168]
Succinylaon Succinate
(Succinyl-coenzyme A)
Lys 116.073 - // Sirtuin 5 [169]
Malonylaon Malonate
(Manolyl-coenzyme A)
Lys 102.047 - // Sirtuin 5 [170]
setardyhobraC
N-Glycosylaon Monosaccharides
(dolilchol pyrophosphate 
or lipid-linked 
oligosaccharide, LLO)
Asn (NxT/S)
liuliul
Olygosaccaryl transferases (OST), glucosyl
transferases // glucosidases I and II, 
mannosidases
[171-174]
O-Glycosylaon Monosaccharides
(GlcNAc, GalNAc, fucose, 
glucose, mannose,…)
Ser             Thr
Trp# Tyr*
~ 200
GlcNAc
O-(monosaccharide)-transferase // Hydrolases [171,172,
174,175]
Others: C-mannossylaon and glypiaon
GPI Glycosyl phosphadyl-
inositol
C-t(1)
ujok
GPI transamidase // Phosphoinositol-specific 
phospholipase C
[176-178]
Li
pi
ds
S-Palmitoylaon Palmic acid
(palmitoyl coenzyme A)
Cys
Ser       Thr
256.424 Palmitoyl acyl transferases (PATs) // 
Thioesterases
[179-181]
N-Myristoylaon Myrisc acid
(myristoyl coenzyme A)
N-t Gly 228.371 N-myristoyltransferase (NMT) [179-181]
S-Prenylaon
Farnesylaon Farnesyl
(Farnesylpyrophosphate)
CysB  (CaaX box) 222.366 Proteinfarnesyl transferase (FT) [181,182]
Geranylgeranylaon Geranylgeranyl
(Geranylgeranyl-pyroP)
290.483 Proteingeranyl-geranyl transferases (GGT I and 
II)
[181,182]
snietorP
Aminoacids
Polyglutamylaon Glutamate (up to 20) Internal Glu > 147.13 Tubulin-tyrosine ligase-like (TTLL) protein family 
// Deglutamylase  
[183]
Polyglycylaon Glycine (up to 34) Glu  > 75.067 Glycylase // Deglycylase [184,185]
Other: Citrullinaon (conversion of Arg to citrulline by PAD enzyme) [186,187]
Ubiquinaon
PDB: 1UBQ
MonoUb Ubiquin Lys          N-t 
Thr#, Cys#, Ser#
8565 E1 acvang enzyme,
E2 conjugang enzyme, 
E3 ligase 
E4//
Deubiquinases
[21,22,14
7]
M1/K63 PolyUB Chain: C-t bond with N-t Met, Lys63 > 8565 [88,147]
K6/K29/K33 PolyUB Chain: C-t bond with Lys6/Lys29/
Lys33
> 8565
K11/K27/K48 PolyUB Chain: C-t bond with Lys11/Lys27/ 
Lys48 
> 8565
Ubiquin-like proteins (UBLs) [34-38]
SUMOylaon SUMO1 Lys 11557 PDB: 1WM3 
(SUMO-2) E1 (SAE), E2 (Ubc9), E3 // 
DeSUMOylases (SENP)
[188]
SUMO 2-3 10871
ISGylaon ISG15 17888
PDB: 1Z2M
E1 (UbE1L), E2 (UbCH8), E3 // DeISGylase
(USP18)
[189]
Neddylaon NEDD8 9072
PDB: 1NDD
E1 (NAE), E2 (UbCH12), E3 // Isopepdase
[40,41]
Others UBLs: ATG12, FAT10, MNSFβ, UFM1, URM, UBL5, SUMO4 [34-38]
Modifica on of  Ub:   Phospho-Ub  and Acetyl-Ub                                     Polyubiqui n chains:        Branched chains    PolyUb mixed chains (modified by SUMO, NEDD8, ISG15) [21-25]
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(NAD+)
Tyr        Asn      Lys
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559.316 ADP-rybosyltransferases (ARTs) // ADP-
ribosylhydrolases
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Poly (PARylaon) Glu      Asp Poly(ADP-ribose)polymerases (PARPs) // 
Poly (ADP-ribose) glycohydrolase (PARG)
[191]
* Found in prokaryotes                                 A Almost followed by a proline                                             (1) Reversible
#   Rare    B Cys - 5 aminoacids from the C-terminus                          (2) Irreversible
Nucleophile or electrophile site          
Structures obtained from ChemSpider Search and share chemistry (Royal Society of Chemistry) and Protein Data Bank (PDB)
≥ 2372.1
~ 1900
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RING Ligases (CRLs) superfamily. RING E3 Ligases trans-
fer ubiquitin directly from E2 enzymes to the substrate pro-
tein forming a complex scaffolding by Cullin. CRLs play 
an important role in protein ubiquitination for proteasomal 
degradation under the control of NEDD8 [39, 40]. NEDD8 
also forms chains through one of its six Lys [41]. Small 
ubiquitin-related modifier (SUMO) is an UBL involved in 
nuclear transport and organization, DNA repair, transcrip-
tion, chromatin remodelling and ribosome biogenesis. It is 
an essential modification to maintain cell homeostasis in 
stress responses and has become relevant in many diseases 
[42]. Interferon-stimulated gene 15 (ISG15) is induced by 
type I interferons (IFN-I), exposure to bacterial lipopoly-
saccharide (LPS), viral double-stranded RNA (dsRNA), 
ischemia and aging [43]. It is an essential part of the innate 
immune response to fight against bacterial and virus infec-
tions [44]. Besides, ISG15 is also overrepresented in various 
types of tumours [45]. Interestingly, ISG15 can also function 
as a free unconjugated form with an immunomodulatory 
role [46].
Exploring the sorting of modified proteins 
into EVs
Sorting mechanisms to MVBs
Exosomes originate in the endocytic pathway, whereas shed-
ding vesicles form from direct budding of plasma membrane. 
Therefore, the mechanisms involved in protein secretion are 
different [18]. Here, we will discuss how PTMs could be 
involved in the sorting of proteins into EVs.
ESCRT‑dependent and independent sorting mechanisms 
into ILVs
Presently, mechanisms of protein incorporation into the ILVs 
of MVBs for exosomal secretion or lysosomal degradation 
remain unclear. One key part of the machinery that con-
trols the incorporation of ubiquitinated proteins into ILVs 
is the ESCRT complex [47, 48]. This complex includes four 
sub-complexes that sequentially recognize protein cargos 
and include them into ILVs. ESCRT-0 comprises HRS and 
STAM1/2 subunits, which are proteins with several distinct 
ubiquitin-binding domains (UBDs) that form a cargo-rec-
ognition module. HRS recognizes ubiquitinated proteins 
through a FYVE domain necessary to interact with phos-
phatidyl inositol 3-phosphate (PI3-P) molecules of endoso-
mal membranes. HRS also displays PSAP domains that con-
nect with the ESCRT-I subunit TSG101, which also binds 
ubiquitinated proteins. Moreover, the PSAP domains of 
small integral membrane protein of the lysosome/late endo-
some (SIMPLE) also bind TSG101. SIMPLE has a PPxY 
motif that interacts with NEDD4 to be ubiquitinated, and 
di-Leu and YKRL motives, which are signatures of endo-
cytic functions [14, 49]. Mutations in these motifs impair 
the secretion of SIMPLE to exosomes, altering MVBs bio-
genesis [49]. Moreover, Hrs conditional knock-out (KO) in 
dendritic cells (DC) significantly reduces exosome release, 
pointing to an important role for ESCRT components in exo-
some secretion [50].
Deubiquitination is mandatory prior to packaging cargo 
into ILVs. To remove ubiquitin, ESCRT-III recruits deu-
biquitinating enzymes. ESCRT-III subunits CHMP2 A, B, 
CHMP3, CHMP4 A, B, C and CHMP6 bind to lipid mem-
branes through their positively charged N-t domains, allow-
ing high order oligomerization that results in structures over 
600 kDa. Yeast ESCRT-III Snf7 (CHMP4 in humans), is 
not only implicated in neck-shaped oligomeric assembly 
for vesicle budding, but also in its scission. In this regard, 
the necessary energy to dissociate budding vesicles from 
membrane is provided by the ATPase activity of the Vacu-
olar protein 4 (VPS4) Complex (SKD1, CHMP5, LIP5) 
(reviewed in [47, 48]).
Ubiquitination of cargo proteins is necessary for rec-
ognition by ESCRT-0 components, whereas deubiquitina-
tion is a crucial step for sorting them into ILVs. However, 
whether ubiquitination is mandatory for driving proteins into 
exosomes is currently controversial. The sorting of some 
proteins seems independent of ubiquitination, e.g. MHCII 
loading into DC exosomes after T cell activation, which is 
associated to tetraspanin-enriched microdomains (TEMs) 
formed by CD9 [13, 51]. Furthermore, CD81 is important 
for the sorting of its associated proteins into exosomes [42]. 
Other studies support that the ubiquitination drives MHCII-
containing MVBs to degradation upon fusion with the lyso-
somal system [52] (Fig. 1).
In addition, ESCRT components can be ubiquitinated 
themselves, for example HRS. HRS mono-ubiquitination 
prevents binding of ubiquitinated cargo, regulating the 
flow of specific proteins into MVBs [47]. The E3 ubiquitin 
ligase implicated in ubiquitin turnover can thus control the 
destiny of MVBs. For example, the activity of Mahogunin 
on TSG101 disrupts MVB lysosomal trafficking, whereas 
another E3 ubiquitin ligase called Tal abrogates MVB bio-
genesis [53, 54]. Associated molecule with the SH3 domain 
of STAM (AMSH) ubiquitin isopeptidase and ubiquitin iso-
peptidase Y (UBPY) removes mono-ubiquitin from HRS to 
recycle ESCRT components, preventing their degradation. 
Moreover, AMSH deubiquitinates cargoes modified with 
K63-linked chains, whereas UBPY recognizes both K63 and 
K48-linked chains. The action of these enzymes indicated 
a deubiquitination step that is required to sort cargoes into 
ILVs, and hence, into exosomes [55, 56].
However, mono and poly-ubiquitinated proteins can 
be found in exosomes, but not associated to the exosomal 
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membrane [57]. Cargo deubiquitination before its packag-
ing into ILVs seems essential, but how some ubiquitinated 
proteins end up in exosomes remains controversial. These 
contradictory results suggest that ubiquitinated proteins can 
evade deubiquitination; or finish up in exosomes through 
ESCRT-independent mechanisms. Such mechanisms do 
exist. In these, sorting depends on tetraspanins, sphingolip-
ids and ceramide [58–60]. For example, LYPX(n)L motifs in 
the protein ALIX are implicated in its interaction with CD63 
tetraspanin, and together with transmembrane proteins syn-
decans and syntenin induce budding and membrane abscis-
sion of ILVs [61]. In fact, an extensive study of ESCRT com-
ponents downregulation revealed that of 23 ESCRT proteins 
studied, not all of them interfered with exosome secretion in 
the same way [11]. When HRS, TSG101, VPS22 and VPS24 
are simultaneously silenced, MVBs are still produced and 
only the formation of Epidermal Growth Factor (EGF)+-
MVBs is affected, highlighting a possible mechanism of 
substrate selectivity [62]. Proteolipid (PLP)+-exosomes 
localize together with flotillin and GPI in endosomal com-
partments, but not with HRS. These vesicles were enriched 
in cholesterol and ceramide, and their secretion depended 
on ceramide production by the activity of sphingomyelinase 
2 (nSMase2) [63]. The enzyme sphingomyelin synthase 
SMS2 regulates the secretion of amyloid-β (Aβ)-peptide+-
exosomes. In addition, the transfer of  CD63+-exosomes 
from T cells to APCs during immune synapse is ceramide-
dependent [59, 60]. This is likely related to the fact that 
ceramide creates spontaneous curvature of endosomal 
membranes, triggering ILVs budding. Besides, other lipids 
metabolites such as sphingosine-1-phosphate (S1P), dia-
cylglycerol (DAG), cholesterol, phosphatidyl choline, or 
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Fig. 1  Schematic representation of some PTMs found in EVs. Endo-
cytosis of plasma membrane receptors (MHC-II, LMP2A and EGFR) 
transfer them into the endocytic pathway. Depending on the added 
PTMs, these receptors can have different fates. Ubiquitinated-MHC-II 
is preferentially directed to degradative MVBs for degradation in lys-
osomes, whereas, Ub-LMP2A and ph-EGFR are usually incorporated 
into ILVs of exocytic MVBs, which are fused with plasma mem-
brane to be secreted as EVs [52, 77, 116]. In the case of acetylated-
GRP78 and ISGylated-TSG101, these PTMs act as cellular retention 
tags, promoting their degradation in lysosomes [128, 129]. However, 
Ub-HSP70, SUMOylated-hnRNPA2B1, SUMOylated-α-synuclein, 
ph-AKT, oxidized and phosphorylated γ-synuclein and citrullinated 
vimentin are loaded into ILVs and driven to EVs [80, 104, 106, 108, 
118, 154]. Besides, unmodified TSG101 and GRP78 proteins can also 
be present in EVs [128, 129]. Figure key is shown at the right side. 
The images in the figures are not scaled
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lysobisphosphatidic acid (LBPA) are involved in the MVB 
biogenesis and exosome secretion, although how protein 
cargoes are selectively transported into this kind of vesicles 
remains unknown [64–71].
Ubiquitinated proteins in EVs
Ubiquitin was first observed in human urine exosomes 
showing a wide range of molecular weight complexes by 
Western blot, which suggested the presence of ubiquitinated 
proteins in exosomes [72]. Specific antibodies for ubiquitin 
and poly-ubiquitin chains allowed to identify mono-, oligo- 
and poly-ubiquitinated proteins in exosomes [57]. Various 
studies and proteomic analysis identified specific ubiquit-
inated proteins (reviewed in [73]) (Table 2 and Fig. 1). For 
example, myeloid-derived suppressor cells (MDSC) secrete 
exosomes enriched in ubiquitinated proteins, including 
endosomal trafficking proteins and histones [74]. Moreover, 
high molecular weight complexes of non-classical human 
leukocyte antigen-G (HLA-G) are ubiquitinated, but not 
glycosylated, in exosomes obtained from ascitic and pleural 
exudates of patients [75]. Shedding vesicles also contain 
modified proteins such as arrestin domain-containing protein 
1 (ARRDC1), which is ubiquitinated by the E3 ubiquitin 
ligase WW domain-containing protein 2 (WWP2). An arres-
tin domain in ARRDC1 anchors it to the plasma membrane, 
enabling its interaction with the PSAP domain of TSG101 
to generate direct membrane budding [76]. In the case of 
ubiquitinated Epstein–Bar virus latent membrane protein 2A 
(LMP2A), exosome sorting depends on cholesterol, whereas 
the phosphorylated form was not detected in exosomes [77] 
(Table 2 and Fig. 1).
Phosphatase and tensin homolog deleted on chromosome 
10 (PTEN) is ubiquitinated on Lys13 by the association and 
regulation of Nedd4 family-interacting protein 1 (Ndfip1), 
an adaptor protein of the Nedd4 family E3 ubiquitin ligases, 
appearing in this form in exosomes, although modified-
Ndfip1 does not. However, its presence is necessary for the 
import of Nedd4, Nedd4-2 and ITCH to exosomes [14, 78]. 
Alanine replacement on di-Leu (LL) and YKRL motifs of 
SIMPLE reduces it secretion into exosomes, as well as a 
mutation on its PTAP motif, which controls SIMPLE bind-
ing to TSG101 for incorporation into ILVs. However, point 
mutations of the two PPxY motifs of SIMPLE, a binding 
domain for Nedd4 type E3 ubiquitin ligases, such as Nedd4 
and ITCH, increase exosomal incorporation; hence SIM-
PLE ubiquitination does not direct its own sorting [49]. In 
other cases, such as Fas Ligand (FasL), ubiquitination of 
the proline-rich domain (PRD)-flanking Lys and phospho-
rylation of multiple tyrosines promote its internalization in 
MVBs and its secretion into EVs [79]. The COP9 signalo-
some (CSN)-associated protein CSN5 mediates ubiquitin 
isopeptidase activity. Deletion of its JAB1/MPN/Mov34 
metalloenzyme (JAMM) domain increases the sorting of 
ubiquitinated HSP70 and HIV Gag proteins into exosomes; 
whereas a mutation of its associated deubiquitin activity 
domain promotes the enrichment of non-modified proteins in 
EVs [80]. These results highlight that CSN5 participates in 
ubiquitin-dependent and independent protein vectorization 
into exosomes [80] (Table 2). MARCH1, an E3 ubiquitin 
ligase for MHCII and CD86, is incorporated into exosomes 
dependent on its C-t tyrosin-based motifs [81]. This endo-
some sorting motif is also important for sorting of transfer-
rin receptor into exosomes due to its interaction with ALIX 
[82]. Nevertheless, whether MARCH1 is ubiquitinated or 
not in exosomes remains unclear, although this region is 
important for MARCH1 auto-ubiquitination [83].
Human urine exosomes contain approximately 15% of 
ubiquitinated proteins. Of these, 21% are transmembrane 
proteins, underscoring that deubiquitination is not manda-
tory for the incorporation of protein cargo into MVBs and 
exosomes [84]. Although, ubiquitination-specific motifs 
remain unidentified, this PTM has preference for basic 
Table 2  Post-translational modified proteins found in EVs
Target protein PTM Residue References 
CryAB Phosphorylaon Ser-59/Ser-45 [112] 
Tau Phosphorylaon Hyperphosphorylated Tau [110] 
 Phosphorylaon Thr-181/Ser-396 [117] 
 Phosphorylaon - [113] 
EGFR Phosphorylaon Tyr-1068 [116] 
IRS-1 Phosphorylaon Ser-312 and Pan-Tyr [111] 
PDK1* Phosphorylaon Ser-241 [108] 
AKT* Phosphorylaon Thr-308 [108] 
SRC* Phosphorylaon Tyr-416 [108] 
ELK1 * Phosphorylaon Ser-383 [108] 
ERK 1/2* Phosphorylaon Thr-202/Tyr-204 [108] 
AMPKα1 * Phosphorylaon Ser-485 [108] 
Acetyl-CoA carboxylase* Phosphorylaon Ser-79 [108] 
NCC Phosphorylaon Thr-46, Thr-50 and Thr-55 [114] 
Aquaporin 2* Phosphorylaon Ser-256 [101] 
GPRC5C* Phosphorylaon Thr-435/Ser-395/Tyr-426 [101] 
CHMP2B* Phosphorylaon Ser-199 [101] 
Fas Ligand  Phosphorylaon Tyr-7/Tyr-9/Tyr-13 [79] 
 Ubiquinaon   Mono- [79] 
Annexin A2 Phosphorylaon Tyr-23 [109] 
γ-synuclein Phosphorylaon - [118] 
 Oxidaon Met-38/Tyr-39 [118] 
TyA* Myristoylaon  MGCINSKRKD N-t tag [124] 
CD55  GPI-anchor - [125] 
Vimenn* Citrullinaon - [154] 
LGALS3BP$ Glycosylaon  - [120] 
Histone H1.2* Ubiquinaon - [74] 
HLA-G complex Ubiquinaon  - [75] 
ARRDC1 Ubiquinaon - [76] 
LMP2A Ubiquinaon - [77] 
PTEN Ubiquinaon  Lys-13 [78] 
HSP70 Ubiquinaon - [80] 
SIMPLE Ubiquinaon - [49] 
Aquaporin-1* Ubiquinaon Mono- and Poly- [84] 
Annexin A1* Ubiquinaon Poly- [84] 
Plasn-3 isoform 1* Ubiquinaon Mulmono- at Lys-11 and 
Lys-18 
[84] 
HspX# Ubiquinaon - [136] 
GroES# Ubiquinaon - [136] 
GFP Ubiquinaon Ubiquin C-t tag [137] 
ATG85B- ESAT6 Ubiquinaon Ubiquin C-t tag [137] 
nHer2 Ubiquinaon Ubiquin C-t tag [137] 
GFP SUMOylaon SUMO-1/SUMO-2 C-t tag [106] 
hnRNPA2B1 SUMOylaon  - [104] 
α-synuclein  SUMOylaon  - [106] 
* More proteins idenfied in a high-throughput screening approach, proteomics [74,84,101,108,120].   
# Mycobacterial proteins detected in exosomes from human and mouse cell lines.  
$ More glycosylated proteins idenfied by lecn blong, NP-HPLC analysis and mass spectrometry [120].  
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amino acids and positively charged residues upstream of the 
ubiquitination site, hydrophobic residues adjacent to it and 
additional Lys 6 amino acids upstream [84]. Besides, poly-
ubiquitin chains appear following this order of enrichment: 
K63 > K48 > K11 > K6 > K29 > K33 > K27. This shows 
that K63, K48 and K11-linked chains are the most repre-
sentative poly-ubiquitin topologies in exosomes [84]. Fur-
thermore, platelet exosomes contain poly-ubiquitin chains 
and in higher numbers compared to platelets microparticles 
[85] (Table 2).
Deciphering the ubiquitin code in EVs
The ubiquitin code comprises the combination of mono-, 
poly- and branched-ubiquitin chains and even other PTMs, 
which allow a wide range of possibilities for the regulation 
of proteins. K48-linked chains require at least four ubiquitin 
units to attach to the target protein to enable recognition by 
the 26S proteasome [86, 87]. In particular, the proteasome 
subunit S5a/Rpn10 contains an ubiquitin-interacting motif 
(UIM) in the hydrophobic patch of its C-t region, which ena-
bles recognition of this specific poly-ubiquitin chain. Inside 
the proteasome, ubiquitin molecules are removed from target 
proteins for recycling, whereas the rest of the proteins are 
cleaved into small peptides (3–25 amino acids of length). 
There is some evidence suggesting that other chains, e.g. 
M1, K6, K11, K27 and K29 could be involved in proteaso-
mal degradation of target proteins [21, 30, 33, 86]. More-
over, a new conjugation factor, named E4, participates in 
the generation of efficient poly-ubiquitinated-linked chains 
under stress conditions to direct modified proteins to the 
proteasome, demonstrating the existence of an E4-dependent 
multi-ubiquitination pathway for degradation [88] (Fig. 2). 
K63-linked chains do not end up in the proteasome as they 
bind specifically to the ESCRT-0 complex, specifically to 
UIMs found in HRS and STAM1 components [27, 89]. 
These interactions condense proteins modified with K63-
linked poly-ubiquitin chains into endosomes, promoting 
their import into ILVs of MVBs and possibly, their subse-
quent delivery into exosomes [90]. In fact, K63-linked chain 
is the most representative ubiquitin topology found in EVs 
[84] (Fig. 2).
How ubiquitin-binding proteins detect unequivocally a 
specific conformation of poly-ubiquitin chains may explain 
the selective targeting of a given protein within the cell. For 
example, M1 and K63-linked chains display a fairly linear or 
open space conformation, whereas K6, K11, and K48-linked 
chains create closed structures [21, 33, 91, 92] (Table 1). 
Open-conformation chains only limitation is that imposed 
by isopeptide bonds that connect them [21, 33]. However, 
closed conformation chains have multiple steric hindrances, 
which alters ubiquitin space structure by exposing and con-
cealing different parts of ubiquitin residues, creating diverse 
topologies intrinsic to a specific type of linkage [21, 91]. 
In the cell, specific proteins bind to a unique type of ubiq-
uitin linkage topology [91]. Because distances between 
ubiquitin units within a chain are different in K63 or K48-
linked chains, UBDs of cellular machinery display small 
spaces between UIMs to specifically recognize K48-chains, 
whereas larger spacers are used for K63 binding [91, 92]. 
The use of a variety of UBDs structures not only allows dis-
criminating between open and close conformations, it also 
enables distinguishing among different open structures such 
as K63- and M1-linked chains [91, 92]. All these possibili-
ties of ubiquitin topologies and UBDs compose a fine and 
selective language among ubiquitinated-target proteins and 
ubiquitin-interacting proteins.
In a similar way, depending on the different distances 
between UIMs inside UBDs, certain E3-ubiquitin ligases 
elongate specific types of K-linked chains associated to 
target proteins. Besides, the wide variety of E3-ubiquitin 
ligases described in eukaryotic cells and their tissue restric-
tions amplify the code of ubiquitin chains. For example, the 
Cbl family of E3-ubiquitin ligases are highly expressed in 
hematopoietic cells and are involved in the downregulation 
of many signalling pathways controlling T and B cell recep-
tors and integrins [93, 94]. However, MARCH1 is repre-
sented in antigen presenting cells (APCs), modifying class 
II MHC molecules, downregulating their expression in the 
plasma membrane, whereas MARCH-IV regulates class I 
MHC molecules using a similar mechanism [95, 96]. In this 
regard, a possible explanation regarding how K48-linked 
poly-ubiquitin chains evade proteasomal degradation and 
travel into exosome involves the collaboration of certain 
ubiquitin-binding proteins located in endosomal pathway 
(Fig. 2).
Branched poly-ubiquitin chains display the particular sig-
nalling properties of their K48 or K63 components, although 
they are recognized by multiple linkage-specific enzymes 
[97]. This underscores the predominance of certain chain 
topologies within a mixed-linkage poly-ubiquitin chain. The 
sorting of ubiquitin chains other than K63-linked requires 
mechanisms different from those dependent on ESCRT 
components. The incorporation of SUMO-2/3 following 
ubiquitination creates heterologous SUMO-2/3-Ubiquitin 
chains responsible for enhancing the degradation of IκBα 
by the proteasome after the activation of the Tumour Necro-
sis α (TNFα) signalling pathway [23]. In stress situations, 
NEDD8 can also modify ubiquitin Lys48 [25]. A recent 
study described how ISGylation of ubiquitin Lys29 nega-
tively controls the turnover of ubiquitinated proteins [24].
Interestingly, ubiquitin can be phosphorylated on Ser65 
by PTEN induced putative kinase 1 (PINK1), enhancing 
its interaction with the mitochondrial E3 ubiquitin ligase 
parkin [98]. This phosphorylation-dependent mechanism 
increases the enzymatic activity of parkin, decreasing the 
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mitochondrial membrane potential [98]. Moreover, ubiquitin 
becomes acetylated in Lys6 and Lys48 without affecting sub-
strate mono-ubiquitination of histone H2B [99]. However, 
both acetylations inhibit K11, K48 and K63-linked poly-
ubiquitin chain elongation, providing a novel regulatory step 
of control of mono- and poly-ubiquitination [99].
Because many PTMs can modify proteins in the same 
residue, competition and crosstalk between different PTMs 
depending on different cell factors can change protein func-
tion and localization [100]. In summary, deciphering the 
sophisticated ubiquitin code is necessary to unveil specific 
functions of every chain topology in the selective import of 
proteins into exosomes.
Other PTMs in EVs
Proteomic studies have contributed extensively to define 
the protein composition of EVs [72, 84, 101–103]. Het-
erogeneous nuclear ribonucleoprotein A2/B1 (hnRN-
PA2B1) is present in exosomes in its sumoylated form, 
and that is necessary for the sorting of EXOmotif-con-
taining microRNAs into exosomes [104]. On the other 
hand, a study suggested that SUMO-1 could modulate 
the toxicity of α-synuclein in neurodegenerative disor-
ders such as Parkinson’s disease (PD) [105]. Besides, EVs 
can contribute to disseminate neurotoxic proteins, which 
favours the development of PD pathogenesis. Hence, 
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Fig. 2  The ubiquitin code in cellular functions. MHC-I and II and 
TCR are preferentially retained in endosomes by the action of spe-
cific E3-Ub-ligases MARCH-IV, I and Cbl, respectively. Whereas 
Ub-MHC-II is mainly degraded by lysosomes, Ub-MHC-I (HLA-
G) can be sorted into EVs. Signalling proteins downstream of TCR, 
TNFR or TLR can be modified by K63-linked chains to mediate sig-
nal transduction or by K48-linked ones, such as IκBα to be degraded 
in the proteasome. M1-linked chain is added to NF-κB to allow its 
nuclear translocation to start gene transcription. K27-linked chains 
are related with DNA repair processes, while K6, K11 and K63 
chains can modify mitochondrial proteins to initiate mitophagy of 
damaged mitochondria by the E3-Ub-ligase Parkin. Proteins with 
K11 and K48-chains are principally transported to the proteasome to 
be degraded. Most of the proteins modified with K63-linked chains 
interact with ESCRT-0 and are vectorised in ILVs of exocytic MVBs 
to be delivered into EVs. Although Ub-MHC-II is mainly degraded, 
unmodified MHC-II and Ub-MHC-I (HLA-G) are usually incorpo-
rated in exosome membrane. Besides, K11, K48 and K63-linked 
chains can be found in EVs. Figure key is shown at the right side. The 
images in the figures are not scaled
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sumoylated α-synuclein is incorporated into exosomes 
by a mechanism dependent on the ESCRT complex and 
phospholipids [106] (Table 2 and Fig. 1).
Nevertheless, ubiquitin and UBLs are not the only 
PTMs detected in EVs [73, 107]. For example, many 
phosphorylated proteins appear in exosomes, including 
the calcium-dependent phospholipid-binding protein 
Annexin A2, which is enriched in cholesterol-rich lipid 
raft micro-domains of exosome membranes [101, 108, 
109]. The localization of this protein depends on the 
phosphorylation of Tyr23, which prevents its endosomal 
degradation and allows its incorporation into exosomal 
membranes [109]. Other phosphorylated proteins found 
in exosomes include Tau, type 1 insulin receptor substrate 
(IRS-1), Crystalline alphaB (CryAB), Epidermal Growth 
Factor Receptor (EGFR),  Na+-Cl− co-transporter (NCC), 
Aquaporin 2, FasL and proteins implicated in cellular pro-
cesses such as apoptosis, survival and metabolism [79, 
101, 108, 110–117] (Table 2 and Fig. 1).
γ-Synuclein acquires features of prion-like proteins by 
oxidation, which triggers the aggregation of other pro-
teins, e.g. α-synuclein [118]. The most frequent oxidized 
residues of γ-synuclein are Met38 and Tyr39. Oxidized 
γ-synuclein is released into exosomes and incorporated 
in neighbouring cells, amplifying the toxic protein-
aggregation cascade that finally causes a degenerative 
synucleinopathy [118]. Besides, other oxidized proteins 
appear in EVs as described in other studies (reviewed 
in [107]) (Table 2 and Fig. 1). Moreover, several stud-
ies have revealed the presence of glycosylated proteins 
in EVs (reviewed in [73, 107]). Notably, EVs contain 
mainly mannose or sialic acid enriched-glycans and 
N-linked glycoproteins. In particular, exosomes contain 
large amounts of the sialoglycoprotein galectin-3-binding 
protein (LGALS3BP) [119–122] (Table 2).
Additionally, plasma membrane anchors induce vesicle 
budding directly from the plasma membrane of highly 
oligomeric proteins, such as the HIV Gag protein and 
the yeast cytoplasmic protein Tya [123, 124]. An evalua-
tion of different membrane anchors for Tya demonstrated 
that myristoylation was the most effective enhancer of the 
formation of shedding vesicles, whereas other types such 
as, phosphatidylinositol-(4,5)-bisphosphate and phos-
phatidylinositol-(3,4,5)-trisphosphate-binding domains, 
prenylation/palmitoylation tag or the type-1 plasma mem-
brane protein CD43 did not cause this effect [124]. This 
illustrates the role of protein anchors for the induction of 
shedding vesicles, which is similar to retrovirus budding 
[124] (Table 2). Besides, CD55 or decay-accelerating 
factor (DAF) anchored to a GPI molecules is selectively 
secreted to EVs [125].
The role of UBL and other PTMs in the sorting of proteins 
to EVs
The function of PTMs such as oxidation, phosphoryla-
tion, glycosylation and citrullination in the incorporation 
of proteins into EVs, has been recently reviewed in [107]. 
Briefly, these PTMs can regulate EVs release and uptake, 
acting as a disposal mechanism for cellular harmful com-
ponents or as a repair mechanism in physio-pathological 
conditions [107]. Similar to ubiquitin, the UBL SUMO 
also plays an important role in protein sorting to EVs. 
For example, SUMOylation is necessary for α-synuclein 
sorting into exosomes in an ESCRT-dependent manner 
[106] (Table 2). A recent study showed that other UBL 
called autophagy-related protein 12 (ATG12) and its E3 
ligase ATG3 interact with ALIX, regulating diverse func-
tions carried out by ALIX, for example, viral budding 
and MVBs biogenesis [126]. This observation suggests 
that ATG12 could also participate in exosome biogenesis. 
Besides, isoprenylation and palmitoylation may also par-
ticipate in protein delivery into exosomes, as in the case of 
the CINCCKVL palmitoylation and isoprenylation motif, 
which is present in human Ras Homolog Family Mem-
ber B (RhoB), determines its incorporation into ILVs in a 
cholesterol-dependent way and consequently in exosomes 
[127]. Furthermore, the expression of reporter proteins 
containing this palmitoylation/isoprenylation motif is 
enough to define a late-endosomal fate for these proteins 
[127].
On the contrary, ISG15, which is recognized as an 
immune alarm signal by cells, has an opposite role in 
protein sorting to exosomes. A recent study showed that 
ISGylation tags proteins for degradation, thereby avoid-
ing exosome secretion and spreading [43, 128] (Fig. 1). 
Besides, acetylation can abrogate the sorting of pro-
teins into exosomes. High glucose-regulated protein 78 
(GRP78) is expressed and secreted into exosomes by 
colon cancer cells to prepare the tumor microenvironment 
[129]. Its secretion in exosomes is impaired by chemical 
inhibitors of histone deacetylases (HDACs) and silenc-
ing of HDAC6 protein, which causes the dissociation of 
GRP78 from HDAC6 and promotes GRP78 aggregation 
and interaction with VPS34 complex [129]. The use of 
an acetylation mimetic mutant of GRP78 (K633Q) also 
impairs exosome sorting and blocks tumour cell growth 
in vivo [129] (Fig. 1).
On the other side, the role of the other PTMs, gathered 
in Table 1, remains largely unexplored. This could suggest 
that a role for these PTMs is unlikely, or that they can work 
as a cellular retaining signal for some proteins, directing 
them to other cellular processes such as the autophagy-
lysosome degradation pathway.
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Targeting post‑translationally modified proteins 
into EVs for biomedical applications
Deciphering the role of PTMs for protein sorting into 
exosomes could be useful for medical purposes, such as 
association of certain modified proteins with concrete 
physio-pathological situations, highlighting PTMs of exo-
somal proteins as biomarkers for prognosis, diagnosis and 
treatment of diseases.
PTM marks in EVs as biomarkers for diagnosis 
and prognosis
EVs have potential as non-invasive biomarkers for several 
pathological conditions, particularly due to their accessibil-
ity from biological fluids, facilitating the detection of certain 
pathologies [130–133]. A specific PTM of a protein in EVs 
in particular diseases could constitute a potential biomarker 
(Fig. 3). For example, the secretion of modified Tau pro-
tein aggravates development and progression of neurode-
generative processes. The majority of modified (phospho-
Thr-181) Tau detected in human cerebrospinal fluid samples 
is secreted via exosomes, constituting a well-characterized 
Fig. 3  Targeting post-translationally modified proteins into EVs 
for biomedical applications. The process for exosome engineering 
to use as a vaccine or treatment comprises various steps: (1) EVs 
can be isolated from different cell cultures, either cell lines or cells 
obtained from human biopsies. (2) These cells can be transfected or 
transduced with specific constructs coding for engineered therapeu-
tic proteins, that will be targeted to EVs by the addition of a specific 
PTM motif or tag. Therapeutic proteins include: pathogen antigens 
for the generation of vaccines; antibodies or nanoantibodies for acti-
vation or blocking of signalling pathways, or any kind of protein with 
a therapeutic potential. Besides, the expression of LAMP2b fused 
to a tissue-delivery targeting-peptide defines a specific fate for these 
EVs once in the blood stream. (3) The EVs can be isolated by diverse 
procedures. (4) Additionally, an extra step can be performed to incor-
porate inside EVs therapeutic small interference RNAs by electropo-
ration. (5, 6) Finally, EVs preparations, once standardized and quan-
tified, could be administered intravenously for disease treatment or 
vaccination. On the other hand, EVs obtained from blood samples (or 
other fluids) can be analysed to identify certain condition biomarkers 
(post-translational modified protein) for disease prognosis and diag-
nosis. The images in the figures are not scaled
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biomarker for Alzheimer’s disease (AD) [115]. In fact, ph-
Tau in combination with Aβ activate diverse signalling 
pathways, increasing the production of hyperphosphorylated 
Tau oligomers, which are then secreted by exosomes within 
the brain, accelerating neurodegeneration [110]. Moreover, 
some AD-related proteins such as ph-Tau, Aβ1-42, neu-
rogranin (NRGN) and the repressor element 1-silencing 
transcription factor (REST) contained in neuronal-derived 
exosomes appear in plasma [117]. The transference of these 
proteins contained in exosomes isolated from AD patients’ 
plasma into the central nervous system of a normal mouse 
causes Tau aggregation and induces AD-like neuropathology 
[117]. Other studies carried out with Tau-transgenic mice 
(rTg4510) revealed a high grade of pathology and higher 
accumulation of Tau in their exosomes compared to control 
ones [113].
On the other hand, several phosphorylations of IRS-1 in 
different residues associate to insulin resistance syndrome 
in diabetes mellitus as well as to degenerative diseases such 
as AD and fronto-temporal dementia [111]. Exosomes 
released by retinal pigment epithelial (RPE) cells into vitre-
ous humour contain a vast subset of phosphorylated proteins 
in age-related macular degeneration (AMD) patients [108]. 
Oxidative stressed RPE cells modify the phosphorylation 
profile of exosomal proteins compared to control cells, thus 
their detection could represent a source of biomarkers for 
diagnosis and prognosis of eye-degenerative diseases [108].
Besides, detection of modified exosomal proteins bears 
potential as a biomarker of treatment progression. For 
instance, cetuximab works as a therapeutic antibody to block 
EGFR activation in tumour cells [116]. EVs coming from 
cetuximab-treated cells represent well their originating cells, 
containing lower level of phosphorylated EGFR after treat-
ment [116]. Monitoring total and phosphorylated forms of 
EGFR present in EVs from patient blood could reflect the 
efficacy of anti-tumour therapy [116].
Moreover, detection of some exosomal biomarkers can 
reveal the existence of side effects during treatment. For 
example, a fraction of kidney transplant patients treated 
with tacrolimus as part of the immunosuppressive therapy 
developed hypertension 6 months after surgery [114]. Uri-
nary exosomes of hypertensive patients are enriched in the 
phosphorylated form of thiazide-sensitive NCC compared to 
non-hypertensive patients [114]. Hence, the measurement of 
total and phosphorylated NCC in urinary exosomes can be 
used as a biomarker of hypertension [114].
Vaccines
EVs also represent a promising tool for other therapeutic 
applications, such as generation of vaccines. EVs and many 
viruses share common mechanisms for protein sorting and 
particle release [134]. The study of EVs physiology can 
help us to understand virus infections, but also to generate 
virus-like particles suitable for vaccination exploiting the 
exosome pathway by sorting virus proteins into exosomes. 
For instance, exosomes isolated from infected cells can 
prime mice and protect them from a following lethal infec-
tion [135]. In the case of macrophages infected with the 
intracellular bacteria Mycobacterium tuberculosis, more 
than 40 mycobacterial components appear in exosomes 
[136] (Table 2). In addition, the administration of soluble 
mycobacterial proteins in human epithelial and mouse mac-
rophage cell lines promotes sorting of similar bacterial pro-
teins into exosomes [136]. Ubiquitination of mycobacterial 
proteins such as HspX and GroES acts as a signal for their 
incorporation into ILVs and secretion as EVs [136]. Moreo-
ver, vaccination using these exosomes in mice protects them 
against subsequent aerosolized infection with the whole 
infective bacteria [136]. This is just an example of how vac-
cination with a PTM-protein is a new strategy to initiate a 
protective immune response against a specific pathogen. An 
option for heterologous protein sorting into exosomes, which 
can be used as a vaccine, consists of protein overexpres-
sion with the addition of an ubiquitin tag, avoiding strate-
gies based on inactivated or non-replicative pathogens [128, 
137] (Fig. 3). This approach enables the exosomal delivery 
of proteins not usually found in exosomes, e.g. GFP. For 
instance, the use of exosomes produced by a stable cell line 
and containing recombinant fusion proteins from M. tuber‑
culosis evoked T cell immune responses [137]. However, 
although exosome-based vaccines could trigger antigen-
specific immune responses, they also contain other proteins 
that could trigger side- or off-target effects. In addition to 
ubiquitin, GFP SUMOylation drives it into exosomes, sug-
gesting that SUMO could work as a specific sorting tool for 
antigen incorporation into exosomes for vaccination schemes 
[106] (Fig. 3).
Disease treatment
EVs are a promising tool to design new strategies for dis-
ease treatment. The size of these small particles make 
them suitable to carry proteins, lipids, RNA, DNA or small 
chemical drugs, protecting them from external factors in 
the blood stream [138, 139]. They can be easily isolated 
in high amounts from diverse culture cells types. Further-
more, the target specificity of EVs prevents some secondary 
effects observed in traditional therapies [138]. One of the 
most potent advantages of exosomes is their capability of 
crossing the brain blood barrier (BBB), which opens a wide 
variety of possibilities for diagnosis and treatment of neu-
rodegenerative diseases [140]. In fact, exosomes carrying 
a specific siRNA and a brain-delivery peptide signal could 
even silence the expression of the targeted gene [141]. Gen-
erating exosomes targeted to a certain type of tissue can be 
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accomplished by the expression of specific tissue-delivery 
peptide fused to the N-t of lysosome-associated membrane 
glycoprotein 2 (LAMP2), a transmembrane protein which 
causes their incorporation into EVs [141]. Engineered tar-
geting peptides-LAMP2 sometimes undergo degradation 
even when localized to exosomes, reducing their potential 
as therapeutic tools. A recent study has discovered that the 
incorporation of glycosylating motifs enhances their deliv-
ery and protects them from damage [142].
The use of engineered EVs based on biologically active 
proteins could be used to treat some diseases. The addition 
of a WW tag (a domain-containing PPxY motif) to a certain 
protein determines its incorporation into exosomes [139]. 
The l-domains of Ndfip1 recognize this particular mark, 
targeting this protein to exosomes [14]. In the same way, we 
propose the use of known PTMs motifs, such as the myris-
toylation sequence MGCINSKRKD, in the N-t of the protein 
of interest to drive it specifically into exosomes, as other 
authors have described for Tya [124]. Moreover, addition 
of a C-t ubiquitin or SUMO tag could deliver proteins into 
exosomes, including targeting-peptides-LAMP2 with glyco-
sylated motifs for specific tissue delivery [106, 137, 142]. 
Besides, protein glycosylation has improved the efficacy 
of therapeutic proteins [143]. Thus, addition of glycosylat-
ing motifs to the protein of interest could also mediate its 
incorporation to exosomes, although protein glycosylation is 
still technically complex for industrial production [73, 107] 
(Fig. 3).
PTM-dependent sorting approaches could contribute 
to halting tumour progression and development. PTEN, a 
tumour suppressor phosphatase, is ubiquitinated in exosomes 
and is active in recipient cells, promoting the dephosphoryla-
tion of AKT [78]. Hence, the uptake of exosomes containing 
the C-t domain of PTEN by cancer cells reduces prolifera-
tion, migration and metastasis, postulating such a strategy 
as an anti-tumour treatment [144]. On the other hand, GPI 
modification of blocking-nanoantibodies that recognize 
receptors present in tumour cells, favours their attachment 
to exosomes. Exosome-attached EGFR-nanoantibodies 
approach can confer a specific selectivity to EVs against 
tumour cells, decreasing their EGFR-proliferative signalling 
pathways [145]. Hence, GPI anchors can be used to target 
particular proteins to EVs for biomedical applications [146] 
(Fig. 3). To sum up, all these strategies remark the potential 
application of EVs-containing post-translational modified 
proteins for selective delivery of therapeutic components 
into specific tissues.
Concluding remarks
Although the mechanisms that define the sorting of proteins 
into EVs are not fully understood, PTMs are likely to play 
an important role. Many post-translationally modified pro-
teins have been detected in EVs [73, 107], whereas others 
that have not been identified in EVs could have a role in 
protein delivery, participating in the incorporation of other 
proteins, or being removed before secretion. Ubiquitina-
tion or SUMOylation of some proteins have a clear role in 
their incorporation into exosomes, whereas others such as 
ISGylation or acetylation oppose such mechanisms, driv-
ing the modified protein to degradation [106, 128, 137]. 
Moreover, exosome secretion can be mediated by diverse 
mechanisms, such as the ESCRT complex, lipids and tet-
raspanins, increasing the complexity and diversity of ILV-
protein sorting and exosome release [18]. In this regard, EVs 
populations are heterogeneous as each vesicle contains a 
specific repertoire of proteins potentially different from its 
neighbours [10, 11]. In addition, there are other factors that 
increase the complexity of this system, for example the fact 
that almost every cell can secrete EVs containing common 
and cell-type-specific markers. Then, the final destination 
of each population of EVs can be different, working as an 
autocrine or paracrine signal or even travelling throughout 
the blood stream to other tissues.
Regarding ubiquitination, its own structure and functional 
complexity increases the number of factors to be taken into 
consideration. Compartimentalization and specificity of the 
different E3 ligases participate in protein localization [93, 
94]. In addition, competition or crosstalk with other PTMs 
such as SUMOylation or Neddylation alters the fate of the 
modified protein [100]. Also, the complexity of the ubiquitin 
code includes homotypic, heterotypic, mixed or branched 
chains that distribute protein populations among many cel-
lular processes such as proteasome degradation or endocytic 
trafficking, forming a ubiquitin-based protein ZIP code that 
has yet to be revealed [20–25, 33, 147]. Finally, the study 
of ubiquitinated proteins or even UBLs is difficult techni-
cally. Proteomics approaches to find ubiquitinated proteins 
in whole proteome typically used trypsin digestion of the 
sample. Nowadays, the discovery of new UBLs highlights 
that the sole use of this enzyme may mask the appearance 
of additional variations due to the same di-Gly residue 
shared by all these kind of modifications [148]. Hence, this 
information can only be used to localize specific sites on 
proteins susceptible to be modified by these kind of PTMs 
[148]. Nevertheless, some approaches tried to discern among 
these PTMs by terminal mutation and protein overexpres-
sion [149]. Besides, these proteomic approaches could also 
help to discover or define any possible consensus sequence 
for protein delivery into EVs, either protein mono-ubiquit-
ination and selective chain formation or other PTMs [102, 
150, 151].
In addition, EVs represent a novel non-invasive and selec-
tive therapeutic tool to be developed for prognosis, diagno-
sis or treatment of diverse diseases, with very promising 
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preliminary results [138, 139, 152, 153]. PTMs confer spe-
cific properties to proteins, playing a relevant role in EVs 
protein sorting. Hence, the use of PTMs represents a useful 
tool for the generation of therapeutically engineered EVs.
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Exosomes mediate intercellular communication and participate in many cell processes
such as cancer progression, immune activation or evasion, and the spread of infection.
Exosomes are small vesicles secreted to the extracellular environment through the release
of intraluminal vesicles contained in multivesicular bodies (MVBs) upon the fusion of these
MVBs with the plasma membrane. The composition of exosomes is not random, sug-
gesting that the incorporation of cargo into them is a regulated process. However, the
mechanisms that control the sorting of protein cargo into exosomes are currently elusive.
Here, we review the post-translational modifications detected in exosomal proteins, and
discuss their possible role in their specific sorting into exosomes.
Keywords: post-translational modifications, exosomes, ubiquitination, sorting, multivesicular bodies
INTRODUCTION
Post-translational modifications (PTMs) of proteins are biochem-
ical changes generated after the synthesis of polypeptides on ribo-
somes. PTMs include changes to the chemical nature of aminoacid
residues and also structural modifications that affect the interac-
tive ability of proteins, and consequently their stability, subcellular
localization, and activation state (1, 2). There are many types of
PTM that can be classified according to the nature of the mate-
rials added: (1) a chemical group (phosphate, acetate, etc.), (2)
carbohydrates, (3) lipids, (4) aminoacids, (5) other polypeptides,
and (6) an isoprenyl group (Table 1). A protein can undergo many
PTMs, changing its properties and broadening its capacity to adapt
to cellular needs (2). Some modifications are reversible and are
strictly regulated by the enzymes responsible for their addition
or removal, acting as a dynamic switch that allows the cell to
adjust protein functions according to requirements. Dysregulation
of PTMs or mutation of modified residues are linked to disease,
including cancer, neurodegenerative disorders such as Alzheimer,
and cardiovascular disease, highlighting the importance of these
protein modifications (3–7).
A specific pattern of PTMs is detected in exosomes, 50–200 nm
diameter vesicles secreted by most cells to the extracellular envi-
ronment. Once released, exosomes can adhere to or be internalized
by recipient cells, and in this way mediate cell-to-cell commu-
nication in a variety of contexts. Exosomes form through the
invagination of the limiting membrane of specific endosomic
compartments called multivesicular bodies (MVBs) (22). The
resulting intraluminal vesicles (ILVs) are released as exosomes
upon fusion of MVBs with the plasma membrane. Alternatively,
MVBs can fuse with lysosomes, leading to degradation of their
content. Exosomes have a specific composition of lipids, proteins,
and RNAs; however, the mechanisms that control the sorting of
molecules into these exosomal-proteins vesicles remain elusive.
Here, we review the PTMs detected in exosomal proteins, and
discuss their possible role in their specific sorting into exosomes.
UBIQUITINATION AND SUMOylation
Post-translational modifications increase the versatility of proteins
by influencing their activation state, stability, subcellular localiza-
tion, and ability to interact with other proteins. A particularly
effective means of increasing protein versatility is the addition of
ubiquitin, which can be attached to a target protein at a num-
ber of positions and in a variety of ways. The C-terminal glycine
of ubiquitin usually forms an isopeptide bond with the ε-amino
group of a lysine residue present in the target protein, resulting in
mono-ubiquitination. In some cases, E4 ubiquitin ligases can add a
poly-ubiquitin chain to a mono-ubiquitinated site (23). The equa-
tion becomes even more complicated considering that ubiquitin
has seven lysines, and the fate of the target protein is determined
by which lysine forms the link in the poly-ubiquitin chain: chains
linked through lysine-48 (Ub-K48) label target proteins for degra-
dation in the proteasome; Ub-K63 chains seem to be important
for the DNA-damage response, endocytosis, autophagy, and sig-
nal transduction; Ub-K11 chains are implicated in endoplasmic-
reticulum-associated degradation (ERAD); and Ub-K29 chains are
involved in lysosomal degradation (24–33). Moreover, in some
cases, ubiquitin can be linked through residues other than lysine,
such as the N-terminal through the free amino group or the
sulfhydryl group of cysteine residues (34).Ubiquitination can also
compete with other PTMs, such as sumoylation or acetylation, and
can enhance others such as phosphorylation (35–37).
Ubiquination, thus denotes a complex network of PTMs, and
its role in the sorting of proteins into exosomes is far from under-
stood. There seems to be consensus that ubiquitination is necessary
for sorting proteins into ILVs destined for degradation through the
fusion of the encompassing MVB with lysosomes. This process is
mediated by the endosomal sorting complex required for transport
machinery (ESCRT complex) and affects proteins such as epithe-
lial growth factor receptor (EGFR) (38) (Figure 1). This machinery
recognizes ubiquitinated cargoes and catalyzes the abscission of
endosomal invaginations, forming ILVs that contain the sorted
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FIGURE 1 | Post-translational modifications of exosomal proteins.
Membrane receptors such as EGFR and MHCII are ubiquitinated and sorted
to MVBs. Then, they follow a degradative pathway by the fusion with
lysosomes. Note that non-ubiquitinated-MHCII can be sorted into
exosomes. Ubiquitinated LMP2A and ubiquitinated and phosphorylated
FasL follow a secretory pathway where both modified proteins are delivered
into exosomes. Non-membrane proteins like SUMOylated hnRNPA2B1,
phosphorylated and oxidized γ-synuclein, and phosphorylated tau are
packed into exosomes. Myristoylated TyA protein is able to oligomerize,
leading to the formation of shedding vesicles. Ubiquitinated ARRDC1 can
induce plasma membrane budding by an ESCRT complex-depending
mechanism, producing ectosomes.
cargo [reviewed in Raiborg and Stenmark (39)]. The ESCRT com-
plex consists of four subcomplexes, ESCRT-0, -I, -II, and -III, and
several accessory proteins. ESCRT-0, -I, and -II contain ubiquitin-
binding subunits that interact directly with ubiquitinated cargo.
The directional flow of cargo from ESCRT-0 to ESCRT-I and -II
might be regulated by PTMs. In fact, the ESCRT-0 subunits are
known to be phosphorylated and to be mono-ubiquitinated (40–
42). The latter modification keeps these subunits in an inactive
form owing to intramolecular interactions between their ubiq-
uitin interacting motifs and the appended ubiquitin (43, 44).
However, the role of ubiquitin and the ESCRT complex in the
sorting of proteins into ILVs for exosome secretion is still unclear,
and MVB biogenesis, exosome secretion, and exosomal-protein
sorting have been reported in an ESCRT/ubiquitin-independent
manner [reviewed at Villarroya-Beltri et al. (45)].
The Epstein-Barr virus (EBV) protein LMP2A (latent mem-
brane protein 2A) is ubiquitinated in exosomal fractions (16).
LMP2A contains two PXYY motifs, through which it associates
with neural precursor cell expressed developmentally down-
regulated protein 4 (Nedd4)-family ubiquitin ligases (16). Ubiq-
uitination of LMP2A leads to endocytic transport of the protein
from the plasma membrane to MVBs. Nedd4 E3 ubiquitin lig-
ases are able to bind directly to target proteins though the PPXY
motif, but proteins lacking this motif can bind Nedd4 through
the adaptor Nedd4-family-interacting protein 1(Ndfip1), lead-
ing to their ubiquitination (46). Ndfip1 is involved not only in
protein degradation, but also in protein traffic to exosomes (46).
Ndfip1 overexpression increases the protein content of exosomes
and enhances exosomal sorting of normally absent proteins, such
as Nedd4, Nedd4-2, and Itch. These exosomal proteins moreover
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appear to be highly ubiquitinated, suggesting that Ndfip1 trans-
fers other ubiquitinated proteins to exosomes (46) (Figure 1).
For example, the Ndfip1 adaptor function is required for exo-
somal export of phosphatase and tensin homolog deleted on
chromosome 10 protein (PTEN) ubiquitinated on lysine 13 (17).
With other proteins, however, ubiquitination appears to be
unimportant or inhibitory to exosomal export. Secretion into exo-
somes of small integral membrane protein of the lysosome/late
endosome (SIMPLE) is enhanced by mutations in its PPXY motif,
which mediates its binding to E3 ubiquitin ligases (18). Ubiqui-
tination is also not required for the packaging of major histo-
compatibility complex II (MHC-II) into exosomes (47). The use
of a chimeric-ubiquitinated-MHC-II molecule does not specif-
ically lead these molecules into exosomes, and forcing MHC-II
ubiquitination by expression of membrane-associated ring finger
(C3HC4) 8 (MARCH) E3 ubiquitin ligase does not enrich MHC-
II molecules in exosomes, though it does completely deplete them
from the plasma membrane. Moreover, directed-mutagenesis of
all MHC-II lysine residues does not impair the exosome sorting
of these receptors (47). However, ubiquitination of the MHC-II
cytoplasmic domain, required for recognition by the ESCRT com-
plex, is important for sorting membrane MHC-II to MVBs for
lysosomal degradation (48). The non-ubiquitination of MHC-
II molecules present in exosomes suggests that this PTM is not
involved in sorting to these vesicles. The two mechanisms for
loading MHC-II into MVBs are engaged for different physi-
ological functions. Thus, whereas ubiquitin-dependent sorting
takes place in immature DCs, in which ubiquitinated receptors
are degraded in lysosomes, in activated-DCs, non-ubiquitinated
MHC-II-containing exosomes are efficiently delivered to interact
with T cells, enhancing antigen specific MHC-II-mediated pre-
sentation (48) (Figure 1). Heat shock protein 70 (HSP70) also
seems to be sorted into exosomes independently of its ubiquitina-
tion. Thus, although deletion of the deubiquitin domain of COP9
signalosome complex subunit 5 (CSN5) enhances packing of ubiq-
uitinated HSP70 into exosomes, knockdown of the entire CSN5
protein increases the levels of both modified and non-modified
HSP70 in exosomes (19).
Mass spectrometry analysis of PTMs in extracellular vesicles
released by insulinoma cells identified multiple poly-ubiquitinated
proteins (49). Enrichment of exosomes in poly-ubiquitinatied
proteins was also demonstrated by an approach based on the use
of FK1 antibody (which only binds poly-ubiquitinated proteins)
and P4D1 (which labels poly- and mono-ubiquitinated proteins)
(50). Other studies suggest that exosomal proteins are preferen-
tially mono-ubiquitinated or de-ubiquitinated, based on western
analysis showing discrete ubiquitinated protein bands rather than
smeared bands (19).
Ubiquitination has been shown to be important for the secre-
tion of a novel type of extracellular vesicle, distinct from exosomes,
called arrestin-domain-containing protein 1(ARRDC1)-mediated
microvesicles (ARMMs). ARMMs directly bud from the plasma
membrane upon interaction of the tumor susceptibility gene
101 protein (TSG101) with a PSAP motif in ARRDC1, which
is localized through its arrestin domain at the plasma mem-
brane (20). ARRDC1 in vesicles is ubiquitinated by the E3 ligase
WW domain-containing protein 2 (WWP2). Down-regulation of
WWP2 decreases ARRDC1 protein level in vesicles, and a PPXY-
mutant of ARRDC1 strongly inhibits ARMM secretion, suggesting
that ARRDC1 ubiquitination promotes ARRDC1 sorting into
vesicles and ARMM secretion (20) (Figure 1).
Another ubiquitin-like modifier called small ubiquitin-related
modifier (SUMO) has been found to modify the exosomal-protein
heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1).
This modification affects the ability of this protein to export micro
ribonucleic acids (miRNAs) into exosomes, probably by affecting
its binding to miRNAs (21). hnRNPA1 in exosomes was also found
to be modified, increasing its molecular weight by about 12 kDa
on gel electrophoresis (21) (Figure 1). This change in molecu-
lar weight of hnRNPA2B1 and other proteins has been shown
before (49).
OTHER PTMs: PHOSPHORYLATION AND GLYCOSYLATION
Mass spectrometry analysis of extracellular vesicles also detects
phosphorylated proteins (49). Phosphorylation and ubiquitina-
tion co-regulate sorting of Fas ligand (FasL) into secretory lyso-
somes by controlling its entry into MVBs (8). FasL contains a
proline-rich domain (PRD) in the cytosolic tail to which tyrosine
kinases, such as FGR, FYN, and LYN bind, and phosphorylation
of tyrosine residues by these kinases enhances internalization to
MVBs. The flanking regions of the PRD contain lysines, which are
mono-ubiquitinated. Mutation of these lysines impairs the local-
ization of FasL in MVBs, but mutation of the tyrosines does not
affect mono-ubiquitination. Phosphorylation is thus not required
for ubiquitination, but both PTMs are necessary for incorporation
of FasL into to MVBs (8) (Figure 1).
Phosphorylation is also involved in incorporation of the Ca2+-
dependent phospholipid-binding protein Annexin A2 into exo-
somal membranes, through the action of raft-resident kinases,
such as SRC or LYN on Tyr-23 (9). Aberrant phosphorylation of
the protein tau on threonine-181 promotes its incorporation into
exosomes, resulting in the spreading of this abnormally processed
protein in Alzheimer disease patients (10).
The protein γ-synuclein is transported in exosomes in its mod-
ified form. This modification consists of oxidation of Met-38 and
Tyr-39, which confers prion-like properties and causes the forma-
tion of toxic aggregates. The spreading of these aggregates is in
part mediated by the exosomal transport of oxidated-γ-synuclein
to glial cells (11) (Figure 1).
Carbohydrate modifications, involved in protein trafficking,
cellular recognition, and communication of cells with their extra-
cellular environment, have also been studied in extracellular vesi-
cles (12, 13, 51). Vesicles of diverse cells types are enriched in
proteins with high mannose, polylactosamine, α-2,6-sialic acid,
and complex N-linked glycans adjuncts; in contrast, there is a com-
parative under-representation of specific glycan epitopes, such as
terminal blood group A and B antigens (12, 13). Exosome glycan
profiles of different cell sources, such as T-cells, melanoma and
colon cancer cells, and biological fluids like breast milk, are very
similar, although they conserve some features of their parent mem-
branes (13). The carbohydrate fingerprint detected in exosomes is
less diverse than that observed in parent cells, but correspond to
a conserved fraction of the parent cellular membrane that display
a particular glycan profile (13). The variability observed between
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cellular and exosomal carbohydrate signatures has been suggested
to indicate different membrane microdomain origins of these vesi-
cles (13). It has been described that polyLacNac and high mannose
modifications associated with galectins and VIP36 are responsible
for the oligomerization of glycoproteins that mediate their sorting
into Golgi-derived vesicles (12, 52–55). Galectins and galectin-
associated proteins have also been detected in exosomes so it is
possible that glycosylation may also play a role in the sorting cargo
into extracellular vesicles (12, 13).
Membrane anchors have also been shown to be important
for the budding of vesicles derived from the plasma membrane.
An N-terminal acylation tag serves as a signal for the import
of highly oligomeric cytoplasmic proteins, like the yeast protein
TyA, into shedding vesicles (56). The membrane anchor that
most effectively promotes TyA budding is myristoylation. How-
ever, targeting of TyA to the endosomal membrane by fusion to
a Phosphatidylinositol-3-phosphate (PI3P) binding domain does
not produce the same effect (15) (Figure 1).
CONCLUDING REMARKS
Post-translational modifications decorate proteins and drive their
fate in cells by affecting multiple parameters including stabil-
ity and localization. Different modifications can affect the same
protein; sometimes competing with each other or being mutu-
ally exclusive, but in other cases can promote other modifica-
tions. Enzymes controlling PTMs additionally show very specific
patterns of expression, activation, and subcellular localization,
exponentially increasing the diversity and potentiality of cellular
proteomes.
Different types of PTMs have been found in exosomal pro-
teins; however, the role of these modifications in the localization
of proteins into exosomes is not clear. The enigmatic role of ubiq-
uitination, whose final consequences seem to differ depending on
the target protein, is a particular case in point. The type of ubiq-
uitination may also account for the fate of the modified protein,
and could be a key determinant for its loading in exosomes. In
some cases, ubiquitination seems to target the protein into MVBs
destined for degradation, whereas sorting of proteins into MVBs
that fuse with the plasma membrane to release exosomes seems
to be ubiquitin-independent, clearly pointing to the existence of
different types of MVB with different sorting mechanisms.
Specific protein modifications can reflect a particular patholog-
ical condition. The presence of modified proteins in exosomes can
therefore make them invaluable tools for diagnosis, since modifi-
cations could be easily detected in exosomes obtained from body
fluids without the need for invasive tissue biopsies.
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